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Tuberculosis (TB) is an infectious bacterial disease mainly infecting the pulmonary system of 
the human body. It affects around 1.5 million people every year, most of whom live in 
developing countries. The incidence of TB has increased in line with the rise in incidences of 
Human Immunodeficiency Virus (HIV) infections and Acquired immune deficiency syndrome 
(AIDS). Due to the pressing concerns of TB, the World Health Organisation (WHO) came up 
with the Direct Observed Treatment (DOTS) programme. Unfortunately, the development of 
several resistant strains against first-line drugs and consequently second and third-line drugs 
have developed. As the current TB drug regimen is inadequate, a good screening strategy, 
discovery of newer drugs and identification of the mode of action would help in developing 
better treatment routines and determining bacterial pathways more clearly. Drug discovery 
follows two major routes, one leading from the drug to the target and the other from target to 
the drug. Both methods have been applied in this work in order to identify new drugs effective 
against mycobacteria. Screens performed against a drug library approved by the Food and Drug 
Administration (FDA) have resulted in some promising hits. Functional characterisation of a 
putative enoyl CoA hydratase EchA12, which was targeted by florfenicol, revealed a novel lipid 
chaperone functionality associated with cell wall lipid biosynthesis. Furthermore, a target based 
phenotypic drug screen of the GSK177 box set against Mtb-PrsA provided further evidence that 
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Chapter 1  
Introduction  




1.1 The etiology of Tuberculosis  
 
Tuberculosis (TB) is a severe bacterial infection that predominantly affects the lungs leading to 
its most prevalent form of infection that is pulmonary tuberculosis. It has been known to affect 
around 1.5 million people every year most of whom are affected in developing countries 
(Fleischman and Greenberg, 1998). The incidences of tuberculosis have increased in line with 
the rise of HIV infections and AIDS, which compromise the hosts immunity, making it easier 
for the disease to develop. Statistically TB affects around 19-43% of populations infected with 
HIV (Fleischman and Greenberg, 1998; Flynn and Chan, 2001)  
Tuberculosis has afflicted humans for several thousand years, the oldest case was reported in 
Hungary 7000 years ago (Knechel, 2009). The causal organism of this disease is 
Mycobacterium tuberculosis (Mtb) which was reported by Robert Koch on March 24, 1882. In 
1881, based on the lesions Koch observed in the lungs of infected animals, he named the 
bacteria the tubercle bacillus (Koch, 1982; Rook and Bloom, 1994). The lesions had been also 
described as “pthisis” which were initially thought to be hereditary and not infectious (Pease, 
1940). After developing a new staining method and the ability to culture these bacilli, Koch 
named the bacillus M. tuberculosis in 1882 (Cambau and Drancourt, 2014). It has been posited 
that mycobacteria have existed for approximately 150 million years (Hayman, 1984) and Mtb 
has been isolated from mummies during the Egyptian pre-dynastic era (Cave and Demonstrator, 
1939; Morse et. al., 1964). The oldest isolates of Mtb were found in the 9000 kiloannus (ka) 
old skeletal remains of a woman and child from a settlement in Israel and from the remains of 
an extinct bison (17,000 ka) found in the Natural Trap Caves in Wyoming. The Mtb from these 
isolates were confirmed by analysing the samples and identifying lipid biomarkers unique to 
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this species (Lee et. al., 2015). 
Once Mtb invades the lungs and establishes an infection it causes symptoms such as persistent 
coughing, tiredness, exhaustion, night sweats and clubbing of fingers (possibly due to low 
oxygenation of the extremities). Prolonged infection can result in secondary symptoms such as 
sputum production (sometimes with blood) when coughing, pain in the chest and joints, 
shortness of breath and leucocytosis (immune cell migration towards the site of infection) 
(Cambau and Drancourt, 2014). 
TB is spread through aerosolised bacilli through droplet nuclei approximately 1-5µm in 
diameter. These droplets are spread through coughing, sneezing, spitting and singing by an 
actively infected host. These aerosolised bacilli tend to be airborne for a longer period of time, 
although that does not necessarily entail infection in people coming in contact with the aerosol. 
There are 4 main factors which govern potential infection in a healthy individual: 1) The 
number of organisms expelled in the aerosol, 2) The concentration of the bacilli within the 
column of air and ventilation in that area, 3) Length of exposure to the aerosol, 4) Immune 
status of the exposed individual (Glickman and Jacobs, 2001). Once a person inhales the droplet 
nuclei, the bacilli enter the bronchioles and alveolus through the pharynx and bronchial tree. 
The infection may or may not be established depending on the immune response generated in 
the individual’s body against the bacilli. Mtb does not have any known endo- or exo-toxins 
therefore it does not elicit an immediate immune response in the host when the bacterial load is 
low. The bacteria reside within the alveolus and multiply over a period of time, which is 
approximately a few weeks, to get to a count of 103-104; this amount of bacterial load then 
triggers an immune response (Glickman and Jacobs, 2001; Gupta et. al., 2012). The primary 
immune response against the bacteria is via the recruitment of alveolar macrophages, although 
the bacillus has a special mechanism of avoiding destruction by the macrophages by obtaining 
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entry into the macrophage with the help of cell surface receptors; it then proceeds to modify the 
maturation of the phagosome to increase its survival possibility (Glickman and Jacobs, 2001). 
Once the bacilli have been phagocytosed into the macrophage, an inflammatory response is 
generated by recruitment of mononuclear cells leading to the formation of a granuloma. A 
granuloma is the main centre of infection, where foamy giant cells and other lymphocytes 
surround the infected macrophages in order to contain the infection. Within the macrophage, 
the bacilli create an environment to help its survival by not allowing the fusion of the 
phagosome with the lysosome, acidifying the phagosome and resisting the oxygenated 
metabolites (Basu, 2004). 
The continued clash between the immune cells and the bacteria causes the formation of a 
caseating tubercle which leads to the leaking of the bacilli into the extracellular milieu of 
cellular debris. This further leads to a caseating necrosis, whereby the T-cells and activated 
macrophages surround the tubercle. In immunocompromised patients, due to the weakened 
immune system, new macrophages are low in supply and this leads to non-specific destruction 
of lung tissue, as opposed to patients with a good immune system where activated macrophages 
and cytotoxic T-cells continue fighting the infection. Once the infection causes necrosis, the 
bacilli might disperse through the lung tissue causing an active infection which can be 
transmitted to other people. In some cases, if the bacilli leak into the blood vessels they can 
travel to various parts of the body causing extrapulmonary tuberculosis (Clark-Curtiss and 
Haydel, 2003). Approximately 913,000 people developed extrapulmonary tuberculosis in 2015 
according to the World Health Organisation (WHO, 2016).   
Statistically, 10% of the infections are likely to become symptomatic while 90% of infected 
individuals develop a latent infection. A latent infection involves a delayed hypersensitivity to 
the purified protein derivative (PPD) that delivers a positive tuberculin test without presenting 
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any symptoms of the disease. 5-10% of the latent infections are said to develop into active 
infections when hosts are immunocompromised due to chemotherapeutic influence or age 
(Clark-Curtiss and Haydel, 2003; Tufariello et. al., 2003).  
 
1.2 Taxonomy of M. tuberculosis  
 
Mycobacterium tuberculosis, the causative agent of tuberculosis in humans, belongs to the 
phylum and class Actinobacteria (which is found mostly in the soil) and order Actinomycetales 
based on the high guanine and cytosine residue content in its DNA and the complex cell wall 
of the bacteria. The bacteria belong to the suborder Corynebacterium and is a member of the 
Mycobacteriaceae family. It is genetically similar to other mycobacterial species and some 
species of the Corynebacterium sub order such as Corynebacterium glutamicum. Mtb belongs 
to a group of closely related mycobacterial species which belong to what is known as the 
mycobacterial complex. The complex includes other mycobacterial species such as M. 
africanum, M. microti, M. canetti and M. bovis.  
M. africanum is phenotypically very similar to Mtb and M. bovis. Mycobacterium microtii was 
isolated for voles in the UK in the 1930s and was causing tuberculosis in rodents (Lapage, 1947; 
Cavanagh et. al., 2002). 
 Mycobacterium bovis is a strain of mycobacteria that predominantly causes tuberculosis in 
animals. Earlier it was assumed that the Mtb developed only from M. bovis, a species of 
Mycobacterium which has been known to infect animals and humans. The latest genomic 
experiments have proved this theory to be false, instead it was proved that the Mtb species 
developed from a variety  of species in the Mycobacterium complex such as M. microti, M. 
canetti and M. bovis (Smith, 2003). 
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The vaccine strain M. bovis BCG (Bacillus Calmett-Guérin) against tuberculosis was developed 
from M. bovis. M. bovis BCG is an attenuated strain of M. bovis with three of the major virulent 
regions known as the region of difference (RD) deleted from the genome. There are primarily 
three regions of difference RD1, RD2 and RD3 which are found both in Mtb and M. bovis. 
Overall, there are 16 regions of differences throughout the mycobacterium complex involving 
genes which have regulatory roles and secret proteins involved in virulence and survival of the 
bacterium. M. africanum has RD3 and RD9 missing compared to Mtb, while the closely 
associated strain M. bovis has RD4 to RD10 and RD12 to RD13 missing in its genome 
(Magdalena et. al., 1998).  
M. cannetti is a strain from the complex that causes tuberculosis, although is different from Mtb 
in its colony morphology given that it produces smooth colonies as opposed to the rough 
crenulated colonies of Mtb. In addition, Mtb also has a longer generation time (around 24 h) 
than M. cannetti  (James et. al., 2000; Koeck et. al., 2011; Van Soolingen et. al., 1997). There 
are other mycobacterial species which are considered to be in the complex such as M. caprae 
(can cause TB), M. pinnipedii (causes TB in seals) (Cousins, 2003), M. suricattae and M. mungi 
(Huard et. al., 2006). 
Due to their infectious nature, Mtb and M. bovis are classified as biosafety level 3 organisms 
and while in use within laboratories they have to be handled as per such guidelines. The 
vaccinated strain of M. bovis BCG along with the saprophytic mycobacterial strain M. 
smegmatis have been designated to a biosafety level 2, as they possess a lower threat to humans 
in terms of infectivity (Mahairas et. al., 1996) 
 




In 2015, 10.4 million new cases of TB were reported globally. Of these, 5.9 million cases (56%) 
were men, 3.5 million cases (34%) were women and 1 million (10%) were children. 
Approximately 1.2 million cases were amongst patients with the human immunodeficiency 
virus HIV, constituting 11% of the global cases reported. The largest number of cases reported 
were from Asia (61%) and Africa (26%), these continents accounting for 87% of all cases. 
India, Indonesia, China, Nigeria, Pakistan and South Africa were the countries with the highest 
burden, combining to represent 60% of the global incidences reported in 2015. The cases 
reported from the Eastern Mediterranean region (7%), European region (3%) and the Americas 
(3%) form a smaller percentage of the cases reported (figure 1.1) (WHO, 2016). 
 
Figure 1.1: The global map depicting the new cases of TB in 2015. The map illustrates that 
most cases were reported in south east Asia and Africa and the least number of incidences were 
reported in the Mediterranean region, Europe and America. 
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:: FIG. 3.4 
Estimated HIV prevalence in new and relapse TB cases, 2015
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Although the TB mortality rate has shown a decrease of 34% from 2000 to 2015, there were an 
estimated 1.4 million deaths among HIV negative people. 85% of deaths were in African 
regions and Southeast Asia (figure 1.2). India and Nigeria comprised 48% of the total deaths 
caused amongst HIV negative patients infected with TB. Despite this statistic, the TB treatment 
programme averted the deaths of 39 million patients (HIV negative) and with the additional use 
of anti-retroviral treatment, 9.6 million HIV positive patients (WHO, 2016).  
 
Figure 1.2: The global map of morbidity caused by TB infections in HIV negative patients 
in 2015. The map highlights that most deaths occurred in Africa and Southeast Asia. 
 
With the launch of the drug resistance surveillance in 1994, the WHO took the necessary steps 
to monitor the development of drug resistance globally. In 2015, 3.9% new and 21% of 
previously treated cases reported multidrug resistant tuberculosis (MDR-TB) and rifampicin 
resistant tuberculosis (RR-TB). Out of the 580,000 resistant cases reported, MDR-TB 
comprised 83% of the total. China, India and the Russian Federation form the majority of the 
34  ::  GLOBAL TUBERCULOSIS REPORT 2016
:: FIG. 3.12 
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resistance cases reported globally (figure 1.3). There were 250,000 deaths reported for patients 
infected with resistant tuberculosis (WHO, 2016).  
 
Figure 1.3: The global map of multidrug resistant TB incidences reported in 2015.  
The map depicts that most cases were reported from the Russian Federation, followed by China 
and India.  
 
117 of the WHO member states reported the occurrence of extensively drug resistant 
tuberculosis (XDR-TB) although the average proportion of the XDR-TB cases within the 
MDR-TB cases remains similar to the previous years at approximately 9.5% in 2015. 
There is an expected proportional increase in the MDR-TB cases, with the increasing global 
burden of TB highlighting the importance of the need for new drugs and a better understanding 
about the resistance mechanism of Mtb. 
 
40  ::  GLOBAL TUBERCULOSIS REPORT 2016
:: FIG. 3.18 









a Figures are based on the most recent year for which data have been reported, which varies among countries. Data reported before the year 2001  
are not shown.
:: FIG. 3.19 









a Figures are based on the most recent year for which data have been reported, which varies among countries. Data reported before the year 2001 are not 
shown. The high percentages of previously treated TB cases with MDR-TB in Bahamas, Bahrain, Belize, Bonaire – Saint Eustatius and Saba, French Polynesia 
and Sao Tomé and Principe refer to only a small number of notified cases (range: 1-8 notified previously treated TB cases). 
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1.4 The cell wall 
 
The cell wall of mycobacteria is a special feature of the bacillus which acts as a barrier for 
penetration of drugs and creates a protective layer against host immune cells. The cell wall 
essentially is comprised of two major components which are the mycolyl arabinogalactan 
peptidoglycan (mAGP) complex and lipoarabinomannan (LAM) (Tam and Lowary, 2009). The 
mycobacterial cell wall is known for its low permeability and an unusually high amount of 
unique lipid molecules in the cell wall which constitute approximately 60% of the wall and are 
responsible for its waxy nature of the cell wall (Kolattukudy et. al., 1997). The core of the cell 
wall is essentially made up of the mAGP complex, with lipids and carbohydrates covalently 
attached to the core (figure 1.4) (Brennan, 2003). The free lipids, lipoglycans and phosphatidyl-
myo-isnositols (PIMs) are components that make up the outer leaflet of the cell wall. These 
molecules, along with other important molecules such as lipoarabinomanan (LAM) and 
lipomanan (LM), have a key role in host immune evasion (Wolfe et. al., 2010). The suborder 
Corynebacterianeae which includes organisms such as Mtb, M. smegmatis and C. glutamicum 
have various liposaccharides in their cell wall. The LAM and other related glycoconjugates 
vary minutely within these organisms (Tam and Lowary, 2009). The lipids in the cell wall 
involved in virulence are trehalosemonomycolate (TMM), trehalosedimycolate (TDM), 
sulpholipids (SL) and phthiocerol dimycocerosate (PDIM). The cell wall associated proteins 
such as LpqH (19kDa), PstS1 (38kDa) and Toll-like receptor-2 (TLR-2) agonists play a more 
regulatory role. They are mainly involved in regulating the activity of macrophages and 
dendritic cells. On the other hand, the secreted proteins act as antigens and genes involved in 
the production of these proteins are considered important drug targets and the proteins 
themselves act as biomarkers (Wolfe et. al., 2010). 
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Figure 1.4: The mycobacterial cell wall. The cell wall structure of Mycobacterium 
tuberculosis depicting the major components such as peptidoglycan, arabinogalactan, 
phthiocerol dimycocerosate (PDIM), phosphatidyl-myo-inositol mannosides (PIMs), 
lipomannan (LM), lipoarabinomannan (LAM), mannosylated lipoarabinomannan (ManLAM) 
and mycolic acids. Other molecules that are interspersed into the mycolate layer such as 
trehalose monomycolate (TMM), trehalose dimycolate (TDM), diacyltrehalose (DAT), 
polyacyltrehalose (PAT) and sulfoglycolipid (SGL) (Abrahams and Besra, 2016). 
 
The biosynthesis of the cell wall involves a series of interconnected cycles and enzymes 
(Acharya and Goldman, 1970). The synthesis of the mAGP complex mainly involves the 
synthesis of its key component, arabinogalactan (AG), which is sandwiched between the 
peptidoglycan (PG) layer and mycolic acid (MA) layer (figure 1.4).  
The biosynthesis of peptidoglycan begins with the formation of Uridine diphosphate N- acetyl 
glucosamine (UDP-GlcNAc) which is synthesised by the addition of N- acetyl glucosamine 
(GlcNAc) to enoylpyruvate derived from phosphoenoylpyruvate (PEP) (Young et. al., 1999). 
The UDP-GlcNAc is then converted to Uridine Diphosphate N- acetyl muramic acid (UDP-
MurNAc) in two consecutive reactions catalysed by two enzymes, MurA (Rv1315) and MurB 
(Rv0482) (figure 1.5). MurA catalyses the addition of the enoylpyruvate residues onto the 
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GlcNAc which is then reduced by MurB to form UDP-MurNAc (Mahapatra et. al., 2000; 
Raymond et. al., 2005). 
 
Figure 1.5: The biosynthesis of peptidoglycan. The figure depicts the stepwise conversion of 
initial peptidoglycan substrates into the peptidoglycan polymer (Jankute et. al., 2015). 
 
The synthesis cycle then continues with a sequential addition of molecules, beginning with the 
attachment of the L-alanine (L-ala) moiety to the UDP-MurNAc by the MurC (Rv2152c) 
enzyme to form UDP-Muramyl-L-ala (Mahapatra et. al., 2000; Raymond et. al., 2005). The 
UDP-Muramyl-L-ala is then transformed into UDP-Muramyl-L-ala-D-glutamic acid by the 
addition of D-glutamate by MurD (Rv2155c). MurE (Rv2158c) then adds the m-
diaminopimelic acid (DAP) onto the UDP-Muramyl-L-ala-D-glutamic acid to form UDP-
Muramyl-L-ala-D-glutamate-m-DAP (Morayya et. al., 2015; Munshi et. al., 2013). The final 
step in the formation of “Park’s nucleotide”, UDP-Muramyl-L-ala-D-glutamate-m-DAP-D-ala-
D-ala is the addition of the D-alanyl-D-alanine (D-ala-D-ala) residue by MurF (Rv2157c) to 
































































































































The biosynthesis pathway of peptidoglycan in Mycobacterium tuberculosis.
(21, 104). Tetrapeptide side chains are attached to the muramyl components of the backbone that
become cross-linked to provide a mesh-like structure. In M. tuberculosis, these side chains consist
of L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine that is cross-linked between meso-
diaminopimelic acid (m-DAP) and D-alanine (3→4), which means M. tuberculosis has an A1γ-group
PG, based on the classification system of Schleifer & Kandler (108). However, mycobacterial PG
also has a high number of m-DAP to m-DAP linkages (3→3), which increase in abundance when
the bacilli enter the stationary phase (up to 80% of cross-linkages) (Figure 2) (67). M. tuberculosis
has the ability to modify these cross-linkages from (3→4) to (3→3) without the requirement of de
novo synthesis of PG, which could provide the bacilli with protection from endopeptidases (67).
Another unique feature of mycobacterial PG is that it provides the site for AG attachment. The
6 position of some muramyl units of the PG backbone provides a site for a phosphodiester bond
to an α-L-rhamnopyranose-(1→3)-α-D-GlcNAc-(1→P) disaccharide bridge (78).
Biosynthesis of Peptidoglycan
The sequential Mur ligase pathway is the major contributor to the biosynthesis of PG. MurA
(Rv1315) has enoylpyruvyl transferase activity that adds phospho-enol-pyruvate to UDP-GlcNAc
to form UDP-enoylpyruvyl-GlcNAc (59). MurB (Rv0482) then utilizes NADPH to reduce
the enoylpyruvyl moiety from the product of MurA, to a lactoyl ether moiety, to form UDP-
MurNAc (12). NamH (Rv3808) then hydroxylates UDP-MurNAc to UDP-MurNGlyc to pro-
vide both types of UDP-muramyl substrates (104). From this point, amino acid residues are
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form the UDP-MurNAc pentapeptide (Feng and Barletta, 2003; Kurosu et. al., 2007). This 
pentapeptide molecule is transferred over to the cell membrane beginning with the initial 
attachment of the molecule with an undecaprenyl phosphate (Und-P) and a membrane bound 
enzyme called MurX/MraY (Rv2156c) to form Lipid I. GlcNAc is then added to this Lipid I 
molecule by MurG (Rv2153c) to form Lipid II, a β 1-4 linked GlcNAc-Muramyl-pentapeptide 
(Kurosu et. al., 2007). Lipid II is the monomer of the peptidoglycan polymer and is flipped over 
by a transmembrane protein MurJ or FtsW (Rv2154c) which has been proven to have flippase 
activity in vitro (Meeske et. al., 2015). The monomer is added to other monomers to form a 
polymer by sequential transglycosylation and transpeptidation reactions catalysed by enzymes 
PonA1/PBP1 (Rv0050) and PonA2/PBP2 (Rv3682). PonA1/PonA2 (PBP1/PBP2) is a 
bifunctional enzyme which attaches the muramyl molecule to the PG chain and then crosslinks 
the m-DAP to the neighbouring D-ala moiety through a 3®4 linkage by cleaving the terminal 
D-ala (Hett et. al., 2010; Chang et. al., 1990; Ghuysen, 1991) (figure 1.5).  
The peptidoglycan is then covalently attached to the arabinogalactan via a linker unit. This 
unique structure of the linker unit found in mycobacteria and Actinomycetes has a 
diglycosylphosphoryl bridge, a-L-Rhap-(1®3)-a-D-GlcNAc-(1®P) (Daffe et. al., 1990). The 
linker unit links the galactan chain at the C-6 position of the N-glycocylmuramic acid 
(MurNGly) (McNeil et. al., 1987; 1990). This linker unit is synthesised by the addition of a 
UDP-GlcNAc residue onto a lipid carrier by a GlcNAc transferase WecA (Rv1302) which is 
homologous to gram negative bacteria such as E. coli (Jin et. al., 2010). This UDP-GlcNAc 
moiety attached to the lipid carrier is then converted to the linker unit by the addition of a 
Rhamnosyl residue (Rha) by a rhamnosyltransferase WbbL (Rv3265c) (Mikušová et. al., 1996). 
The WbbL enzyme is essential in mycobacteria for the formation of the linker unit (C50-P-P-
GlcNAc-Rha) (Mills et. al., 2004). The linker unit acts as an acceptor for the formation of the 
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galactan chain which has 30 units of galactofuranose (Galf) with alternating b (1®5) and 
b(1®6) residues (McNeil et. al., 1987; 1990; Kremer et. al., 2001). This addition of the residues 
is performed by two bifunctional enzymes GalfT1 and GalfT2. The GalfT1 recognises the linker 
unit and adds the initial 2 Galf residues at the C-4 position of the Rha in the linker unit while 
GalfT2 adds the rest of the residues to the chain (Belanova et. al., 2008; Kremer et. al., 2001).  
This linear galactan chain is then connected to a highly-branched structure containing three 
arabinan chains at position 8, 10 and 12 (Alderwick et. al., 2006). The a-D-arabinofuranosyl  
(Araf) residues are added onto the linker unit containing the 30 Galf residues (C50-P-P-
GlcNAc-Rha-Galf30). These residues are supplied by the only known contributor in 
mycobacteria, decapreylmonophosphoryl-D-arabinose (DPA) (Wolucka, 2008). The Araf 
residues are generally added in a linear chain with a-5 linkages with branching at C-3 
introducing an a-3,5 DPA, which is synthesised through a multienzyme cycle. This begins with 
the conversion of 5-phosphoribosyl-1-pyrophosphate (pRpp) into decaprenylphosphoryl-5-
phosphoribose (DPPR) by an enzyme UbiA (Rv3806c) (Alderwick et. al., 2005; 2011) which 
has also been predicted to be a target for an antimycobacterial drug ethambutol (Safi et. al., 
2013). Prpp is synthesised by an essential enzyme PrsA (phosphoribosyl synthetase, Rv1017c) 
utilising ribose-5-phosphate (R-5-P) acquired from the pentose phosphate pathway. Prpp can 
also be redirected to be used for the biosynthesis of amino acid, purines and pyrimidines in the 
cell cytoplasm (Alderwick et. al., 2011). The gene responsible for the conversion of pRpp to 
DPPR (ubiA) when disrupted in C. glutamicum leads to the loss of cell wall arabinan and a 
mutant that has a truncated or variant version of LAM indicating a different pathway for LAM 
synthesis (Tatituri et. al., 2007). The DPPR is then flipped over to the extracellular space and 
dephosphorylated to form decaprenol-1-monophosphoribose (DPR) by a phospholipid 
phosphatase (Rv3807c) (Jiang et. al., 2011). The DPR is then oxidised to form decaprenol-1-
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phosphoryl-2-keto-b-D-erythropentofuranose (DPX) which is then consequently reduced to 
form decaprenol-1-monophosphoarabinose (DPA).  
There are two key enzymes involved in these two steps, decaprenylphosphoryl-β-D-ribose 
oxidase, DprE1 (Rv3790) and decaprenylphosphoryl-β-D-ribose-2-epimerase, DprE2 
(Rv3791) which are present as heterodimers. Deletion studies in C. glutamicum and conditional 
knock-out studies in mycobacteria revealed that out of the two enzymes, DprE1 is essential and 
has recently proven to be targeted by a class of new drugs called benzothiazinones (Meniche 
et. al., 2008; Batt et. al., 2012; Crellin et. al., 2011).  
The arabinose residue is then transferred from the DPA molecule by an 
arabinofuranosyltransferase (ArafT) forming decaprenol-1-monophosphate onto the galactan 
chain at positions 8, 10 and 12 by the enzyme AftA (Rv3792) (Alderwick et. al., 2006). This 
ultimately primes the galactan chain for the addition of further arabinose molecules and the 
extension of the polymeric chain. The AftA enzyme is essential for the cell viability and has 
also been recognised as a target for ethambutol (Safi et. al., 2013; Shi et. al., 2008). The 
extension of the arabinan chain by polymerisation and the formation of the terminal hexa-
arabinofuranosyl unit is then taken over by a heterodimeric set of enzymes EmbA (Rv3794) 
and EmbB (Rv3795) from the emb locus having transferase activity. The M. smegmatis and C. 
glutamicum homolog of these enzymes produce viable mutants with truncated or decreased 
amounts of arabinan (Escuyer et. al., 2001; Shi et. al., 2008). The other ArafT enzymes such as 
AftC (Rv2673) are involved in the internal domain of the arabinan to form a-1,3 branches along 
with the AftD (Rv0236c) (which is the largest mycobacterial glysoyl transferase) and together 
they most likely act as a large scaffold for the arabinosylation of the cell wall. The final addition 
of the Araf residues at the b (1®3) position is performed by AftB (Rv3805c), bringing the 
synthesis of arabinogalactan to completion (Birch et. al., 2010; 2008).  
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The attachment of the arabinogalactan layer to the peptidoglycan layer is achieved by the 
mycobacterial enzyme Lcp1 (Rv3267) belonging to the LytR-CysA-Psr (LCP) family, which 
ligates the AG to the PG layer through the a-L-rhamnopyranose–(1→3)-a-D-GlcNAc-(1→P) 
linker unit. The finished arabinogalactan polymer is transferred over to the Lcp1 enzyme which 
attaches the polymer to the 6¢-OH of the muramyl residue of the peptidoglycan via a 
phosphodiester bond, consequently releasing a decaprenol-1-monophosphate (Harrison et. al., 
2016). Two essential enzymes belonging to the LCP family, CpsA1(Rv3267) and CpsA2 
(Rv3484),  have also been discovered to have the same activity and are known to be involved 
in the ligation of the AG to the PG (Grzegorzewicz et. al., 2016).   
The non-reducing part of the arabinogalactan structure is attached to the mycolic acid (MA) via 
the branched arabinan to form the mAG complex (Kaur et. al., 2009). The mycolic acid is 
attached to the hexa-arabinofuranosyl structure at the 5th position of both the terminal b-D Araf 
and 2-a-D Araf. The mycolyl units are attached to the hexa-arabinofuranosyl structure in groups 
of four, of which only 2 of the hexa-arabinofuranosyl residues are mycolated in physiological 
conditions. There are other molecules that are interspersed and attached covalently to the 
arabinogalactan unit in slow growing mycobacterial species (McNeil et. al., 1990; 1991).  
There are non-acylated galactosamines (D-GalN) which attach to the arabinogalactan at the C-
2 position of the inner 3,5-a-D-Araf units. It was found that succinyl esters were attached to the 
arabinogalactan and non mycolated chains. In non-mycolated chains, succinyl esters were 
considered to control mycolation through negative regulation. Together, the galactosamine and 
succinyl esters enhance the rigidity and tightness of the arabinogalactan component of the cell 
wall (Draper et. al., 1997; Bhamidi et. al., 2008). 
There are a number of non-covalently bound glycophospholipids present in the outer leaflet of 
the cell wall such a PIMs, LM and LAM. PIMs are the precursors to the synthesis of LM and 
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LAM, which are important molecules for recognition by macrophages (Wolfe et. al., 2010). 
PIMs are glycolipids which are synthesised from the starting molecule phosphatidyl-myo-
inositol (PI) which is mannosylated twice sequentially by PimA (Rv2610c) and PimB 
(Rv2188c) to form phosphatidyl-myo-inositol mannoside (PIM1) and then phosphatidyl-myo-
inositol dimannoside (PIM2) respectively (Ballou et. al., 1963). The PIM2 is then acylated to 
form monoacyl-phosphatidyl-myo-inositol dimannoside (Ac1PIM2) which acts as a base for 
other PIMs molecules and can be further acylated to form diacyl-phosphatidyl-myo-inositol 
dimannoside (Ac2PIM2) (Kordulakova et. al., 2002; 2003). PimC then further adds another a-
mannopyranosyl (Manp) residue to Ac1/Ac2PIM2 to form Ac1/Ac2PIM3. PimE then adds two 
mannose residues consecutively to form Ac1/Ac2PIM4 and Ac1/Ac2PIM6 (figure 1.6). The 
Ac1/Ac2PIM4  are also redirected towards synthesis of lipomannan (LM) and lipoarabinomanan 
(LAM) by glycosyltransferases belonging to the GT-C superfamily (Lea-Smith et. al., 2008; 
Mishra et. al., 2008).  
  
 
Figure 1.6: Biosynthesis of Phosphatidyl-myo-inositol mannoside. The figure is a pictorial 
depiction of the sequential biosynthesis of PIMs involving the various enzymes (PimA, PimB, 
PimC, PimD and PimE) (Jankute et. al., 2014). 
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Mycolic acids are long chain a-alkyl b-hydroxy fatty acids and are a characteristic of Mtb 
contributing to their high hydrophobicity (Takayama et. al., 2005). Bioinformatic study and the 
knowledge of the M. leprae genome unravelled the genes which play a vital role in the survival 
and virulence of mycobacteria. This is due to the fact that M. leprae has undergone reductive 
evolution and therefore potentially only retained essential genes required for survival (Bhatt et. 
al., 2005). Most genes involved in the mycolic acid biosynthesis are essential for the survival 
and virulence of the bacteria. Understanding the importance of the genes in the mycolic acid 
biosynthesis pathway came through conditional mutants in M. smegmatis which gave the 
functional importance of essential genes and the ability of C. glutamicum to survive in the 
absence of mycolic acids when these essential genes are knocked out of the organism (Gande 
et. al., 2004).  
Mycobacterial mycolic acids are made of merochains which are of three different types: a-
mycolates, methoxy-meromycolates and keto-mycolates. The a-mycolates also known as the 
cis-dicyclopropyl fatty acids are the most abundant type in the bacterial cell wall (~70%) and 
is a cis only mycolate (Takayama et. al., 2005). It has two variations in its structure based on 
the length of the alkyl groups at the terminal ends and the number of methylene groups between 
the cyclopropane rings and the carboxyl group. The methoxy- and keto-mycolates on the other 
hand form only a minor proportion of the mycolates and consist of both cis- and trans-
cyclopropane rings (Glickman et. al., 2000; 2001; Dubnau et. al., 2002).  
In 1970, Bloch discovered that mycobacteria have two fatty acid synthase cycles (FAS). The 
Fatty Acid Synthase-I (FAS-I) is similar to the synthase cycle in eukaryotes and evolved 
prokaryotes and Fatty Acid Synthase-II (FAS-II) is found in plants and bacteria (Bloch, 2006). 
The bimodal FAS-I utilizes an acetyl CoA molecule to produce an acyl CoA after addition of 
2 carbon units per cycle, forming an elongated chain of C16-C18 carbon units and then feeding 
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it into the FAS-II system. The FAS-II system utilizes a malonyl CoA which is synthesised from 
the acetyl CoA by an acetyl CoA carboxylase (AccD6, Rv2247) and is further converted into a 
malonyl-ACP (acyl carrier protein) by FabD, a ketoacyl synthase (Rv2243) (Bhatt et. al., 
2007b). From this point forward there are a few key enzymes involved in FAS-II which are the 
b-ketoacyl ACP synthase, b-ketoacyl ACP reductase, b-hydroxyacyl-ACP hydratase and enoyl 
ACP reductase (Bhatt et. al., 2007b).  
 
  
Figure 1.7: Synthesis of Mycolic acids. A pictorial depiction of the biosynthesis of mycolic 
acids through the two major fatty acid synthase cycles (FAS-I and FAS-II) highlighting the 
presence of more than one FAS-II cycle (Nataraj et. al., 2015). 
 
The malonyl-ACP chain is extended by the addition of the acyl CoA from FAS-I into b-
ketoacyl-ACP by the b-ketoacyl ACP synthases, KasA (Rv2245) and KasB (Rv2246). Out of 
the two synthases it was demonstrated that KasA is essential while KasB is not, although  the 
kasB mutant produced shorter mycolic acid chains (Bhatt et. al., 2005; 2007a). The ketoacyl-
ACP then follows a chain of reduction by the b-ketoacyl ACP reductase (MabA, Rv1483) 
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followed by dehydration by the b-hydroxyacyl-ACP dehydratase forming a trans-2-enoyl-ACP 
(Labesse et. al., 2002).  
There are three functional dehydratase enzymes involved in the FAS-II cycle: HadA (Rv0635), 
HadB (Rv0636) and HadC (Rv0637) which form heterodimers in different combinations with 
each other based on the type of mycolic acid being synthesised (Cantaloube et. al., 2011) (figure 
1.7). The trans-2-enoyl-ACP is then reduced by the enoyl ACP reductase (InhA, Rv1484), 
which is the site of action for isoniazid, forming the acyl-ACP with C16-C32. The acyl-ACP 
formed is then condensed with the acyl CoA from the FAS-I by Pks13 (Rv3800c) to form an 
oxomycolic acid intermediate and then reduced by a mycolyl reductase (Rv2509) into the 
mature mycolic acid (Portevin et. al., 2004; Gande et. al., 2004; Bhatt et. al., 2008).  
It has been recently suggested that there might be more than one FAS-II cycle. The new model 
posites a chain of individual FAS-II cycles that feed the product sequentially to each other and 
culminate in the condensation of the merochains and formation of a mature mycolate at the end. 
In this model, there are five arrays of an assembly chain which lead to the final condensation 
by Pks13 involving a variable combination of FAS-II, FAS-IIA, FAS-IIB and enzymes 
involved in mycolic acid modifications to synthesise a-mycolic acids, cis-methoxy mycolates, 
trans-methoxy mycolates, cis-keto mycolates and trans-keto mycolates (Nataraj et. al., 2015). 
 The first array is the FAS-II complex, which links the FAS-I to FAS-II and contains the core 
(MabA, InhA, FabD) and FabH. The FAS-II then interacts with two elongation complexes E1-
FAS-II and E2-FAS-II. The E1-FAS-II is the initial elongation complex consisting of the core, 
KasA and a HadA-HadB heterodimer while the E2-FAS-II is responsible for further elongating 
mycolic acid chains from the E1 complex utilizing the core, KasB and HadB-HadC heterodimer 
(Bhatt et. al., 2007b; Cantaloube et. al., 2011) (figure 1.7). The meromycolate chain is then 
passed onto the termination FAS-II (T-FAS-II) which involves Pks13 condensing the 
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meromycolate chain with the C26 fatty acid molecule from FAS-I to an oxomycolic acid. This 
is then reduced by a mycolyl reductase (Rv2509) to form concluding mature mycolate. This 
“mycolic acid biosynthesis interactome” was deciphered using protein-protein interaction 
studies with two- and three-hybrid systems. The modifying enzymes involved in these cycles, 
which introduce modifications such as methylations, isomerisation etc., show a specific 
preference towards a certain type of Had heterodimer which therefore govern the kind of 
modification the meromycolate chain undergoes (Nataraj et. al., 2015).  
Once the mycolates have been synthesised they are utilised for the synthesise of mycolate 
containing cell wall components such as TMMs and TDMs. The antigen 85 complex has three 
proteins which possess mycolyl transferase activity. The proteins FbpA (Rv3804c), FbpB 
(Rv2886c) and FbpC (Rv0129c) are involved in the transfer of mycolates onto the trehalose 
components which form TMMs which are then further converted to TDMs (Belisle et. al., 
1997).   
Cell wall mycolic acids are main components for the growth and survival for the bacilli both in 
vivo and in vitro. As depicted in Figure 1.4, the mycolic acids are bound to the mAG complex 
and are involved in the inflammatory response involving activation of macrophages and 
dendritic cells through the TLR-2 and TLR-4 receptors. Free mycolates in the outer periphery 
of the cell wall are responsible for maintaining the structure of granulomas (Verschoor et. al., 
2012). In the host system, it has been observed that mycolic acids stimulate production of 
antibodies which could be important for diagnostic and therapeutic purposes (Tam and Lowary, 
2009). 
Many of the genes involved in the biosynthetic cycles of cell wall components and related 
enzymes involved in these pathways have been deemed essential for the survival of the 
mycobacterial cell. Due to the essentiality of the genes, understanding these cycles and the roles 
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the enzymes play within them is important in order to develop new inhibitors and unearth new 
drug targets (Mishra et. al., 2011). 
 
1.5 Tuberculosis treatment  
 
Due to the pressing concerns of the increasing instances of tuberculosis the WHO came up with 
the Direct Observed Treatment Short-course (DOTS) programme. The DOTS programme was 
developed with five major elements: 1) Political commitments to TB affected areas in various 
countries, 2) Detection of the infection by analysing the sputum of patients, 3) Short course 
chemotherapy (SCC) administered to the people with a positive infection as per the sputum 
analysis, 4) Proper case management by DOTS, 5) Regular recording and reporting of every 
case. With the application of this programme, there was an increased control of tuberculosis 
with proper drug administration for a period of time (Gupta et. al., 2001). Unfortunately, 
resistance to first line drugs started to develop after a few years which led to a new strain of TB 
called Multidrug resistant tuberculosis (MDR-TB). The strain of Mtb causing this infection was 
resistant to isoniazid and rifampicin, the key first line drugs (FLDs) administered in the DOTS 
programme (Blanchard, 2003). Resistance is thought to have been caused through lack of 
knowledge, improper prescription of the drugs, a non-standardised regimen and poor patient 
adherence to the antibiotics prescribed. In order to deal with the MDR-TB problems, a Green 
Light Committee was formed to monitor the proper use of second line drugs (SLDs) to combat 
this resistant strain (Shah et. al., 2007). Under this programme, 4 or more SLDs were 
administered in different combinations to those people diagnosed with MDR-TB. 
Unfortunately, cases of resistance against the SLDs developed shortly after, forming yet another 
strain of TB called extensively drug resistant (XDR-TB). XDR-TB is defined as the strain of 
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TB resistant to isoniazid, rifampicin, any of the flouroquinolones and at least one injectable 
SLD (Shah et. al., 2007; Munro et. al., 2007). A more recent strain of resistant tuberculosis 
known as extremely drug resistant tuberculosis (XXDR-TB) or totally drug resistant 
tuberculosis (TDR-TB) resistant to both first and second line drugs has taken us back into the 
era without any antibiotic resources to treat it (Farnia et. al., 2010). The recent resistant strain 
has been seen to show morphological changes affecting 15-20% of the cell population of the 
bacillus by changing its shape into an oval or round shape while 5-7% of the cell population 
show extremely thick walls (21-26nm) similar to non-replicating bacilli (NRP) or anaerobic 
dormant bacilli (Farnia et. al., 2010).  
It has still not been conclusively defined how the bacteria acquire resistance to the antibiotics. 
It is thought to be because of chromosomal alterations (Cole, 1994) due to sequential mutations 
(mutations that would develop for one drug at a time) (Fenner et. al., 2012; Motiwala et. al., 
2010). The bacilli seem to use efflux pumps to resist dying in the presence of the antibiotics 
and this attribute could play an important role in developing long term resistance. It is thought 
that horizontal gene transfer of genetic elements such as plasmids, integrons and transposons 
could also be responsible for the development of resistance, but this has not been clearly proven 
(Srivastava et. al., 2010). 
The standard drug regimen for DOTS involves these first line antimycobacterial antibiotics: 
 
1.5.1 Isoniazid 
Isoniazid or isonicotinylhydrazide is an antibiotic containing a pyridine ring with a hydrazide 
group, both of which are essential to its activity (figure 1.8). Its complex mode of action is via 
interference with the mycolic acid synthesis process (Middlebrook and Cohn, 1953). It does 
so by inhibiting the NADH dependant enoyl ACP reductase that is encoded by the gene inhA 
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(Rawat et. al., 2003) which is involved in the final step in the FAS-II cycle of the mycolic 
acid biosynthesis process (Marrakchi et. al., 2000; Kremer et. al., 2003). 
 
 
Figure 1.8: Structure of Isoniazid.  
 
Isoniazid enters the cells through passive diffusion and needs to be activated by a catalase 
enzyme KatG in the presence of manganese dichloride (MnCl2) (Zabinski and Blanchard, 1997) 
to form an anion which then covalently attaches to NADH to form the adduct that inhibits the 
InhA protein (Marrakchi et. al., 2000). Strains of Mtb which developed resistance against 
isoniazid showed mutations in two genes inhA and katG (Silva et. al., 2003; Ramaswamy et. 
al., 2003). In 40% of the strains resistant to isoniazid a mutation in the katG gene was identified, 
which causes the amino acid substitution of a serine to a threonine at the 315 position 
(Somoskovi et. al., 2001). The study of three genes ihhA, katG and kasA revealed that the drug 
targeted only KatG and subsequently InhA without any activity against KasA, a ketoacyl ACP 
(Kremer et. al., 2003). The most prominent mutation observed in the inhA gene was a point 
mutation causing a substitution of Ser94Ala which causes a decrease in the affinity of the 
Isoniazid-NAD adduct to the active site of the InhA protein. The loss of serine in the mutated 
InhA protein causes the disruption of hydrogen bonding due to movement in an ordered water 
molecule which in turn reduces the binding capability of the drug NAD complex (Vilchèze et. 
al., 2000). katG mutations are seen to be more in case of MDR strains as opposed to 
monoresistant strains (Hazbón et. al., 2006).  




Figure 1.9: Structure of Rifampicin. 
 
Rifampicin is a lipophyllic ansamycin drug with a heterocyclic structure and a napthoquinone 
core depicting an antimicrobial action (Rattan et. al., 1998) (figure 1.9). Its mode of action 
involves the molecule binding to the β-subunit of the RNA polymerase enzyme, by inhibiting 
the binding of the first triphosphate to the polymerase and consequently inhibiting the 
elongation process of mRNA (McClure and Cech, 1978; Blanchard, 2003). The drug is active 
against both replicating and non-replicating bacteria. The resistance to rifampicin is seen due 
to mutations in the rpo gene in the region of 507-533 codons now known as the rifampicin 
resistance-determining region (RRDR) (Ramaswamy and Musser, 1998). Analysis of 29 
rifampicin resistant strains from Hungary revealed an 81-bp region and a N-terminal region in 
the rpo gene where most mutations occurred. The most common substitutions observed were 
Asp516Val, Ser531Leu, His526Tyr and His526Asp (Bártfai et. al., 2001). Of these common 
mutations, the Ser531Leu and His526Asp depicted the highest amount of resistance to the drug 
by disrupting the hydrogen bonds, increasing repulsion and therefore decreasing the affinity of 
the drug to the polymerase protein (Pang et. al., 2013; Bártfai et. al., 2001). These substitutions 
increased the minimum inhibitory concentration (MIC) values against the drug to more than 
32µg/mL (Somoskovi et. al., 2001). Resistance to rifampicin has shown co-resistance to other 
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Figure 1.10: Structure of Ethambutol. 
 
Ethambutol is a linear alcoholic molecule ((2S)-2-[2-[[(2S)-1-hydroxybutan-2-
yl]amino]ethylamino]butan-1-ol) (figure 1.10) which was first used as a first line drug in 
combination with isoniazid, rifampicin and pyrazinamide (Sreevatsan et. al., 1997). The mode 
of inhibition of this drug is by the interference with the biosynthesis of cell wall arabinogalactan 
(Takayama et. al., 1979). Ethambutol blocks the polymerisation step in the arabinan synthesis 
causing the accumulation of the precursor b-D-arabinofuranosyl-P-decaprenol (C50-P-D-Araf). 
The drug partially blocks the synthesis of LAM leading to the production of truncated LAM 
which has a knock-on effect on the mycolic acids. Due to the absence of LAM moieties the 
mycolic acids cannot be attached to them which therefore causes redirection of these molecules 
towards non-arabinan pathways and accumulation of trehalose dimycolates (Mikusova et. al., 
1995a). The gene producing arabinosyl transferase is embC, embA and embB (Sreevatsan et. 
al., 1997). EmbA and EmbB form heterodimers to synthesise the hexa-arabinoside structures 
and disruptions of genes encoding these enzymes produce a growth defective mutant. Although 
embA and embB are co-transcribed, it was proven that the embA is essential for the survival of 
the cell (Amin et. al., 2008). Mutation in the 306th codon of the embB gene was seen in 50% of 
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the resistant strains. Amino acid substitution in embB was observed in 69% of the resistant 
isolates (Telenti et. al., 1997). The Met306Leu and Met306Val mutations cause an increase in 
the MIC from 5µg/mL to ~40µg/mL while the Met306Ile caused the MIC to increase to only 
20µg/mL. The mutation in the embC gene causing the substitution Val981Leu increased the 
MIC to 15µg/mL(Sreevatsan et. al., 1997; Rinder et. al., 2001). It has been mentioned that 
although the majority of mutations occur in the embB gene, this does not present resistance to 
the drug but only makes the bacteria susceptible to acquiring more mutations (Srivastava et. al., 
2009).  
The aftA gene, essential for the bacteria and encoding the enzyme which catalyses the addition 
of the first arabinofuranosyl residue to galactan, has been indicated to confer resistance to 
ethambutol, increasing the MIC value to 8µg/mL (Alderwick et. al., 2006). A mutation in 
another gene called ubiA (Rv3806c) not only leads to increased resistance with an MIC value 




Figure 1.11: Structure of Pyrazinamide. 
 
Pyrazinamide is a pyrazinoic acid amide analogous to nicotinamide (figure 1.11). It is a 
prodrug, which needs activation through an enzyme pyrazinamidase (Pzase), which converts it 
into pyrazonoic acid (Konno and Feldmann, 1967). The enzyme is encoded by the gene pncA 
(Scorpio and Zhang, 1996). The active drug component destroys the bacterial membrane 
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energetics and inhibits membrane transport. The antibiotic is known for its activity against 
semi-dormant bacilli surviving within an acidic environment and it kills the bacteria by 
changing the membrane potential of the cell (Zhang et. al., 2003; Mitchison, 1985). Another 
mechanism of action is thought to be via inhibition of the fatty acid synthase type-I in the 
replicating bacteria (Zimhony et. al., 2007). Resistance develops when mutations are observed 
in the promoter region of the pncA gene (Scorpio et. al., 1997; Jureen et. al., 2008). Mutation 
in the pncA gene causes an amino acid substitution of Cys169Gly, which does not allow the 
drug to be activated and produces a 3-fold resistance to the drug (Shi et. al., 2011). 
1.6 New antitubercular drugs in the pipeline 
 
An estimated 0.6 million cases were diagnosed with MDR-TB in 2015 (WHO, 2016) and with 
almost 11 million people co-infected with HIV, the TB drug regimen is failing against 
upcoming challenges (Sala and Hartkoorn, 2011).  To make matters worse, the recent 
developments of lifestyle diseases like diabetes mellitus is affecting treatment of TB (Sala and 
Hartkoorn, 2011) and necessitates the development and discovery of new drugs. The current 
TB pipeline has not produced many new drugs since the mid-1980s (figure 1.12), although 
recent developments have led to newer drugs undergoing trials to be used as combinatorial 
therapy for tuberculosis including non-resistant, latent and resistant strains (Lalloo and 
Ambaram, 2010).  
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Figure 1.12: The TB drug discovery timeline. The figure represents the drugs discovered 
over the years from the identification of the bacteria to the recent development of resistant 
strains of M. tuberculosis  (Lalloo and Ambaram, 2010) 
 
Several new drugs as illustrated in figure 1.13 detailed as follows: 
 
1.6.1 Diarylquinolones TMC-207 
 
Bedaquiline (also known and TMC-207 or R207910) was discovered after screening 70,000 
compounds against M. smegmatis (Lounis et. al., 2006; Huitric et. al., 2007). The drug is 
effective against mono and multi-resistant strains of tuberculosis. The drug target was identified 
as the c subunit of the ATP synthase enzyme by mutations caused in the atpE gene in resistant 
mutants of Mycobacterium (figure 1.14). The drug also binds to the epsilon subunit (Koul et. 
al., 2006; Ji et. al.,2006). 
The drug seems to have other targets or mechanism of resistance, which is drug efflux. 
Although the FDA recently approved the use of bedaquiline as a combinatorial therapy for 
resistant tuberculosis it does have serious side effects such as induction of arrhythmia, tissue 
testing so that optimal drug regimens can be constructed for
these patients. Antituberculous drug resistance stems from
the interplay of several factors that include the long
treatment duration; organisms in sanctuary sites such as
fibrotic, calcific lesions; side effects and drug interactions
such as with antiretrovirals; unpredictable absorption; and
poor adherence and failure to implement directly observed
treatment.
New Antituberculous Drugs
Several new antituberculous agents are currently under
clinical investigation. There is a global urgency to
accelerate their development and bring them to market.
Table 2 shows a summary of the key antituberculous drugs
under clinical development.
Rifamycins
Because rifampin-based regimens have to be adminis-
tered for at least 6 months for optimal effectiveness, a
number of alternative drugs that have longer serum
half-lives have been evaluated. Rifalazil, rifabutin, and
rifape tine are newer rifampin-based compounds and
have the same mechanism of action as rifampin, but
have a significantly improved minimum inhibitory
concentration (MIC) than the parent compound. The
first of these is rifabutin. Rifabutin is primarily used as
a rifampin substitute when there is a significant risk of
drug–drug interactions [18, 19]. However, there is a high
risk of acquired rifamycin resistance, which has led the US
Centers for Disease Control and Prevention (CDC) to
recommend against the use of widely spaced rifamycin
regimens [20].
Rifalazil
This drug has a longer half-life than rifampin: 9 h compared
with 2.5 h following a single 25-mg oral dose. It has
increased potency and lower cytochrome enzyme induction
[21]. Initial phase1I trials, however, have demonstrated
high rates of side effects proposed to be due to release of
interleukins such as IL-6. Although the mouse studies were
encouraging, only one study is reported for rifalazil in TB-
infected humans [22]. In an early bactericidal activity
clinical trial, patients were given isoniazid alone or
isoniazid in combination with either 10 or 25 mg of
rifalazil. Not surprisingly, since isoniazid has potent activity
against M. tuberculosis in the first few days of therapy, no
additive antituberculosis activity (or decreased sputum
bacillary count) over isoniazid was demonstrated in the
patients who received isoniazid plus rifalazil, possibly
because the rifalazil doses were almost insignificant
compared to the standard rifampi dose (600 mg) [21,
22]. Dosing of rifalazil was likely limited by toxicity that
has been reported for this drug [17••]. Further clinical
studies of rifalazil as an antituberculous drug have been
stopped in view of its poor activity after good initial
bacteriocidal activity [18].
Fig. 1 Epochs in TB and antituberculous drug development. DOTS directly observed therapy, MDR multidrug resistant, MTB Mycobacterium
tuberculosis, TB tuberculosis, XDR extensively drug resistant
Curr HIV/AIDS Rep (2010) 7:143–151 145
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accumulation, elevated transaminase levels and high mortality rates (Lounis et. al.,2006; Arjona 




A specific characteristic of nitroimidazoles is that they are active against both replicating and 
non-replicating Mycobacterium. Currently two major drugs under this class are under clinical 
trials (Sala and Hartkoorn, 2011). 
The first drug PA-824, is a potent drug showing cidal activity against MDR-TB. It is a prodrug, 
which is activated by the enzyme deazaflavin dependant nitroreductase (Ddn) by forming three 
different metabolites (Singh et. al., 2008; Dogra et. al.,2010). The target of the drug, although 
unclear, is thought to affect cell wall biosynthesis and cause respiratory poisoning (figure 1.13) 
(Manjunathan et. al., 2009; Jawed Ahsan et. al., 2015). The response to the drug was seen by 
activation of various genes involved in cell wall synthesis such as FAS-I and FAS-II operon 
genes. Several genes involved in respiration were also activated such as nyd (Manjunathan et. 
al.,2009). 
The other drug, OPC-67683, is also a prodrug requiring activation potentially by Ddn. The drug 
inhibits the mycolic acid synthesis. It shows activity against drug sensitive TB and MDR TB 
(Matsumoto et. al., 2006; Dogra et. al.,2010). It is unaffected by liver microsomal enzymes 
which gives it an advantage to be used in combination with antiretroviral therapies. Both the 
drugs have now entered the second phase of clinical trials (Matsumoto et. al., 2006).  
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Figure 1.13: Potential new antimycobacterial drugs in clinical trials. The figure illustrates 




Drugs based on the structure of 1,2- ethylenediamine in ethambutol have led to a potential new 
drug, SQ109 (Boshoff et. al., 2004) (figure 1.13). SQ109 is an ethambutol analogue identified 
by screening 60,000 compounds from a library (Reddy et. al., 2010). The target of the drug is 
a trehalose meromycolate (TMM) transporter, Mmpl3. The drug therefore affects mycolic acid 
synthesis principally the cord factor (figure 1.14) ( Boshoff et. al., 2004). Used with bedaquiline 
it seems to have a synergistic effect and therefore is a more effective combinatorial therapy. 
The drug is under phase II clinical trials (Cole and Riccardi, 2011).  
 
the current TB pipeline (Fig. 2) is slowly expanding, although it is inad-
equate for the development of a completely novel regimen. A key ques-
tion is: how to search for new TB drugs and where to look for them?
Novelty in screening
Advances in the identification of new TB drug targets have been driven
largely by the availability of the genome sequence of M. tuberculosis20,
but unfortunately this approach has yet to lead to the identification of
new drug candidates. Genome-derived, target-based approaches have
had little success in the antibacterial therapeutic area in general18. The
essentiality of a target for replication may be a prerequisite but it does
not ensure its druggability; for many essential targets we are unable to
identify specific inhibitors with drug-like properties. For example, several
high-throughput screening campaigns for identifying inhibitors of iso-
citrate lyases, which are key glyoxylate-shunt-pathway enzymes found to
be essential for mycobacterial intracellular growth and their long-term
persistence in mice, were discontinued owing to lack of druggability of
these targets21. Second, we have often failed to understand how to convert
good bacterial enzyme inhibitors into a compound that can easily pene-
trate the highly impermeable bacterial cell wall. Without proper under-
standing of the entry mechanisms of antibiotics across bacterial cell walls,
any medicinal chemistry approach to engineer (via chemical modifica-
tions) a ‘permeability property’ into an enzymatic inhibitor has proven to
be quite challenging.
Over time, it has emerged that shifting the screening strategy from
single-enzyme targets to phenotypic screens at a whole bacterial cell level
is a much more successful strategy18. Such a strategy recognizes the
potential holistic interactions of a drug target(s) with one or more com-
ponents in a bacterial cell and defines its essentiality in a more relevant
physiological space. One of the drawbacks of the whole-cell-screening
approach is that upfront knowledge regarding the mechanism of action
remains largely lacking, thereby preventing any input from structural
biology into medicinal chemistry efforts around drug design. Another
challenge of whole-cell screening is to identify the right in vitro growth
conditions that are relevant for in vivo infections, as certain metabolic
targets behave differently depending on the composition of the growth
medium22. Whole-cell screening can deliver many hits, but several of
these may work via non-specific mechanisms (such as detergent effects)
and have cytotoxic effects. As such, the key in a whole-cell-screening
campaign is to identify the ‘quality hits’ by certain counter-screening
assays (for example, cytotoxicity across several cell lines, monitoring
non-specific membrane leakage, analysing red-blood-cell haemolysis),
so as to account for good selectivity and specificity.
The recent success with the whole-cell-screening approach is particularly
exemplified by the identification of new TB drug candidates such as dia-
rylquinolines (TMC207), which target ATP synthesis, and benzothiazines
(BTZ043), which target essential cell-wall arabinan synthesis23–25. An
interesting feature of both these molecules is that they target membrane-
associated proteins that may be more easily accessible to drugs from the
periplasmic space (that is, the target binding sites are exposed to the
periplasm) and this to some extent may overcome certain issues of myco-
bacterial membrane permeability.
Interestingly, more refined multi-target ‘pathway’ screens can be
initiated to search for inhibitors blocking validated metabolic or signalling
pathways. In this regard, respiratory membrane vesicles of M. tuberculosis,
which have been grown in a variety of conditions in order to simulate the
host microenvironment, can be used to screen drug classes or analogues
inhibiting respiratory chain components (Fig. 3). For example, such a
pathway screen could monitor a drug’s influence on diverse mycobacterial
respiratory chain functions such as ATP synthesis, redox homeostasis and
proton gradients26. Modulating external growth stimuli, such as the car-
bon source, micronutrients, or oxygen levels in such an assay, results in
target respiratory proteomes that can be used to screen against functions
essential during those metabolic states. For instance, ATP synthase is
highly downregulated during hypoxic conditions, and its inhibition by






































































































Figure 2 | A bull’s-eye representation of the
current clinical pipeline for TB. Each drug
candidate is shown with its current clinical phase of
development along with the target family. TMC207
is in phase IIb trials for MDR-TB and in phase IIa
trials for DS-TB. The structure of AZD-5847 has
not been disclosed. NDA, new drug application (for
regulatory approval).
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Oxazolidinones are one of the novel classes of antibacterial drugs which target the protein 
synthesis. They bind to 23S rRNA of the 50S ribosomal subunit of the bacteria (Arias et. 
al.,2008) (figure 1.14). There are three drugs in this category which have been approved by the 
FDA: linezolid, Sutezolid (PNU-100480) and AZD5847. Linezolid was approved by the FDA 
in 2000 and although it is very effective against MDR-TB and XDR-TB, it has a lot of side 
effects and toxicity (Sbardella et. al.,2004; Lee et. al., 2012).  
A safer drug, Sutezolid (PNU-100480), shows higher efficacy when used in combination either 
with SQ-109 or in combination with moxifloxacin and pyrazinamide is very effective against 
the MDR strain (Williams et. al., 2009; Reddy et. al., 2012) (figure 1.13). AZD5847 also has a 
strong bactericidal activity and also targets the 50S ribosomal RNA. Both these drugs are under 




Benzothiazinones are a new class of drugs, highly potent against MDR and XDR-TB. The drug 
affects an essential enzyme decaprenyl phosphoryl-β-D-ribose 2¢ epimerase encoded of dprE1 
gene. The enzyme is a major player in the synthesis of arabinogalactan. Inhibition of this 
essential enzyme causes cell lysis and cell wall damage ( Makarov et. al., 2009; Lechartier et. 
al., 2012). 
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Figure 1.14: Modes of action of the potential new antitubercular drugs. The figure 
elucidates the various modes of actions of drugs currently in phase 2 and 3 of clinical trials 




A new class of flouroquinolones are currently in phase III clinical trials (Ma et. al., 2010). 
Gatifloxacin and moxifloxacin are being studied to be used as a combinatorial therapy with first 
line drugs in the TB regimen (Ahmad et. al., 2011; Engohang-Ndong, 2012) (figure 1.13). Their 
basic mode of action is through inhibition of the protein synthesis machinery chiefly by 
interacting with DNA gyrase (Jawed Ahsan et. al., 2015) (figure 1.14). Although these drugs 
reached phase III clinical trials neither seem to be particularly potent in converting sputum, 
reducing bacterial load or preventing morbidity when compared to exisiting mycobacterial 
drugs (Ruan et. al., 2016; Anthony T Podany, 2016). 
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Fig. (1). Mode of action of the antitubercular agents currently in Phase 2/3 clinical trials. 
 
Table 4. Development of antitubercular agents from old drug classes. 





















































































































5. MOLECULAR ENGINEERING 
 The molecular modification, a chemical alteration in a 
molecule (lead or drug), is an important tool for medicinal 
chemist to alter the pharmaceutical, pharmacokinetic, and 
pharmacodynamics properties. The compound SQ109 was 
developed by the molecular hybridization of isoprenyl units, 
ethambutol pharmacophore, and adamantane moiety. The 
nitroimidazole analogues TBA-354, PA-824, and OPC-67683 
were designed by molecular hybridization using nitroimida-
zole scaffold, which in turn was repurposed  as antitubercu-
lar agent currently in Phase II studies. DC-159a, gatiflox-
acin, and moxifloxacin were derivatized scaffolds from the 
parent nalidixic acid using bioisosterism as molecular modi-
fication. The oxazolidinone derivatives PNU-100480 and 
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1.7 High throughput screening (HTS) strategies for tuberculosis 
drug discovery 
 
The development of MDR and subsequent rapid succession to both XDR and XXDR/TDR 
strains of Mtb has rendered the current drug regimen ineffectual. A good screening strategy, 
discovery of newer drugs and identification of the mode of action would help in developing 
better treatment regimens and determining bacterial pathways more clearly. 
 
Figure 1.15: A flowchart representing drug discovery strategies describing the drug 
development from drug to target and from target to drug. The two strategies overlap at a 
level for in vivo studies. HTS – High throughput screening (Sala and Hartkoorn, 2011). 
There are predominantly two strategies undertaken for performing drug screens in the drug 
discovery process: one type of assay is target specific while the other is a whole cell screening 
assay. Both are implemented against compound or inhibitor libraries and performing mode of 
action studies with the latter leads to the discovery of the target (Sala and Hartkoorn, 2011) 
(figure 1.15). Phenotyping screening strategies have improved and branched out to utilise 
indicators to scale up screens to make them high throughput. Although they provided kinetic 
Future Microbiol. (2011) 6(6)618 future science group
discovery, focusing on the two main discovery 
routes: the drug-to-target and the target-to-
drug approaches (FIGURE 1). The needs, advan-
tages, drawbacks and results of both strategies 
are also discussed.
Most recent advances in TB 
drug discovery
In recent years there has been consider-
able progress in identifying and developing 
novel anti-M. tuberculosis agents. While all of 
them were discovered by whole-cell screening 
approaches, several of these leads target new 
pathways or enzymes, thus providing encour-
agement for the TB drug discovery field. Some 
of these compounds (summarized in TABLE 1 a d 
recently reviewed by Shi and Sugawara [9]) are 
now in various phases of clinical trials and are 
describe  in the following paragraphs. 
Diarylquinolines
Whole-cell scree ing against M. tuberculosis 
led to the development and optimization of a 
series of novel diarylquinolines, whose leads 
are R207910 or TMC207 [10]. The compounds 
are characterized by a low MIC (30–60 ng/ml 
in vitro), activity restricted to mycobacteria and 
efficacy against mono- and multi-drug-resistant 
M. tuberculosis strains [10]. This lack of cross-
resistance with other anti-TB drugs suggested a 
new mechanism of action, which was found to 
be inhibition of ATP synthase. Indeed, genetic, 
biochemical and binding assays demonstrated 
that AtpE, a component of this multisubunit 
enzyme, is the target [10,11], although a recent 
report showed that more than 70% of resistant 
mutants carried no mutations in the ATP syn-
thase genes [12], thus implying alternative mecha-
nisms of resistance. Interestingly, TMC207 dis-
played activity against dormant bacteria in two 
persistence models [13–15]. In vivo studies with 
TMC207 as monotherapy or combination ther-
apy were carried ut in mic  and i  guinea pigs 
and revealed that the bacterial burden can be 
significantly reduced in both chronic and acute 
TB-infection models [10,16,17]. Interestingly, the 
few acid-fast bacilli remaining after TMC207 
treatment in guinea pigs were found to be 
Potential anti-TB 
compound





























In silico drug design
and fragment-based
screening
Figure 1. Synopsis of TB drug discovery programs. The figure illustrates the two main approaches to TB drug development: from 
drug to target and from target to drug. Targets identified in the drug-based procedure can enter the target-based protocol. The two 
strategies overlap at the end with further development and in  vivo  studies.
HTS: High-throughput screening. 
Review Sala & Hartkoorn
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data in a high biocontainment level, BACTEC based radiometric assays proved to be more 
expensive and less adaptable to high throughput strategies than alamar blue susceptibility tests 
(MABA) (Collins and Franzblau, 1997). Luminescence based assays have been proactively 
used and have now been adapted to screen antimicrobials against non-replicating (NRP) 
bacteria either under the influence of a selectable promoter such as acetamidase (Cho et. al., 
2007) or a constitutive promoter such as for heat shock proteins (Cooksey et. al., 1993). 
Phenotypic screens are also improvised to mimic physiological challenges that bacteria 
experience such as nutrient starvation, hypoxia and non-replicating states which cause the 
bacteria to be tolerant to the antimicrobials and prolong treatment duration accordingly. Assays 
adopted for hypoxia involve the application of the Wayne model of hypoxia and dormancy 
(Wayne and Hayes, 1996) and can be combined with indicators of cell physiology such as ATP 
depletion (Mak et. al., 2012) or luciferase activity under the influence of an anhydrotetracycline 
inducible promoter (Grant et. al., 2013) to screen antimicrobials or chemical compounds against 
the bacteria. Models for starvation were designed to mimic the in vivo conditions the bacteria 
encounter during infection and involve reducing the available nutrients in growth media, 
typically containing a minimal salt media without additional supplements like Middlebrook 
OADC/ADC. The Middlebrook 7H9 medium is used with a detergent to reduce clumping of 
the bacteria, one such approach used tylaxopol in combination with the media to screen 
compounds and read the assays using luciferase or the expression of green fluorescent protein 
(Pethe et. al., 2010; Grant et. al., 2013). Cell based kinetic assays have been designed to be 
combined with high content screening to understand infection in vivo and effectiveness of 
antimicrobials on infected mammalian cells. A real time electronic sensing (RT-CES) was 
designed with E-plates that contained gold microelectrodes at the bottom of the wells in assay 
plates which generated an electric field in the presence of media. This electric field is disrupted 
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with the growth of cells and the kinetic curves vary depending on cell type, morphology and 
adherence characteristics to give a time dependent cell response profile (TDCRPs) (Abassi et. 
al., 2009). Another assay was designed using macrophage cell lines (RAW264.7) infected with 
green fluorescence protein expressing Mtb and automated high content microscopy to screen 
compounds that are active against intracellular bacteria (Christophe et. al., 2009). 
Target based screening assays generally involve screening drugs against validated drug targets 
which are mainly essential enzymes involved in cell wall biosynthesis, shikimate pathway, 
folate pathways and other physiologically important processes. The issue with target-based 
discovery is the validation of targets and the understanding of the role of the target in vivo 
versus in vitro. Assays designed to screen validated targets involve biochemical assays often 
using enzyme couples, for example some assays used an enzyme couple to screen 
dihyrdrofolate reductase (DHFR) inhibitors comprised of NADH, which in the presence of an 
active enzyme and substrate (dihydrofolate) produced trihydrofolate (THF) and a NADP+ 
molecule (Kumar et. al., 2012). The presence of an active DHFR enzyme can be measured by 
the NADP+ accumulation at absorbance at 340nm and when the enzyme is inhibited in the 
presence of antimicrobials the addition of resazurin leads to the formation of resorfin (emission 
at 590nm) due to the excess NADPH in the assay mix (Kumar et. al., 2012). New target based 
assays have been designed utilizing chromatographic principles to understand ligand-enzyme 
interactions. Ultrafitration-liquid chromatography/mass spectrometry (UF-LC/MS) has been 
used to allow interaction of the ligand and enzyme through LC and then the complex is analysed 
by MS while the UF element helps with the separation of the complex and unused ligand. This 
process has been tested to screen inhibitors against shikimate kinase an enzyme involve in the 
shikimate biosynthesis process (Mulabagal and Calderón, 2010). For targets that are difficult 
to approach, fragment based approaches have been undertaken to identify inhibitors based on 
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target substrates. The targets are screened spectroscopically for activity against analogues of 
substrates and then the most potent substrate molecules are modified with pharmacophores to 
get a custom designed inhibitor (Matthew B Soellner et. al., 2007).  
Due to the success of phenotypic screening for tuberculosis drug discovery over target based 
screening, the recent advances have combined these two approaches. Target based whole cell 
screening approaches have been implemented to screen targets in a whole cell by generating 
mutant strains for these targets involving either underexpressing or overexpressing the target in 
a whole cell in the presence of an inducible promoter. The strains underexpressing the targets 
are hypersensitive to the inhibitors which inhibit the target gene while overexpressing strains 
are resistant to the inhibitors (Abrahams et. al., 2012). Along with these two major approaches, 
virtual screening of inhibitors directed towards specific targets is another way of looking for 
potential drugs. In silico screening for drugs against targets involve software which can perform 
structural matching, docking of the inhibitor molecule on target structures and deciphering 
affinity of the binding between the inhibitor and the target molecule (Segura-Cabrera and 
Rodríguez-Pérez, 2008; Jadaun et. al., 2015).  
Although drug screening and discovery efforts are being made for tuberculosis treatment and 
overcoming the treatment failure issues due to resistance, it is important to be aware of the 
failures of drug discovery and the reasons for it. It is imperative that there is an awareness 
among researchers involved in drug discovery regarding the false positive inhibitors which are 
misleadingly highlighted as potential drugs due to their ability to interfere with assay signalling, 
formation of aggregates and reactivity towards protein molecules (Baell and Holloway, 2010). 
Identifying Pan Assay Interference compounds (PAINs), which comprise 5-12% of a 
compound library in academia and are found repeatedly in different assay settings, is vital. 
These compounds form artefacts which may mislead researchers towards considering the 
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inhibitors as positives due to their molecular properties such as the fluorescent nature of the 
compound, its ability to coat proteins and sequester the metal ions in an assay. A lot of these 
compounds also act as chemical moieties releasing hydrogen peroxide which kill the cells and 
can seem to be a potent inhibitor (Baell and Walters, 2014). It is therefore useful to have a 
counteractive methodology by understanding the common structures depicted by the PAINs 
molecules. Approximately 400 structural classes form these molecules and using tools and 
filters to understand the structural basis of the inhibitors and diversity metric of the molecules 
can help to identify the inhibitors that seem like prospective drugs (Ekins et. al., 2014; Baell 
and Walters, 2014). Another key aspect to bear in mind when screening for drug like 
compounds is using Lipinski’s rule of five which defines the criteria to consider which 
compounds or chemical molecules lead to a high possibility of good inhibitors. These mainly 
involve the physiochemical properties of the compound wherein the molecules with a molecular 
weight of less than 500, log P (partition coefficient to measure solubility) value of less than 5, 
less than 5 donor hydrogen bonds and less than 10 acceptor hydrogen bonds have a high 
possibility of making a good drug. However, this list of physiochemical characteristics does not 
guarantee a strong drug like compound it increases the likelihood of a successful positive 
outcome (Lipinski, 2004). Awareness of the pitfalls of the current drug discovery strategies and 
a keen eye for false positive results can reduce the high iteration rate in the tuberculosis drug 





Aims and Objectives 
 
There is an imminent requirement to develop and discover new drugs to treat tuberculosis due 
to the development of resistance against the current antitubercular drugs.  
This thesis can be divided into three major objectives: 
1. Using a high throughput screening platform, the screening of the Prestwick FDA library 
will be implemented against both slow and fast-growing strains of mycobacteria, M. 
bovis BCG and M. smegmatis respectively. Compounds will be evaluated for potency 
by minimum inhibitory concentration (MIC) determination. Preliminary mode of action 
studies will be undertaken by the generation of spontaneous resistant mutants with 
subsequent whole genome sequencing. 
2. A comprehensive mode of action decovolution study of florfenicol (a hit emerging from 
aim 1) will be undertaken. This will involve both genetic and biochemical investigation 
of the function of the target within the mycobacteria and its essentiality will be tested. 
3. To perform a target based phenotypic screening of the GSK177 box set (Ballell et. al., 
2013) against Mtb-PrsA, a well validated target. The inhibitors will be screened using a 
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2. Screening the FDA approved library against 
mycobacteria 
 
2.1 Introduction  
 
All the front line drugs used to treat tuberculosis were discovered through a drug to target based 
approach using phenotypic screening of drugs against mycobacteria, where the study of the 
inhibitory activity of the drug was followed by target deconvolution (Konno et. al., 1967; 
Mitchison, 1979; Crofton and Mitchison, 1948; Bernstein et. al., 1952; Ramaswamy and 
Musser, 1998; Maiga et. al., 2012). Phenotypic assays are more beneficial over target based 
assays as they are helpful in identifying compounds which show activity against whole cells 
bypassing permeability issues and generating lead compounds for further optimisation 
simultaneously giving us tools for finding newer drug targets (Ballell et. al., 2013; Brown, 
2007). This method has proved more useful in terms of generating lead compounds, which are 
currently under clinical trials or have been approved for use by the FDA such as bedaquiline, 
benzothiazinone (BTZ), nitroimidazole such as PA-824 and OPC-67683 (also known as 
Delaminid), diamine SQ-109 (Stover et. al., 2000; Protopopova et. al., 2005; Matsumoto et. al., 
2006; Makarov et. al., 2009). Delaminid and nitroimidazole PA-824 also known as Pretomanid 
are prodrugs that inhibit mycobacterial F-420 dependant nitroreductase mediated activation 
releasing nitric oxide which causes a pleiotropic effect, killing the bacterium (Evangelopoulos 
et. al., 2015; Manjunatha et. al., 2009). 
Bedaquiline or TMC 207 was another important drug discovered through a screen against M. 
smegmatis using a corporate collection screen at Tibotec. The compound then underwent 
further medicinal chemistry iterations (Andries et. al., 2005). It has been recently approved by 
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the FDA after 16 years of going through the drug pipeline to be used for MDR-TB treatment 
only due to the toxicity issues with the drug (Mikušová and Ekins, 2017; Cooper, 2013; Mdluli 
et. al., 2014; Lechartier et. al., 2014). BTZ was detected from a phenotypic screen through the 
NM4TB programme while 2- aminothiazole-4-carboxylases also known as ATC were 
identified from the TBD-UK consortium (Al-Balas et. al., 2009). BTZs are a class of sulphur 
containing heterocyclic drugs which inhibit mycobacteria by targeting the DprE1 protein which 
is involved in the cell wall synthesis (Mikušová and Ekins, 2017). The disadvantages of whole 
cell screening is mainly issues with target identification of ‘active’ compounds which creates a 
bottleneck with taking the compound forward as a ‘lead’ for clinical trials (Mdluli et. al., 2014). 
  
2.1.2 Drug repurposing 
 
In recent years, even though we have antibiotics available to treat most infections, there are 
diseases which are causing substantial levels of morbidity and mortality due to factors including 
resistance, socio-economic factors etc. Although we need to develop new antibiotics against a 
plethora of organisms, the cost estimated to bring a new drug to market is approximately 800 
million euros. This includes approximately 10 years of research and development and clinical 
trials. There have been very few drugs which have come into the market since the mid-1980s 
especially ones with a unique mechanism of action (Vicente et. al., 2006). For example, 
Bedaquiline is the first drug in 40 years to have been approved after the approval of Rifampicin 
in 1967 (Mikušová and Ekins, 2017). Most drugs from the 1980s were screened from natural 
products and have been improvised on structurally ever since (Vicente et. al., 2006). There is 
now a need for alternate strategies for discovering and developing new drugs (Vicente et. al., 
2006). There are several new ways in which new antimicrobials for bacteria can be discovered 
and developed, these include finding new targets and processes, blocking multidrug efflux 
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channels and using alternative methods such as bacteriophages. Repurposing existing drugs is 
an expedient option because in theory these drugs do not require toxicity profiling, hit to lead 
optimisations and in vivo metabolic studies. In addition to that, it has been known that drugs 
used to treat one specific condition or disease interact with other targets which can be an 
assortment of enzymes, transport channels or myriad cellular components causing secondary 
biological consequences (Maitra et. al., 2015). Sildenafil by Pfizer is one of the best examples 
of repurposing, as the drug was initially designed for hypertension but had a secondary effect 
of inhibiting the phosphodiesterases in humans. The result being that the drug is now used for 
patients with erectile dysfunction (Moreland et. al., 1998). Based on the results from the mouse 
model studies it has recently been advocated to be used as an adjuvant host directed therapy in 
order to shorten treatment time in patients with TB. Another example of repurposing is 
Thalidomide, which is prescribed for leprosy and meningitis albeit judiciously due to its 
teratogenic effects on unborn babies. The drug is currently being progressed to treat meningitis 
symptoms in children caused due to tuberculosis (Maiga et. al., 2012).  
 It has been suggested that certain classes of drugs already approved by the FDA have 
antimicrobial properties. Certain classes of anti-cancer drugs and gallium containing 
compounds have been proven to have anti-microbial properties, possibly due to the similarities 
between certain cancer cells and bacterial cells (Rangel-Vega et. al., 2015). Gallium 
compounds are known to have anti-mycobacterial properties as well as being toxic to certain 
other classes of bacteria. 5-fluorouracil is another drug, which has antibacterial, anti-biofilm 
properties and acts as a virulence inhibitor to many gram-negative bacilli. It inhibits ribosome 
and protein synthesis in the bacteria which are mainly deprived of magnesium ions (Rangel-
Vega et. al., 2015). The above examples prove that repurposing drugs could be an alternative 
to screening against compound libraries using a reliable screening assay. 
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2.1.2 Phenotypic drug screening strategy 
 
Earlier screening of antibiotics was carried out using whole cell-based assays, which were 
performed manually and therefore had to be optimised individually (Singh et. al., 2011). The 
process of drug screening has become more efficient and less time consuming due to the 
development of assay/ micro well plates with 96, 348 and 1536 wells in terms of the number of 
antibiotics/ compounds screened at a time. The advent of automated liquid handling systems 
helped by improving the speed and accuracy of screening assays by reducing any discrepancies 
caused by manual handling (Singh et. al., 2011). Assays designed to screen out compounds 
were mainly based on cell density using optical density (O.D) of cell cultures as a parameter to 
decide the effectiveness of a compound/ antibiotic. But O.D based assays had their own 
drawbacks primarily variability in cell number and growth rate of cells. In order to get a more 
reliable assay the use of redox dyes such as alamar blue or tetrazolium were employed which 
used molecular conversion in ATP, FAD and NADH to determine cell activity level (Singh et. 
al., 2011, Collins et. al., 1998).  Unfortunately, use of redox dyes (even though much reliable 
than optical density based assays) could cause possible physiological changes in the cell when 
mixed in and incubated (Singh et. al., 2011) and is not very useful to perform kinetic assays or 
real time monitoring (Collins et. al., 1998). Colony forming unit (cfu) based assays are 
challenging for mycobacterial screening due to slow cell growth (Singh et. al.,2013) and it is 
difficult to handle Mtb for screening as it requires a BSL-3 facility. But in order to overcome 
that, most primary screens use model organisms from the mycobacterial species such as 
Mycobacterium bovis, Mycobacterium smegmatis and the weakened vaccine strain 
Mycobacterium bovis BCG. Nowadays, fluorescence assays utilising either green fluorescence 
protein (GFP) (Christophe et. al.2009) or resazurin dyes (Kumar et. al., 2012) are frequently 
used to do kinetic and end point assays respectively. Around 20,000 molecules were screened 
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in the Broad institute against inhibitors targeting DprE1 (enzyme involved in cell wall 
synthesis) and Mmpl3 (a mycobacterial cell membrane protein large 3) using GFP fluorescence 
as a reporter in the assay (Stanley et. al., 2012). Therefore, an optimised and validated assay 
utilizing fluorescent proteins produced by the bacillus could give real time results of 
antitubercular activity as well as decreasing the risk of interaction with other dyes and reagents 
at the same time, which would not influence the physiology of the bacillus.  
Figure 2.1: A flowchart depicting the whole cell screening strategy employed in this 
chapter. The top funnel represents the preliminary screen of the Prestwick library, the subsequent 
funnels represent the filtering of the hits through a shortlisting procedure and then MIC studies moving 
towards target deconvolution through generation of spontaneous resistant mutants.  
 
In this study, we have performed a drug screen using a library of FDA approved drugs against 
GFP expressing strains of fast and slow growing mycobacteria based on the drug to target 
approach of drug discovery. The strategy involved preliminary screening of the drugs against 
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both the mycobacterial strains and then filtering down the hits based on various criteria in order 
to deconvolute the mode of actions of the drugs (figure 2.1). 
 
2.2 Results  
 
2.2.1 Primary screening of the Prestwick library against M. 
smegmatis_pSMT3_eGFP and M. bovis BCG_pSMT3_eGFP 
 
The 1200 FDA approved drugs in the Prestwick library were screened against the GFP 
expressing strain of M. smegmatis and M. bovis BCG (Section 6.11.1). The data generated from 
these screens were then normalised against the positive and negative controls to produce a 
scatter graph of the survival percentages for every drug on each plate for both the mycobacterial 
species (figure 2.2).  
 
Figure 2.2: The cumulative percentage survival values observed during the whole cell 
screening of the Prestwick library. The graph represents the scatter graph of average 
percentage survivals from a duplicate data set for M. smegmatis_pSMT3_eGFP (A) and M. 
bovis BCG_pSMT3_eGFP (B) when screened against the Prestwick library.  
 
The initial screen against M. smegmatis generated 133 hits which inhibited the survival of this 
fast-growing species of mycobacterium below 50% (appendix 3). As observed in the scatter 
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graphs (figure 2.2) representing the cumulative survival percentages of each strain for all the 
drugs in the library, there were some drugs specially the ones screened against M. smegmatis 
that depict very high survival percentages. (appendix 1). This was potentially caused due to the 
growth rate of this fast-growing mycobacterial strain and some artefacts observed in the 
controls during plate incubation and cross contamination due to condensation of some of the 
wells. The drugs showing such high survival percentages were discounted as the cut off window 
was set to 50% survival.  
The screen against the GFP producing slow growing mycobacterial strain M. bovis BCG 
revealed 138 hits (appendix 3) which inhibited the growth of the bacteria below 50% (figure 
2.2). 
 
2.2.2 Analysis of correlation  
 
The preliminary screens performed for both the fast and slow growing mycobacterial strains 
were performed in duplicates (Section 2.2.1). screen a correlation analysis was performed in 
order to determine the coefficient of correlation for individual plates for both strains. 
It was observed that the coefficient of correlation values ranged from 0.53 to 0.86 (appendix 4) 
representing a positive correlation between both sets of the screen against M. smegmatis. When 
the data was plotted as a cumulative the overall correlation observed was 0.64 as an average 
which relates to 60% positive correlation of the data from the preliminary screen against M. 
smegmatis (figure 2.3).  
 




Figure 2.3: A correlation analysis of the whole cell screen against the Prestwick library. 
Scatter graphs representing correlation analysis of the cumulative data of the average 
percentage survivals between plate A and B (duplicates) during the preliminary screen of the 
Prestwick library against M. smegmatis pSMT3_eGFP (A) and M. bovis BCG_pSMT3_eGFP 
(B). 
 
In order to understand the variability in the data and significance of the hits retrieved from the  
The coefficient of correlation values ranged from 0.54 to 0.98 (appendix 5) for the screen 
performed against M. bovis BCG leading to a very high positive correlation between the 
screens. The cumulative correlation for M. bovis BCG was 0.89 leading to 89% positive 
correlation of the replicate data sets (figure 2.3).  
A significant correlation between each replicate was therefore observed for both screens 
performed, which verified the validity and reproducibility of the screens against both strains.   
 
2.2.3 Comparative analysis of the hit frequency based on the preliminary hits 
between M. smegmatis and M. bovis BCG  
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In order to understand the variation between the two strains of mycobacteria and the frequency 
of hits between them a comparative analysis was performed (figure 2.4). It was seen that the 
majority of the drugs had a survival percentage of 100%, which is valid as there were a high 
number of drugs that did not inhibit the growth of mycobacteria during the preliminary screen. 
It was also noted that there were some drugs with frequency ranging from 1 to 25 that had 
survival percentages higher than 100%. This was observed during the initial analysis of the 
preliminary screening data as mentioned in section 2.2.1. The frequency data verifies that the  
 
Figure 2.4: Hit frequency distribution of the whole cell screening against the Prestwick 
library. The bar graph represents the frequency distribution of the hits observed during the 
preliminary screen of M. smegmatis_pSMT3_eGFP (A) and M. bovis BCG_pSMT3_eGFP (B) 
against the Prestwick library.  
 
outliers were in low numbers and were caused due to experimental conditions but not to the 
extent to discount the overall results obtained from the screens. 
The cut off survival percentage for a drug to be considered as a “hit” was set to a percentage 
survival of 50%. It was observed that in case of the fast-growing strain of mycobacteria, M. 
smegmatis had a higher frequency of hits that had survival percentages ranging from 0-20% 
while in case of the slow growing strain M. bovis BCG the hits were mainly clustered in the 
















Range of percentage survival






















































Range of percentage survival
Hit Frequency for M. smegmatis
A B





Figure 2.5: A comparative frequency distribution of the hit frequency distribution 
observed from the whole cell screen against the Prestwick library. The bar graph represents 
the comparative frequency distribution of the hits observed during the preliminary screen of M. 
smegmatis_pSMT3_eGFP (A) and M. bovis BCG_pSMT3_eGFP (B) against the Prestwick 
library.  
 
It was also observed that in the survival percentage ranges of 10-14% and 30-34% the frequency 
of hits for both these strains was identical (figure 2.5).  
The comparative analysis of the hits gave a general idea as to what category of drugs inhibits 
each strain and to what extent. A detailed analysis based on chemical properties of the drugs 
and literature based evidence for antimycobacterial activity was then performed for all the hits 
in order to shortlist a set of potentially useful drugs perform mode of action studies. 
 
2.2.4 Z` analysis of the whole cell screen against the Prestwick library 
  
As mentioned in Section 6.11.4, Z` factor analysis of the screen has been described and it 
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smegmatis vary between different plates to a greater extent within the drug set (figure 2.6). The 
plates qualify for a robust screen as most of them have a value greater than 0.5. Those with the 
lower Z factor values were caused due to artefacts created in the plates during incubation and 
cross contamination due to condensation. This probably explains some of the variation 
observed. In case of the primary screen for M. bovis BCG, the Z` factor values are consistent 
and very robust, all of them being above 0.5 with some close to the ideal value of 1. The Z` 
factor was improved due to change in incubation strategy and plate handling during that period 
(figure 2.6).  
 
Figure 2.6: Z`analysis of the whole cell screen against the Prestwick library. A scatter graph 
representing the Z`-factor values for each plate in the Prestwick library screened against both 
M. smegmatis_pSMT3_eGFP and M. bovis BCG_pSMT3_eGFP. 
 
Overall, based on the previous correlation analysis (section 2.2.2) and the Z` factor values 
observed for each the plate, the screens have produced reliable outcomes which were further 
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2.2.5 Distribution of the preliminary hits 
 
While classifying the hits observed during the preliminary drug screen against both the fast and 
slow growing strains of mycobacteria, a clear majority of hits were antimicrobials. These were 
then further sub divided into various classes to give a deeper understanding of the types of 
antimicrobials inhibiting the two strains.  
Amongst the 28 hits observed within the 10-14% survival percentage range for both strains in 
section 2.2.3, there were eight drugs which were common between the strains, while in the 30-
34% range they only have one drug in common. The common drugs were chlortetracycline, 
clarithromycin, rifapentine, rifamixin, vancomycin, pentamidine, tylosin, moxifloxacin and 
carbadox. All of these drugs are antibiotics of which some have known antitubercular activity.  
Chlortetracycline is a tetracycline derivative used as broad spectrum antibiotic in veterinary 
medicine (Lewis, 2013). Although it hasn’t been reported to be effective against a 
mycobacterial infection as it shares its chemical structure with tetracycline, which is an 
antimycobacterial drug, it would therefore be expected to have some inhibitory activity against 
mycobacteria. Rifapentine is a known antimycobacterial drug used to treat pulmonary 
tuberculosis (Munsiff et. al., 2006). It has also been used in conjunction with isoniazid to treat 
latent tuberculosis and HIV positive patients having tuberculosis (Sterling et. al., 2011; 2016). 
Rifamixin is an antibiotic based on rifamycin and is known to inhibit both gram negative and 
gram positive bacteria. It also kills mycobacteria in vitro but due to the low absorption 
properties of the drug, it is ineffective in vivo (Soro et. al., 1997). Another antibiotic which 
inhibits both the strains is clarithromycin, it is an antibiotic commonly used to treat pneumonia 
and throat infections. It was initially reported to have a synergistic effect on rifampicin during 
inhibition of Mtb (Luna-Herrera et. al., 1995) but was later discovered to have a bacteriostatic 
effect and not provide any additional inhibitory effects to rifampicin (Almeida et. al., 2011). 
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Moxifloxacin on the other hand, which is a fluoroquinolone antibiotic, has been proven to clear 
mycobacterial infections and help in culture conversion (Gillespie, 2016) and has been enrolled 
to be considered for a TB Alliance phase III clinical trial after successfully treating human 
patients with pulmonary tuberculosis (Maitra et. al., 2015). Vancomycin is a well-known 
antibiotic used for treating symptoms caused by methicillin resistant Staphylococcus aureus 
infections (Griffith, 1981) but has not been reported to have any antimycobacterial activity. 
Two other drugs mentioned earlier have no known antimycobacterial activity. These are, tylosin 
which is a veterinary antibiotic used as a bacteriostat in animal feed (Books, LLCGeneral Books 
LLC, 2010) and carbadox, which is used to treat swine dysentery (Carbadox, 2014) and has 
been known to cause phage mediated gene transfer in Salmonella, Shiga toxin production in 
Shiga toxin-producing Escherichia coli and antibiotic resistant gene transfer in Brachyspira 
hyodysenteriae (Bearson et. al., 2014). Among the aforementioned drugs the one that was of 
interest based on the literature search was Pentamidine, an antimicrobial used in the treatment 
of parasitic infections (Dorlo and Kager, 2008) Its mechanism of action is not completely 
understood but it involves the inhibition of topoisomerase II causing damage to the organism 
(Singh and Dey, 2007). 
 There was an indication of some of the classes affecting one type of strain more than the other. 
It was noticed that the aminoglycosides and antifungal drugs were prominently inhibiting M. 
smegmatis than M. bovis BCG (figure 2.7 A and B). Antifungal drugs mostly comprising of 
azoles are known to inhibit mycobacteria by interacting with the cytochrome P450; this has 
been specifically proven in M. smegmatis (Jackson et. al., 2000a; Warrilow et. al., 2009) while 
the susceptibility of M. smegmatis to aminoglycosides has been dependant on the presence of 
the aminoglycoside transferase gene. This gene has been shown to be present in all 
mycobacterial species and is responsible for resistance against aminoglycosides although the 
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sequence identity is variable among different species (Aínsa et. al., 1997) which might be the 
cause of the variation in inhibition observed between the two species. A higher number of 
aminoglycosides seem to inhibit the M. smegmatis strain, this might be due to the higher efflux 
pump activity in M. bovis BCG (Li et. al., 2004) in addition to the sequence variation in the 
aminoglycoside transferase gene mentioned earlier.  
It was also observed that a higher number of drugs from the beta-lactam category inhibited M. 
bovis BCG as opposed to M. smegmatis (figure 2.7B). Mtb is known to be intrinsically resistant 
to beta-lactam due to its ability to produce the beta-lactamase enzyme BlaC (Chambers et. al., 
1995; Flores, 2005). Although, imipenem a beta-lactam antibiotic has been used to treat patients 
with MDR-TB successfully and meropenem, another antibiotic belonging to this class, has been 
known to have synergistic antitubercular effects (Chambers et. al., 2005; Diacon et. al., 2016). 
Meropenem-clavulanic acid has been proven to reduce the bacterial load in vivo. Amoxicillin-
clavulanic acid has been listed as a third line treatment without known efficiency by the WHO 
(Diacon et. al., 2016). The drugs mentioned here have shown activity against M. bovis BCG 
and some against M. smegmatis. This proves that the drugs within this class have activity 
against mycobacteria, not all of which have been explored in detail.  
Cephalosporins is another class of drugs which inhibit M. bovis BCG more than M. smegmatis 
(figure 22B). In a recent screen against 600 commercially available drugs from the Sweet 
library, it was shown that cephalospoins had a high synergy with rifampicin although that was 
not particularly the case when tested with rifapentine and rifabutin. Cephalosporins also show 
synergies with the recently approved anti-TB drugs bedaquiline and delaminid (Ramón-García 
et. al., 2016). These orally bioavailable drugs have activity against non-replicating Mtb without 
causing any lethal effects to the mammalian cells or macrophages (Gold et. al., 2016; Ramón-
García et. al., 2016). Carbapenems, which are members of the beta lactam family, and 
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cephalosporins work by deactivating the L,D-transpeptidase responsible for the 3,3 crosslinking 
in the peptidoglycan and therefore affects the cell wall of the bacterium (Dubée et. al., 2012). 
 
Figure 2.7: A distribution and classification of the hits from the whole cell screen against 
the Prestwick library. A. Represents the different classes of drugs that inhibited the growth of 
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There were other interesting classes of drugs which inhibited the growth of mycobacteria in 
this in vitro screen such as antihistamines, calcium channel blockers, oestrogen modulators, 
anti-cancer drugs. The drugs from the preliminary screen were carefully evaluated and 
compared to compile a list of hits for further studies. 
 
2.2.6 Rationale for selection of hits  
 
The primary hits were shortlisted based on several factors such as physiochemical properties of 
the drug and the evidence of anti-mycobacterial activity of the drugs. Drugs which were 
formulated for use as topical creams or eye drops were not taken to the next stage of secondary 
studies in order to avoid bioavailability and solubility issues. Drugs which are currently being 
used for anti-TB treatment such as isoniazid, rifampicin, ethambutol, chloramphenicol, 
tetracycline, streptomycin and modified structural analogues of these drugs were not considered 
for further study.  
Drugs belonging to the antiseptic and disinfectant category, which are known to affect the 
bacterial membranes in various ways such oxidation of thiol groups by generation of free 
radicals, protein damage on the membranes, membrane leakage and disturbance of the cell 
homeostasis (McDonnell and Russell, 1999), were disregarded to avoid the study of dirty drugs 
which might not have a selective mode of action and may just be causing general damage to the 
cells leading to cell death.  
An extensive literature search was performed in order to find out if some of the hits already had 
known activity against mycobacteria and were then omitted from the shortlist. Antifungal drugs 
have been known to have inhibitory effects against mycobacteria as mentioned earlier and 
therefore were carefully researched and selected based on absence of any mode of action 
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evidence and known functionality. Some compounds containing heavy metals such as mercury 
(Thimerosol) were not studied due to possible implication of presence of heavy metal use in 
drugs. Other drugs that were taken off from further investigation were those with known activity 
in pulmonary or respiratory infections and steroidal hormones which had side effects. 
 
2.2.7 Determination of the minimum inhibitory concentration (MIC) in a liquid 
broth 
 
The liquid MIC concentrations were determined against M. smegmatis_pSMT3_eGFP and M. 
bovis BCG_pSMT3_eGFP as mentioned in section 6.11.2. In order to determine the MIC values 
a dose response curve was plotted on graph representing percentage survival against the long 
concentrations of the respective drug being tested (appendix 6).  
Among the drugs tested for M. smegmatis_pSMT3_eGFP the most potent drug was 
meclocycline sulfosalicylate with a liquid MIC of 0.1µM (table 2.1) and is a known broad 
spectrum antibacterial (Fritzler and Zhu, 2012). Other drugs tested for MIC determination were 
alexidine and chlorhexidine which both had low MIC values, 6.15µM and 1.98µM and are used 
as antimicrobials in dentistry (McDonnell and Russell, 1999). Estrogen receptor modulating 
drugs clomiphene citrate, raloxifen, toremifene, and tamoxifen citrate (Boostanfar et. al., 2001; 
Khovidhunkit and Shoback, 1999) had MIC values ranging from 9.03µM to 26.64µM (table 
2.1). GBR12909, a dopamine transport inhibitor (Andersen, 1989) has a liquid MIC of 26.48µM 
(table 1). Other drugs which were tested had very high liquid MIC values ranging from 77µM 
to greater than 8x106µM (table 2.1). Two of the drugs which were tested against M. 
smegmatis_pSMT3_eGFP; auranofin and ebselen had MIC values of 0.27µM and 18.5µM 
respectively. Both of these drugs were partially pursued further and will be discussed in detail. 
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Dose response studies against M. bovis BCG revealed thonzonium bromide as the drug with the 
lowest MIC value of 0.16µM (table 2.1). Thonzonium bromide is a quaternary ammonium 
compound which is used as a surface active agent (Chafetz et. al., 1986) and has been known 
to disrupt ATP dependant proton transport in vacuolar membranes along with alexidine 
dihydrochloride, which are responsible for pH regulation in yeast and Candida albicans causing 
growth defects (Chan et. al., 2012). It is also used to treat osteolytic diseases as it deters the 
formation of osteoclasts and has a protective effect in mice models (Zhu et. al., 2016).  
Florfenicol, a fluorinated analog of thiamphenicol with known broad spectrum activity against 
gram negative bacteria and strains which were resistant to chloramphenicol and thiamphenicol 
(Syriopoulou et. al., 1981), exhibited a MIC values of 0.67µM against M. bovis BCG (table 
2.1). The drug influences the microbiota of the intestine reducing the amount of uncultured 
bacterial species similar to Corynebacterium and Mycobacterium (He et. al., 2010). It shows in 
vitro potency against Actinobacillus pleuropneumoniae and Pasteurella multocida from pig 
isolates with higher potency in sample media containing animal serum (Dorey et. al., 2016). 
Another antibiotic called josamycin, which is a 16-membered macrolide with inhibitory activity 
against gram negative and positive bacteria (Arsic et. al., 2017), had a dose dependant activity 
against M. bovis BCG with a MIC of 0.1µM (appendix 2).  
Antihistamines were another class of drugs that had inhibitory activity against Mycobacterium 
bovis BCG during the preliminary screen, of which a few were selected to study further. Three 
antihistamines, namely astemizole, tripelennamine and olopatadine which, are H1 receptor 
antagonists used for allergies, asthma and rhinitis; and allergic conjunctivitis and rhinitis 
respectively (Tardioli et. al., 2012; Mah et. al., 2008; Pipkorn et. al., 2008), were examined for 
MIC values. Astemizole had the lowest MIC value of 17.8µM within the group followed by  
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tripelennamine with 41.9µM and olopatadine with the highest MIC value of 202.3µM in the 
group (appendix 2).  
 
Table 2.1: Liquid minimum inhibitory concentration of hits from the whole cell screen 
against the Prestwick library. The table lists the drugs selected for further study which were 
seen to have activity against M. smegmatis and M. bovis BCG based on the preliminary screen 
and their minimum inhibitory concentrations (MIC) in liquid media  
 
Antidiabetic drugs was another class of drugs that was analysed against M. bovis BCG. Among 
the class, glipizide and rosiglitazone were two drugs that showed an MIC value of 191.1µM 
and 43.15µM (table 2.1). Glipizide is a second-generation sulfonylurea drug that is prescribed 
for hypoglycaemia in type II diabetes. It is known to act by stimulating insulin production and 
correcting cellular lesions which occur during diabetes mellitus (McCaleb et. al., 1984; 
Pontiroli et. al., 1984; Riddle, 1999). Rosiglitazone, on the other hand, functions by activating 
peroxisome proliferator activated receptors in adipocytes and sensitising them to insulin 
Shortlisted Drugs (M. smegmatis)  Liquid MIC 
(µM) 
Shortlisted Drugs 
(M. bovis BCG)  
Liquid MIC 
(µM) 
Meclocyline sulfosalicylate 0.1013 Thonzonium  0.1586 
Auranofin 0.2681 Florfenciol 0.6746 
Chlorhexidine 1.948 Pentamidine 3.223 
Alexidine 6.147 Astemizole 17.78 
Clomiphene citrate 9.03 Pinaverium 28.29 
Ebselen 18.51 Josamycin 0.1011 
Raloxifene 22.1 Tripelennamine 41.87 
Toremifene 23.76 Rosiglitazone  43.15 
Tamoxifen citrate 26.48 Glipizide ~ 191.1 
GBR 12909 26.64 Olopatadine ~ 202.3 
Fendiline hydrochloride 77.57 Granisteron ~ 210.6 
Sulocitidil 87.22 Phenteramine ~ 37530 
Apomorphine 241.7   
Nisoldipine 396.2   
Sertraline 526.7   
Fluspirilene 8275000   
Chapter 2                                         Screening the FDA approved library against mycobacteria 
 
 66 
(Hwang et. al., 2011). Pinaverium, that inhibits L-type calcium channels stopping influx of the 
ions (Christen, 1990), had an MIC of 28.3µM. 
Two other drugs which depicted high MIC values were granisetron and phentermine. 
Granisetron an antiemetic drug which is an agonist to the 5-hydroxytryptamine-3 receptor 
which stimulates the vagus nerve responsible for reflex motility response (Navari et. al., 1994; 
Grundy et. al., 1994), had an MIC value of 210.6µM. Phentermine, which has been prescribed 
as an appetite suppressant to control obesity and acts as an agonist to the human TAAR1 (trace 
amine associate receptor 1), displayed a MIC of 37.5mM and was not tested further due to the 
high inhibitory concentrations.  
These drugs were then further tested for inhibitory concentrations on solid media to determine 
accurate concentrations for mode of action studies. 
 
2.2.8 Determination of the solid minimum inhibitory concentration (MIC) 
 
Inhibitory concentrations of selected drugs were tested in solid media as mentioned in section 
6.11.3. Drugs tested against M. smegmatis_pSMT3_eGFP presented a MIC ranging from 
0.2µM to 625µM (table 2.2).  
Some drugs were not tested in solid media, these were alexidine dihydrochloride, ebselen and 
fluspirilene. Fluspirelene had a high liquid MIC as mentioned in section 2.2.7 therefore it was 
not considered feasible to study it further. Alexidine dihydrochloride was discounted for further 
study due to its structural and functional similarity to chlorhexidine. Among the two drugs, 
alexidine had a higher liquid MIC and therefore was deemed to be less potent than 
chlorhexidine which had a solid MIC of 15.6µM (table 2.2).  
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Ebselen studies were ceased due to the mode of action deconvolution that was discovered by 
Favrot et. al., 2013. Ebselen is an organoselenium compound approved by the FDA with a 
well-known pharmacological profile and is being currently tested for use in case of bipolar 
disorders and strokes. It was shown that the drug has antimycobacterial properties and is also 
effective against multidrug resistant Staphylococcus aureus (MRSA) (Thangamani et. al., 
2015). In Mtb, the drug acts on the bacillus by covalently binding to a cysteine residue near the 
active site of antigen 85. Antigen 85 is a complex of secreted proteins which play an important 
role in the synthesis of trehalose dimycolates (TDM) and mycolylarabinogalactan (mAG) 
(Favrot et. al., 2013).  
Inhibitory concentrations in solid media were very high for apomorphine and sulocitidil at 
0.625mM, while for sertraline and nisoldipine it was 0.09mM and 0.1mM with the drugs 
precipitating out into the media at higher concentrations. Apomorphine also seemed to produce 
a colorimetric reaction while in the solid media (table 2.2); it was unclear if that impeded the 
drug’s capability to inhibit the strain. Meclocycline sulfosalicyalte had a low solid MIC value 
of 0.2µM which was very close to its liquid MIC value (0.1µM) and can be visibly seen in 
appendix 8. Auranofin also depicted a fairly low solid MIC of 6.25µM although not very close 
to its liquid MIC values (0.27µM).  
The estrogen modulating drugs tamoxifen citrate, toremifene and clomiphene had MIC values 
in a close range from 31µM to 62.5µM, to which raloxifen was an exception with a MIC value 
of 312.5µM (table 2.2). All MIC values were tested with a positive and negative control to be 
sure that there was no contamination of the media and that the inoculum contained actively 
growing cells (appendix 8 and 9). After performing the solid MIC testing for M. bovis BCG as 
mentioned in section 6.11.3, it was observed that the general MIC trend was that the drugs 
inhibited the strain in solid media at 5 to 100-fold higher concentrations. For some of the drugs 
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this was attributed to low solubility in the solid media and precipitation during the cooling 
process of the agar medium. 
Table 2.2: Solid minimum inhibitory concentration of the shortlisted hits from the whole 
cell screen against the Prestwick library. The table lists the MIC values in solid media for 




As mentioned in section 2.2.7, phentermine was not tested for solid MIC studies. Glipizide, 
olopatadine and granisetron had solid MIC values greater than 0.5mM, the drugs precipitated 
out at concentrations that were higher than that and did not seem to inhibit M. bovis BCG 
(appendix 9). Rosiglitazone had the highest MIC value at approximately 1.5mM without any 
inhibition. Thonzonium and florfenicol had a 5-fold increase in their solid MIC values but were 
still around 5µM and effectively inhibited the growth of the M. bovis BCG.  
Shortlisted Drugs 
 (M. smegmatis)  
Solid MIC (µM) Shortlisted Drugs  
(M. bovis BCG)  
Solid MIC (µM) 
Meclocyline sulfosalicylate 0.1953125 Thonzonium  ≥ 5.5556 
Auranofin 6.25 Florfenciol 5.56 
Chlorhexidine 15.625 Pentamidine ~ 50 
Alexidine N/T Astemizole ~ 50 
Clomiphene citrate 37.5 Pinaverium ~ 50 
Ebselen N/T Josamycin ~ 100 
Raloxifene 312.5 Tripelennamine ~ 500 
Toremifene 62.5 Rosiglitazone  ~ 1500 
Tamoxifen citrate 31.25 Glipizide ≥ 500 
GBR 12909 62.5 Olopatadine ≥ 500 
Fendiline hydrochloride 15.625 Granisteron ≥ 500 
Sulocitidil 625 Phenteramine N/T 
Apomorphine 625   
Nisoldipine 100   
Sertraline 90   
Fluspirilene N/T   
Chapter 2                                         Screening the FDA approved library against mycobacteria 
 
 69 
Pentamidine, astemizole and pinaverium had solid MIC values of around 0.05mM while there 
was a 10-fold increase in the MIC value for tripelennamine with an MIC of 0.5mM (table 2.2). 
 
2.2.9 Generation of spontaneous resistant mutants to determine mode of action of 
selected drugs 
 
Mutants were generated for meclocyline sulfosalicylate, tamoxifen citrate and GBR12909 in 
M. smegmatis and for florfenicol, pentamidine and tripelennamine in M. bovis BCG as 
mentioned in section 6.12. 
The whole genome sequencing revealed mutations in genes for each drug indicating towards 
the mode of actions (table 2.3). Meclocyline sulfosalicylate mutants revealed mutations in the 
gene Rv1856c, a probable oxidoreductase deemed non-essential by the Himar-I based 
transposon mutagenesis (Sassetti et. al., 2003). A point mutation was observed in the gene glyA 
which is a serine hydroxymethyltransferase (table 2.3) responsible for interconversion of 
glycine and serine in the presence of a single carbon carrier. It plays an important role in 
providing single carbon groups required in purine, thymidylate and methionine biosynthesis. It 
has also been identified as one of the proteins which undergoes PUPylation (Ubquitinylation 
by prokaryotic ubiquitin protein) (Watrous et. al., 2010).  
The tamoxifen citrate mutant exhibited a frame shift mutation in the gene espR (Rv3849) (table 
2.3) which produces a protein involved in transcriptional regulation of the three genes Rv3136c-
Rv3614c required for the ESX-1 system. The protein binds to the DNA and regulates ESX-1 
therefore controlling the virulence of mycobacteria (Raghavan et. al., 2008). The crystal 
structure of the protein shows that it is a dimer in its physiological form with each monomer 
having the N-terminal helix-turn-helix which is the DNA binding domain and the C-terminal 
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domain which is where the protein dimerises (Gangwar et. al., 2014). Spontaneous resistant 
mutants raised against GBR12909 in M. smegmatis produced consistent multiple mutations in 
Rv2538c (table 2.3) an essential gene for Mtb (Sassetti et. al., 2003) which encodes for 3-
dehyoquinote synthase which is one of the enzymes participating in the shikimate pathway 
(Garbe et. al., 1991). This homomeric enzyme encoded by the gene aroB is the second enzyme 
in the pathway and is present in various bacterial strains such as Corynebacterium glutamicum, 
Escherichia coli, Bacillus subtilis and other fungi, plant and apicomplexan parasites (de 
Mendonça et. al., 2007; Zhang et. al., 2015; Lee et. al., 2017). It makes for an important target 
due to its essentiality in Mtb and absence of the pathway in mammals (de Mendonça et. al., 
2007). 
Table 2.3: Mode of action determination through spontaneous resistant mutants for drugs 
inhibiting M. smegmatis. The table represents the single nucleotide polymorphisms obtained 
through whole genome sequencing of the spontaneous resistant mutants raised against selected 





Mutated Genes Rv 
Number 
Positions Amino acid 
substitutions 
Probable function 
Meclocycline MSMEG_3619 Rv1856c A/G  Short chain dehydrogenase/ 
oxidoreductase 
Meclocycline MSMEI_5111  Ccg/Tcg  P122S Serine 
hydroxymethyltransferase 
Tamoxifen MSMEG_6431        Rv3849 ttc/ 
(Frame 
shift) 
F24 Conserved hypothetical 
protein  
 
GBR12909 aroB Rv2538c 
 
Ggg/Agg G282R Involved at the second step 
in the biosynthesis of 
chorismate within the 
biosynthesis of aromatic 







GBR12909 aroB Rv2538c gGc/gAc G284D 




GBR12909 aroB Rv2538c cTa/cCa L363P 
 
Auranofin, a gold atom containing FDA approved drug used in the treatment of rheumatoid 
arthritis, was found to be active against M. smegmatis as mentioned previously in section 2.2.7. 
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It was recently proved to have activity against Mtb amongst other gram positive bacteria 
including MRSA. It inhibits the thioredoxin reductase enzyme in the bacterial cell, which is  
Table 2.4: Mode of action determination through spontaneous resistant mutants for drugs 
inhibiting M. bovis BCG. The table represents the single nucleotide polymorphisms obtained 
through whole genome sequencing of the spontaneous resistant mutants raised against selected 
drugs in drug sensitive M. bovis BCG. 
 
Drug Name 







Positions Amino acid 
substitutions 
Probable function 
Florfenicol EchA12 Rv1472 Gga/Aga G239R Possible enoyl-CoA 
hydratase echA12 
[Mycobacterium bovis 
BCG str. Pasteur 1173P2] 
Florfenicol PPE50 Rv3135 gGc/gAc G251D PPE family protein 
Florfenicol rpsI Rv3442c Ccc/Gcc P17A Probable 30S ribosomal 
protein S9 RPSI 
Florfenicol glpK Rv3696c gTc/gCc V271A Probable glycerol kinase 
GlpK (ATP glycerol 3-
phosphotransferase) 
Pentamidine BCG_0763 Rv0713 aTt/aCt I274T Probable conserved 
transmembrane protein 
[Mycobacterium bovis 
BCG str. Pasteur 1173P2] 
 BCG_0763 Rv0713 gCg/gTg A281V Probable conserved 
transmembrane protein 
[Mycobacterium bovis 
BCG str. Pasteur 1173P2] 
Pentamidine mmpL6 Rv1557 Gcc/Acc A31T Probable conserved 
transmembrane protein 
Pentamidine glpK Rv3696c gTc/gCc V271A Probable glycerol kinase 

















 glpK Rv3696c 
 
gTc/gCc V271A Probable glycerol kinase 
GlpK (ATP glycerol 3-
phosphotransferase) 
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responsible for helping the cell to cope with reactive oxidative stress and is also involved in 
DNA synthesis and protein repair. The impairment of the enzyme leads the cell to become 
susceptible to a variety of oxidative stresses in the body while also compromising its replicating 
machinery (Harbut et. al., 2015).  
Due to the target deconvolution study presented by Harbut et. al. in 2015, further studies were 
ceased for this drug and no spontaneous resistant mutants were raised against it. Spontaneous 
resistant mutants were generated for florfenicol in M. bovis BCG, showing a point mutation in 
echA12 gene which produces an enoyl CoA hydratase (table 2.4). The protein is located in the 
membrane fraction (Mawuenyega et. al., 2005) but the gene was not found to be essential 
through the Himar-I based transposon mutagenesis (Sassetti et. al., 2003). The protein has been 
known to be involved in the lipid membrane metabolism and is found to co-localise with 
thioredoxine A (Mawuenyega et. al., 2005) and CtpD which is an ATPase involved with the 
metalation of the proteins secreted during redox stress (Raimunda et. al., 2014). There were 
two other point mutations observed in the florfenicol mutant, one was in the gene Rv3135 which 
produces a protein belonging to the PPE family and the other was in the gene rpsI producing a 
probable 30S ribosomal protein (table 2.4). Florfenicol is a fluorinated form of thiamphenicol 
which belongs to the chloramphenicol family, whose mode of action is through binding to the 
23S rRNA of the 50S ribosomal unit (Schifano et. al., 2013). Therefore, it is fair to expect that 
the mode of action of florfenicol might be similar to that of chloramphenicol.  
The mode of action suggested through the spontaneous resistant mutants for pentamidine was 
through mmpl6 (table 2.4). Mycobacterial membrane protein large (Mmpl) are membrane 
proteins involved in shuttling lipid components across the cell membrane and have been known 
to play an important role in membrane physiology and virulence of the bacterium (Viljoen et. 
al., 2017).  
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Tripelennamine mutants had a point mutation in the promoter region of the mmr gene (table 
2.4) which is a known efflux pump involved in drug resistance with high susceptibility to 
quaternary compounds (Rodrigues et. al., 2013). This might indicate a regulatory action of the 
drug affecting the production of the Mmr proteins which might therefore cause a change in the 
ability of the bacterium to pump out drugs.  
It was observed that there was a point mutation in the glpK gene in each of the M. bovis BCG 
mutants (table 2.4). This gene encodes for a glycerokinase which catalyses the rate limiting step 
in glycerol metabolism of converting glycerol to glycerol-3-phosphate (Domenech et. al., 2014; 
Keating et. al., 2005). The protein is essential for glycerol metabolism and the knockout mutant 
of the gene struggles to grow in the presence of glycerol therefore reducing its ability to grow 
(Sassetti et. al., 2003; Keating et. al., 2005). 
 The single nucleotide polymorphisms revealed through whole genome sequencing indicate 
towards the mode of actions of these drugs and are a key component in understanding the 




Screening the Prestwick library of 1200 FDA approved drugs against a fast growing and slow 
growing strain of mycobacteria revealed an array of active inhibitors against both these strains. 
A higher number of drugs inhibited the slow growing vaccine strain M. bovis BCG versus the 
fast-growing M. smegmatis. There were categories of drugs which affected each of these 
mycobacterial strains individually which indicates variation in the physiology and genetics of 
each of them.  
For screening compounds, M. smegmatis has an obvious advantage over the slow growing M. 
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bovis BCG strain, as it has a shorter generation time therefore boosting the high throughput 
nature of screening and is lower risk bacteria to work with. However, it is less efficient in 
availing antitubercular compounds than M. bovis. It was observed during a screen of the 
LOPAC library against M. tuberculosis, M. smegmatis and M. bovis BCG; 50% of the drugs 
that inhibited Mtb were not identified in M. smegmatis while it was only 21% of the drugs that 
were not identified in M. bovis BCG. It was observed that 30% of proteins in Mtb do not have 
conserved orthologs in M. smegmatis (Altaf et. al., 2010). Despite this fact, bedaquiline, the 
most recent drug approved for the treatment of tuberculosis, was discovered through a whole 
cell screen assay against M. smegmatis (Cooper, 2013) which makes the case for the use of the 
strain as a model for drug screening. A comparative DNA analysis of different strains from the 
mycobacterial complex such as Mtb, M. bovis, M. bovis BCG, M. microti and M. africanum 
was performed to reveal that 90% of the DNA amongst the strains matched. 85-89% of 
similarity was observed between the M. bovis, M. bovis BCG and M. africanum with M. microti. 
The analysis was performed through the restriction enzyme cleavage analysis which works on 
the premise that the enzyme sites are located in specific locations on the chromosome and do 
not change a lot when the species are related (Imaeda, 1986).  
Although genetically similar, there are obvious physiological variations between Mtb and M. 
bovis which have been attributed to differential gene expression of around 6% of genes in the 
genome. The main class of genes which are upregulated in Mtb were the PE/PPE genes which 
are involved in some of the cell wall proteins while in case of M. bovis it was the genes encoding 
for transcriptional regulators. Major variations were observed for genes involved in cell wall 
processes, intermediary metabolism and respiration and hypothetical proteins (Rehren et. al., 
2007). The variations in the strains of mycobacteria explain why there are different classes of 
drugs that inhibit each strain individually (figure 14). The genetic and physiological similarities 
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explain the overlapping drugs and drug categories (appendix 3) that inhibited the fast and slow 
growing mycobacteria. Apart from a few categories of drugs which inhibited the strains 
individually, the majority of the drugs that inhibited both the strains belonged to a similar class 
of drugs such as antibiotics, antifungal, calcium channel blockers, antihistamines, estrogen 
modulators and of course the antitubercular drugs. 
Target deconvolution through whole cell screening has long been the bottleneck of this drug 
discovery strategy. There is an apparent trend observed for inhibitors obtained through whole 
cell screening against mycobacteria. A high number of targets are membrane based albeit 
susceptible and in a lot of cases essential to the survival of the bacterium. Some examples of 
these targets include dprE1, a gene encoding the arabinose precursor for the synthesis of cell 
wall components mainly arabinogalactan and lipoarbinomanan; MmpL3 which is a membrane 
protein involved in translocation of trehalose monomycolate across the periplasm, this is the 
target protein for SQ109. QcrB, another regular target observed during whole cell screening 
which encodes for the b subunit of the cytochrome bc1 oxidase that plays an important role in 
the electron transport in the cell and the inhibition of which leads to ATP depletion. Pks13 is 
another gene which comes up as a frequent target in whole cell screens, this gene encodes for 
a protein with a thioesterase activity releasing mycolates. This high probability of membrane 
proteins as targets for the bacterium could be due to the high hydrophobicity of the inhibitors 
screened against the cell (Cole, 2016). The drugs from the Prestwick library have an average 
log P value of 5.7, which is the partition coefficient and is used to measure the lipophilicity of 
a molecule (Goldman, 2013). This therefore affects the ability of the drug to move across the 
cell membrane. Hydrophobic drugs have a tendency to enter into the lipid bilayer and then 
move laterally through the membrane due to their inability to cross the lipid bilayer into the 
cytoplasm easily. While traversing the bilayer they interact with membrane proteins and thus 
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there is a high probability of the drugs inhibiting membrane proteins thereby producing 
membrane protein related mutations in spontaneously generated mutants during mode of action 
studies (figure 2.8) (Goldman, 2013).  
 
Figure 2.8: A model describing the movement of drug molecules across and through the 
cell membrane. The drugs partition through the membrane based on their hydrophobicity. The 
drug entering the bilayer then generally moves through the membrane laterally interacting with 
various protein in the bilayer and some on the surface or boundary. It is quite rare for very 
hydrophobic drugs (Goldman, 2013).  
 
Membrane proteins are also selected if the inhibitor is an uncoupling agent causing disruption 
of the proton motive force and therefore affecting synthesis of ATP (Goldman, 2013). Alexidine 
dihydrochloride and thonzonium bromide were amongst the hits that have uncoupling 
properties and would have possibly generated a membrane protein mutation. Another factor 
that might cause most inhibitors to target membranes is the location of these proteins which are 
mostly localised at the cell pole where the cell wall synthesis takes place; murG and wag31 
involved in peptidoglycan production, glfT2 responsible for arabinogalactan production and 
mmpL3, pks13 in mycolic acid translocation (Cole, 2016).  
Some resistant mutants depict a mutation in the glpK (table 2.4) for the drugs, which encodes 
for an enzyme involved in glycerol uptake and metabolism. This mode of action is due to in 
vitro growth conditions where the inhibitor causes a disturbance in the glycerol metabolism 
leading to accumulation of toxic metabolites in the cell inhibiting the growth of the organism 
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(Goldman, 2013). This explains the mutations observed in the spontaneous mutants generated 
in M. bovis BCG against the shortlisted drugs.  
The screening of the Prestwick library, generates inhibitors such as calcium channel blockers, 
antihistamines, antifungal azoles and anti-infectives. The calcium channel inhibitors are 
generally small and hydrophobic molecules which have the ability to enter the phospholipid 
bilayer and can diffuse through the membrane inhibiting metabolic functions due to interactions 
with proteins and boundary lipids. Antifungal azoles which have known activity against 
mycobacteria act by targeting the CYP121 and CYP130. The antihistamine mefloquine, which 
disrupts membrane transport and the regulators involved in cellular replication, gives an idea 
about possible mode of actions for this class (Goldman, 2013). Tripelennamine, which is an 
antihistamine, had a mutation in the promoter of the mmr gene which is an efflux pump (table 
2.4), this is an example of a combination of regulation and efflux pump mediated inhibition of 
the drug (Goldman, 2013).There were anti-infective drugs which had inhibitory activity against 
both the strains but were not pursued due to the possibility of their pleiotropic activity. Anti-
infectives have been recently approved to be used as a systemic treatment for infection. They 
act by disrupting the membrane integrity and in some cases inhibit processes like 
transpeptidation this suggests that it is still unclear whether or not they have specific targets 
(Goldman, 2013). 
The screening of the Prestwick library and generation of a high number of hits which had 
antimycobacterial activity proves that repurposing is a feasible and efficient way of mining for 
new drugs against TB. The drugs shortlisted and studied here have given us an idea of the 
potential drug targets to pursue and a possibility for designing drug scaffolds based on the 
antimycobacterial activity of the current FDA approved drugs in the scenario where there is 
low feasibility of using them against TB directly. Florfenicol although being a potentially active 
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drug against M. bovis BCG might not be considered for administration in humans as it is 
currently a veterinary drug. Although the protein that is targeted by it that is echA12 belongs to 
a family of non-catalytic enoyl coenzyme A hydratases whose function is not clearly 
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3. Genetic and biochemical characterisation of the 
florfenicol target echA12 
 
3.1 Introduction  
 
The cell wall plays a major role in the survival and virulence of this organism due to its high 
lipid content and low permeability, making it very difficult for antibiotics to enter the cell 
(Brennan and Nikaido, 1995; Jarlier and Nikaido, 1994). The cell wall contains peptidoglycan 
which is covalently bound to the mycolylarabinogalactan (mAG) complex via phosphodiester 
bonds, this forms the core of the cell wall. The mycolic acids in this core complex are attached 
to the arabinan molecules in groups of four through ester bonds to a terminal hexa-
arbinofuranosyl unit (Brennan and Besra, 1997). The arabinan units are linked linearly through 
glycosidic bonds to D-galactan. The mycolic acid chains run perpendicular to both the 
arabinogalactan and other cell wall associated glycolipids, which intersperse into the mycolic 
acid layer (Chatterjee, 1997). Mycolic acids are a-alkyl b-hydroxy very long chain fatty acids, 
the longest chains are around C70-C90 with the largest a-branch with C20-C25. The synthesis of 
these fatty acids occurs through two fatty acid synthase cycles called FAS-I and FAS-II. The 
FAS-I cycle is a multifunctional cycle which produces de novo fatty acyl-CoA with two types 
of chain lengths (C16-C18 and C24-C26). These products are then distributed through a bimodal 
system based on the presence of methylglucose or methylmannose containing polysaccharides. 
The FAS-I system has a limited capacity to generate long chains and cannot extend fatty acid 
chains. This function is performed by the acyl carrier protein (ACP) utilizing FAS-II system 
(Brennan and Besra, 1997; Kolattukudy et. al., 1997). While the cell wall is anchored to the 
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inner membrane with PI, PIMs, LAM and LM molecules (Hunter and Brennan, 1990) it is also 
covered in a capsule mainly made up of polysaccharides and lipid-glycans which play an 
important role in virulence and infection (Minnikin, 1982; Daffé and Lanéelle, 2001). 
 
Figure 3.1: A pictorial depiction of the drugs targeting various enzymes in the biosynthesis 
of essential cell wall components in mycobacteria. A. Represents inhibitors targeting the 
biosynthesis of phosphatidylinositol mannosides (PDIM), lipomannan (LM) and 
lipoarabinomannan (LAM) including ethambutol. B. Presents the drugs that inhibit the enzymes 
in mycolic acids biosynthesis (Abrahams and Besra, 2016).  
A B
A B
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Given that the cell wall is important for the bacteria to survive in the host and establish an 
infection, its components and the enzymes involved in the biosynthesis of the cell wall have 
been attractive drug targets. A host of antibiotics that are used to treat tuberculosis or considered 
to be potential antitubercular drugs target components of the cell wall. Prominent examples 
amongst the front-line drugs which target cell wall biosynthetic components are isoniazid and 
ethambutol (Freiberg and Brötz-Oesterhelt, 2005; Abrahams and Besra, 2016) (figure 3.1). 
Isoniazid inhibits the mycolic acid synthesis when activated by the catalase-peroxidase KatG, 
this therefore affects the integrity of the cell wall causing the bacterium to become vulnerable 
to the immune system (Hu et. al., 2017; Winder and Collins, 1970; Vilchèze et. al., 2000). On 
the other hand, ethambutol disrupts the synthesis of arabinogalactan causing an accumulation 
of the precursors involved in the formation of this macromolecule, chiefly β-D arbinofuranosyl-
1-monophosphoryldecaprenol (DPA) (Wolucka et. al., 1994; Mikusova et. al., 1995b). Given 
the fact that the current drug regimen is failing due to the rise in resistant strains, there is a need 
to understand unexplored biosynthetic components of the cell wall as these could be potential 
drug targets. In recent drug discovery attempts, it has been highlighted that drugs shortlisted 
through whole cell drug screens target cell wall components or enzymes involved in the 
synthesis of the cell wall. 




Figure 3.2: The phylogenetic tree of the 21 EchA proteins observed in Mtb. The figure 
details the different EchA enzymes found in Mtb with the structure IDs and notable genes 
surrounding the gene encoding the enzyme. The EchA enzymes highlighted in red are the only 
enzymes in the family that have catalytic residues in their structure. 
Although some of these targets recur frequently and are promiscuous (for example DprE1), it 
is prudent to have a keen interest in novel unknown targets whose functions are not completely 
understood.  
Enoyl CoA hydratases are involved in fatty acid b-oxidation and elongation of fatty acids in 
mammalian mitochondria (Fujita et. al., 1980). The enoyl CoA hydratase belongs to the 
crotonase family, depicts a variable structural framework and has been found in prokaryotes, 
eukaryotes and archaea (Kinsella et. al., 2003; Hamed et. al., 2008). The hydratase enzyme 
found in animals’ hydrates C4-C16 enoyl CoAs while the enoyl CoA hydratase in C. 
acetobutylicum is incapable of hydrating those chain length enoyl CoAs. The enoyl CoA 
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hydratase is also found in E. coli and other mycobacterial strains (Fujita et. al., 1980; Beckman 
and Kranz, 1991). In M. smegmatis, the enoyl CoA hydratase has two forms. As opposed to the 
enoyl CoA hydratase II, the enoyl CoA hydratase I am not involved in fatty acid chain 
elongation using acetyl CoA. It has been predicted that this form might instead be using malonyl 
CoA or be involved in amino acid metabolism (Shimakata et. al., 1980). The Mtb enoyl CoA 
hydratase or the Mtb-EchA family consists of 21 enzymes which are probably involved in the 
fatty acid biosynthesis pathways (Mawuenyega et. al., 2005) (figure 3.2). 
It was noted that EchA16, EchA9 and EchA3 were isolated to the cytoplasm while EchA7, 
EchA12, EchA17, EchA20 and EchA21 were present in the membrane. EchA6 was found to 
be present in the cell wall, whereas the EchA10 was found to be both cytoplasm and present in 
the membrane (Mawuenyega et. al., 2005). It was also interesting to note that the EchA12 
proteins demonstrated strong functional linkages with the FadB2 and FadB3 enzymes, both of 
which are involved in fatty acid degradation (Mawuenyega et. al., 2005). The gene encoding 
for the Fad proteins in Mtb are notably observed in the vicinity of the EchA encoding gene, 
potentially indicating their role in fatty acid biosynthesis. Among the EchA enzymes it was 
observed that the EchA1 enzyme contained a glutamate residue in the position 149 which 
correlates to the catalytic residues noted in E.coli (Humanes et. al., 1999). The EchA19 and 
EchA21 proteins contain acidic residues which are active site residues, indicating that they are 
catalytic enzymes. EchA9 contains a glutamate and an aspartate residue in the catalytic site 
(Srivastava et. al., 2015). These are the only four enzymes which are catalytic within the EchA 
family of proteins in mycobacteria. Although the echA genes have been predicted to be involved 
in fatty acid biosynthesis, the regulation of these genes can vary. The genes are expressed 
differently under various environmental conditions. The echA8, echA11 and echA12 genes are 
upregulated during nutrient starvation while the echA10 and echA21 genes are downregulated 
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during this process. The echA genes are also expressed variably based on infection, for example, 
the echA19 gene is upregulated during macrophage infections in THP-1 cell lines while in the 
case of mouse infection, echA7 is upregulated (Williams et. al., 2011; Dubnau, 2002). It was 
also recently proved that EchA6 is a non-catalytic essential enzyme involved in phospholipid 
biosynthesis (Cox et. al., 2016a). 
In this chapter, we have discussed the mycobacterial enoyl CoA hydratase EchA12 which, as 
discussed in chapter 2, was discovered to be a target for florfenicol through spontaneous mutant 
generation. EchA12 has been found in the membrane fraction and Himar-I based mutagenesis 
has presented this gene to be non-essential in vivo (Sassetti et. al., 2003; Mawuenyega et. al., 
2005). In this chapter, we have attempted to deconvolute the function of EchA12 in 
mycobacteria.  
 
3.2 Results  
 
3.2.1 Genetic synteny of the echA12 gene  
 
A genomic alignment of the echA12 genes was performed using ClustalOmega for 4 different 
mycobacterial species against the Mtb echA12 gene. It was observed that the echA12 gene from 
M. bovis (Mb1507) had a maximum genomic identity of 99.88% with the echA12 (Rv1472) 
gene from Mtb. 
The lowest identity of 70.6% was with the M. leprae echA12 gene (ML1241), but despite this, 
it shared more than a 50% similarity, which could mean that the important bases required for 
the functions of the protein were conserved within the sequence. The echA12 gene in M. 
smegmatis (MSMEG_3139/MSMEI_3508) shares only 74.7% similarity, closely followed by 
M. leprae. genome of different mycobacterial species was localised around the same position. 
In Mtb and M. bovis the genes upstream and downstream to the echA12 gene were the same.  
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The genes upstream were trxB1 and trxA (figure 3.3) which encode for thioredoxin molecules 
involved in redox reactions during oxidative stress in Mtb (Mehta et. al., 2016). The gene 
ML1240c encodes for the first part of the transporter and ML1239c encodes the second part. In 
M. smegmatis, the genes that are present upstream and downstream to the echA12 gene were 
the same as those observed in Mtb and M. bovis. With this observation, it is clear that the genetic 
synteny is conserved to a high degree between all the species of mycobacteria.  
 
Figure 3.3: A comparative representation of the gene placement of the echA12 gene across 
different mycobacterial species. The figure depicts the various genes found upstream and 
downstream of the echA12 gene in different species of mycobacteria to represent the genetic 
synteny of echA12. The table below the diagram lists the prominent genes observed on either 
side of echA12 in each of the mycobacterial species. 
Based on the genes flanking it, it was observed that the position of the echA12 gene within the  















Species name Notable gene upstream to echA12 Notable gene downstream to 
echA12
M. tuberculosis H37Rv trxB1, trxA Rv1473
M. bovis trxB1, trxA Mb1508
M. leprae ML1240c ML1242
M. smegmatis mc2155 trx MSMEG3140
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This includes M. leprae which has a reduced genome generated through reductive evolution to 
in order to conserve only the most important genes for survival and virulence. The gene 
downstream to the echA12 gene encodes for an ABC transporter involved in the export of 
macrolides (figure 3.3). In the case of M.leprae, the genes encoding for the ABC transporter 
for macrolides are upstream to the echA12 gene and are potentially the cause of macrolide 
resistance (Braibant et. al., 2000). 
 
3.2.2 Cloning of echA12 into pVV16 for constitutive overexpression.  
 
The echA12 gene from M. tuberculosis H37Rv, M. bovis BCG and the spontaneous mutant 
raised against florfenicol in M. bovis BCG (table 4, section 2.2.9) were cloned into the pVV16 
vector (section 6.4.1.2) for constitutive overexpression of the gene.  
The gene was amplified (figure 3.4A) and cloned into the vector through double digestion 
(figure 3.4B) (section 6.4). Once the cloned plasmids were sequenced, the plasmids were 
electroporated into M. bovis BCG and M. smegmatis (section 6.9.2.2). 
 
 
Figure 3.4: Cloning of the echA12 (858bp) gene into the pVV16 (5.8Kb) vector. A. 
Represents the agarose gel of the PCR products of the echA12 with a 1Kb ladder (L), 1. 
echA12_Rv, 2. echA12_M. bovis BCG, 3. echA12_G239R. B. Agarose gel depicting the double 
digest (HindIII and NdeII) products of a cloned pVV16 vector containing the echA12 gene. The 
products were run alongside a 1Kb ladder (L), 1. pVV16_echA12_G239R, 2. 
pVV16_echA12_M. bovis BCG and 3. pVV16_echA12_Rv 
  L          1                     L                 2         3 
1Kb
1Kb
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3.2.3 Overexpression of echA12 in M. bovis BCG and M. smegmatis to test 
resistance against florfenicol 
 
The overexpression strains with constitutive expression of echA12 were tested for resistance 
against florfenicol (Section 6.18.1). It was observed that the echA12 overexpression strains with 
the different genes had a higher tolerance to florfenicol when compared to the strains containing 
the empty vector (figure 3.5). It was observed that the echA12 overexpression strain with the 
amino acid substitution G239R had the highest tolerance to florfenicol, depicting approximately 




Figure 3.5: IC50 shift against florfenicol in echA12 overexpressing strains in M. smegmatis 
and M. bovis BCG. A. The figure represents the average survival percentage at various drug 
concentration leading to an IC50 shift in echA12 overexpressing strains in M. smegmatis 
containing pVV16 plasmids with the echA12 gene from M. tuberculosis H37Rv, M. bovis BCG 
and the spontaneous resistant mutant raised in M. bovis BCG. B. The figure represents the 
average survival percentage at various drug concentration leading to an IC50 shift in echA12 
overexpressing strains in M. bovis BCG containing pVV16 plasmids with the echA12 gene from 































































Figure: IC50 shift against florfenicol in echA12 overexpessing strains in M. smegmatis and M. bovis BCG
A. IC50 shift in echA12 overexpressing strains in M. smegmatis containing pVV16 plasmids with the echA12 
gene from M. tuberculosis H37Rv, M. bovis BCG and the spontaneous resistant mutant raised in M. bovis BCG.
B.  IC50 shift in echA12 overexpressing strains in M. bovis BCG containing pVV16 plasmids with the echA12 
gene from M. tuberculosis H37Rv, M. bovis BCG and the spontaneous resistant mutant raised in M. bovis BCG.
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The M. smegmatis strain containing the H37Rv gene and the M. bovis BCG gene had similar 
growth profiles and survival percentages at the highest concentration of florfenicol (figure 
3.5A). The overexpression strains in M. bovis BCG depicted similar profiles, albeit with higher 
tolerances as compared to the empty vector containing strain at the highest concentration of 
florfenicol (figure 3.5B). The percentage survivals for the strains were observed to be fairly 
high yet consistent, so this could perhaps be the effect of the vector, which has inherent 
antibiotic resistant markers. There is, however, a clear difference of an IC50 shift between the 
strain containing the empty vector when compared to the strains expressing the echA12 gene 
(figure 3.5B). 
3.2.4 Lipid analysis of the echA12 overexpression strains in the presence of 
florfenicol 
 
Lipid analysis was carried out using four different overexpression constructs electroporated in 
M. smegmatis and M. bovis BCG. The overexpression strains containing the 
pVV16_echA12_G239R, pVV16_echA12_M. bovis BCG and pVV16_echA12_Rv were 
compared with the empty vector containing strain. The extractions were performed after 
radiolabelling the M. smegmatis and M. bovis BCG cultures with C14-acetate and then 
extracting the lipids (section 6.18 to 6.19).  
 
3.2.4.1 Apolar lipid analysis in M. smegmatis echA12 overexpressors 
 
In the apolar lipid extractions we generally observe free fatty acids, free mycolic acids, triacyl 
glycerols, trehalose monomycolate and trehalose dimycolate moieties based on the various 
solvent systems that are undertaken to perform the thin layer chromatography. When the apolar 
lipids were separated in different solvent systems on the 2-D TLCs (figure 3.6,3.7; appendix 
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11,12), there were no differences observed among the different overexpression strains 
compared to the empty vector strain. 
 
Figure 3.6: Apolar lipids separated by 2-D TLC on a silica gel plate using Petroleum ether: 
Ethyl acetate (98:2)x3 in direction one (D1) and Petroleum ether: Acetone (98:2) in 
direction two (D2). The TLC separation of apolar lipids from four different strains of M. 
smegmatis mc2155 was carried out using two different solvent systems in two directions. The 
M. smegmatis strains used are depicted based on the overexpression plasmids they contain: A. 
mc2155_pVV16, B. mc2155_pVV16_echA12_Rv, C. mc2155_pVV16_echA12_BCG, D. 
mc2155_pVV16_G239_echA12. The strains were treated with 0x, 0.5x, 1x,2x and 5x MIC of 
florfenicol.  TAG, triacylated glycerol; the spot encircled is a mixture or ketones.  
 
Amongst the lipids separated in system A however, it was observed that there was an 
accumulation of a mixture of ketones that increased in abundance with the increase in the 
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been previously described as a mixture of unsaturated branched ketones which are similar to 
tuberculenone from M. tuberculosis.  
 
Figure 3.7: Apolar lipids separated by 2-D TLC on a silica gel plate using Petroleum ether: 
Acetone (98:2)x3 in direction one (D1) and Toluene: Acetone (95:5) in direction two (D2). 
The TLC separation of apolar lipids from four different strains of M. smegmatis mc2155 was 
carried out using two different solvent systems in two directions. The M. smegmatis strains used 
are depicted based on the overexpression plasmids they contain: A. mc2155_pVV16, B. 
mc2155_pVV16_echA12_Rv, C. mc2155_pVV16_echA12_BCG, D. 
mc2155_pVV16_G239_echA12. The strains were treated with 0x, 0.5x, 1x,2x and 5x MIC of 
florfenicol. FA, fatty acids.  
 
These ketones were potential shuttle products of mycolic acid precursors such as a-alkyl b-oxo 
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was comparatively lower in the construct with the mutated echA12 gene containing the amino 
acid substitution G293R. It was also observed that there was an accumulation of free fatty acids 
when the apolar lipids were separated using solvent system B (figure 3.7). When compared to 
all the other constructs of the echA12 overexpression, there was comparatively less 
accumulation of the free fatty acids in the G239R substituted overexpression strain.  
 
3.2.4.2 Polar lipid analysis in M. smegmatis echA12 overexpressors 
 
After the initial extraction of the apolar lipids from the mycobacterial overexpression strains,  
 
Figure 3.8: Polar lipids separated by 2-D TLC on a silica gel plate using Chloroform: 
Methanol: Water (60:30:6) in direction one (D1) and Chloroform: Acetone: Methanol: 
Water (40:25:3:6) in direction two (D2). The TLC separation of polar lipids from four 
different strains of M. smegmatis mc2155 was carried out using two different solvent systems 
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plasmids they contain: A. mc2155_pVV16, B. mc2155_pVV16_echA12_Rv, C. 
mc2155_pVV16_echA12_BCG, D. mc2155_pVV16_G239_echA12. The strains were treated 
with 0x, 0.5x, 1x,2x and 5x MIC of florfenicol. P, phospholipids; PI, phosphatidylinositol; 
Ac1PIM2, monoacylated phosphatidylinositol dimannoside; Ac2PIM2, diacylated 
phosphatidylinositol dimannoside; Ac1PIM6, monoacylated phosphatidylinositol 
hexamannoside; Ac2PIM6, diacylated phosphatidylinositol hexamannoside.  
the polar lipids were extracted (section 6.18.5). The polar lipids were separated using solvent  
system E to visualise the acylated phosphatidylinositol mannosides, phoshpotidylinositols, 
phospholipids, trehalose monomycolates and trehalose dimycolates. A notable change in the 
phospholipid profile with the increase in the florfenicol concentration is seen at 2x and 5x MICs 
without any obvious change in the PIMs or phosphatidylinositol moieties (figure 3.8).  
 
3.2.4.3 Apolar lipid analysis in M. bovis BCG echA12 overexpressors 
 
Apolar lipid extraction was carried out on overexpression strains in M. bovis BCG labelled with 
[14C]-acetate in the presence of florfenicol. Here we observe triacylglycerols, free fatty acids, 
free mycolic acids, diacylglycerols, glucose monomycolate, trehalose dimycolate, diacylated 
trehalose, sulpholipid and phthiocerol dimycocerosate in different solvent systems (figure 
3.9,3.10; appendix 13,14). There was no specific trend observed in apolar lipids in M. bovis  




Figure 3.9: Apolar lipids separated by 2-D TLC on a silica gel plate using Petroleum ether: 
Ethyl acetate (98:2) x3 in direction one (D1) and Petroleum ether: Acetone (98:2) in 
direction two (D2). The TLC separation of apolar lipids from four different strains of M. bovis 
BCG was carried out using two different solvent systems in two directions. The M. bovis BCG 
strains used are depicted based on the overexpression plasmids they contain: A. M. bovis 
BCG_pVV16, B. M. bovis BCG_pVV16_echA12_Rv, C. M. bovis 
BCG_pVV16_echA12_BCG, D. M. bovis BCG_pVV16_G239_echA12. The strains were 
treated with 0x, 1x, 2x, 5x and 10x MIC of florfenicol. TAG, Triacyl Glycerol, PDIMs, 
Phthiocerol dimycocerosate. 
 
BCG overexpressing echA12 in the presence of florfenicol, except for the increased 
accumulation of triacyl glycerols and phthiocerol dimycocerosate in apolar lipids separated in 
system A. In the empty vector, an increase was observed in the triacyl glycerol with the increase 
in florfenicol as opposed to the consistent high expression of the triacyl glycerols in the 














Figure 3.10: Apolar lipids separated by 2-D TLC on a silica gel plate using Petroleum 
ether: Acetone (98:2) x3 in direction one (D1) and Toluene: Acetone (95:5) in direction 
two (D2). The TLC separation of apolar lipids from four different strains of M. bovis BCG was 
carried out using two different solvent systems in two directions. The M. bovis BCG strains 
used are depicted based on the overexpression plasmids they contain: A. M. bovis 
BCG_pVV16, B. M. bovis BCG_pVV16_echA12_Rv, C. M. bovis 
BCG_pVV16_echA12_BCG, D. M. bovis BCG_pVV16_G239_echA12. The strains were 
treated with 0x, 1x, 2x, 5x and 10x MIC of florfenicol. DAG, Diacyl Glycerol.  
 
3.2.4.4 Polar lipid analysis in M. bovis BCG echA12 overexpressors 
 
The polar lipid extractions that followed the apolar extractions were then separated on a 2-D 
TLC in system E. The system allows the visualisation of the acylated PIMs, 
phosphatidylinositol, phospholipids, trehalose mono- and di-mycolates. There were no changes 
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Figure 3.11: Polar lipids separated by 2-D TLC on a silica gel plate using Chloroform: 
Methanol: Water (60:30:6) in direction one (D1) and Chloroform: Acetone: Methanol: 
Water (40:25:3:6) in direction two (D2). The TLC separation of polar lipids from four 
different strains of M. bovis BCG was carried out using two different solvent systems in two 
directions. The M. bovis BCG strains used are depicted based on the overexpression plasmids 
they contain: A. M. bovis BCG_pVV16, B. M. bovis BCG_pVV16_echA12_Rv, C. M. bovis 
BCG_pVV16_echA12_BCG, D. M. bovis BCG_pVV16_G239_echA12. The strains were 
treated with 0x, 1x, 2x, 5x and 10x MIC of florfenicol.  P, phospholipids; PI, 
phosphatidylinositol; Ac1PIM2 monoacylated phosphatidylinositol dimannoside; Ac2PIM2 
diacylated phosphatidylinositol dimannoside; Ac1PIM6 monoacylated phosphatidylinositol 
hexamannoside; Ac2PIM6 diacylated phosphatidylinositol hexamannoside. 
 
3.2.4.5 FAMEs and MAMEs analysis in M. smegmatis and M. bovis BCG echA12 
overexpressors 
 
Extraction of the fatty acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs) 
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ether/acetone (95:5) on a 1-D TLC. There were no changes observed in any of the FAMEs and 
the a, a¢, epoxy and the hydroxylated MAMEs in the M. smegmatis extracts (figure 3.12). 
Similarly, there were no changes observed in the M. bovis BCG extracts with the FAMEs and 
the a and keto MAMEs (figure3.12). 
 
 
Figure 3.12: FAMES and MAMES extraction on a 1-D TLC separated on a solvent system 
containing petroleum ether/acetone (95:5, v/v). 1.The TLCs representing the cell wall bound 
lipids in the presence of 0x,0.5x,1x,2x and 5x of florfenicol in  M. smegmatis  mc2155: A. 
mc2155_pVV16, B. mc2155_pVV16_echA12_Rv, C. mc2155_pVV16_echA12_BCG, D. 
mc2155_pVV16_G239_echA12constructs. 2. The TLCs representing the cell wall bound lipids 
in the presence of 0x,1x,2x,5x and 10x of florfenicol in M. bovis BCG; A. M. bovis 
BCG_pVV16, B. M. bovis BCG_pVV16_echA12_Rv, C. M. bovis 
BCG_pVV16_echA12_BCG, D. M. bovis BCG_pVV16_G239R_echA12 
FAMEs, Fatty acid methyl esters; MAMEs, Mycolic acid methyl esters. 
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3.2.5 Generation of a knockout strain for echA12 
 
In order to determine the essentiality of echA12, an attempt was made to generate a knockout 
mutant using specialised transduction (section 6.16) in M. smegmatis and M. bovis BCG. A 
knockout mutant was successfully generated.  
 
Figure 3.13: Generation of knockout mutants for echA12 in  M. smegmatis.A. A schematic 
representation of the gene map corresponding to the echA12 (MSMEI_3508) gene in M 
smegmatis along with flanking genes, following which is the map of the M. smegmatisΔechA12 
mutant. The dotted line cutting through the gene represents the region of the echA12 gene 
replaced by the Hygromycin resistance gene (hyg) from S. hygroscopicus and the sucrose 
counter-selectable marker (sacB) from B. subtilis. Flanking DNA fragments upstream and 
downstream from the gene (~1Kb) linked with digoxigenin were used as molecular probes to 
construct the knockout plasmid; these are represented as solid lines with diamond shaped ends 
in the gene map of the echA12 gene. The expected band sizes for each strain after digestion 
with KpnI enzyme are represented as I, II and III. B. The southern blot of the KpnI-digested 
genomic DNA from both the wild type strain (a) and knockout mutant (b) strain of echA12 in 
M smegmatis. Bands I, II and III correspond to the expected sizes for the wild type and knockout 
mutant gene map.  
I (3812 bp)






























Figure: Generation of knock mutants for echA12 in M. smegmatis
A. A schematic representation of the gene map corresponding to the echA12 (MSMEI_3508) gene in M
smegmatis along with flanking genes, following which is the map of the M. smegmatisΔechA12 mutant.
The dotted line cutting through the gene represents the region of the EchA12 gene replaced by the
Hygromycin resistance gene (hyg) from S. hygroscopicus and the sucrose counter-selectable marker
(sacB) from B. subtilis. Flanking DNA fragments upstream and downstream from the gene, ~1Kb in size
linked with digoxigenin were used as molecular probes to construct the knock out plasmid; these are
represented as solid lines with diamond shaped ends in the gene map of the echA12 gene. The expected
band sizes for each strain after digestion with KpnI enzyme are represented as I, II and III.
B. The southern blot of the KpnI-digested genomic DNA from both the wild type strain (a) and knock
out mutant (b) strain of echA12 in M smegmatis. Bands I, II and III correspond to the expected sizes for
the wild type and knock out mutant gene map.
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As depicted in figure 3.13, the M. smegmatis gene MSMEI_3058, which is homologous to the 
Mtb echA12 gene, was knocked out and replaced with a hygromycin antibiotic marker and 
sucrose counter selectable marker (figure 3.13A). A southern blot was performed, in order to 
check if the colonies observed for the knockout mutant were true mutants (section 6.17).  
As depicted in figure 3.13A, the knockout mutant will produce two bands of 3.3Kb and 3.9Kb 
when the DNA is digested with a KpnI restriction endonuclease. It was confirmed with the 
southern blot that the mutants obtained had the echA12 gene in M. smegmatis knocked out 
(figure 3.13B). As the gene was knocked out of the organism to produce a null mutant, it was 
inferred that echA12 is not essential for the survival of mycobacterium. 
 
3.2.6. A comparative growth curve analysis between the wild type and echA12 null 
mutant in M. smegmatis  
 
It was observed that although echA12 is not essential for the survival of M. smegmatis due to  
  
Figure 3.14: Graphical representation of a comparative growth curve between M. 
smegmatis mc2155 and M. smegmatisDechA12. The graph represents the growth of both the 
wild type and echA12 null mutant by measuring the O.D600 against time.  



















Figure: Graphical representation of a comparitive growth curve between 
M. smegmatis mc2155 and M. smegmatisΔechA12
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the successful generation of a knockout mutant, the absence of the gene caused a significant 
growth defect in the strain. The echA12 knockout mutant had a slower growth rate when 
compared to wild type M. smegmatis mc2155 (figure 3.14). The echA12 mutant was almost 
twice as slow as the wild type M. smegmatis, for example, when the mutant reached an O. D600 
of 1 the wild type M. smegmatis strain was reaching a growth plateau at an O. D600 of 2.0. This 
means that echA12 has an important role in growth and multiplication of the cell despite being 
non-essential. 
 
3.2.7 Morphological variation of the M. smegmatis echA12 null mutant 
 
In order to determine a morphological difference between the wild type and knock mutant of 
echA12, the strains were plated on to TSB agar plates in the presence and absence of tween 
(section 6.23) 
 
Figure 3.15: Morphological difference between M. smegmatis mc2155 and M. 
smegmatisΔechA12 in the presence and absence of 0.05% Tween-80. Isolated single 
colonies grown on TSB agar with the addition of 0.0.5% Tween 80 in the column represented 
as +Tween.  
- Tween + Tween
M. smegmatis mc2155
M. smegmatisΔechA12
Figure: Morphological difference between M. smegmatis mc2155 and M. smegmatisΔechA12 in the presence and absence of 0.05% Tween-80. 
Isolated single colonies grown on TSB agar with th addition of 0.0.5% Tween 80 i  the column represented as +Tween.
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The wild type M. smegmatis had the expected colony morphology with irregular edges and 
crenulated structures in the absence of tween, while the null mutant presented a glossier and 
less crenulated colony (figure 3.15). The difference was more prominent with the addition of 
0.05% tween in the media. The null mutant showed an interesting nodulated colony morphology 
as opposed to the non-crenulated dome-shaped glossy colony of the wild type M. smegmatis. 
The growth of the bacteria on the agar plates mirrored the growth defect observed in liquid 
culture (section 3.2.6). 
 
3.2.8 Loss of acid fastness in the null mutant of echA12 in M. smegmatis  
 
Mycobacteria are classified as acid fast bacteria and take up the stain of carbol fuchsin due to 
the high lipid content cell wall. The wild type M. smegmatis mc2155 and the null mutant of 
echA12 were stained using the Ziehl Neelson stain (section 6.22).  
 
Figure 3.16: Acid fast staining of M. smegmatis mc2155 and M. smegmatisΔechA12. The 
echA12 knockout mutant displays loss of acid fastness and decrease in cell size. 
The echA12 knockout mutant took up the secondary stain of methylene blue, causing the 
bacteria to look purple under the microscope, as opposed to the red stained bacteria for the wild 
A B
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type M. smegmatis (figure 3.16). This therefore indicates loss of lipid content or modifications 
in the cell wall of the mutant which would lead to loss of the primary stain during washing. It 
was also observed that the cell size of the null mutant was smaller than the elongated cell 
structures of the wild type M. smegmatis. This further adds to the previous observation that 
change in colony morphology and growth rate of the cell are caused by the loss of the echA12 
gene in the null mutant.  
 
3.2.9 Lipid analysis of the echA12 null mutant  
 
The lipid analysis was performed for the null mutant of echA12 and compared against the wild 
type strain of M.smegmatis mc2155. The apolar and polar lipid extractions did not depict any 
major variations when compared to the wild type. There was some loss of free fatty acids 
observed in system B when compared to the wild type strain (figure 3.17). As the cell bound 
lipids from the overexpression strains did not show any changes, the lipids were separated in a 
different solvent system which revealed phosphatidylinositols, phosphatidylethanolamine and 
cardiolipin moieties. There were no prominent changes that were noted in these species either.  
 




Figure 3.17: Lipid separation performed using 2-D TLC on a silica gel plate for apolar 
and polar lipids with System A, B, C, D (1. Apolar lipids) and E (2. Polar lipids). The TLC 
separation was performed for the wild type M. smegmatis mc2155 (WT) and the echA12 null 
mutant M. smegmatis mc2155ΔechA12 (KO). D1 and D2 represent the directions in which the 
TLCs were run in the solvent system. A 1-D TLC with lipids extracted using a 10:10:3 
Chloroform: methanol: water (v/v/v) extraction was separated using a solvent system of 
CHCl3/CH3OH/NH4OH/H2O (65:25:0.5:3.6). P, phospholipids; PI, phosphatidylinositol; FA, 
Free Fatty Acids; TAG, Triacyl Glycerol; TDM, Trehalose dimycolate; TMM, Trehalose 
monomycolate; Ac1PIM2, monoacylated phosphatidylinositol dimannoside; Ac2PIM2, 
diacylated phosphatidylinositol dimannoside; Ac1PIM6, monoacylated phosphatidylinositol 
hexamannoside; Ac2PIM6, diacylated phosphatidylinositol hexamannoside, CL, cardiolipin; 
PE, phosphatidylethanolamine.  
D1
D2
A B C D
E
1. Apolar lipids
























3. Lipid composition 
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3.2.10 Liquid Extraction Surface Analysis (LESA)- Mass Spectrometry analysis of 
the null mutant of echA12 in M. smegmatis 
The extraction of lipids was performed by solvent extraction from colony surfaces using a 
surface based mass spectrometric technique.  
 
Figure 3.18: The spectra from the LESA MS analysis of M. smegmatis wild type mc2155 
and the echA12 null mutant. The figure represents the mass spectrometry data with the masses 
and peak intensities of each peak. The spectras belong to the wild type M. smegmatis mc2155 
and the echA12 null mutant. The peaks have been annotated with the different Ac1PIM1 
molecules containing a different number of carbon atoms and double bonds.  
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The analysis of the lipid moieties extracted from the M. smegmatis  mc2155 and M. smegmatis 
echA12 null mutant was undertaken by assigning the peaks of observed masses from the MS 
analysis to different lipid molecules using LipidMaps Mass Spectrometry Peak Prediction 
software (Sartain et. al., 2011) (figure 3.18). It was observed that in the echA12 null mutant the 
Ac1PIM2 moieties were absent in all the different ionic states. Phosphatidylethanolamine (PE) 
was absent in the knockout null mutant in a C-38 form which contains two acyl groups with a 
total of 38 carbons and no double bonds. Other forms of Phosphatidylethanolamine that were 
present in both the strains were 34:1 and C-35 in a potassiated form, which meant that the 
molecule had two acyl groups containing a total of 34 carbons and 1 double bond and two acyl 
groups containing a total of 35 carbons without a double bond respectively.  
Another important observation made was that Ac1PIM1 molecules in the knockout had acyl 
groups containing only a specific number of carbons and double bonds when compared to all 
the forms observed in the wild type M. smegmatis. In the hydrated state the null mutant had 
only 5 out of the 26 types of monoacylated PIMs observed in the wild type strain, while in the 
potassiated state the null mutant had 8 out of the 16 monoacylated PIMs observed in the wild 
type M. smegmatis. The number of monoacylated PIMs observed in the knockout mutant were 
the least in number in the sodiated adduct when compared to the wild type strain. After the 
analysing the spectra derived from the LESA-MS and assigning the peaks to the molecules 
based on their masses, it was observed that the M. smegmatis wild type mc2155 strain had 
Ac1PIM1 molecules in the 50:2, 51:2, 52:3 and 53:3 at high intensities (figure 3.19). However, 
the other Ac1PIM1 molecules were not particularly intense, specifically 48:2, 49:2, 50:3, 51:3 
and 51:5. In the case of the echA12 null mutant Ac1PIM1 molecules were present in a low 
number and were only intense for the 52:5 form (figure 3.18). 




Figure 3.19: Structures of Ac1PIM1 molecules with different acylation states. The figure 
represents the structures of all the major Ac1PIM1 molecules observed in the wild type M. 
smegmatis which were absent in the echA12 null mutant. 
 
From the acetonitrile and ethanol/water extractions its was observed that the knockout did not 
contain lyso-Phosphatidyl inositol molecules with carbon chain length of 19 with one or two 
double bonds. 
Ac1PIM1 (50:2)
Ac1PIM1 (52:3) Ac1PIM1 (53:3)
Ac1PIM1 (51:2)
Ac1PIM1 (52:5) Ac1PIM1 (53:5)
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3.2.11 Amino acid alignment of echA12 orthologs 
 
The alignment of the amino acid sequence revealed similar results to the genomic alignment of 
echA12 in M. bovis. The amino acid sequence showed a 99.65% match to the EchA12 amino 
acid sequence in Mtb. It lost 0.35% identity due to the amino acid substitution in the 
spontaneous mutation caused by florfenicol in M. bovis BCG at the 239 position where the 
glycine residue is obaserved (figure 3.20). It was interesting to observe that although the gene 
alignment depicted that the M. smegmatis echA12 gene was only 74% (section 3.2.1) similar to  
 
Figure 3.20: Protein sequence alignment of EchA12 from different species of 
mycobacteria. The sequence alignment highlights residues which are conserved throughout all 
the different mycobacterial species (in red) showing a high level of homology. The protein 
alignment has been annotated with the various secondary structures in the protein based on the 
crystal structure of the EchA12 protein from M. abscessus (Mabs_EchA12). 
                            TT                              Mtb_EchA12              
  1       10        20        30        40        50        
Mtb_EchA12                                   V     RP  A  TLNRP RMN MA D M      L   V A  LVEHP  EI I     E   S  F V VPLK A V..VPHRCAAQ V GYRSTVSL Q E AQ
Mabs_EchA12                                  V     RP  A  TLNRP RMN MA D M      L   A  LVDRP  EI LV     E     F V LP K M I.....MGTLE QTQGPGSMSF A F Q VD
Msmeg_EchA12(MSMEG_3058)                      V     RP  A  TLNRP RMN MA D M      L   M  LLDR   V LV     E   S  F V VPL L L............ SVTDDTRF S G LE GD
Mlep_EchA12                                  V     RP  A  TLNRP RMN MA D M      L   A L  VLD P  EV LI        S   L LK V IMSQTDASCTI E PYRSVTDL F G L KS Q KR
   TT         TT                 TT                         Mtb_EchA12              
60        70        80        90       100       110        
Mtb_EchA12                D  VR V  TGAG GF  GAD K     P    LT P  ALR ME L  VIL LRR HS  NS  V VL    R      SAG V HVE    T    S  L DD   M   L Y SP H V N R Y
Mabs_EchA12               D  VR V  TGAG GF  GAD K     P    LT P  ALR ME L  VIL LRR HS  N   A VI    K  S    SAG I HI G   T    S  L DE      M H D C Q P G Q I T
Msmeg_EchA12(MSMEG_3058)   D  VR V  TGAG GF  GAD K     P    LT P  ALR ME L  VIL LRR H NS  V IL    R  S    SAG V HVDG   T    S  V D    A   L RH S H S R Y N
Mlep_EchA12               D  VR V  TGAG GF  GAD K     P    LT P  ALR ME L  VIL LRR HT  S  V VL    R  S    V VEG        L EE   A   L Y H C Q FTAP Q Q VR A
                            TT                              Mtb_EchA12              
120       130       140       150       160       170        
Mtb_EchA12              QPVIAA NG AIGGGLCLALA D R A   AYFRAAGINNGL ASELGLSYLLPRA G S      V              I V SS             T             I S P A S
Mabs_EchA12             QPVIAA NG AIGGGLCLALA D R A   AYFRAAGINNGL ASELGLSYLLPRA G S      I              V V SQ             T             I T A C D
Msmeg_EchA12(MSMEG_3058) QPVIAA NG AIGGGLCLALA D R A   AYFRAAGINNGL ASELGLSYLLPRA G S      V              V I             T             I T A C AHN
Mlep_EchA12             QPVIAA NG AIGGGLCLALA D R A   AYFRAAGINNGL ASELGLSYLLPRA G S      I              V V ST             S             V S P A R
                                                            Mtb_EchA12              
180       190       200       210       220       230        
Mtb_EchA12              RA  IML GRDV A EAE IGLVS  V    LL  C     R   FSR G ELTKR  W   FE   T     E   R     R  DE   D  Y IA  MAG   P I     TL SS Q P Q A A A
Mabs_EchA12             RA  IML GRDV A EAE IGLVS  V    LL  C     R   FSR G ELTKR  W   D   T     D   R     R  E   E  Y I  IAG   P I     TI SS D K AS S E A GE
Msmeg_EchA12(MSMEG_3058) RA  IML GRDV A EAE IGLVS  V    LL  C     R   FSR G ELTKR  W   FE   T        R     R  DD   E  F MA  M G   P I     TL SD A T P D T E Q R
Mlep_EchA12             RA  IML GRDV A EAE IGLVS  V    LL  C     R   FSR G ELTKR  W   FE   S     E         DD   D  Y IA  MA          L G Q YR S R T S A T S T A G
                                                            Mtb_EchA12              
240       250       260       270       280                  
Mtb_EchA12              GLDAASL  HM  E L QL   L T NFEEA A   E R     D                      E   Q  G G  FVR L      V AR   VF  A A A A Q AP T DT.......
Mabs_EchA12             GLDAASL  HM  E L QL   L T NFEEA A   E R     D                      E    G G  YVR L       AR  K P F  RS HQ D T K AE R K .......
Msmeg_EchA12(MSMEG_3058) GLDAASL  HM  E L QL   L T NFEEA A   E R     D                      E   Q  G G  FVR L      V AR  K P AF  KG A A A P T D .......
Mlep_EchA12             GLDAASL  HM  E L QL   L T NFEEA A   E R     D                      D   Q     FI        A  K P V  RK S S A A H S PCT T LV A GCATSPG
β1 β2 η1 α1 
β3 α2 
β4 β5 α3 β6 β7 α4 
α5 β8 α6 β9 η2 α7 α8 
α9 α10 
 




the Mtb echA12 gene, the amino acid sequence similarity was almost 80%. This potentially 
means that the protein structures might be fairly similar to each other. The secondary structure 
annotations revealed that the protein contains 10 a-helices and 9 b-sheets in its structure based 
on the crystal structure of M. abscessus EchA12 structure. The residue which underwent the 
amino acid substitution in response to florfenicol occurs in a a-helix loop (figure 3.20). 
3.2.12 Purification of the EchA12 protein from the M. smegmatis overexpression 
strains 
 
The EchA12 protein was purified from M. smegmatis overexpression strains containing the 
pVV16_echA12_Rv and the pVV16_G239_echA12 constructs. The protein was initially 
extracted at a small scale and confirmed colourimetrically for size on a western blot. The 
EchA12 protein is 30.6KDa in size and presents a band on the SDS- gel and the blot just above 
the corresponding 25KDa band on the protein ladder (figure 3.21A). The protein purification 
was subsequently scaled up to get a higher amount of protein, although it was difficult to obtain 
the protein in very high concentrations due to its membrane bound nature and low affinity to 
the nickel column, which might be due to its structural nature. Both the EchA12 proteins elutes 
at imidazole concentrations of 150 and 200mM (figure 3.21 B1 and B2).  




Figure 3.21: Protein expression of echA12 protein using the pVV16_EchA12_Rv and 
pVV16_EchA12_G239R construct in M. smegmatis. A. A SDS protein gel with a 
corresponding western blot depicting the protein fractions from a small-scale protein extraction. 
1. EchA12 protein from the pVV16_echA12_Rv construct, 2. EchA12 protein from the 
pVV16_echA12_Rv construct. The band can be visualised at the 25kDa band on the protein 
ladder for the 30.6KDa EchA12 protein and colourimetrically on the western blot to confirm 
the histidine linked EchA12 protein. B SDS protein gels depicting the protein fractions at 
various imidazole concentrations collected during the large-scale protein expression. 1B. 
EchA12 protein from the pVV16_E- chA12_Rv construct; 2B. EchA12 protein from the 
pVV16_EchA12_Rv construct. The gel contains (from left to right) a protein ladder (L), cell 
lysate (Lys), flow through (FT), the wash fraction (W) at 25mM imidazole concentration and 
then the other fractions for imidazole concentrations 50mM, 75mM,100mM,150mM,200mM 
and 225mM. The Echa12 protein (30.6KDa) was eluted at imidazole concentrations 150mM 
and 200mM. B. The band can be visualised at the 25kDa band on the protein ladder.  
 
3.2.13 EchA12 interaction with palmitoyl coenzyme A (Palmitoyl CoA) 
Solvent extraction of the EchA12 protein revealed that the protein co-eluted with a coenzyme 
A molecule.  






L        1        2       
25KDa
30.6KDa








Figure 3.22: The mass spectrometric analysis of the EchA12 protein solvent extracted and 
run on a silica TLC (inset) with other controls on the TLC. 1. Coenzyme A, 2. C8-Coenzyme 
A, 3. C12- Coenzyme A, 4. C14- Coenzyme A, 5. C16- Coenzyme A, 6. EchA12 solvent extract, 
7. Buffer control. The mass spectrometric analysis of the solvent extract of the protein depicts 
a peak with the m/z ratio of 1027.66 which correlates to the sodium adduct of C16-Coenzyme 
A.  
 
In order to determine the chain length of the eluted coenzyme A, standard CoA with different 
chain lengths were run alongside the solvent extracted EchA12 (figure 3.22 inset). The protein 
extract showed a spot in line with C12 to C16 coenzyme A and therefore in order to confirm the 
exact chain length, the spot was then extracted and tested using mass spectrometry. The mass 
spectrometric analysis confirmed that the EchA12 protein interacted and co-eluted with a 
plamitoyl coenzyme A (figure 3.22). The peak of the extract had a mass/size ratio of 1027.66 
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3.2.14 EchA12 binds to Phosphatidylinositolmannosides (PIMs) 
 
The EchA12 protein was purified from the M. smegmatis strains containing the 
pVV16_echA12_Rv and pVV16 G239R_echA12 vectors (figure 3.23).  
 
Figure 3.23: The mass spectrometric analysis of the solvent extract of EchA12 from M. 
smegmatis. The peaks show the sodium and potassium adducts of phosphatidylinositol (PI) and 
phosphatidylinositol mannoside (PIM1). A. Represents the data for Echa12 from the 
pVV16_echA12_Rv construct and B. Represents the data for EchA12 from the pVV16_ 
G239R_echA12 construct. C. Presents the structural details and formulas of PI and PIM1.  
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Lipid extractions were performed on the proteins to determine the binding of the proteins with 
lipid moieties. The extracts were then sent for MALDI-TOF mass spectrometric analysis and it 
was observed that both EchA12_Rv (figure 3.23A) and EchA12_G239R (figure 3.23B) had 
phosphatidylinositol and phosphatidylinositolmannoside1 molecules.  
 
Figure 3.24: Structure of PI and PIM1. Represents the data for EchA12 from the pVV16_ 
G239R_echA12 construct. C. Presents the structural details and formulas of PI and PIM1.  
 
The peaks depicted in the mass spectrometry graph matched the sodium and potassium adducts 
of PI and PIM1 (figure 3.23A and B). The molecular masses were confirmed to be the same 
when the molecular mass of sodium and potassium were deducted from the observed masses 
(figure 3.24). 
 
3.2.15 Model structure of EchA12 illustrating site of mutation (likely interaction 
site with florfenicol) and Palmityl-CoA.  
 
The structure of the EchA12 protein was determined using the 




















































































Figure 3.25: An I-TASSER model of the EchA12 protein using the EchA6 protein 
structure as a scaffold. A. The model structure of EchA12 in beige has been modelled on to 
one of the monomers of the EchA6 trimer, presented by the three monomers in pink, purple and 
green. On the EchA12 monomer, the red residue on the a-helix indicates the site of the mutation 
causing the G239R substitution. B. The model structure of the EchA12 monomer on the EchA6 
scaffold with the palmitoyl CoA docked into the potential binding site. The mutation G239R 
has been highlighted in red on the hinge region of the a-helix loop. 
 
We used the EchA6 protein model (Cox et. al., 2016a) as a template to act as a scaffold to 
generate the EchA12 protein structure. The model represented here is of the monomer of the 
EchA12 protein superimposed on one of the monomers of the EchA6 trimer (figure 3.25A). 
The protein structure contains the mutated amino acid residue highlighted in red where there 
was substitution at the 239 position from glycine to an arginine residue.  
I-TASSER utilises a template model to thread the predicted protein structure. The substitution 





Figure 3.8: EchA12 monomer fitted onto scaffold of EchA6 trimer. Proposed monomer structure 
of EchA12 in beige (A) superimposed onto the trimer of EchA6 (in pink, green and purple). High-
lighted in red is the G239R substitution. The α-helices of EchA12 change position when bound with 
substrate (dotted arrow) (B). Also depicted is the protein trimer in complex with CoA substrate (pink, 
blue and red).  
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to the substituted residue. The binding pocket for the Palmitoyl CoA is situated above this a-
helix loop (figure 3.25B). The predicted interaction of florfenicol seems to occur in the hinge 
region of this protein due to the occurrence of the mutation. The interaction potentially caused 
a disruption in the movement of the hinge in the a-helix loop which interacts with a-helix loop 
on another EchA12 protein, forming a dimer. This disruption of the a-helix interaction and 
movement of the hinge region could lead to the inability of the protein to interact with another 
EchA12 monomer and affect the docking of the Palmitoyl CoA into the binding site. The amino 
acid substitution probably causes a change in the interaction with florfenicol, while at the same 
increasing the hydrogen bonding with the neighbouring asparagine residues thereby increasing 




In understanding the functional and genetic importance of the enoyl CoA hydratase targeted by 
a chloramphenicol derivative (chapter 2), we have discovered that the echA12 gene is a 
conserved gene between major classes of pathogenic and non-pathogenic mycobacteria. The 
gene has a highly-conserved region with M. leprae, which has the smallest genome in 
mycobacteria due to reductive evolution (Singh and Cole, 2011). This evidence, along with the 
presence of the gene in M. bovis and the saprophytic strain M. smegmatis, indicates that the 
gene might be important for the bacteria to grow or survive. Further investigations revealed that 
the gene was not required for survival and therefore was non-essential due to the generation of 
a null mutant of the gene. However, it was observed that the null mutant of the gene exhibited 
physiological changes such as change in the colony morphology, growth rate and loss of acid 
fastness. This suggested potential changes in the cell wall components or metabolism. Due to 
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its potential involvement in fatty acid biosynthesis (Beckman and Kranz, 1991), analysis of 
lipids from overexpression strains of echA12 in M. smegmatis  and M. bovis  BCG was 
undertaken. This revealed that there was an accumulation of ketones and a change in 
phospholipid profiles in bound lipids. Solvent extractions of the proteins revealed that the 
protein interacted with PI and PIM1. Phosphatidyl-myo-inositol is an essential phospholipid in 
the cytoplasmic membrane, it is synthesised from inositol by an enzyme PgsA 
(phosphatidylinositol synthase) (Jackson et. al., 2000b) and acts a starting molecule for the 
formation of PIMs and LAM. PIMs are important cell wall molecules which are present in both 
mycobacteria and corynebacteria (Crellin et. al., 2008). It has been observed that depletion of 
PI and PIMs does not affect the viability of mycobacteria, but depleting polar PIMs such as 
Ac1PIM6 and Ac2PIM6 does effect the viability by compromising the cell wall integrity. It is 
known that apolar PIMs are precursors to the synthesis of polar PIMs, yet reserves of PI and 
apolar PIMs (Ac1PIM2 and Ac2PIM2) are not necessary to maintain the synthesis of polar PIMs. 
De novo synthesis of PI or production of PI through the catabolism of lyso-PI is used as a 
supplement for the synthesis of PIMs and LM/LAM, circumventing the absence of apolar lipids 
(Haites et. al., 2005). In the echA12 null mutant, it was observed that apolar PIMs, along with 
Lyso-PI, were absent in certain chain lengths, yet the cells were viable albeit slow growing. 
This could be a possible reason as to why the cell wall integrity was not majorly affected in the 
absence of the apolar PIMs. Polar PIMs are synthesised in the plasma membrane and cell wall, 
the role of some of the enzymes involved in the biosynthetic pathway is to take the transitional 
components from the cytoplasmic face of the plasma membrane to the periplasmic side of the 
plasma membrane. This variation helps to regulate the synthesis of the cell wall and growth rate 
of the bacterium (Morita et. al., 2005). It was noted that the Ac1PIM1 molecules observed in the 
M. smegmatis wild type strain in various acylated states had the presence of a palmitoyl group 
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attached to the mannose residue in the PIM molecule. However, this was not found to be the 
case when the analysis was performed for the acylated Ac1PIM1 molecules observed in the 
echA12 null mutant. As our analysis showed that the EchA12 protein interacts and carries the 
palmitoyl CoA, it is therefore clear that due to the absence of the enzyme the metabolism was 
skewed towards non-palmitoyl CoA groups. PatA is a membrane associated acyl transferase 
which has been identified as the enzyme that transfers the palmitoyl CoA on to the 6th position 
of the mannose ring in PIM1 or PIM2 molecule (Albesa-Jové et. al., 2016). On the basis of our 
observations, it was inferred that PatA might be a promiscuous enzyme which, in the absence 
of a palmitoyl CoA donor, is able to incorporate non-palmitoyl CoA moieties on to the 
mannoside residue, driving the PIM biosynthesis forward. This would explain the presence of 
PIM molecules observed during the TLC analysis of lipids. The PIMs observed in that scenario 
were of a different acylation state not containing the palmitoyl moieties, therefore depicting no 
obvious variation. The metabolic shift in the lipid biosynthesis and variation in the lipid 
composition of the cell wall could therefore explain the loss of acid fastness and the slow 
growing null mutant.  
Enzymes and molecules involved in cell division are contributing factors to cell growth. 
Cardiolipin is an acidic phospholipid synthesised by cardiolipin synthase which is present in 
the cell membrane of mycobacteria. A higher concentration of the lipid is observed at the septa 
in the middle of the cell and at the poles of actively dividing cells (Maloney et. al., 2011). It 
has also been known to interact with gyrases and activates polymerases in the cell (Sarma et. 
al., 1998). This indicates that it has a role in cell division (Maloney et. al., 2011; Sarma et. al., 
1998). The lipid analysis of the echA12 knockout revealed the absence of cardiolipin which 
would explain the slow growth of the mutant. The synthesis of cardiolipin has been predicted 
to involve that utilisation of phosphatidylethanolamine (Aktas et. al., 2014), this might explain 
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the absence of cardiolipin in the echA12 null mutant as the PE is absent in the mutant when 
observed via the LESA-MS analysis. This subtle change identified through the LESA study 
could explain why there were no obvious changes observed in the TLC analysis previously 
undertaken. The structural prediction studies and the analysis of the cell lipid content in the 
echA12 null mutant indicate the role of the enzyme in shuttling the palmitoyl CoA molecule for 
PIM synthesis. The interaction of florfenicol with the enzyme might be hindering the binding 
of the palmitoyl CoA, leading to the enzyme’s inability to carry the molecule. Although this 
causes a non-lethal change in the composition of the cell wall, it causes the bacterium to slow 
down and potentially leads to a more vulnerable pathogen, indicating that EchA12 could still 





Target based phenotypic screen of the 
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Target based drug screening is another approach in drug discovery which has been utilised to 
discover new antimicrobials. The target based drug discovery approach rests on a hypothesis 
that the target protein/ enzyme/ mechanism is potentially disease modifying. This method is 
technically less labour intensive when compared to a more genralised phenotypic screen which 
involves a longer and more tedious process of identifying targets of the identified inhibitors for 
a specific pathogen. Pathway specific screens and promoters are limited in many ways as they 
only work for specific metabolic pathways (Singh et. al., 2013) and also affect drug interaction 
in vivo with a lower possibility of growth inhibition (Mdluli et. al., 2014). Target based 
approaches have a high attrition rate which affect the efficiency of the screen in general (Singh 
et. al., 2013). The prevailing methodology used in TB drug discovery is phenotypic screening 
as target based screening has largely been abandoned. The lack of detailed understanding of the 
cellular metabolism of Mtb during infection limits the target validation. Furthermore, the 
hydrophobic cell wall acts as a barrier which, when combined with the limited availability of 
chemically diverse groups, leads to issues with cell wall permeability at a later stage (Kana et. 
al., 2014). It is therefore important to understand the initial criteria for target selection in order 
to avoid failure at a later stage of the drug discovery process. A good target should have 
important properties such as; essentiality to cell growth or viability in vivo, druggablility and 
location in a position easily accessible by the inhibitory molecule (Kana et. al., 2014). In 
addition, there needs to be a clear understanding of whether it is a genetic target, which involves 
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one specific gene having a specific function during stages such as infection and host invasion, 
or a mechanistic target, which affects a chain of molecular events in a biosynthetic cycle (Sams-
Dodd, 2005). This is important as Mtb has a genetic redundancy which probably increases the 
robustness of an organism and its ability to survive under stress (Kafri et. al., 2006). For 
example, there are approximately 100 genes in the mycobacterial genome designated for the 
five biochemical reactions in the b-oxidation cycle. Although most of these genes are non-
essential some of the genes which have been known to be essential via transposon mutagenesis 
are not essential when tested experimentally and vice versa (Williams et. al., 2011). Another 
interesting thing about these paralogues is the roles that they play in vivo are different to the 
assigned or expected roles. The enzyme encoded by fadB3 which catalyses the fourth reaction 
in the b-oxidation cycle and is the only one deemed as essential out of the five encoded by Mtb 
to be essential. Studies in vivo have depicted up- and down-regulation of fadB3, fadB2, fadB4 
and fadB5 in the mice infections, macrophage infections, nutrient deprivation and acidic 
conditions. This clearly indicates towards a different role of these genes in vivo (Williams et. 
al., 2011). Mtb and C. glutamicum multiple copies of the GroEL gene which are essential and 
conserved although seemingly accumulate non-conserved mutations which affect the structure 
and function of the protein (Goyal et. al., 2006). Therefore, it is very important to have a clear 
understanding of the target in order to avoid a high attrition rate which is the main issue for 
target based drug discovery for tuberculosis. 
Primarily there are three ways of validating the targets and confirming mode of actions of the 
compound active against a target in the drug discovery process. These are: 1) generation of 
spontaneous resistant mutants, 2) over or under-expressing the target gene in a conditional 
mutant and 3) culturing pooled mutants in the presence and absence of the compound to see 
phenotypic variation (Schnappinger, 2015). Once a drug target has been validated it can then 
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be used in a combined approach involving target based phenotypic screening. This allows the 
benefit of having a targeted screen but in a whole cell which minimizes the issues that occur 
downstream from a target based screen. There have been recent examples of compound hits 
generated against validated targets using this approach. Inosine monophosphate dehydrogenase 
(IMPDH) or GuaB2 is an enzyme involved in purine biosynthesis. A class of 7 chemical clusters 
were identified to be targeting this enzyme through M. bovis BCG overexpression strains (Cox 
et. al., 2016b). A compound from the GSK library was identified against a CTP synthetase 
PyrG through a conditional knock strain generated for PyrG after target validation, The 
compound 4-(pyridine-2-yl)thiazole derivate showed a high inhibitory activity against 
mycobacterial CTP synthetase and a low activity against human CTP synthetase (Esposito et. 
al., 2017). This is a potentially more feasible and effective approach which could generate a 
higher amount of lead compounds.  
The current TB drug regimen includes drugs which inhibit the cell wall synthesis processes 
such as isoniazid and ethambutol (Breda et. al., 2012; Alderwick et. al., 2011), but in view of 
the emerging drug resistant strains newer drugs are required and the metabolic pathways 
involved in energy exchange mechanisms and cell wall synthesis are interesting targets. DprE1 
is the most prominent example of a target gene involved in cell wall synthesis which has led to 
a new class of drugs that have been approved for tuberculosis treatment. DprE1 is a vulnerable 
target involved in the epimerisation of decaprenylphosphoryl-b-D-ribose (DPR) to 
decaprenylphosphoryl-b-D-arabinose (DPA), the precursor to arabinose in the cell wall (figure 
4.1) (Trefzer et. al., 2010). With the deconvolution of the structure of the protein it was found 
that benzothiazinones (the class of drugs inhibiting the enzyme) interact with the protein 
through covalent bonding at the cysteine 387 residue and Van der Waals interaction between 
the triflouromethyl group of the inhibitor and protein backbone residues 132-134 (Batt et. al., 
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2012). This target has now lead to the synthesis of new drug classes and modification of the 
current drug classes such as azaindoles, dinitrobenzamide and 8-pyrrole benzothiazinones all 
inhibiting the DprE1 enzyme (Trefzer et. al., 2010; Shirude et. al., 2013; Makarov et. al., 2015). 
  
Figure 4.1: The biochemical pathway describing the synthesis of cell wall components. 
The figure details the synthesis of DPA through utilisation of ribose-5-phosphate by the PrsA 
enzyme and shuttling of the decaprenol-1-monophosphate 5-phosphoribosyltransferase into the 
extracellular space to be converted into cell wall macromolecules.  
pRpp : Phospho-α-d-ribosyl-1-pyrophosphate; DP: decaprenol-1-monophosphate; DPR 
decaprenol-1-monophosphoribose; DPX: decaprenol-1-monophosphoryl-2-keto-β-erythro-
pentofuranose; DPA: decaprenol-1-monophosphoarabinose (Alderwick et. al., 2011) 
 
PrsA is a phosphoribosylpyrophosphate synthase that is upstream of the DprE1 protein in the 
synthesis of the cell wall macromolecules (figure 4.1). The PrsA protein has been divided into 
three classes based on its molecular and kinetic characters (Alderwick et. al., 2011). The 
mycobacterial PrsA has been defined as class I due to its hexameric structure which is very 
specific to its substrate and needs an inorganic phosphate for activation. The mycobacterial 
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PrsA depicts 40% identity to the three human PrsA isoforms although there are two major 
substitutions in the mycobacterial PrsA at the substrate binding site when compared to the 
human PrsA protein (Lucarelli et. al., 2010; Breda et. al., 2012). 
Phospho-α-D-ribosyl-1-phosphate (pRpp) is the metabolite which links the pentose phosphate 
pathway to the de novo and salvage pathway for purine and pyrimidine production (Alderwick 
et. al., 2011). The gene responsible for the production of the enzyme converting ribose-5-
phosphate into pRpp in the presence of ATP is PrsA. The gene has been determined to be 
essential for the survival of the cell and a decrease in the product has a pleiotropic effect on the 
cell such as cell elongation and implosion (Kolly et. al., 2014; Alderwick et. al., 2011). This 
protein has therefore been validated as a suitable drug target that could be used in target-based 
drug discovery screen. 
In this chapter, we screened a library of compounds synthesised by GlaxoSmithKline (GSK). 
This library contains 177 compounds depicting inhibitory activity against M. bovis BCG and 
M. tuberculosis H37Rv which were shortlisted from approximately 2x106 chemical compounds 
after several iterations. The initial screen was performed against M. bovis BCG which has 
almost 99% similarity to the genome of Mtb H37Rv leading to a subset of approximately 
20,000. These 20,000 compounds were selected from the hits based on permeability, stock 
availability within the company and followed the guidelines of a drug. These were then further 
assayed against Mtb H37Rv and M. bovis BCG to compare the hit rates. 127 hits from the 
primary screen inhibited M. bovis BCG and 112 compounds inhibited Mtb H37Rv. They also 
analysed which compounds where cross inhibiting both strains with two concentrations of the 
compounds which were 10µM and 25µM. They found a 97% increase in cross-reactivity for 
the compounds when they increased the concentration from 10µM to 25µM. The compounds 
were then further shortlisted based on inhibition percentage of >90%, log P vale of >6, presence 
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of new chemical cluster while discarding any known antibacterial structures and compounds 
with reactive groups. After the dose response studies and cytotoxicity testing against the HepG2 
cells, 177 compounds were shortlisted which had MIC values of less than 10µM and a 
therapeutic index of more than 50. They were then tested for broad spectrum activity against 8 
different bacterial strains where 7 specific chemical clusters depicted very high affinity for 
mycobacteria and were classified as potential leads. Although these compounds have shown a 
high antitubercular activity, it is still unclear as to what is the target of these chemical entities 
in Mtb. In an attempt to de-orphanise the GSK177 compound set we screened this library 
against a validated drug target which is essential for the survival of the mycobacteria and is 
involved in the synthesis of the cell wall using a target based phenotypic approach.  
 
4.2 Results  
 
4.2.1 Cloning of Mtb-prsA in pMV261 for the Mtb-prsA overexpression strain 
 
In order to develop an overexpression strain of Mtb-prsA gene was cloned into a pMV261  
 
Figure 4.2: Plasmid map of the pMV261 vector. The pMV261 vector is a 4.5 Kb plasmid 
containing multiple cloning sites and a kanamycin antibiotic selection marker (Stover et. al., 
1991).  
assay plate had a positive control and a negative control. The n gative control had no enzyme 
present. The screen was performed in duplicat s.  
 
4.8 Cloning of prsA gene into pMV261 and pET vectors 
 
4.8.1 pMV261 vector 
pMV261 is a mycobacterial replicating vector, which has a kanamycin antibiotic marker and a 
hsp80 promoter. The vector was derived from pBR322 and has three open reading frames and a 
number of restriction enzyme sites as shown in fig.5. 
 
                                              
             Figure 24: A plasmid map of the pMV261 vector (Stover et al., 1991) 
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shuttle vector which replicates inside mycobacteria. The vector is derived from a pBR322 
vector and contains three open reading frame with multiple cloning sites (MCS). The plasmid 
is 4.48Kb in size and contains a kanamycin antibiotic selection marker (figure 4.2).  
The Mtb-prsA gene was amplified by PCR (figure 4.3A) and cloned into the mycobacterial 
vector pMV261 as mentioned in section 6.8.  
 
Figure 4.3: Cloning of the Mtb-prsA gene into the pVV16 vector. The figure shows agarose 
gel images of the amplified Mtb-prsA gene at 981bp (A) with respect to a 1Kb DNA ladder and 
double digest of gene cloned into to the pmV261 vector 4.45Kb (B). 
 
The overexpression strains were generated in M. smegmatis, M. smegmatis _psMT3_eGFP, M. 
bovis BCG and M. bovis BCG_pSMT3_eGFP (section 6.9) once the clones were confirmed 
through double digestion (figure 4.3B) and sequencing the plasmid. 
 
 





  L          
1Kb prsA (981bp)
A B
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4.2.2 Screening the GSK177 library against Mtb-prsA overexpressing strains 
 
An overexpression screen at single compound concentration was performed against an extended 
library of the GSK 177 collection containing 201 compounds (Appendix 16). The compounds 
from the library were re-distributed into three separate plates in order to accommodate columns 
for positive and negative controls. The compounds from the extended GSK177 library were 
screened, against A GFP fluorescing strain of M. bovis BCG overexpressing the Mtb-prsA gene, 
at a final concentration of 10µM with Z¢ score for all the plates being 0.7 on an average. Since 
there are no known inhibitors of the Mtb-PrsA enzyme it was not possible to have a control 
with an inhibitor for the overexpression screen. The overexpression of the pMV261_prsA 
containing strain was compared to a wild type GFP expressing M. bovis BCG strain. The 
average fold change (for the two replicates) was calculated after the data was normalised against 
the controls to determine percentage survival values and a cutoff of 1.5-fold change was set for 
M. bovis BCG (figure 4.4).  
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Figure 4.4: Fold change in survival percentages against the extended GSK177 compound 
library. The scatter graphs in the figure represent the average fold change of two replicate 
plates comparing the overexpression of the Mtb-prsA overexpression strains with respect to the 
empty vector containing strain. The X-axis represent the sample number in each plate against 
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20 hits were observed amongst the three plates containing the GSK compounds out of which 
GSK1051703A, GSK135487X and GSK1829728A had fold change of 2 or higher (table 4.1) 
indicating a strong possibility of the target of these compounds being the Mtb-PrsA enzyme. 
There were 4 other compounds which had a fold change of ~1.9 and therefore represented 
strong candidates as Mtb-PrsA inhibitors (table 4.1). The remaining compounds had fold 
change values of 1.6 or higher which could be either weak inhibitors or false positive values 
which would be confirmed through biochemical assays (Appendix 15).  
Table 4.1: Table representing the compounds that showed activity against Mtb-prsA based 












1/X10 1.56 G214G8D GSK353071A A11 
1/X11 1.69 G214G8D GSK1857145A B2 
1/X19 1.76 G214G8D GSK921295A B10 
1/X22 1.97 G214G8D GSK2059310A C3 
1/X23 1.59 G214G8D GSK1329151A C4 
1/X26 1.75 G214G8D GSK1783710A C7 
1/X29 2.20 G214G8D GSK1051703A C10 
1/X34 1.77 G214G8D GSK1985270A D5 
1/X38 1.76 G214G8D GSK2379464A D9 
1/X41 1.55 G214G8D GSK1925843A E2 
1/X42 1.86 G214G8D GSK2215855A E3 
1/X48 1.57 G214G8D GR153167X E9 
1/X49 2.15 G214G8D GR135487X E10 
1/X52 1.53 G214G8D GSK735816A F3 
1/X57 1.86 G214G8D GSK2247256A F8 
1/X61 1.58 G214G8D GSK1829729A G2 
2/X13 2.00 G214G8E GSK1829728A B4 
2/X15 1.98 G214G8E GSK810016A B6 
2/X34 1.59 G214G8E GSK2200160A D5 
3/X23 1.62 G214FNZ GSK2595882A C4 
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4.2.2 Cloning the Mtb-prsA gene into a pET-SUMO expression vector 
 
The Mtb-prsA was cloned into a pET-SUMO expression vector which was used as an 
expression vector for the production of the Mtb-PrsA protein.  
 
Figure 4.5: Plasmid map of the pET-SUMO vector. The pET-SUMO vector contains a 
region with multiple cloning sites (MCS) which is placed downstream to the lac operon and the 
SUMO gene. The plasmid has an antibiotic marker for kanamycin. 
 
The protein production could be induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) 
under the control of the lac operon (figure 4.5) and the plasmid containing colonies could be 
selected with the kanamycin antibiotic marker.  
The Mtb-prsA gene was amplified using PCR to give 918bp amplified fragments of the gene 
(figure 4.6A). This gene was then ligated to the pET-SUMO vector after double digestion and 
the positively selected colonies containing the kanamycin resistance gene were tested for the 
presence of the plasmid containing the Mtb-prsA gene through double digestion (figure 4.6 B).   
4.8.2 pETSUMO 
                                             
    
                                   Figure 25: A plasmid map of the pETSUMO MCS vector 
4.8.3 PCR amplification of the prsA gene 
Requirements: Primer pairs (table 6), Phusion enzyme, dNTPs, GC buffer, Water, DMSO, MgCl2, 





SUMO with MCS – P. Moynihan 
Invitroge  Champion p T-SUMO with MCS 
 
I have modified the original pET-SUMO vector to include an MCS. When cloning if possible use 
the BamH I site for your 5’ restriction site. This will add an N-terminal Glycine and Serine, which 
should not have a significant impact on protein function. If you use the other sites it will result in 
additional non-native amino acids at the N-terminus of your final protein product. Any of the 
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Figure 4.6: Cloning of the Mtb-prsA gene in the pET-SUMO expression vector. A. 
Represents the PCR amplified Mtb-prsA gene (981bp) product on an agarose gel. The PCR 
product is separated with a 1Kb ladder and the amplified bands can be seen lined up next to the 
1Kb band on the ladder. B. Represents an agarose gel of the double digested plasmids isolated 
from positively selected colonies. Lane 1 and 3 show the presence of the Mtb-prsA gene at the 
1Kb band on the ladder while the pET-SUMO vector (5.6Kb) can be observed next to the 6Kb 
band on the ladder. Lane 2 represents a negative result with the absence of the gene drop out.  
 
Plasmids containing the Mtb-prsA genes were sent for sequencing for further confirmation 
before use for producing expression strains. 
 
4.2.3 Expression and purification of the Mtb-PrsA enzyme  
 
The Mtb-PrsA enzyme was expressed and purified as mentioned in section 6.13.1, for target 
based screening against the GSK177 library. As shown in figure 4.7A, the enzyme elutes 
(35.459KDa) at 200mM and 225mM on the imidazole concentration gradient. The histidine 









  L             1       2                                            L          1           2            3    
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Figure 4.7: Protein expression of Mtb-PrsA using the pET-SUMO_prsA construct. A. SDS 
protein gels depicting the protein fractions at various imidazole concentrations collected during 
the large-scale protein expression. The gel contains (from left to right) a protein ladder (L), cell 
lysate (Lys), flow through (FT), the wash fraction (W) at 50mM imidazole concentration and 
then the other fractions for imidazole concentrations 75mM, 100mM, 125mM, 150mM, 
175mM, 200mM, 225mM, 275mM and 500mM. The Mtb-PrsA protein (35.459KDa) was 
eluted at imidazole concentrations 200mM and 225mM. B. The figure depicts a SDS gel and a 
western blot to confirm the histidine linked Mtb-PrsA protein through a colorimetric detection 
procedure. The band can be visualised at the 35kDa band on the protein ladder.  
 
4.2.4 Optimisation of the Mtb-PrsA enzyme assay 
 
The purified protein was tested for activity and titrated to monitor substrate utilisation in order 
to extend the length of the assay. The enzyme was titrated to approximately 0.1µg/µL so that 
the substrate conversion could take place over approximately half an hour. As mentioned in 
section 4.2.3, the enzyme was used to screen the GSK177 library for target protein inhibition. 
In order to be able to analyse the inhibition of the enzyme with the compounds in the GSK177 
library, an enzyme titration was performed to enable measurement of NADH conversion over 
a reasonable period of time. The Mtb-PrsA enzyme was titrated at 0.75µg/µL, 0.5µg/µL and 
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0.1µg/µL and tested for NADH conversion till the fluorescence level reached zero indicating 
utilisation of the substrates. 
 
Figure 4.8: Optimisation of Mtb-PrsA and DMSO concentration in the enzyme assay. A. 
Represents the conversion of NADH by Mtb-PrsA enzyme at different concentration measured 
in fluorescence units. B. Represents the rate of conversion of NADH in the enzyme couple at 
different DMSO concentrations relating its effect on Mtb-PrsA enzyme activity.  
 
It was observed that 0.1µg/µL was the optimum enzyme concentration to be used as it allowed 
for the reaction to progress for nearly half an hour while at other two concentrations the enzyme 
utilizes the substrate within 10-20mins (figure 4.8A). 
The compounds that were screened against Mtb-PrsA were solubilised in DMSO and therefore 
it was imperative to test the effect of the solvent on the activity of the enzyme. The activity of 
the enzyme was studied by its ability to be able to convert substrates and measured by the rate 
of depletion of the NADH. Five different concentrations of DMSO were tested in the assay at 
0.25%, 0.5%, 1%, 1.5% and 2%. The rate of NADH depletion remained fairly stable at 
0.016mM/min at DMSO concentrations of 0.25%, 5%, 1% and 1.5% matching the rate in the 
absence of DMSO. The rate decreased at 2% DMSO concentration to 0.015mM/min (figure 
4.9B). 
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Figure 4.9: Calibration of NADH concentration and conversion in the assay. A. Represents 
the fluorescence units of NADH at different NADH concentration in the assay mixture relating 
the amount of fluorescence to the amount of NADH added into the mixture. B. The rate of 
NADH conversion at different Mtb-PrsA enzyme concentrations. 
 
In order to determine the amount fluorescence emitted by NADH in a concentration dependant 
manner the fluorescence units were measured against the NADH concentration in the assay. 
The fluorescence follows a concentration dependant linear pattern (figure 4.9A) and was helpful 
in determining the upper limit of the fluorescence when normalising the enzyme screen data. 
The NADH turnover was tested with different concentrations of the Mtb-PrsA enzyme in order 
to confirm that the concentration of Mtb-PrsA enzyme being considered was appropriate. The 
NADH turnover rate at 0.1µg/µL was 0.016mM/min while the rates for 0.5µg/µL and 
0.75µg/µL were 0.12mM/min and 0.22mM/min respectively. The rate was 7.5 time faster at an 
enzyme concentration of 0.75µg/µL in comparison to 0.1µg/µL which explains the relatively 
quick decline in fluorescence units observed before (figure 4.9A). It was therefore confirmed 
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4.2.4 GSK177 compound screens against Mtb-PrsA enzyme 
 
The GSK177 compound library was reintroduced into new intermediate plates for use with new 
annotations to include columns for positive and negative controls (Appendix 17). Two separate 
sets of compound screenings were performed against the Mtb-PrsA enzyme with the final 
compound concentration of 20µM in 30% DMSO therefore making the final DMSO 
concentration 1.5% in the assay along with both positive and negative controls (section 6.14.2). 
Since there are no known inhibitors of the Mtb-PrsA enzyme it was not possible to have a 
control with an inhibitor. The compounds were incubated initially with the substrate and read 
as an end point assay after incubation with the Mtb-PrsA enzyme for ~30mins.  
 
4.2.4.1 GSK177 compound screen against Mtb-PrsA enzyme 
 
Hits were shortlisted based on their ability to limit enzyme activity to or below 50% (figure 
4.10, 4.12).  The initial set of biochemical screening against the GSK 177 library did not reveal 
as many hits as observed from the overexpression screen. The screen also depicted fairly high 
(almost 100%) activity percentages against most of the compounds. Although two hits were 
observed from plate 1 of the GSK 177 plate GSK1829727A and GR135487X which inhibited 
the enzyme activity to 45% and 24% respectively. GR135487X was one of the compounds that 
was highlighted as inhibiting the Mtb-PrsA enzyme in the overexpression screen performed 
again M. bovis BCG. This proved that this particular compound is potentially a strong inhibitor 
of the enzyme both in the biochemical assay and a target based whole cell assay.  
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Figure 4.10: Biochemical screen of the GSK177 library against Mtb-PrsA.The scatter graph 
represents the average percentage activity of the Mtb-PrsA enzyme against 20µM concentration 
(in 30% DMSO) of the GSK 177 drug library. The table below each scatter graph lists the hits 
with details of the compound identification and percentage activity. 
 
4.2.4.2 IC50 analysis of the compound GR135487X 
 
The IC50 analysis was performed for the compound GR135487X which displayed a very strong 
inhibitory activity in both the whole cell screen and the biochemical assay against Mtb-PrsA. 
The GR135487X IC50 was 0.62µM against the Mtb-PrsA enzyme. The IC50 value observed here 
was much lower to the in vivo inhibitory concentration (MIC90) observed against H37Rv was 
2.2µM (Sorrentino et. al., 2015). The compound was tested against intracellular mycobacteria 













































































































G8 GSK1829727A 45.37280278 
H8 GR135487X 24.40757357 
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compound is potent at clearing the bacterial load within macrophages at a very low 
concentration (Sorrentino et. al., 2015). 
 
 
Figure 4.11: IC50 analysis of the compound GR135487X. The graph depicts the normalised 
percentage activity of the Mtb-PrsA enzyme in presence of the serially diluted compound 
GR135487X. 
 
4.2.4.3 GSK177 compound screen against Mtb-PrsA enzyme repeat 
 
There was an expected drop in the hits as the screen was performed against the smaller and 
original set of the GSK 177 collection. Another set of biochemical screens was performed to 
check if the compounds depicted any inhibitory activity against the Mtb-PrsA enzyme using a 
fresh purified preparation of the enzyme and plating out the compounds in new intermediate 
plates. More hits were observed in this screen against the Mtb-PrsA enzyme (figure 4.12).  
 
IC50 analysis of GR135487X
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Figure 4.12: Biochemical screen of the GSK177 library against Mtb-PrsA. The scatter 
graph represents the average percentage activity of the Mtb-PrsA enzyme against 20µM 
concentration (in 30% DMSO) of the GSK 177 drug library. The table below each scatter graph 
lists the hits with details of the compound identification and percentage activity.  
 
The most potent inhibitor in the second set of biochemical screens was GW664700A which 
limited the activity of the enzyme to 25% (figure 4.12). The other compounds were either 
inhibiting enzyme activity to approximately 30-37% and 40-48% (figure 4.12). Once the 
inhibitory activity was confirmed to be against Mtb-PrsA alone within the multienzyme 
biochemical assay the drugs were then screened against a Mtb-prsA overexpression strain in M. 
bovis BCG. 
 
4.2.5 Whole cell overexpression screens of the GSK177 compound library 
 
In order to test the inhibitors that were revealed in the second biochemical screen against Mtb-
PrsA (section 4.2.4.3), an overexpression screen was performed against the hits observed. 
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4.2.5.1 Mtb-prsA overexpressing screen using the GFP expressing strains of M. bovis BCG 
 
The overexpression screen was initially performed using the GFP fluorescing strain of M. bovis 
BCG overexpressing the Mtb-PrsA enzyme (section 6.15.1). The results observed from this 
screen did not particularly reflect the results observed in the biochemical screen. There was no 
resistance observed in the Mtb-prsA overexpressing strain against the selected inhibitors (figure 
4.13). This is depicted by a higher survival percentage of the overexpression strains with respect 
to a strain without the overexpression plasmid. The discrepancy between the biochemical screen 
and target based whole cell screening was deemed to be caused by the molecular interactions 
of two plasmids in the cell or characteristics of the GFP molecule. The compounds have been 
tested for whole cell activity in M. bovis  BCG (Ballell et. al., 2013) and therefore the 
permeability of the drug would not have been an issue.  The screens were then repeated further 
using the non-fluorescing strain of M. bovis BCG.  
 
Figure 4.13: Whole cell overexpression screen using the fluorescing strain of M. bovis 
BCG. The bar graph represents the average percentage survival (from duplicates) for both the 
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4.2.5.1 Mtb-prsA overexpressing screen using the end point luminescence cell viability 
assay 
 
The overexpression screen was then repeated at an initial concentration of 20µM and then at a 
lower concentration of 10µM for selected compounds against a non-GFP expressing strain of 
M. bovis BCG containing the pMV261_prsA vector. The overexpression of the Mtb-prsA strain 
was compared to the strain containing an empty pMV261 vector and the results were observed 
using an end point Cell Titer Glo assay (section 6.15.2). 
 
Figure 4.14: End point whole cell overexpression screen using M. bovis BCG and the Cell 
Titer Glo assay. The bar graph depicts the average percentage survival (from duplicates) of the 
M. bovis BCG strain containing the empty vector versus the strain containing the Mtb-prsA 
overexpression plasmid and the survival percentages against each selected compound. Below 
the graph the table lists the fold change observed for each drug. A. Drugs were tested at 20µM 
concentration against M. bovis BCG, B. Drugs were tested at 10µM concentration against M. 
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In the initial screen at 20µm compound concentration, it was observed that GSK237561A had 
a 99-fold overexpression in the presence of the inhibitor. This resistance against the inhibitor 
from the overexpression strain indicated a strong possibility of the compound targeting the Mtb-
PrsA enzyme. Alongside the above-mentioned inhibitor, GSK353069A, BRL-10988SA, 
GSK1788487A and SB-204804-A depicted a fold difference of 62, 19,18 and 8 respectively 
with respect to the non-overexpressing strain (figure 4.14A).  
Based on the results observed in this initial screen at 20µM, the screen was repeated at 10µM 
concentrations against selected inhibitors based on the high fold changes and the availability of 
the inhibitors   
It was seen that although SB-204804-A had high fold change at 20µM, the inhibitor fold change 
increased with a corresponding decrease in concentration, this could be due to the high error 
bars observed for the inhibitor in the first screen (figure 4.14B). It was observed that the fold 
change was concentration dependent for the inhibitors GSK1788487A, SB-746177 and 
GSK237561A. This combined with the biochemical screen data indicated that the target for 
these inhibitors was the Mtb-PrsA enzyme. The compounds displayed potency by inhibiting the 
enzyme in both the biochemical and whole cell screen. Not all the potential hits identified 
during the Mtb-PrsA enzyme assay could be screened due to the unavailability of some specific 
compounds from the library.  
 
4.2.6 Potential hits against Mtb-prsA from the GSK177 compound library 
 
9 potential hits were shortlisted against Mtb-PrsA based on the biochemical and whole cell 
overexpression screens (figure 4.15). The compound GR135487X is seemingly the most potent 
inhibitor which has been analysed in detail to determine the IC50 values. The other hits 
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mentioned here were observed during a second biochemical assay performed against Mtb-PrsA 
and confirmed for activity in a whole cell phenotypic overexpression assay. 
 
Figure 4.15: Hits from the GSK177 screen against Mtb-prsA. The figure represents 
structures of the potential hits from the GSK177 screen with the structures and fold changes for 
each compound. The fold change of GR135487X mentioned here is from the initial 
overexpression screen against the extended GSK177 library while the fold changes for all the 
other compounds was based on the results from the end point luminescent assay at 10µM final 
concentration.  
 
It was observed that SB-746177, GSK1788487A and GR135487X have molecular weights of 
305.4, 386.9 and 253.2 respectively. All of these compounds also had logP values of less than 
5. Therefore, these drugs obey the Lipinski’s rule of 5 and could potentially be probable drug 
like inhibitor molecules targeting Mtb-PrsA. 
 
GSK1783710A gskversion CCc1c(C)nc([nH]c1=O)-n1nc(C)cc1NC(=O)c1ccccc1SC 1,15 BCGset TBset
SB-204804-A gskversion C[C@@H](NCCc1nc(no1)-c1cn(C)c2ccccc12)C1CCCCC1 1,15 BCGset TBset
GSK1567463A gskversion CC(C)Sc1ccc(cc1)C(=O)Nc1nc(cs1)-c1ccccn1 1,20 BCGset
GSK1783695A gskversion CCc1c(C)nc([nH]c1=O)-n1nc(C)cc1NC(=O)c1ccc(OC)cc1OC 1,20 BCGset
GSK1783704A gskversion CCC(C(=O)Nc1cc(C)nn1-c1nc(C)c(CC)c(=O)[nH]1)c1ccccc1 1,20 BCGset
GSK468296A gskversion CC(C)c1ccc2oc(nc2c1)-c1ccc(NC(=O)c2cccnc2)cc1 1,20 BCGset
GSK905372A gskversion Cc1ncc(C(=O)Nc2cccc(c2)-c2cc(no2)-c2c(Cl)cccc2Cl)c(n1)-c1ccccc1 1,20 BCGset
GSK1180781A gskversion Cc1ccc(CNC(=O)c2cnn3C(CC(Nc23)c2ccc(C)cc2)C(F)F)cc1 1,23 BCGset TBset
GSK1783652A gskversion Cc1cc(NC(=O)C2(CCCC2)c2ccc(Cl)cc2)n(n1)-c1nc(C)cc(=O)[nH]1 1,30 BCGset
GSK1825997A gskversion COc1ccc(cn1)-c1ccc(Nc2cccc(c2)S(=O)(=O)CCNCC=C)nc1 1,30 BCGset
GSK1829819A gskversion Cc1nc2ccc(C)cn2c1C(=O)NCc1ccco1 1,30 BCGset TBset
GSK1220329A gskversion CCCCS(=O)(=O)Nc1ccc2cn(C)nc2c1 1,30 BCGset TBset
GI210527X gskversion N[C@@H]1CCN(C1)c1nc(nc2ccccc12)-c1ccccc1 1,40 BCGset
SB-204804-A
8 fold
GSK1385423A gskversion CCn1c2ccc(cc2[nH]c(=O)c1=O)C(=O)Nc1ccccc1Nc1ccc(OC)cc1 8,40 BCGset TBset
GSK1372568A gskversion Cc1ccc(s1)C(=O)Nc1nc(cs1)-c1ccccn1 8,41 BCGset TBset
GSK1788487A gskversion Clc1cccc2sc(nc12)N(CCCn1ccnc1)C(=O)c1ccco1 8,41 BCGset TBset
GSK920703A gskversion Clc1ccc(SCCC(=O)Nc2nc(cs2)-c2ccccn2)cc1 8,41 BCGset TBset
GSK1079318A gskversion O=C(Nc1nc(cs1)-c1ccccn1)c1cccc(c1)-n1cnnn1 8,50 BCGset
GSK1132084A gskversion Clc1cccc(c1)-c1cnn2ccc(nc12)C(=O)Nc1ccc(cc1)N1CCNCC1 8,50 BCGset
GSK1406589A gskversion CN(C)C1CCN(C1)C(=O)c1csc(n1)-c1cccc(Cl)c1Cl 8,50 BCGset
GSK1556382A gskversion Cc1ccc(NC(=O)C2COc3ccccc3C2)cc1Cl 8,50 BCGset
GSK1770209A gskversion CN(C)CCCSc1nc(N2CCCC2)c2CCCCc2c1C#N 8,50 BCGset
GSK746360A gskversion Fc1ccc(cc1)-c1cccc2ccc(nc12)N1CCNCC1 8,50 BCGset
SB-577234 gskversion N[C@H]1CC[C@@H](CC1)NCc1ccc(O)c(c1)C(=O)NCc1ccc(Cl)c(Cl)c1 8,50 BCGset
GSK1170100A gskversion Fc1ccc(cc1)-c1nnc2sc(Cc3ccccc3)nn12 8,60 BCGset
GSK1863941A gskversion COc1ccc(Nc2nc(CN3CCN(Cc4ccc(cc4)C#N)CC3)cs2)cc1 8,60 BCGset
GSK1788487A
18 fold
GSK352635A gskversion FC(F)(F)c1nnc2ccc(Cl)nn12 9,10 BCGset TBset
GSK1637967A gskversion Fc1cccc(-c2nc(NCC3COc4ccccc4O3)no2)c1F 9,20 BCGset
GSK350834A gskversion O=C(NNC(=O)c1cc2cc(ccc2s1)N(=O)=O)c1cccs1 9,20 BCGset
SB-388225-A gskversion CCOc1ccc(cc1C(C)=O)C(=O)Nc1cc(Cl)c2CCNCc2c1 9,20 BCGset
GSK1518999A gskversion Cc1cnc(nc1Oc1ccc(cc1)-n1ccnc1)N1CCN[C@@H](Cc2ccccc2)C1 9,23 BCGset TBset
SB-746177 gskversion CCCCc1ccc(nc1)C(=O)Nc1nccc2ccccc12 9,23 BCGset TBset
GSK1117127A gskversion Cc1ccc(cc1Cl)S(=O)(=O)N1CCC(CC1)n1nnc2cc(ccc12)C(F)(F)F 9,30 BCGset
GSK2250079A gskversion NC1CCCN(C1)c1ncnc(n1)-c1ccc2CCCc2c1 9,30 BCGset
GSK472569A gskversion C(Cn1ccnc1-c1ccccc1)NCc1ccc(cc1)-c1ccccc1 9,30 BCGset
GW678927A gskversion CCOC(=O)c1csc(n1)-c1ccccc1NC(=O)OCC1CCNCC1 9,30 BCGset
SB-204827-A gskversion Cn1cc(-c2noc(CCNCCC(C)(C)C)n2)c2ccccc12 9,30 BCGset
GSK1570606A gskversion Fc1ccc(CC(=O)Nc2nc(cs2)-c2ccccn2)cc1 9,30 BCGset TBset
GSK1073410A gskversion CSc1ccc(cc1)-c1nnc(NC(=O)c2cc(Cl)sc2Cl)o1 9,40 BCGset
SB-746177
~6 fold
GSKnumber Structure Database SMILES BCG_MIC90_(µM) list list2
GSK1452496A gskversion O=C(Nc1ccc(cc1)C(=O)N1CCCCC1c1nc2ccccc2s1)c1ccco1 0,10 BCGset
GSK1452498A gskversion O=C(Nc1cccc(c1)C(=O)N1CCCCC1c1nc2ccccc2s1)c1cccs1 0,10 BCGset
SB-790594-A gskversion Clc1csc(n1)-c1ccccc1NC(=O)OCCC1CCCCN1 0,20 BCGset
GSK1829676A gskversion FC(F)(F)c1nc2ccccn2c1C(=O)NCc1ccc(Oc2ccccc2)cc1 0,20 BCGset TBset
GSK1829820A gskversion Cc1nc2ccc(C)cn2c1C(=O)NCc1cccs1 0,20 BCGset TBset
GSK353069A gskversion CNc1nc(SC)nc2ccccc12 0,20 BCGset TBset
GR135486X gskversion Nc1cccnc1Nc1ccc(Cl)cc1 0,23 BCGset TBset
GSK1917391A gskversion CC(N(C)C(=O)c1cccc(NC(=O)c2cccs2)c1)c1nc2ccccc2s1 0,30 BCGset
GSK2057544A gskversion CCC(C)CC(=O)Nc1nc2CC(CC(=O)c2s1)C(=O)N(C)Cc1cccc2ncccc12 0,30 BCGset
GSK749336A gskversion COc1ccc2nc(C)cc(OCC(=O)Nc3cc(C)cc(C)c3)c2c1 0,30 BCGset TBset
GW861072X gskversion O=C(C Cc1cccs1)N1CCN(Cc2ccc3OCO 3c2) C1 0,30 BCGset TBset
GSK163574A gskversion Cc1csc2nc(nc(Nc3ccncn3)c12)-c1cccc(C)n1 0,30 BCGset TBset
GSK1329419A gskversion Nc1nc2ccc(cc2[nH]1)-c1cncc(Oc2ccc(F)cc2)c1 0,35 BCGset TBset
GSK353069A
62 fold
SB-293671-A gskversion CCOc1ccc( c1Br)C(=O)Nc1 cc2CCN( )C(C)c2c1 4,00 BCGset
GSK237561A gskversion Cc1occc1C(=O)Nc1nc(nc2ccsc12)-c1ccccn1 4,00 BCGset TBset
GSK262906A gskversion CC(C)(C)C(=O)CC1(O)Oc2ccccc2N=C1C=C(O)C(C)(C)C 4,03 BCGset TBset
GR153167X gskversion CCOC(=O)c1cc(on1)-c1csc(Nc2c(C)cc(C)cc2C)n1 4,07 BCGset TBset
GSK1013542A gskversion O=S(=O)(NCC1CCCO1)c1ccc(s1)-c1ccc(CN2CCOCC2)cc1 4,10 BCGset
GSK1079325A gskversion CC(C)Oc1ccc(cc1)C(=O)Nc1nc(cs1)-c1ccccn1 4,10 BCGset
GSK1188389A gskversion C1CC1c1nc(N2CCCNCC2)c2cnn(-c3ccccc3)c2n1 4,10 BCGset
GSK1216252A gskversion O=C(Nc1nnc(o1)-c1ccccc1)c1ccc2CCCCc2c1 4,10 BCGset
GSK963391A gskversion Fc1cc(F)cc(c1)C(=O)Nc1nnc(o1)-c1ccc(Cl) 1 4,10 BCGset
GSK975842A gskversion Cc1ccc(C)c(c1)-c1nnc(NC(=O)c2cccc(c2) (F)(F)F)o1 4,10 BCGset
GR51104X gskversion Fc1c[nH]c(=O)nc1Oc1ccccc1 4,20 BCGset
GSK1214451A gskversion CN(C)CCN(C(=O)c1cccc(c1)S(C)(=O)=O)c1nc2c(C)ccc(Cl)c2s1 4,20 BCGset
GSK148788A gskversion COc1ccc(CCNC(=O)c2cc(on2)-c2ccc(OC)c(OC)c2)cc1OC 4,20 BCGset
GR153167X
0.6 fold
SB-293671-A gskversion CCOc1ccc(cc1Br)C(=O)Nc1ccc2CCN(C)C(C)c2c1 4,00 BCGset
GSK237561A gskversion Cc1occc1C(=O)Nc1nc(nc2ccsc12)-c1ccccn1 4,00 BCGset TBset
GSK262906A gskversion CC(C)(C)C(=O)CC1(O)Oc2ccccc2N=C1C=C(O)C(C)(C)C 4,03 BCGset TBset
GR153167X gskversion CCOC(=O)c1cc(on1)-c1csc(Nc2c(C)cc(C)cc2C)n1 4,07 BCGset TBset
GSK1013542A gskversion O=S(=O)(NCC1CCCO1)c1ccc(s1)-c1ccc(CN2CCOCC2)cc1 4,10 BCGset
GSK1079325A gskversion CC(C)Oc1ccc(cc1)C(=O)Nc1nc(cs1)-c1ccccn1 4,10 BCGset
GSK1 88389A gskversion C1C 1c1nc(N2CCCNCC2)c2cnn(-c3ccccc3)c2n1 4,10 BCGset
GSK1216252A gskversion O=C(Nc1nnc(o1)-c1ccccc1)c1ccc2CCCCc2c1 4,10 BCGset
GSK963391A gskversion Fc1cc(F)cc(c1)C(=O)Nc1nnc(o1)-c1ccc(Cl)cc1 4,10 BCGset
GSK975842A gskversion Cc1ccc(C)c(c1)-c1nnc(NC(=O)c2cccc(c2)C(F)(F)F)o1 4,10 BCGset
GR51104X gskversion Fc1c[nH]c(=O)nc1Oc1ccccc1 4,20 BCGset
GSK1214451A gskversion CN(C)CCN(C(=O)c1cccc(c1)S(C)(=O)=O)c1nc2c(C)ccc(Cl)c2s1 4,20 BCGset
GSK148788A gskversion COc1ccc(CCNC(=O)c2cc(on2)-c2ccc(OC)c(OC)c2)cc1OC 4,20 BCGset
GSK237561A
99fold
GSK1215270A gskversion Cc1ccc(cc1C)-c1nnc(NC(=O)c2ccc(F)cc2)o1 2,30 BCGset
GSK2200174A gskversion C(N1CCC2(CC1)OCCc1sccc21)c1cccc(n1)-c1ccc2OCOc2c1 2,30 BCGset
GSK735791A gskversion Fc1cccc2sc(Nc3nc(cs3)-c3ccccn3)nc12 2,30 BCGset
SB-277574 gskversion Cc1csc2nc(Cc3ccc(cc3)C(=O)c3ccc(cc3)C(=O)OCc3ccccc3)oc(=O)c12 2,30 BCGset
SB-439950 gskversion COc1ccc(Nc2ccccc2N)cc1Cl 2,30 BCGset
BRL-7940SA gskversion CC(C)(C)c1ccccc1OCCCON1C(=N)N=C(N)NC1(C)C 2,30 BCGset TBset
GSK124576A gskversion Cc1cc(OCC(=O)NCc2ccccc2)c2cc(Br)ccc2n1 2,30 BCGset TBset
GSK735816A gskversion Fc1ccc2nc(Nc3nc(cs3)-c3ccccn3)sc2c 2,30 BCGset TBset
BRL-8088SA gskversion CC1(C)N=C(N)N=C(N)N1OCCc1ccc2ccccc2c1 2,32 BCGset TBset
BRL-10988SA gskversion CCCc1cc(ccc1OCCCON1C(=N)N=C(N)NC1(C)C)C(C)=O 2,34 BCGset TBset
CCI7967 gskversion Cc1cc(NCCc2ccccc2)nc(NC(=N)Nc2ccc(Cl)cc2)n1 2,37 BCGset TBset
GSK1839939A gskversion Cc1ccc(cc1C)N1CCN(CCOc2cccc(c2)-c2ccc(cc2)C(=O)N2CCCC2)CC1 2,40 BCGset
GSK441195A gskversion Brc1ccc(OCC(=O)NNC(=O)c2cccs2)cc 2,40 BCGset
BRL-10988SA
19 fold
GSK1956503A gskversion CCc1c(C)nc(nc1N1CCNCC1)-c1cccc(c1)C(F)(F)F 8,60 BCGset
SB-579760 gskversion O=C(CCC(=O)NNC(=O)c1ccco1)NNC(=O)c1ccco1 8,60 BCGset
GSK1107112A gskversion Fc1ccc2c(Cl)c(sc2c1)C(=O)NC1=NCCS1 8,61 BCGset TBset
GSK1598164A gskversion C(Nc1cccnc1)c1ccc(s1)-c1cc2ccncc2cc1OC1CCNCC1 8,61 BCGset TBset
GR118224A gskversion CN1CCC(COC(=O)c2cn(C)c3ccc(Cl)cc23)CC1 8,70 BCGset
GSK1484742A gskversion CN(Cc1ccccc1)c1ncc(cn1)-c1ccc(CNCC2CCCO2)cc1 8,70 BCGset
GSK512438A gskversion CCCn1nc(C(=O)N2CCN(CC2)c2ccccc2F)c2ccccc2c1=O 8,70 BCGset
GSK920694A gskversion Fc1ccccc1OCC(=O)Nc1nc(cs1)-c1ccccn1 8,70 BCGset
GSK921295A gskversion CSc1ccc(cc1)C(=O)Nc1nc(cs1)-c1ccccn1 8,71 BCGset TBset
GW664700A gskversion O= (Nc1ccccc1-c1nc(cs1)C1CCC1)OC 1CCNCC1 8,71 BCGset TBset
GW369335X gskversion Nc1nc(N)c2c(Sc3ccc4ccccc4c3)cccc2n1 8,71 BCGset TBset
GSK1459976A gskversion COc1ccc(cn1)-c1cccc(NC(=O)NC2CCCCC2)c1 8,80 BCGset
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4.3 Discussion  
 
There have been some target based screening programmes that have produced potential 
molecular scaffolds and groups useful against a specific target in Mtb. As an example, FtsZ is 
a protein that has been deemed as an important target for target based drug discovery. The FtsZ 
protein is involved in cell division and cytokinesis by utilizing GTP to form a polymeric ring 
(Ojima et. al., 2017). This temperature sensitive filamentous protein is homologous to the 
eukaryotic tubulin. Compound screens have been performed against this protein using a 20,000-
compound containing library to reveal a compound 297F which had inhibitory activity on the 
protein leading to a decrease in the polymers formed. The compound had low cytotoxicity and 
maintained specificity against Mtb as it did not show activity against any other gram negative 
or gram positive bacteria (Lin et. al., 2014). There have been developments in generating a 
class of compounds that are effective against this protein by combining pharmacological study 
with the protein structure and a generic screening of the compound classes against the protein 
to detect inhibitory activity. A fluorinated benzimidazole has been designed as a possible 
contender which stops the polymerisation and aggregation of the protein in a dose dependent 
manner (Ojima et. al., 2017).  
PanC is another example of a target based approach for Mtb drug discovery. The gene encodes 
for pantothenate synthetase which is responsible for ATP-dependent condensation of pantoate 
and b-alanine into panthothenate with the release of AMP and pyrophosphate molecules. This 
gene has been known to be essential both for in vitro growth and in vivo as tested in mouse 
models. A new class of compounds was discovered that inhibited this enzyme both in 
biochemical assays and whole cell screening against Mtb. The screen was executed against a 
library of 4080 compound from which two compounds showed activity against the enzyme and 
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belonged to the 3-biphenyl-4-cyanopyrrole-2-carboxylic acid class (Kumar et. al., 2013). 
Due to the pitfalls of target based assays there has been a certain level of interest in developing 
specialised whole cell based assays which target a specific gene or enzyme considered to be a 
possible drug target (Mdluli et. al., 2015). In order to test the activity of compounds against 
PanC and other targets, conditional mutants were designed to underexpress the protein and were 
then screened against a library of 600 compounds, out of which 37 presented activity against 
the PanC enzyme. Out of these hits, 4 were commercially available flavones which had almost 
16 fold activity against the under-expressing mutant (Abrahams et. al., 2012).  
The target based study involving the Mtb-PrsA enzyme as a potential drug target revealed 
compounds from the GSK177 collection with activity against the protein. The compounds 
identified as most promising by comparing the fold change of wild type M. bovis BCG against 
M. bovis BCG overexpression strain were GSK 1788487A, SB-746177 and GSK 237561A with 
MIC90 values of 8.4µM, 9.2µM and 4µM against Mtb H37Rv (Sorrentino et. al., 2015). These 
compounds depicted a dose dependent activity against M. bovis BCG. The target of these 
compounds was therefore validated to be the Mtb-PrsA enzyme. GW664700A has been 
predicted to target a serine/threonine kinase (Rv0014c) (Martínez-Jiménez et. al., 2013) with a 
MIC90 of 5.55µM in Mtb H37Rv (Sorrentino et. al., 2015). The compound GR135487X also 
depicted a strong potential to be a Mtb-PrsA inhibitor based on the biochemical and 
overexpression study performed with a low MIC value of 0.6µM against the enzyme and a 
MIC90 of 2.2µM (Sorrentino et. al., 2015). Some of these compounds were also tested for 
activity against intracellular Mtb H37Rv infecting THP-1 cells, a macrophage cell line. GSK 
1788487A, SB-746177 and GSK 237561A depicted an intracellular MIC90 of 50µM, 1.85µM 
and 1.85µM respectively (Sorrentino et. al., 2015). 
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Unfortunately, attempts to crystallise the enzyme failed due to issues with enzyme quantity 
during purification and salt crystal formation. It would have been useful to understand the 
interaction between these compounds and the protein structurally in order to decipher the 
mechanism of inhibition. Recently the PrsA enzyme from M. smegmatis was crystallised and 
the structure was as expected for a class I phosphoribosylpyrophosphate synthase. The crystal 
presented with a quaternary hexamer, whose oligomerisation is a requirement for complete 
enzymatic activity. The enzyme has a catalytic and allosteric regulatory site which has 
conserved residues to the nearby subunits (Donini et. al., 2017). It is 88% similar to the Mtb 
PrsA and 43% similar to the human isoform. The protein requires phosphate and magnesium 
ions for activity. The major differences observed between the M. smegmatis PrsA and the 
human isoform was the substitution of the glutamic residue to alanine in the human PrsA and 
the change from Glycine 236 to Cysteine 226 in the ribose-5-phosphate binding site (Donini et. 
al., 2017). These differences are important to design compounds that are specific to the 
mycobacterial protein in order to inhibit the cell wall synthesis.  
An understanding of the structural interaction of the GSK 177 compounds which depict activity 
against M. bovis BCG would help to gauge the feasibility of using these compounds and/or their 
structural scaffolds as drugs or potential drug classes, chemical modification of the latter can 
improve activity. Toxicity studies and structure activity relationship data could provide 
information regarding the suitability of the compounds. Although more work needs to be done 
on these compounds and how they interact with the protein, here we have successfully screened 
a compound library against a potential drug target, isolating compounds showing inhibitory 






General Discussion   
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5.1 Conclusion and future work 
 
Tuberculosis is currently a major global health concern and the continual increase in the number 
of drug resistant cases is exacerbating the situation. Given the steady rise in the number of  
MDR, XDR and TDR cases, it has become imperative to understand the cause of resistance in 
TB and have new ammunition to combat it. Mtb is a very robust bacterium and its ability to 
survive within the host is largely due to the unique structural nature of its cell wall. This 
structure allows the bacterium to sustain itself for prolonged periods in the presence of 
environmental pressure (caused by immune cells and physiological conditions) and evolve to 
resist inhibitory antibiotics. In view of the current crisis, progress is largely dependent on 
understanding how the bacteria survive within the host, this includes a better understanding of 
cell wall functions. Although numerous efforts have been made to develop new drugs for TB 
treatment, few have successfully transitioned from bench to bedside. Furthermore, although a 
lot of studies have been carried out on the various biosynthetic pathways of Mtb, there are still 
some pathways that are not completely understood.  
In light of this information, the aim of this thesis was to employ various methods of drug 
discovery to generate inhibitors against mycobacteria and understand how they inhibit the 
bacteria. In chapter 2, we attempted to shorten the time from bench to bedside by screening a 
library of FDA approved drugs to see if they inhibited two strains of mycobacteria. We observed 
that similar numbers of drugs were inhibiting both the fast and slow growing strains of 
mycobacteria. Some known inhibitors of Mtb, which included antitubercular drugs and some 
newly discovered inhibitors such as Auranofin and Ebselen (Favrot et. al., 2013; Harbut et. al., 
2015), came through as hits in the screening assay that we performed, validating the screening 
process that we utilised. The process of deconvolution of the drug targets for the shortlisted 
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drugs led to a lot of interesting targets. Among the targets observed, it would have been 
fascinating to further investigate the function of the enzyme targeted by the GBR12909 drug. 
The enzyme AroB is a dehydroquinate synthase involved in the shikimate pathway (Cheng et. 
al., 2012; de Mendonça et. al., 2007) and could be an attractive drug target for further 
development using the GBR12909 as a scaffold for designing compounds. It is also necessary 
to understand that the in vitro assays do not replicate the heterogeneity and metabolic state of 
the bacteria in vivo during infection or under the selective pressure of antimicrobials. Utilising 
in vitro models to mimic the state of the bacterium in vivo through various stimuli is a good 
way of investigating the efficacy of the drug in a real-world scenario (Evangelopoulos et. al., 
2015). It would be useful to have insights into the efficacy of the hits observed during this 
screen in cell lines, or under stress conditions that imitate the in vivo pressures the bacterium 
faces. A combinatorial approach to this drug screen could help to identify any synergistic 
properties that the hits or the drugs in the library could contribute to the existing drug set.  
It was interesting to observe that a chloramphenicol derivative inhibited an enoyl CoA 
hydratase as a secondary target. Chloramphenicol has been proven to interact and bind at the 
2451 and 2452 of the 23SrRNA in the 50S ribosomal subunit (Schifano et. al., 2013), therefore 
causing a disruption in the biosynthesis of proteins. During the mode of action study of 
florfenicol (the chloramphenicol derivative), it was observed that the drug not only inhibited 
protein biosynthesis but also targeted the EchA12 protein in M. bovis BCG. After analysing 
various drug targets revealed during the mode of actions studies, a further investigation into the 
role of EchA12 was undertaken.  
In chapter 3, we investigated the role of EchA12 in mycobacteria. It was recently determined 
that EchA6 (an enoyl CoA hydratase) was actually essential due to the inability to obtain a null 
mutant for the gene (Cox et. al., 2016a), despite being predicted to be non-essential through 
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Himar-I based transposon mutagenesis (Sassetti et. al., 2003). The echA6 gene was revealed to 
be an important target due to its involvement in mycolic acid synthesis where the enzyme 
encoded is an acyl CoA carrier to the FAS-II cycle. A new set of chemical inhibitors were found 
to be active against this particular enzyme, causing a disruption in the mycolic acid synthesis 
(Cox et. al., 2016a). The essentiality testing of echA12 revealed that the gene was non-essential 
as we were able to generate a null mutant in M. smegmatis. Further testing did not reveal a clear 
function of the enzyme in the biosynthetic pathway. A detailed investigation of the lipids using 
surface solvent extraction and mass spectrometry uncovered that the enzyme was involved in 
shuttling the palmitoyl CoA which is added on to the mannose sugar in the PIM molecule. The 
change in acylation states in the null mutant confirmed that the EchA12 is the carrier protein 
for palmitoyl CoA, although the absence of the palmitoyl CoA only redirected the PIM 
synthesis pathway towards differently acylated molecules. Although this change in the lipid 
composition was not lethal, it triggered a morphological change causing the null mutant to be 
slower than the wild type M. smegmatis. We also developed a protein structure model in I-
TASSER using the solved protein structure of EchA6 (Cox et. al., 2016a). The EchA12 
monomer was modeled on to one of the EchA6 monomers and illustrated that the mutation 
generated against florfenicol in the protein was present in the hinge of an a-helix loop. The 
increased hydrogen bonding, caused due to the amino acid substitution from a glycine to an 
arginine (Borders Jr et. al., 2008) , would therefore allow the protein to keep the hinge region 
in operation. We docked the palmitoyl CoA into the binding pocket to understand the 
interaction of the protein with the coenzyme A. The protein appears to be quite difficult to 
isolate and purify under in vitro conditions. This limited our ability to generate feasible crystals 
for the protein and potentially perform a ligand binding assay, although the shift in IC50 against 
the drug confirms the interaction of the ligand with the protein. It would be interesting to be 
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able to generate a crystal structure of this protein in order to improve the understanding of the 
binding pockets and interaction of the drug with the protein. PatA is an acyltransferase enzyme 
which is regulated by cyclic AMP and helps the bacteria adapt to change in carbon sources. It 
also plays a role in assisting the bacteria to slow down its growth rate, which is helpful for the 
bacteria to reach a non-replicating state. It would be intriguing to see what other enzymes PatA 
interacts with given the fact that in our study it was proven to have a promiscuous nature. 
Although a lot is now known about the PIM pathway, there are still holes in the models 
surrounding acylations of the PIMs and it is still debated if the acylation of the PIM1 molecule 
comes before the mannosylation of PIM1 into PIM2 (Albesa-Jové et. al., 2016; Guerin et. al., 
2009). A two-hybrid analysis of protein-protein interaction could unravel a part of the protein 
network involved in the biosynthesis of PIMs.  
In chapter 4, we explored another area of drug discovery by looking for inhibitors against a 
validated target. The Mtb-PrsA enzyme has been determined as essential for the survival of the 
bacterium as in its absence the cell wall biosynthetic pathway breaks down, causing the 
bacterial cell to collapse (Alderwick et. al., 2011; Donini et. al., 2017). This target was screened 
against a compound library of inhibitors with confirmed activity against Mtb but without known 
modes of action. In this chapter ww to utilised a target based phenotypic assay to allow the cell 
wall barrier to be present while still targeting the desired enzyme target. This allowed us to 
isolate compounds that inhibited the target, but were also active within a whole cell as opposed 
to a purely biochemical approach. Several compounds depicted activity against the target but 
we could perform detailed analysis of only one compound due to limited supply of the 
compounds. The Mtb-PrsA protein purified extremely well with a phosphate based purification 
buffer however this caused issues during the crystallisation process. The Mtb-EchA12 protein 
structure has been predicted through homology modelling against the Bacillus subtilis PrsA, 
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which is 43% homologous to the Mtb-PrsA. The enzyme has been predicted to have a hexameric 
form with each monomer containing two subunits. The residues involved in the catalytic 
domain of the enzyme are conserved and retain important residues such as Asp42. It contains a 
His109 in a flexible loop which ranges from Lys108 to Arg112, helping it to form hydrogen 
bonds with the ATP substrate (Alderwick et. al., 2011). The ability to crystallise and 
consequently deconvolute the crystal structure of the Mtb-PrsA enzyme would be of notable 
importance. This would help in understanding not only the interaction of the enzyme with its 
substrate, but also the newly found ligands from this screen. It would be also be of significant 
value to be able to perform the IC50 analysis of the enzyme with all the other compounds that 
seem to inhibit the enzyme both in the biochemical assay and in the phenotypic assay.   
Here we have presented a phenotypic drug discovery model involving two major strategies 
which have revealed inhibitors and drugs active against the surrogate models of Mtb. The 
analysis of one of the targets investigated through the phenotypic screens revealed its role in 
the biosynthetic pathway of cell wall glycolipids. The strategy employing targeted drug 
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6. Materials and Methods 
 
6.1 Media Preparation 
6.1.1 Luria – Bertani (LB) broth  
37g LB (Merck Millipore) broth powder was added to 1l water and autoclaved at 121°C for 15 
min. 
6.1.2 Luria – Bertani (LB) agar                                                                                                  
37g LB broth powder (Merck Millipore) and 12g Bacto Agar (BD, Difco) was added to 1l water 
and autoclaved at 121°C for 15 min. Once autoclaved the media was kept at 55°C and then 
poured into 90 mm petri dishes (25mL/petri dish). 
6.1.3 Tryptic Soy broth (TSB) 
30g TSB powder (BD, Difco) was added to 1L water and autoclaved at 121°C for 15 min. 
6.1.3 Tryptic Soy agar (TSA) 
30g TSB powder (BD, Difco)  and 12g Bacto Agar (BD, Difco) was added to 1L water and 
autoclaved at 121°C for 15 min. Once autoclaved the media was kept at 55°C and then poured 
into 90mm petri dishes (25mL/petri dish). 
6.1.4 Middlebrook 7H9 broth 
1.31g Middlebrook 7H9 (BD, Difco) in 225mL of water. To this solution 556µL 100% 
Glycerol, 25mL OADC enrichment and 125µL Tween 80 was added. The solution was 
thoroughly mixed and then filter sterilsed through a filteration unit containing a 0.2µm pore 
size filter. 
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6.1.5 Middlebrook 7H9 basal agar 
4.7g Middlebrooke 7H9 powder (BD, Difco) and 12g Bacto Agar (BD, Difco) in 1L of water 
was autoclaved at 121°C for 15 min. 
6.1.6 Top agar 
4.7g Middlebrook 7H9 Broth (BD, Difco), 6 g Bacto Agar (BD, Difco) in 1L water (without 
ADC supplement) was autoclaved at 121°C for 15 min.  
6.1.7 Terrific broth 
47.6g terrific broth powder (Merck Millipore) and 4mL of 100% glycerol in 1L of water. The 
solution was dissolved and autoclaved at 121°C for 15 min. 
6.1.8 Terrific salts 
23.1g Potassium dihydrogen phosphate (KH2PO4) and 125.4g Dipotassium hydrogen 
phosphate (K2HPO4) were dissolved in 1L of water and autoclaved at 121°C for 15 min. The 
solution was added to terrific broth in a 9:1 (Terrific broth: Terrific salts) ratio before use. 
6.1.9 Tween- 80 (10%) 
A 10% tween-80 solution was prepared by dissolving 10mL of tween-80 in 90mL of water 
followed by filter sterilisation using a 0.2µm pore size filter. The solution was used at 0.05% in 
liquid media to culture mycobacterial strains. 
6.1.10 Transformation Buffers 
6.1.10.1 Transformation buffer I (TFBI)  
30mM Potassium acetate (KAc), 10mM calcium chloride (CaCl2), 50mM manganese chloride 
(MnCl2), 100mM Rubidium chloride (RbCl2) and 15% glycerol (v/v) were prepared in water. 
The solution was adjusted to a pH of 5.8 and filter sterilized. 
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6.1.10.2 Transformation buffer II (TFBII) 
10mM MOPS, 75mM Calcium chloride (CaCl2), 10mM Rubidium chloride (RbCl2) and 15% 
glycerol (v/v) were prepared in water. The solution was adjusted to a pH of 6.5 and filter 
sterilized.  
6.1.11 Protein Purification buffers 
6.1.11.1 Protein Purification buffer 1  
100mM potassium dihydrogen phosphate (KH2PO4) and 600mM sodium chloride (NaCl) were 
dissolved in water and the pH was adjusted to 7.9. 
 
6.1.11.2 Protein Purification buffer 2  
1M Tris and 300mM sodium chloride (NaCl) were dissolved in water and the pH was adjusted 
to 7.8. 
 
6.1.12 Dialysis Buffer  
6.1.12.1 Dialysis buffer 1  
50mM potassium dihydrogen phosphate pH 7.9, 150mM sodium chloride (NaCl), 5mM EDTA 
pH 7.5 and 1mM DTT were prepared in water.  
6.1.12.2 Dialysis buffer 2 
 50mM potassium dihydrogen phosphate pH 7.9, 150mM sodium chloride (NaCl), 10% 
glycerol and 1mM DTT were prepared in water.  
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6.1.12.3 Dialysis buffer 3 
1M Tris, 100mM of sodium chloride (NaCl), 5mM of EDTA and 1mM DTT were dissolved in 
water and the pH was adjusted to 7.8. 
 
6.1.12.4 Dialysis buffer 4 
1M Tris, 100mM of sodium chloride (NaCl) and 1mM DTT were dissolved in water and the 
pH was adjusted to 7.8. 
 
6.1.13 Western blot transfer buffer 
3.03g of Tris, 14.4g Glycine pH 7.5 and 100ml methanol were dissolved in 1l of water. 
 
6.1.14 Tris Buffered Saline (TBS) 
2.42g of Tris and 8g of sodium chloride (NaCl) were dissolved in 500ml of water. An addition 
of 0.05% Tween 20 was done to make Tris Buffered Saline with Tween (TBS-T). 
 
6.1.15 Mycobacteriophage (MP) buffer 
50mM Tris HCl pH 7.6, 150mM sodium chloride (NaCl), 10mM magnesium chloride (MgCl2), 
2mM calcium chloride (CaCl2) were dissolved in water and filter sterilised. 
 
6.1.16 Southern blotting buffers 
6.1.16.1 Depurination buffer  
0.25M hydrochloric acid (HCl) was prepared in water. 
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6.1.16.2 Denaturation buffer  
1.5 M of sodium chloride (NaCl) and 0.5 M sodium hydroxide (NaOH) was prepared in water. 
 
6.1.16.3 Neutralisation buffer 
0.5M Tris HCl and 1M sodium chloride (NaCl) were dissolved in water and the pH adjusted to 
7.2. 
 
6.1.16.4 SSC buffer (20x) 
3M sodium chloride (NaCl) and 0.3 M sodium citrate were dissolved in water and the pH was 
adjusted to 7. 
The 20x was diluted to 2x and 0.5x with an addition of 0.1% sodium dodecyl sulphate (SDS). 
 
6.1.16.5 Maleic acid buffer  
0.1M Maleic acid and 0.15M sodium chloride (NaCl) were dissolved in water and adjusted to 
a pH of 7.5. 
6.1.16.6 Detection buffer  
0.1M Tris HCl and 0.1M sodium chloride (NaCl) were dissolved in water and adjusted to a pH 
of 9.5. 
 
6.2 Antibiotic stocks 
Antibiotics were prepared as stocks at higher concentrations to be diluted out to lower 
concentrations during screens. 
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6.2.2 FDA Drugs 
To prepare 250 µL of 10mM stocks of the FDA approved antibiotics the quantity of antibiotics 
in table 6.1 were weighed out. The FDA drugs were prepared in 10mM stocks in 100% DMSO 
except for Phentermine which was available is a solution in methanol. The stocks were used to 
prepare intermediate plates having 3-fold dilutions of the drugs in 30% DMSO.  
Table 6.1: Stock preparation of FDA approved drugs. The table enlists the weight of the 
antibiotics to be measured out to make a 10mM stock solution. 
Antibiotic Name (Sigma) Molecular weight (g/mol) Weight (mg) 
Josamycin 827.99  2.069 
Pentamidine isethionate 592.68 1.48 
Thonzonium bromide 591.71 1.479 
Florfenicol 358.21 0.895 
Glipizide 445.54 1.113 
Granisetron 348.87 0.872 
Olopatadine hydrochloride 373.87 0.934 
Astemizole 458.57 1.146 
Tripelennamine 291.82 0.729 
Rosiglitazone 357.43 0.893 
Pinaverium bromide 511.51 1.47 
Phentermine 149.23 1mg/mL 
Meclocyline sulfosalicylate 695.05 1.738 
Auranofin • 678.48 1.696 
Chlorhexidine • 505.45 1.263 
Alexidine dihydrochloride 581.71 1.454 
Clomiphene citrate 598.08 1.495 
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Ebselen 274.18 0.618 
Raloxifen hydrochloride 510.04 1.275 
Toremifene citrate salt 598.08 1.495 
Tamoxifen 371.51 1.409 
GBR12909 dihydrochloride 523.49 1.309 
Fendiline hydrochloride 351.91 0.88 
Suloctidil 337.56 0.844 
Apomorphine hydrochloride 312.79 0.782 
Nisoldipine 388.41 0.971 
Sertraline hydrochloride 342.69 0.857 
Fluspirelene 475.57 1.19 
 
6.2.2 Stock antibiotics for screening transformed M. smegmatis, M. bovis BCG and 
E. coli (Top 10, BL21 DE3)  
 
For Kanamycin (Sigma) stocks and Hygromycin B stock (Thermofisher). Kanamycin was 
prepared as a stock solution of 50mg/mL in water and was filter sterilized using a 0.2µm pore 
size filter. The working concentration of Kanamycin was 25µg/mL for M. smegmatis, M. bovis  
BCG and 50µg/mL for E. coli strains . Hygromycin B was available as a stock solution in PBS 
at a concentration of 50mg/mL and was used at a working concentration of 20µg/mL for M. 
smegmatis and M. bovis BCG. 
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6.3 Preparation of competent cells  
6.3.1 Preparation of chemically competent E. coli cells 
 
E. coli cells (Top 10 or BL21 DE3 strains) were grown for 4 h to an O.D600-0.4 to 0.5 and then 
incubated on ice for 10mins. The cells were then pelleted by centrifugation at 4000 rpm for 
15mins. The supernatant was discarded and the cells were re-suspended in 400µL of cold TFB1 
and incubated on ice for 15mins. The cells were then centrifuged at 4000rpm for 15mins at 4°C 
and the supernatant was discarded. The cells were then re-suspended in 200µL of TFB2 and 
incubated for 30mins on ice. The cells were then aliquoted into cryovials or microcentrifuge 
tubes then flash frozen in liquid nitrogen and stored at -80°C until use. 
 
6.3.2 Preparation of electrocompetent mycobacteria cells 
 
To produce genetically modified strains of M. smegmatis and M. bovis BCG expressing green 
fluorescence protein for HTS screening of drugs and overexpressing genes. The procedure 
involved producing electrocompetent cells to electroporate the said plasmid (such as 
pSMT3_eGFP, pVV16 empty vector, pVV16_echA12_Rv, pVV16_echA12_BCG and 
pVV16_G239_echA12) and then screening out the transformed cells. A 50mL culture of the 
appropriate mycobacterial strain (M. smegmatis and M. bovis BCG) was cultured in 7H9 (with 
tween-80 and OADC). The cells were allowed to grow to an appropriate O.D600 of 0.4-0.5 at 
37°C. The grown culture was then incubated on ice for 1.5h and centrifuged at 3000g for 
10mins. The cell pellets were then consecutively washed in 10% cold glycerol decreasing the 
volume everytime. For a 50mL culture the pattern of incubation, centrifugation and 
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resuspension with 12.5mL, 5mL to a final 2.5mL of 10% ice-cold glycerol continued. The 
electrocompetent cells were then aliquoted and stored at -80°C after flash freezing with liquid 
nitrogen (-196°C). 
6.3.3 Glycerol Stocks 
 
Glycerol stocks were prepared using fresh cultures with an O.D600 of 0.5-0.6. The stocks were 
prepared by adding 1mL of bacterial culture, 357 µL of sterile glycerol (70%) so that the final 
concentration of glycerol reaches 25% in the culture. The cryovials were then flash frozen using 
liquid nitrogen (-196°C) and then stored at - 80°C. 
 
6.4 Polymerase chain reaction  
 
6.4.1 Primers used for PCR amplification of genes for different vectors 
6.4.1.1 Primer pairs for Mtb-prsA overexpression plasmid 
 















Reverse 5'-GATCGATCAAGCTTTCATGCGTCCCCGTCGAAAAGT-3 HindIII 
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6.4.1.2 Primer pairs for echA12 overexpression plasmid 
 
Table 6.3: PCR primers for pVV16 cloning of echA12 
 
6.4.1.6 Primer pairs for Mtb-prsA protein expression plasmid  
 











reverse 5'-GATCGATCGGATCCATGTTGAGCCACGACTGGACCGATA-3' BamHI 
  
6.4.2 PCR conditions 
 
The PCR mastermix comprised of the components in table 6.5. Each tube had a 20µL of the 
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Table 6.5: PCR mastermix. The table details the two mastermix combinations used to 
conduct amplification of genes. 
Component (for a strip of 
12) 
Condition 1 Condition 2 
F. Primer (100 pmol/µL) 1.12 µL 1.12 µL 
R. Primer (100 pmol/µL) 1.12 µL 1.12 µL 
Genomic DNA (~0.05-0.1 
µg/µL) 
5.6 µL 5.6 µL 
dNTPs (0.001µmol/µL) 5.6 µL 5.6 µL 
GC Buffer (5x) 56 µL 56 µL 
DMSO (100%) 14 µL 14 µL 
MgCl2 (50mM) 0 µL 5.6 µL 
Phusion enzyme (2U/ µL) 2.8 µL 2.8 µL 
dH2O 193.76 µL 188.16 µL 
 
6.4.3 PCR programme 
 
The PCR programme used for the amplification of the genes is detailed in table 6.6. 
Table 6.6: PCR amplification programme. The table details the PCR amplification 
conditions in terms of the amplification time and temperatures used. 
Step Temperature  Time Go To  Passes Gradient 
1 98.0°C 60s  1  
2 98.0°C 30s  35  
3 60.0°C 60s  35 10 
4 72.0°C 60s 2 35  
5 72.0°C 10min  1  
6 4.0°C ∞  1  
 
6.5 Agarose Gel Electrophoresis  
 
The agarose gel was prepared at a percentage of 0.8% by adding 0.8g of agarose powder to 
100mL of 1x TAE buffer (40mM Tris acetate, 1mM EDTA buffer, pH 8.0) and heated till 
dissolved. The solution was then cooled to approximately 50°C. To this warm solution, midori 
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green 5% (v/v) was added, dissolved and poured into the gel tray. The gel was allowed to 
solidify and the samples loaded with a loading dye (5% glycerol (v/v), 0.4% Bromophenol blue) 
into the wells. The gel was run in 1x TAE at 140V, 400mA for 50mins and visualised using a 
Gel Doc XR (Bio-Rad) with Image Lab software. 
 
6.6 DNA extraction from Agarose Gels  
 
DNA was extracted from the agarose gel using the QIAquick gel extraction kit. The DNA band 
was carefully excised from the agarose gel using a scalpel and weighed. The QG buffer was 
added in three times volume of the weight of the gel slice and placed on a heating block at 50°C. 
The tube was mixed frequently for 10mins until the gel slice was completely dissolved. The pH 
of the mixture was checked by ensuring that it was yellow in colour (indicator shows pH £ 7.5). 
One volume of isopropanol was added to the solution and mixed. The dissolved mixture was 
then added to a QIAquick column provided in the kit and spun at 13,000rpm for 1min.  The 
flowthrough was discarded and 0.75mL of PE buffer was added to the QIAquick column and 
centrifuged for 1min. After discarding the flowthrough the column was centrifuged again for 
1min to remove residual buffer and ethanol. The column was then placed in a new 
microcentrifuge tube and 30µL of EB buffer was added to the center of the column and allowed 
to stand for 1min. The tube along with the column was centrifuged for a minute at 13,000rpm.  
The extracted DNA was stored at -20°C for later use.  
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6.7 Plasmid DNA extraction 
 
Plasmid DNA was extracted from a 5mL overnight bacterial culture using the QIAprep spin 
miniprep kit (Qiagen). The cells from the overnight bacterial culture were pelleted by 
centrifugation at 5000rpm for 15min. After the supernatant was discarded the pellet was 
resuspended in 250µL of Buffer P1 containing RNAse (Qiagen) and transferred to a 
microcentrifuge tube. After transferring the suspension, 250 µL of Buffer P2 (Qiagen) was 
added to the tube and gently mixed by inverting the tube a few times. Following this 350 µL of 
Buffer N3 (Qiagen) was added to the tube and mixed by inversion. This mixture was then 
centrifuged at 13000rpm for 10mins. The supernatant from this tube was transferred to a 
miniprep spin column (Qiagen) and centrifuged at 13000rpm for 1min and the flow through 
was then discarded. The column was then washed with 500 µL of Buffer PB (Qiagen) by 
centrifuging at 13,000rpm for 1min and the flow through was discarded. The column was then 
washed using 750 µL of Buffer PE (Qiagen) and centrifuged at 13000rpm for 1 min with the 
flow through being discarded. The spin column was then centrifuged again at 13,000rpm for 
1min to remove any residual buffer which was then discarded. The spin column was then 
transferred to a new microcentrifuge tube and then 50 µL of EB buffer was added to the centre 
of the column. The column was allowed to sit for 1min and then centrifuged at 13000rpm for 
1min. The extracted plasmid DNA in the eluate was stored at -20°C. 
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6.8 Cloning of genes into plasmid vectors 
 
6.8.1 Double digestion of PCR products and plasmids  
 
The PCR products and plasmids had to be double digested to get sticky ends and ligated to get 
clones. 
 
Table 6.7: Restriction digest mastermix. 
DNA (~0.5-0.1 ng/µL) 10.0 µL 
Restriction buffer (10x NEBuffer) 2.0 µL 
Restriction enzyme 1  0.5 µL 
Restriction enzyme 2  0.5 µL 
Water 7.0 µL 
 20.0 µL 
For pMV261  
Restriction enzyme 1(NEB) - BamHI (20U/µL) 
Restriction enzyme 2 (NEB) - HindIII (20U/µL) 
For pVV16 
Restriction enzyme 1 (NEB) - NdeI (20U/µL) 
Restriction enzyme 2 (NEB) - HindIII (20U/µL) 
For pET SUMO 
Restriction enzyme 1 (NEB) - HindIII (20U/µL) 
Restriction enzyme 2 (NEB) - BamHI (20U/µL) 
 
The double digest mixture was incubated for 2h at 37°C. The double digested products for 
plasmids were run on an agarose gel and purified through gel extraction to be used for ligation. 
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6.8.2 Ligation of digested and purified PCR products and plasmids 
 
The digested plasmid were ligated to the digested PCR products using a T4 DNA ligase. Three 
conditions were prepared for ligation (table 6.8). 
 
Table 6.8: Ligation mastermix. 
Components Condition 1 Condition 2 Condition 3 
Insert (~30 ng) 16 µL 5 µL 0 µL 
Water 0 µL 11 µL 16 µL 
Plasmid/Vector (~50 ng) 1 µL 1 µL 1 µL 
T4 DNA ligase (400 U/µL) (NEB) 1 µL 1 µL 1 µL 
T4 DNA ligase buffer (10x) (NEB) 2 µL 2 µL 2 µL 
 
Condition 3 was used to see the presence of self-ligation for the plasmid DNA. The ligation 
was carried out overnight at 4°C. The next day the ligated products were transformed as per 
section 6.9. The presence of colonies for conditions 1 and 2 would be suggestive of presence of 
clones, which was confirmed by double digesting plasmids, isolated form colonies. 
 
6.9 Transformation of bacterial cells 
 
6.9.1 Transformation of E. coli cells by heat shock method 
 
100µL of chemically competent E .coli (Top10 or BL21_DE3) were added to 1µL of the 
pET23b_prsA plasmid and incubated on ice for 15mins. The mixture was then subjected to a 
heat shock of 42°C for 1min. The cells are then incubated on ice for 2 mins and recovered at 
37°C after the addition of 250µL of LB broth for 1h. The suspension was then plated at various 
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volumes (50µL and 100µL) on LB agar plates containing kanamycin (50µg/mL) and incubated 
overnight at 37°C. 
 
6.9.2 Transformation of mycobacterial cell by electroporation 
 
6.9.2.1 Mtb-prsA overexpression strains in M. smegmatis and M. bovis BCG 
 
5µL of plasmid DNA at approximately 0.2-1mg/mL (pMV261 plasmid and pMV261_prsA 
plasmid) was added to 200 µL of electrocompetent cells (M. smegmatis mc2155, M. smegmatis 
pSMT3_eGFP, M. bovis BCG, M. bovis BCG pSMT3_eGFP) and kept in ice for 10minutes. 
An electroporation cuvette (0.2cm gap electrodes) was put on ice until cold and the cells were 
then transferred to the sterile cuvette ensuring that no bubbles are produced. The bubbles reduce 
the efficiency of electroporation. A single pulse of 1.8kV with pulse controller resistance set at 
1000Ω resistance was given to the cells. The cuvette was then placed back onto ice for 10min. 
5mL of TSA with tween (for M. smegmatis) and 7H9 with tween (for M. bovis BCG) was added 
to recover the cells. The cells were allowed to incubate at 37°C for 4h. They were then plated 
out onto TSA (for M. smegmatis) and 7H10 plates containing OADC (for M. bovis BCG) and 
selective antibiotic (kanamycin 25µg/mL) for each plasmid and strain and incubated at 37°C 
for 2-3 days for M. smegmatis and 7-10 days for M. bovis BCG till colonies appeared. 
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6.9.2.2 Tranformation of echA12 overexpression plasmid into M. smegmatis and M. 
bovis BCG 
 
5µL of plasmid DNA at approximately 0.2-1mg/mL (pVV16 empty vector, 
pVV16_echA12_Rv, pVV16_echA12_BCG and pVV16_G239_echA12) was added to 200 µL 
of electrocompetent cells (M. smegmatis mc2155, M. smegmatis pSMT3_eGFP, M. bovis BCG, 
M. bovis BCG pSMT3_eGFP) and kept in ice for 10 min. An electroporation cuvette (0.2cm 
gap electrodes) was put on ice until cold and the cells were then transferred to the sterile cuvette 
ensuring that no bubbles are produced. The bubbles reduce the efficiency of electroporation. A 
single pulse of 1.8kV with pulse controller resistance set at 1000Ω resistance was given to the 
cells. The cuvette was then placed back onto ice for 10minutes. 5mL of TSB with tween (for 
M. smegmatis) and 7H9 with tween (for M. bovis BCG) was added to recover the cells. The 
cells were allowed to incubate at 37°C for 4h. They were then plated out onto TSA (for M. 
smegmatis) and 7H10 plates containing OADC (for M. bovis BCG) and selective antibiotic 
(kanamycin 25µg/mL) for each plasmid and strain and incubated at 37°C for 2-3 days for M. 
smegmatis and 7-10 days for M. bovis BCG till colonies appeared. 
 
6.10 Genomic DNA extraction from M. smegmatis and M. bovis 
BCG 
 
25mL of a mid-log cell culture of the specific mycobacterial species was centrifuged at 
5000rpm for 10mins and the pellet was resuspended in 450µL GTE-RNAse buffer [200 µL 
RNase A + 20 mL GTE buffer (25mM Tris pH8, 10 mM EDTA pH8, 50 mM glucose)]. 10 µL 
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of lysozyme was added and the mixture was then incubated at 37°C overnight without shaking. 
To the overnight incubated mixture, 10 µL of 10% SDS and 20µL of Proteinase K (15mg/ml) 
was sequentially added. The mixture was then incubated at 55°C for 3h. After the incubation, 
200 µL of 5M NaCl, 1mL of chloroform: isoamylalcohol (24:1) was added and centrifuged at 
13,000rpm for 5-10mins. The aqueous layer was carefully transferred to a new eppendorf tube 
and an additional 1mL of chloroform: isoamyalcohol (24:1) was added. The mixture was then 
centrifuged again at 13,000rpm for 10mins. The aqueous layer was again carefully transferred 
to a new tube and 0.7 volumes of ice-cold isopropanol was added to the tube and gently mixed 
by inverting the tube. The tube and reagents were kept cold from this step onwards.  The mixture 
was then centrifuge at 4°C, 13,000rpm for 30mins. The supernatant was decanted and the pellet 
was washed with 700 µL of 70% ice cold ethanol. The tube was centrifuged again at 4°C, 
13,000rpm for 30mins-1h.  The supernatant was carefully pipetted out and the DNA pellet was 
left to dry. After the pellet was completely dry, it was resuspended in 20µL of water. The DNA 
was quantified using a nanodrop. 
 
6.11 Screening Assays against M. bovis BCG (pSMT3_eGFP) and 
M. smegmatis (pSMT3_eGFP) 
 
6.11.1 Screening the Prestwick library against M. bovis BCG (pSMT3_eGFP) and 
M. smegmatis (pSMT3_eGFP) 
 
The FDA screen was performed using GFP expressing strains of M. smegmatis and M. bovis 
BCG containing the pSMT3_eGFP plasmid (provided by Dr. Apoorva Bhatt, University of 
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Birmingham, UK). The pSMT3_eGFP plasmid used to get GFP fluorescent strains of M. 
smegmatis and M. bovis BCG has a shuttle vector pSMT3 for Mycobacterium with a hsp60 
promoter (Hayward et. al., 1999). The plasmid has been cloned with an enhanced GFP codon 
and an antibiotic marker for hyrgromycin. The expression of GFP is independent of hygromycin 
B induction and is constitutively expressed under the hsp60 promoter (Hayward et. al., 1999). 
Assay plates were prepared to have a drug concentration of 0.05mM by dispensing 10µL of the 
drug in the assay plate from an intermediate plate containing the drugs at a concentration of 
1mM.The first column as the negative control (only media, 7H9 and OADC with 10µL 30% 
DMSO) and the last column as a positive control (culture with 10µL 30% DMSO). 200µL of 
the culture (O.D600 – 0.2) without any Hygromycin B was dispensed and the plates were then 
incubated statically at 37°C and read over a period of 48h. 
 
6.11.2 Dose response study of the hits from the Prestwick library against M. bovis 
BCG (pSMT3_eGFP) and M. smegmatis (pSMT3_eGFP) 
 
For the dose response study concentrations, a 3-fold dilution were performed using the highest 
drug concentration of 0.5mM in the stock plate; which presented concentrations as 0.167mM 
as the maximum concentration as 10µL of the drug was added to the assay plate and then 
moving on to ten 3-fold dilutions of the same from well 2 to 11 in 30% DMSO. The plate had 
the first column as the negative control (only media, 7H9 and OADC with 10µL 30% DMSO) 
and the last column as a positive control (culture with 10µL 30% DMSO). 190µL of cells 
(O.D600- 0.2) were added to the plates containing the drugs without any hygromycin B in the 
media. The plates were incubated statically at 37°C and read over a period of 48h. 
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6.11.3 MIC determination on solid media against M. bovis BCG and M. smegmatis  
 
Stocks of 10mM antibiotics were dispensed in 2-fold concentrations and mixed with 2mL of 
liquid agar into a partitioned petri dish. This was done for 5 wells each of every concentration. 
After the media had solidified, 10 µL of cells (0.D600-0.2) were inoculated onto the agar 
containing the 5 different antibiotic concentrations and incubated for 2 days for M. smegmatis  
and 7-10 days for M. bovis BCG. 
6.11.4 Statistical Validation of Assays 
 
The statistical validation of the assay was carried using the Z` factor analysis. The Z` factor is 
the value depicting the total variation between the negative and positive control which generally 
defines the assay signal window. The formula for calculating the Z` factor is: 
                                                
Where, σ+c, σ-c, µ+c and µ-c are the standard deviation (σ) and the averages (µ), respectively of 
the negative (-c) controls.positive (+c) and negative (-c) controls. 
The Z` factor describes the assay quality and reliability of the assay results. For an assay to be 
reliable and the data to be validated the Z’ factor should at least be 0.5. An assay with a Z` 
factor ≥ 0.6 is considered very good while an assay quality is considered poor when the value 
is less than 0.5. The Z` factor value of 1 is considered as an ideal value. 
! 108!
period was used to attain growth curves, survival percentages and percentage activity 
of the drugs in variation with doses. 
4.60Statistical0Validation0of0Assays0
 
All assays which were run were statistically validated for their quality using Z’ factor 
values. The Z’factor mainly depicts the total separation between values of both 
positive and negative controls and the error within each control; describing the 
available signal window. The formula for calculating the Z’ factor values is  
 
                                        
where σ+c, σ-c, µ+c and µ-c are the standard deviation (σ) and the averages (µ) of the 
positive (+c) and negative (-c) controls. 
 
The values of Z’ factor depicts how good or bad an assay is in terms of its reliability. 
In order for an assay to be ready for screening, the Z` should be at the very least 0.5, 
and much more preferably ≥ 0.6. If the Z` is <0.6, the assay quality is not good or 
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Getting an Ass y HTS-ready: the Z` Factor 
 
Definition of Z` 
 
When screening for inhibitors of a target, the metric used to determine the optimal signal window is the 
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where σ+c, σ-c, µ+c, and  µ-c are the standard deviations (σ) and the averages (µ) of the positive (+c) and 
negative (-c) controls.   
 
The Z` factor describes the available signal window for an assay in terms of the total separation 
between negative and positive controls minus the error associated with each type of control.  For a well 
defined signal window, Z` should be greater than 0.5; that is, the sum of the errors of the controls 
























Parameters for above plot: 
 
In this example, Z` = 0.64, or 64% of the total 
potential signal window is available to define when a 
tested compound in a screen behaves significantly 
differently from either control.  Note that for this 
example, the fold-difference between the positive & 




Separation between negative 
& positive controls (between 
two red solid lines) = 100% 
of potential signal window 
Dashed black line = 3 
standard deviations from the 
average of the negative 
controls  
Dashed black line = 3 
standard deviations from the 
average of the positive 
controls  
Actual signal window = separation 
between two dashed error lines = 64%.   
Parameter Value (arbitrary activity units) 
Avg of Neg Ctrls 200 
Avg of Pos Ctrls 68 
Fold-diff bwn Neg & 
Pos Ctrls 2.9 
Std. Deviation of Neg 
Ctrls 13 
Std. Deviation of Pos 
Ctrls 3 
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6.12 Generation of Spontaneous resistant mutants 
 
Mutants were generation based on solid MIC values (appendix). Drugs were mixed into 20mL 
of 7H10 or TSB agar for M. bovis BCG and M. smegmatis, respectively in concentrations of 
2.5x, 5x and 10x the MIC values. Cells from a mid-log culture (O.D600-0.6) were plated at a 
concentration of 1x108 cells per plate and incubated at 37°C until colonies were observed. Once 
the colonies were observed they were inoculated in liquid media and cultured in the absence of 
drug. Once the cultures were grown the cells were streaked on the same plate (containing 
antibiotics) with the wild type strain and growth was compared. This was done in order to 
validate true mutants. After the mutants were validated the genomic DNA extraction was 
performed for each mutant strain and glycerol stocks were prepared. The genomic DNA was 
sent for genome sequencing and sequence analysis to MicrobesNG for detection of SNPs. 
 
6.13 Protein Expression and Purification  
 
6.13.1 Expression and Purification of the Mtb-PrsA protein from the transformed 
BL21 (pET-SUMO prsA) strain 
 
A single colony of E. coli (BL21 cells transformed with plasmids) was inoculated in 5mL of 
LB broth with the appropriate antibiotic (kanamycin 50µg/mL) and incubated at 37°C, 180rpm 
overnight. 2mL of the overnight culture was then added to 1L of terrific broth (For each 1L of 
the broth – 900mL terrific broth + 100mL terrific salts). The inoculated culture was incubated 
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at 37°C, 180rpm for 4-5 h until the O.D600 had reached ~0.5. 1mL of IPTG was added to every 
1L of the culture and incubated at 16°C, 180rpm overnight.  
The overnight-induced culture was pelleted down at 5000rpm for 25mins at 4°C. The pellets 
were resuspended in ~30-35mL of PBS and pelleted again at 4000rpm for 15mins at 4°C. The 
supernatant was discarded. The pellet was immediately used but can also be stored at -20°C for 
processing later.  
The cell pellet was then resuspended in the lysis buffer (Purification buffer with 20mM 
imidazole + proteinase inhibitor). The cells were then lysed using a sonicator (soniprep 150) 
(30s on, 30s off; 10 cycles).  The lysed cell suspension was centrifuged at 15,000rpm for 40mins 
at 4°C.  
Column preparation: A 5mL HiTrap chelating HP column (GE Healthcare) was charged with 
0.1M NiCl2 until the flow through ran green. The excess NiCl2 was washed using 50mLs of 
water. The column was then equilibrated with the lysis buffer to provide the same environment 
as the sample to be loaded onto it.  
After centrifugation, the supernatant was loaded on to the column with a flow rate of 1mL/min. 
After the clarified lysate was run through the column was washed using the wash buffer (1x 
purification buffer + 50mM imidazole). An imidazole gradient was run through and 5mL 
fractions were collected for each gradient concentration. The gradient concentrations were run 
as 75mM, 100mM, 125mM, 150mM, 175mM, 200mM, 225mM, 275mM and 500mM of 
imidazole in the purification buffer. 
The protein was added to a dialysis membrane (prepared by boiling and cooling it in 500mM 
EDTA and 300mL water). The fraction containing the band with the required protein was 
dialysed overnight in the dialysis buffer a. (2L) overnight at 4°C. The protein was transferred 
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to the dialysis buffer b. (1L) for 5-6 h the next day. The purified protein was then concentrated 
and quantified by A280 value and stored at 35-40% glycerol at -20°C. 
 
6.13.1 Expression and Purification of EchA12 protein from the transformed strain 
on M. smegmatis containing the pVV16_echA12_Rv and pVV16_echA12_G239R 
 
A single colony of the M. smegmatis mc2155_pVV16_echA12_Rv and M. smegmatis 
mc2155_pVV16_echA12_G239R was inoculated in 5mL of TSB broth with the appropriate 
antibiotic (kanamycin 25µg/mL) and incubated at 37°C, 180rpm overnight. 2mL of the 
overnight culture was then added to 1L of TSB broth with kanamycin 25µg/mL. The inoculated 
culture was incubated at 37°C, 180rpm overnight at 37°C. 
The overnight culture was pelleted down at 5000rpm for 25mins at 4°C. The pellets were 
resuspended in ~30-35mL of PBS and pelleted again at 4000rpm for 15mins at 4°C. The 
supernatant was discarded. The pellet was immediately used but can also be stored at -20°C.  
The cell pellet was then resuspended in the lysis buffer (Purification buffer with 20mM 
imidazole + proteinase inhibitor). The cells were then lysed using a French press at ~20,000MPa 
and repeated three times. The lysed cell suspension was centrifuged at 15,000rpm for 40mins 
at 4°C.  
Column preparation: A 5mL HiTrap chelating HP column (GE Healthcare) was charged with 
0.1M NiCl2 until the flow through ran green. The excess NiCl2 was washed using 50mLs of 
water. The column was then equilibrated with the lysis buffer to provide the same environment 
as the sample to be loaded onto it.  
After centrifugation, the supernatant was loaded on to the column with a flow rate of 1mL/min. 
After the clarified lysate had run through, the column was washed using the wash buffer (1x 
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purification buffer 2 + 25mM imidazole). An imidazole gradient was run through and 5mL 
fractions were collected for each gradient concentration. The gradient concentrations were run 
as 50mM, 75mM, 100mM, 150mM, 200mM and 225mM of imidazole in the purification 
buffer. 
The protein was added to a dialysis membrane (prepared by boiling and cooling it in 500mM 
EDTA and 300mL water). The fraction containing the band with the required protein was 
dialysed overnight in the dialysis buffer 3 (2L) overnight at 4°C. The protein was transferred to 
the dialysis buffer 4 (1L) for 5-6 h the next day.  
 
 
6.13.3 SDS-PAGE and western blotting 
 
The protein fractions were run onto a SDS PAGE, 10µL of each sample (prepared by boiling 
with the SDS loading buffer) was run at 200V, 25-30mA until the dye front reached the end of 
the gel. The gel was then stained using Instant blue for 10-20 mins and diluted with water to 
view.  
The samples run on the SDS-PAGE gel were then transferred onto a nitrocellulose membrane 
using a western blot cassette.The western blot cassette was submerged in the western transfer 
buffer and run at 20V, 300mA for 1h. The membrane was then blocked using a 5% skimmed 
milk solution made in TBS-T followed by incubation at room temperature in 0.1% skimmed 
milk. The primary antibody (mouse anti-His, Qiagen) was added (1:1000) to the membrane and 
incubated at room temperature. The membrane was then washed with TBS-T followed by the 
addition of the secondary antibody (goat anti-mouse, Sigma Aldrich) at 1: 25,000. The 
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membrane was washed with TBS-T and then in TBS. The bands were developed 
colourimetrically using a BCIP (5-Bromo-4-chloro-3-indolyl phosphate) solution. 
 
6.14 Enzyme Assay with Mtb-PrsA  
 
The enzyme assay for Mtb-PrsA enzyme is based on a coupled reaction with other enzymes. 
The reaction proceeds with the conversion of ribose-5-phosphate utilizing ATP to produce Prpp 
with AMP. The AMP with another ATP is converted by a kinase enzyme to ADP, which is 
used to produce pyruvate molecules from phosphoenol pyruvate regenerating ATP molecules. 
The pyruvate is then converted to lactate utilizing the NADH molecule, which is detected via 
fluorescence. Therefore, the reduction of NADH fluorescence acts as an indication of Mtb-PrsA 
enzyme activity (figure 6.1). 
 
Figure 6.1: The Mtb-PrsA enzyme couple for the biochemical assay. The flowchart depicts 
the coupled reaction in the enzyme assay which is used to detect the activity of the Mtb-PrsA 
enzyme by the fluorescence of NADH. Phosphoenol pyruvate [PEP], Myokinase (MK), 
PyruvateKinase/LacatateDehydrogenase [PK/LDH], Ribose-5-phosphate [R-5-P] 
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6.14.1 Optimisation of the Mtb-PrsA enzyme assay  
 
Components required for the assay were ATP (100mM), Phosphoenol pyruvate [PEP] 
(100mM), NADH (100mM), Ribose-5-phosphate [R-5-P] (100mM), Myokinase (MK), 
PyruvateKinase/LacatateDehydrogenase (PK/LDH), 4x Assay Buffer (150mM NaCl, 1mM 
KH2PO4, 1mM MgCl2), DTT (1M), MgCl2 .   
An enzyme mix was prepared with various concentrations of the purified enzyme to determine 
the lowest volume needed which showed activity. Injecting ribose-5-phosphate through a 
period of approximately 30mins induced the enzyme reaction. The activity was determined by 
detection of decrease in fluorescence by the NADH utilised during the reaction through a 
fluorescence spectrophotometer (PHERAstar FS, BMG LabTech). 
 
6.14.1.1 Optimisation of enzyme activity  
 
The enzyme assay was tested for activity, at an enzyme concentration of 0.1µg/µL which gave 
a consistent fluorescence for a period of at least ~30mins. 
For testing effect of DMSO on enzyme activity 
The decided enzyme volume was used with three conditions that were absence of DMSO 
(positive control), 30% DMSO and 100% DMSO and a negative control without the enzyme. 
Table 6.9: Mtb-PrsA biochemical enzyme assay mix. 
Components Stock concentration Final 
concentration 
Volume 
ATP 100mM 0.5mM 2 µL 
PEP 100mM 4mM 2 µL 
NADH 100mM 0.5mM 0.5 µL 
R-5-P 100mM 4mM 4 µL 
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MK 1,500-3,000 U/mg  0.25 µL 
PK/LDH 0.6-1U/µL (PK) 
0.9-1.4U/µL (LDH) 
 0.25 µL 
4x Buffer   25 µL 
DTT 1000mM 10mM 1 µL 
MgCl2 1000mM 10mM 1 µL 
DMSO 30%   5 µL 
Water   60.5 µL 
Mtb-PrsA  0.1 µg/ µL 2.5 µL 
 
6.14.2 GSK177 compound screen against the Mtb-PrsA enzyme 
 
A drug screen was performed against the purified enzyme to detect possible compound 
interaction. The drug screen was performed with a library of 177 drugs (GSK_177) which were 
identified as potent compounds with anti-tubercular activity by GSK (Mdluli et. al., 2014; 
Ballell et. al., 2013). 5µL of drugs (400µM) were added to the assay plate and 96µL of enzyme 
mixture was added to each well keeping the first column for negative control and last column 
for positive control. The final compound concentration on the assay plate would be 20µM. 
Injecting ribose-5-phosphate same as previously mentioned (6.14.1) induced the enzyme 
activity. The assay plate had a positive control and a negative control. The negative control had 
no enzyme present while positive control had enzyme without any compound. The screen was 
performed in duplicates.  
The enzyme mix for the GSK 177 compound screen is mentioned in table 6.10. 
Table 6.10: Mtb-PrsA biochemical enzyme assay mix for the GSK177 screen. 
Components Stock concentration Final 
concentration 
Volume 
ATP 100mM 0.5mM 2 µL 
PEP 100mM 4mM 2 µL 
NADH 100mM 0.5mM 0.5 µL 
R-5-P 100mM 4mM 4 µL 
MK 1,500-3,000 U/mg  0.25 µL 
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PK/LDH 0.6-1U/µL (PK) 
0.9-1.4U/µL (LDH) 
 0.25 µL 
4x Buffer   25 µL 
DTT 1000mM 10mM 1 µL 
MgCl2 1000mM 10mM 1 µL 
Compound in DMSO 
30% 
  5 µL 
Compound  10mM 20 µM 5 µL 
Mtb-PrsA  0.1 µg/ µL 2.5 µL 
Water   60.5 µL 
 
6.14.3 IC50 analysis of the compound GR135487X 
 
The IC50 analysis of GR135487X was performed by serially diluting the drug 3-fold in 30% 
DMSO from a starting concentration of 20µM. 5µL of the serially diluted compounds were 
added to the assay plate with the assay mastermix (section 6.14.2). The compounds were 
incubated with the drugs before the addition of the Mtb-prsA enzyme. The assay was incubated 
for 30mins after the addition of the enzyme and was read as an end point assay through a 
fluorescence spectrophotometer (PHERAstar FS, BMG LabTech).  
 
6.15 GSK177 overexpression screens 
 
6.15.1 GSK177 overexpression screen with the M. bovis BCG pSMT3_eGFP 
 
The hits that came off from the biochemical screen from the Mtb-PrsA biochemical screen were 
tested in whole cell overexpression strains. The percentage survival of the fluorescent 
overexpression strains was compared to the empty pMV261 containing fluorescent strains. 
Chapter 6                                                                                                    Material and Methods 
 180 
The pMV261 vector is a mycobacterial shuttle vector which constitutively expresses the 
integrated gene under a hsp60 promoter (Stover et. al., 1991). Therefore, the cells added to the 
assay did not contain any kanamycin. The compounds were plated at a concentration of 20µM 
onto the assay plate with the cell volume at 200µL. The cells were incubated for 2 days at 37°C 
and read as an end point assay.  
 
6.15.2 GSK177 overexpression screen using Cell Titer Glo  
 
The hits that came off from the biochemical screen from the Mtb-PrsA biochemical screen were 
tested in whole cell overexpression strains. The percentage survival of the overexpression 
strains was compared to the empty pMV261 strain. 
The compounds were plated in an appropriate 96-well plate for luminescence at a concentration 
of 20µM onto the assay plate with the cell (O.D- 0.2) volume at 100µL. The cells were incubated 
for 2 days at 37°C and read as an end point assay using the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega). The reagents were thawed to room temperature before use. The 
Cell Titer Glo substrate was solubilised using the 100mL of the Cell Titre Glo buffer. The 
substrate was mixed thoroughly by vortexing. The reagents were titrated to be used at 1/8th the 
prescribed concentration. To the incubated cells 100µL of the reagent (diluted by 1/8) was 
added and incubated for 60mins at 37°C. The plates were then read in a spectrophotometer to 
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6.16 Generation of the echA12 gene knockout mutant  
 
In order to generate a knockout mutant for the gene of interest, a 1kB flanking region both up 
and downstream of the gene were amplified. These amplified flanking fragments were then 
digested using Van91I and then ligated into a Van91I digested p0004S plasmid (a gift from T. 
Hsu and W. R. Jacobs Jr., Albert Einstein College of Medicine, New York). The correctly 
cloned plasmids were then digested using PacI and packaged into a temperature sensitive 
mycobacteriophage phAE159 to yield the knockout phage containing the phasmid DNA. In 
vitro packaging was done by adding 5µL of the ligation mixture to the MaxPlax packaging 
extract and then incubated the mix at RT for 1hour. The reaction was then stopped using 200 
µL of MP buffer and incubating the mix at RT for 30min. After the incubation period 100 µL 
of prepared HB101 (E.coli) host cells were added to the mix and incubated at 30 oC for 1h. The 
cells were then centrifuged at 13000rpm for a minute and the pellet was then resuspended in 
1mL of fresh LB media. The cells were then plated onto LB agar plates containing hygromycin 
(150 µg/mL) and incubated at 37 oC overnight. Colonies were selected the next day and cultured 
for plasmid isolation. Once the plasmids were isolated they were digested with PacI to select 
for the required phasmid DNA. 
The phasmid DNA was then electroplated into electrocompetent M. smegmatis mc2155  strain 
and recovered in 1mL of TSB at 30oC for 4h. After the incubation period, two dilutions were 
setup: A. 300 µL of the transformed cells were mixed with 200 µL of freshly cultured  M. 
smegmatis mc2155 cells and B. 100 µL of the transformed cells were mixed with 200 µL of 
freshly cultured M. smegmatis mc2155 cells. These dilutions were then added to 4mL of molten 
top agar in separate tubes, mixed gently and poured on top of pre-warmed 7H9 agar plates. The 
plates were incubated at 30 oC for 3 days until plaques are observed. The plaques were then 
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picked out using a sterile pipette tip and soaked into 200 µL of MP buffer and allowed to recover 
at room temperature for 1.5 h and then stored at 4 oC.  
In order to calculate the phage titre, 4mL of top agar was mixed with 400 µL of actively growing  
M. smegmatis mc2155 cells and overlayed on top of 7H9 basal agar. 10-fold dilutions of the 
phage from the afore mentioned soak was made using MP buffer (dilutions upto 10-6). 10 µL 
of these dilutions were spotted onto the overlayed plate and incubated for 3 days at 30 oC until 
plaques were observed in the spot zones. The plaque zones were used to calculate the plaque 
forming units (PFU) per mL of the ‘soak’. 
The plates were then overlayed in triplicate containing 400 µL of actively growing  M. 
smegmatis mc2155 cells and the appropriate dilution of the soak and incubated at 30oC for 3 
days. Ideally the plates would yield a lacy pattern at the appropriate 1000 pfu/mL due to 
confluent lysis. The plates were then soaked with 3-4mL of MP buffer and incubated at RT for 
3-4h. The MP buffer was then pipetted out and filtered using a 2-micron filter to get a sterile 
phage filtrate and stored at 4oC. 
In order to transduce mycobacterial strains; a 50mL culture was prepared to an O. D600 of 0.8-
1. The cells were pelleted at 4000rpm for 15mins. The pellet was then resuspended in 5mL MP 
buffer and then further diluted by the addition of 45mL of MP buffer. The suspension was 
centrifuged again at 4000rpm for 15mins. The pellet was then resuspended in 5mL of MP 
buffer. 2mL of this cell suspension was mixed with 2mL of the high titre knockout phage lysate. 
A negative control was setup using 2mL of MP buffer instead of the phage. The mix was then 
incubated at 37 oC for 1h to allow infection. The tubes were then spun at 4000rpm for 15mins. 
The supernatant was decanted and the pellet was resuspended in 400 µL TSB + 0.05% Tween 
80 and incubated at 37 oC for 3h. 50 µL of the suspension was spread on TSB agar plates 
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containing 100 µg/mL hygromycin. The entire suspension was distributed among 8 plates. All 
plates were incubated for 3 days at 37 oC.  
 
 6.17 Confirmation of the echA12 null mutant by southern blotting 
 
A southern blot was performed in order to confirm the gene knockout in M. smegmatis. The 
genomic DNA was extracted from all the colonies observed and confirmed from the TSB plates 
containing hygromycin B (20µg/µL) (ThermoFisher). The genomic DNA for both possible 
knockouts and wild type was then digested using KpnI (NEB) overnight. On the following day, 
the digested genomic DNAs were run on an agarose gel with a 1kb DNA ladder (NEB). This 
gel was then used to blot the DNA onto a nylon membrane by a southern blot transfer setup 
using transfer buffer overnight. The DNA was transferred onto the nylon membrane using the 
capillary effect generated by the southern blot setup. 
A DNA probe was prepared using the flanking region PCR products 4 µL each of the upstream 
and downstream products. To this mix, 8 µL of milliq water was added and boiled at 95 oC for 
10mins. The tubes were then snap frozen on dry ice. To this frozen mix, 4 µL of the DIG- High 
Prime (Roche) was added and mixed gently until thawed. This mixture was then incubated at 
37 oC overnight. 
Once the DNA had been transferred onto the nylon membrane, it was crosslinked to the 
membrane by exposing the membrane to UV light for 5mins. 10mL of preheated DIG Easy 
Hyb buffer was added to a hybridisation bottle along with the membrane and incubated with 
gentle rotation at 42 oC for 30mins. Meanwhile, a probe hybridisation mixture was prepared 
using 10mL of pre-heated DIG Easy Hyb buffer and 20 µL of the probe prepared earlier. This 
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mixture was added to the hybridisation bottle after the initial incubation period and was 
incubated overnight at 42 oC. 
After the incubation period, the membrane was washed twice for 5mins each using 50mL of 2x 
SSC buffer containing 0.1% SDS at 68 oC with gentle agitation. The membrane was then 
washed twice using 0.5x SSC buffer containing 0.1% SDS at 68 oC for 15mins each. 
The membrane was washed for 2mins in 10mL of washing buffer and then incubated with 
100mL of blocking buffer for 30mins at 50 oC. After which the membrane was incubated with 
20mL of antibody solution for 30min at 50 oC. Following this, two consecutive washes were 
performed for 15mins each using 100mL of washing buffer. The membrane was then 
equilibrated with 20mL of detection buffer for 5mins and bands were observed by incubating 
the membrane with 20mLs of CPID tablets dissolved in detetction buffer for 30mins. The 
membrane was then imaged using a BioRad gel doc XR+ imager.  
 
6.18 Analysis of strains overexpressing echA12 and the echA12 null 
mutant  
 
6.18.1 Analysis of the echA12 overexpressing strains in the presence of florfenicol 
 
The overexpression strains of echA12 in M. smegmatis and M. bovis BCG containing plasmids 
pVV16_empty, pVV16_echA12_G239R, pVV16_echA12_BCG and 3. pVV16_echA12_Rv. 
The pVV16 vector is a mycobacterial shuttle vector which constitutively expresses the gene 
inserted (in this instance echA12) under the hsp60 promoter (O’Gaora, 1998). The cell culture 
therefore added to this assay did not contain any kanamycin. These vectors containing strains 
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were tested for overexpression to observe a shift in IC50 values against florfenicol. The assay 
plate contained a 3-fold dilution of florfenicol in 30% DMSO from a 10mM stock. 10µL of the 
drug was added to the assay plate with a positive and a negative control column containing 
10µL of 30% DMSO.  The positive control column had cells while the negative control column 
only contained media.190µL of the cells from each individual strain were added to the assay 
plate at an O.D of 0.1. The cells were incubated overnight for M. smegmatis and 4 days for M. 
bovis BCG at 37°C. To the incubated plates 0.01% (w/v) of sterile resazurin was added and 
further incubated at 37°C for 24h. The plates were then read as an end point viability assay at 
Exc530/Em590 nm.  
 
6.18.3 Treatment of the overexpression strains with florfenicol for lipid analysis 
 
The overexpression strains of echA12 in M. bovis and M. bovis BCG were prepared grown in 
liquid culture in 10mL tubes in TSB broth for M. smegmatis and 7H9 for M. bovis BCG in the 
absence of kanamycin. The cultures were grown to a log phase to which florfenciol was added 
in concentrations of 0x, 0.5x, 1x, 2x, 5x the liquid MIC as observed from the liquid MIC testing 
earlier. In M. bovis BCG strains, florfenicol was added in concentrations of 0x,1x,2x,5x and 
10x the MIC. The cultures were labelled with [14C] by the addition of [14C]-acetate to the 
culture before incubating the cultures overnight at 37°C, 180rpm.  
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6.18.4 Apolar Lipid extraction from overexpression strains of echA12 and echA12 
null mutant 
 
Lipid extractions were performed using cell cultures of the echA12 overexpression strains in 
M. smegmatis and M. bovis BCG strains and echA12 null mutant in M. smegmatis. The [14C]-
acetate radiolabelled cells (using C-14 acetate) were harvested by centrifuging the cultures in 
glass tubes with lids fitted with Teflon lined stoppers at 3000rpm for 10 minutes. To the dried 
pellet 2mL of Methanol:0.3% NaCl :: 10:1(v/v) was added, followed by 1mL petroleum ether 
(60-80°C). The tube was mixed on a rotary mixer for 15mins and then centrifuged at 3000rpm 
for 5mins. The upper layer from this tube was then transferred over to another tube labelled B 
using a glass Pasteur pipette. To the remaining lower layer in the initial tube A 1mL of 
petroleum ether was added and mixed for 15mins. The tube was then centrifuged again at 
3000rom for 5mins. The upper layer was then transferred to tube B containing the upper layer 
from before. The contents of the tube were then dried by placing the tube on a heating block at 
50°C under nitrogen. This tube contained the apolar lipids. 
 
6.18.5 Polar lipid extraction from overexpression strains of echA12 and echA12 
null mutant 
 
To the tube A from 6.18.4, 2.3mL of chloroform: methanol:0.3%NaCl:9:10:3 (v/v/v) was added 
and mixed on a rotary mixer for 60mins. The tubes were then spun at 3000rpm for 5mins. The 
supernatant was then transferred to a fresh tube C. To the pellet in tube A, 750µL of chloroform: 
methanol:0.3%NaCl:5:10:4(v/v/v) was added and mixed for 30mins.The tube was centrifuged 
at 3000rpm for 5mins and then supernatant was transferred to tube C. The last step was repeated 
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one more time and the supernatant added to the tube C. To the pooled extract in tube C, 1.3mL 
of chloroform and 1.3mL of 0.3% NaCl was added. The tube was then mixed for 5mins and 
then spun at 3000rpm for 5mins. The lower layer of the biphase was transferred over to a fresh 
tube, labelled as tube D. The tube D containing the polar lipids extract was then dried at 50°C 
under nitrogen. The remaining cells here are delipidated cells containing non-extractable lipids 
and used for extraction of mycolates. 
6.18.6 Extraction of mycolates from overexpression strains of echA12 and echA12 
null mutant 
 
To the delipidated pellet from section 6.18.5, 750µL of 0.5% methanolic KOH was added and 
incubated at 37°C for 3 days. The cells were then centrifuged at 3000rpm for 5mins and the 
supernatant discarded. The cells were then washed using 375µL methanol twice with the 
supernatant discarded each time. The mycolic esters were then extracted using 500µL of diethyl 
ether incubated at room temperature for 5mins. The ether phase was collected into a separate 
tube after centrifuging the tube at 3000rpm for 5mins. This step was repeated three times. The 
ether phase in the new tube now contained crude mycolates from the cells. The ether phase was 
dried and resuspended in 2:1::chloroform:methanol (v/v). The samples were then visualised 
through thin layer chromatography described in section 6.19.    
 
6.19 Thin Layer Chromatography of lipid extracts 
 
Analysis of samples was done by separating samples on a silica plate run in different solvent 
systems. Polar and apolar lipids were analysed through a 2-D TLC run in different solvent 
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systems as mentioned in table 6.11. Apolar lipids were analysed using system A, B, C and D 
while polar lipids were analysed using systems D and E. 
For analysing radiolabelled lipid extracts 10,000-50,000cpm (measured using a liquid 
scintillation analyser, Tri-Carb 2700TR by mixing sample with scintillation fluid in a tube) 
were loaded onto a silica plate and run in the respective solvent systems. Once the TLCs were 
dried and the solvent had evaporated the TLCs were placed in a shielded cassette with an X-ray 
radiograph and left for 24-48h depending on the amount of counts loaded. After the exposure 
period the x-ray radiographs were developed. Samples that were not labelled with radioactive 
carbon acetate were stained with phosphomolybdic acid (PMA) and visualised under UV light. 
Table 6.11: Solvent systems used to analyse lipid extract on 1-D and 2-D TLCs. 
System  Direction  Solvent  Proportions  Number  
of runs  
A  1 petroleum ether 60-80°C/ethyl acetate  98:2 (v/v)  3 
A  2 petroleum ether 60-80°C/acetone  92:8 (v/v)  1 
B  1 petroleum ether 60-80°C/acetone  92:8 (v/v)  3 
B  2 toluene/acetone  95:5 (v/v)  1 
C  1 chloroform/methanol  96:4 (v/v)  1 
C  2 toluene/acetone  80:20 (v/v)  1 
D  1 chloroform/methanol/water  14:0.8 (v/v/v)  1 
D  2 chloroform/acetone/methanol/water  50:60:2.5:3 
(v/v/v/v)  
1 
E  1 chloroform/methanol/water  60:30:6 (v/v/v)  1 
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6.20 Solvent extraction of the EchA12 protein 
 
The solvent extraction of the EchA12 protein involved mixing 2mL of the purified protein 
(~1mg/mL) with 2mL of chloroform: methanol (2:1, v/v). The mixture was then centrifuged at 
3000rpm for 10mins. The organic phase (lower phase) was removed and transferred to a 
separate tube. The tube containing the organic phase was dried in the presence of nitrogen at 
50°C. The dried residue was then resuspended in 200µL of chloroform. This dissolved residue 
was then subjected to electrospray mass spectrometry in the positive mode on a Micromass 
LCT mass spectrometer. 
6.21 Growth curve analysis of the echA12 null mutant in M. 
smegmatis 
 
A growth curve analysis was performed on M. smegmatis mc2155 and the echA12 null mutant 
in M. smegmatis. A single colony was inoculated into tubes containing 10mL of TSB media. 
The overnight cultures were then inoculated into fresh 100mL TSB flasks in triplicate to get a 
starting O.D600 of 0.1 and incubated at 37°C, 180rpm. The O.D600 was then measured using a 
spectrophotometer every hour for 30h.  
 
6.22 Acid fast staining of the echA12 null mutant in M. smegmatis  
 
Acid fast staining was performed on M. smegmatis mc2155 and the echA12 null mutant in    M. 
smegmatis . Smears were prepared and heat fixed on standard clear glass slides. The smear was 
flooded with TB Carbolfuchsin KF for 4mins without heating. The smear was then washed and 
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decolourised using the TB decolorizer for 3 to 5s. The smear was washed with water again and 
counterstained with TB Brilliant Green K for 30s. The smear was then washed and air dried. 
The slides were visualised at 40X magnification and then 100X magnification with oil 
immersion. Acid fast bacilli appear as red stained bacteria on a blue background.  
 
 
6.23 Cell morphology analysis in the presence and absence of 
tween-80 of the echA12 null mutant in M. smegmatis 
 
Colony morphology was analysed for M. smegmatis mc2155 and the echA12 null mutant in M. 
smegmatis. TSB agar plates were prepared with 0.05% tween and without tween. An overnight 
liquid culture was prepared by inoculating a single colony in the TSB and incubating at 37°C, 
180rpm. The culture was streaked onto plates containing 0.05% tween and ones without tween 
for each strain and incubated in a static incubator at 37°C. Once single colonies appeared they 
were photographed to depict the variation in morphology observed. 
 
6.24 Liquid extraction surface mass spectrometry analysis (LESA) 
of the echA12 null mutant in M. smegmatis   
 
A LESA analysis was performed on colonies of M. smegmatis mc2155 and the echA12 null 
mutant in M. smegmatis. A single colony was inoculated into a 10mL TSB media containing 
tube and incubated overnight at 37°C, 180rpm. 1-5µL of the culture was plated onto TSB agar 
containing 30mm petri plates. Once the colonies appeared, the colonies were used to perform 
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surface extraction using various solvent combinations such as chloroform: methanol (2:1, v/v), 
ethanol: water and acetonitrile and analysed mass spectroscopically using a native LESA 









Abassi, Y.A., Xi, B., Zhang, W., Ye, P., Kirstein, S.L., Gaylord, M.R., Feinstein, S.C., Wang, 
X. and Xu, X. (2009) Kinetic Cell-Based Morphological Screening: Prediction of Mechanism 
of Compound Action and Off-Target Effects. Chemistry and Biology, 16 (7): 712–723. 
Abrahams, G.L., Kumar, A., Savvi, S., Hung, A.W., Wen, S., Abell, C., Barry, C.E., Sherman, 
D.R., Boshoff, H.I.M. and Mizrahi, V. (2012) Pathway-selective sensitisation of 
Mycobacterium tuberculosis for target-based whole-cell screening. Chemistry and Biology, 19 
(7): 844–854.  
Abrahams, K.A. and Besra, G.S. (2016) Mycobacterial cell wall biosynthesis: a multifaceted 
antibiotic target. Parasitology, 7: 1–18.  
Acharya, P.V. and Goldman, D.S. (1970) Chemical composition of the cell wall of the H37Ra 
strain of Mycobacterium tuberculosis. Journal of Bacteriology, 102 (3): 733–739. 
Ahmad, Z., Minkowski, A., Peloquin, C.A., Williams, K.N., Mdluli, K.E., Grosset, J.H. and 
Nuermberger, E.L. (2011) Activity of the fluoroquinolone DC-159a in the initial and 
continuation phases of treatment of murine tuberculosis. Antimicrobial agents and 
chemotherapy, 55 (4): 1781–1783. 
Aínsa, J.A., Pérez, E., Pelicic, V., Berthet, F.X., Gicquel, B. and Martin, C. (1997) 
Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: 
characterisation of the aac(2“)-Ic gene from Mycobacterium tuberculosis and the aac(2”)-Id 
gene from Mycobacterium smegmatis. Molecular microbiology, 24 (2): 431–441. 
Aktas, M., Danne, L., Möller, P. and Narberhaus, F. (2014) Membrane lipids in Agrobacterium 
tumefaciens: biosynthetic pathways and importance for pathogenesis. Frontiers in plant 
science, 5 (20130810): 109.  
Al-Balas, Q., Anthony, N.G., Al-Jaidi, B., Alnimr, A., Abbott, G., Brown, A.K., Taylor, R.C., 
Besra, G.S., McHugh, T.D., Gillespie, S.H., Johnston, B.F., Mackay, S.P. and Coxon, G.D. 
(2009) Identification of 2-aminothiazole-4-carboxylate derivatives active against 
Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH. Todd, M.H. 
(ed.). PLoS ONE, 4 (5): e5617.  
Albesa-Jové, D., Svetlíková, Z., Tersa, M., Sancho-Vaello, E., Carreras-González, A., Bonnet, 
P., Arrasate, P., Eguskiza, A., Angala, S.K., Cifuente, J.O., Kordulakova, J., Jackson, M., 
Mikušová, K. and Guerin, M.E. (2016) Structural basis for selective recognition of acyl chains 
by the membrane-associated acyltransferase PatA. Nature Communications, 7: 10906–12.  
Alderwick, L.J., Lloyd, G.S., Lloyd, A.J., Lovering, A.L., Eggeling, L. and Besra, G.S. (2011) 
Biochemical characterisation of the Mycobacterium tuberculosis phosphoribosyl-1-
pyrophosphate synthetase. Glycobiology, 21 (4): 410–425.  
Alderwick, L.J., Radmacher, E., Seidel, M., Gande, R., Hitchen, P.G., Morris, H.R., Dell, A., 
Sahm, H., Eggeling, L. and Besra, G.S. (2005) Deletion of Cg-emb in corynebacterianeae leads 
References 
 194 
to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiA results in an 
arabinan-deficient mutant with a cell wall galactan core. Journal of Biological Chemistry, 280 
(37): 32362–32371.  
Alderwick, L.J., Seidel, M., Sahm, H., Besra, G.S. and Eggeling, L. (2006) Identification of a 
novel arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in 
Mycobacterium tuberculosis. Journal of Biological Chemistry, 281 (23): 15653–15661.  
Almeida, D., Converse, P.J., Ahmad, Z., Dooley, K.E., Nuermberger, E.L. and Grosset, J.H. 
(2011) Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination 
against Mycobacterium ulcerans Disease in Mice. PLoS Neglected Tropical Diseases, 5 (1): 
e933–7.  
Altaf, M., Miller, C.H., Bellows, D.S. and O'Toole, R. (2010) Evaluation of the Mycobacterium 
smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. 
Tuberculosis (Edinburgh, Scotland), 90 (6): 333–337.  
Amin, A.G., Goude, R., Shi, L., Zhang, J., Chatterjee, D. and Parish, T. (2008) EmbA is an 
essential arabinosyltransferase in Mycobacterium tuberculosis. Microbiology, 154 (Pt 1): 240–
248.  
Andersen, P.H. (1989) The dopamine inhibitor GBR 12909: selectivity and molecular 
mechanism of action. European journal of pharmacology, 166 (3): 493–504. 
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H.W.H., Neefs, J.-M., Winkler, H., 
Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., 
Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N. and Jarlier, V. (2005) A 
diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 307 
(5707): 223–227. 
Anthony T Podany, S.S. (2016) Current strategies to treat tuberculosis. F1000Research, 5: 
2579. 
Arias, C.A., Vallejo, M., Reyes, J., Panesso, D., Moreno, J., Castañeda, E., Villegas, M.V., 
Murray, B.E. and Quinn, J.P. (2008) Clinical and microbiological aspects of linezolid 
resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. Journal of 
Clinical Microbiology, 46 (3): 892–896.  
Arjona, A. and Castañer, R. (2008) TMC-207. Drugs of the Future, 33 (12): 1018. 
Arsic, B., Barber, J., Čikoš, A., Mladenovic, M., Stankovic, N. and Novak, P. (2017) 16-
Membered Macrolide Antibiotics: a Review. International journal of antimicrobial agents.  




Baell, J.B. and Holloway, G.A. (2010) New Substructure Filters for Removal of Pan Assay 
Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in 
Bioassays. Journal of Medicinal Chemistry, 53 (7): 2719–2740.  
Ballell, L., Bates, R.H., Young, R.J., Alvarez-Gomez, D., Alvarez-Ruiz, E., Barroso, V., 
Blanco, D., Crespo, B., Escribano, J., González, R., Lozano, S., Huss, S., Santos-Villarejo, A., 
Martín-Plaza, J.J., Mendoza, A., Rebollo-López, M.J., Remuiñan-Blanco, M., Lavandera, J.L., 
Pérez-Herran, E., Gamo-Benito, F.J., García-Bustos, J.F., Barros, D., Castro, J.P. and 
Cammack, N. (2013) Fueling open-source drug discovery: 177 small-molecule leads against 
tuberculosis. ChemMedChem, 8 (2): 313–321.  
Ballou, C.E., Vilkas, E. and Lederer, E. (1963) Structural studies on the myo-inositol 
phospholipids of Mycobacterium tuberculosis (var. bovis, strain BCG). Journal of Biological 
Chemistry, 238 (1): 69–76. 
Bártfai, Z., Somoskovi, A., Ködmön, C., Szabó, N., Puskás, E., Kosztolányi, L., Faragó, E., 
Mester, J., Parsons, L.M. and Salfinger, M. (2001) Molecular characterisation of rifampin-
resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the 
line probe assay. Journal of Clinical Microbiology, 39 (10): 3736–3739. 
Basu, J. (2004) Mycobacteria within its intracellular niche: survival of the pathogen or its host? 
Current science-bangalore, 86 (1): 103-110. 
Batt, S.M., Jabeen, T., Bhowruth, V., Quill, L., Lund, P.A., Eggeling, L., Alderwick, L.J., 
Fütterer, K. and Besra, G.S. (2012) Structural basis of inhibition of Mycobacterium tuberculosis 
DprE1 by benzothiazinone inhibitors. Proceedings of the National Academy of Sciences of the 
United States of America, 109 (28): 11354–11359.  
Bearson, B.L., Allen, H.K., Brunelle, B.W., Lee, I.S., Casjens, S.R. and Stanton, T.B. (2014) 
The agricultural antibiotic carbadox induces phage-mediated gene transfer in Salmonella. 
Frontiers in Microbiology, 5: 52.  
Beckman, D.L. and Kranz, R.G. (1991) A bacterial homolog to the mitochondrial enoyl-CoA 
hydratase. Gene, 107 (1): 171–172. 
Belanova, M., Dianiskova, P., Brennan, P.J., Completo, G.C., Rose, N.L., Lowary, T.L. and 
Mikušová, K. (2008) Galactosyl transferases in mycobacterial cell wall synthesis. Journal of 
Bacteriology, 190 (3): 1141–1145.  
Belisle, J.T., Vissa, V.D., Sievert, T., Takayama, K., Brennan, P.J. and Besra, G.S. (1997) Role 
of the Major Antigen of Mycobacterium tuberculosis in Cell Wall Biogenesis. Science, 276 
(5317): 1420–1422.  
Bernstein, J., Lott, W.A., Steinberg, B.A. and Yale, H.L. (1952) Chemotherapy of experimental 
tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. American 
review of tuberculosis, 65 (4): 357–364. 
References 
 196 
Bhatt, A., Brown, A.K., Singh, A., Minnikin, D.E. and Besra, G.S. (2008) Loss of a 
mycobacterial gene encoding a reductase leads to an altered cell wall containing beta-oxo-
mycolic acid analogs and accumulation of ketones. Chemistry and Biology, 15 (9): 930–939.  
Bhatt, A., Fujiwara, N., Bhatt, K., Gurcha, S.S., Kremer, L., Chen, B., Chan, J., Porcelli, S.A., 
Kobayashi, K., Besra, G.S. and Jacobs, W.R., Jr (2007a) Deletion of kasB in Mycobacterium 
tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in 
immunocompetent mice. Proceedings of the National Academy of Sciences of the United States 
of America, 104 (12): 5157–5162. 
Bhatt, A., Kremer, L., Dai, A.Z., Sacchettini, J.C. and Jacobs, W.R. (2005) Conditional 
Depletion of KasA, a Key Enzyme of Mycolic Acid Biosynthesis, Leads to Mycobacterial Cell 
Lysis. Journal of Bacteriology, 187 (22): 7596–7606.  
Bhatt, A., Molle, V., Besra, G.S., Jacobs, W.R., Jr and Kremer, L. (2007b) The Mycobacterium 
tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, 
pathogenesis and in future drug development. Molecular microbiology, 64 (6): 1442–1454.  
Birch, H.L., Alderwick, L.J., Appelmelk, B.J., Maaskant, J., Bhatt, A., Singh, A., Nigou, J., 
Eggeling, L., Geurtsen, J. and Besra, G.S. (2010) A truncated lipoglycan from mycobacteria 
with altered immunological properties. Proceedings of the National Academy of Sciences of the 
United States of America, 107 (6): 2634–2639.  
Birch, H.L., Alderwick, L.J., Bhatt, A., Rittmann, D., Krumbach, K., Singh, A., Bai, Y., 
Lowary, T.L., Eggeling, L. and Besra, G.S. (2008) Biosynthesis of mycobacterial 
arabinogalactan: identification of a novel alpha (1-->3) arabinofuranosyltransferase. Molecular 
microbiology, 69 (5): 1191–1206.  
Blanchard, J.S. (1996) Molecular Mechanisms of Drug Resistance in Mycobacterium 
tuberculosis. Annual Review of Biochemistry, 65:215-39. 
Bloch, K. (2006) “Control Mechanisms for Fatty Acid Synthesis in Mycobacterium 
smegmatis.” In Advances in Enzymology and Related Areas of Molecular Biology. 
Meister/Advances. vol. Hoboken, NJ, USA: John Wiley & Sons, Inc. pp. 1–84.  
Books, LLC General Books LLC (2010) Veterinary Drugs. Books LLC, Wiki Series. 
Boostanfar, R., Jain, J.K., Mishell, D.R. and Paulson, R.J. (2001) A prospective randomised 
trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertility and 
sterility, 75 (5): 1024–1026. 
Boshoff, H.I.M., Myers, T.G., Copp, B.R., McNeil, M.R., Wilson, M.A. and Barry, C.E. 
(2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of 
metabolism: novel insights into drug mechanisms of action. Journal of Biological Chemistry, 
279 (38): 40174–40184. 
Braibant, M., Gilot, P. and Content, J. (2000) The ATP binding cassette (ABC) transport 
systems of Mycobacterium tuberculosis. FEMS Microbiology Reviews, 24 (4): 449–467. 
References 
 197 
Breda, A., Martinelli, L.K.B., Bizarro, C.V., Rosado, L.A., Borges, C.B., Santos, D.S. and 
Basso, L.A. (2012) Wild-type phosphoribosylpyrophosphate synthase (PRS) from 
Mycobacterium tuberculosis: a bacterial class II PRS? Tyagi, A.K. (ed.). PLoS ONE, 7 (6): 
e39245.  
Brennan, P.J. (2003) Structure, function, and biogenesis of the cell wall of Mycobacterium 
tuberculosis. Tuberculosis, 83 (1-3): 91–97.  
Brennan, P.J. and Besra, G.S. (1997) Structure, function and biogenesis of the mycobacterial 
cell wall. Biochemical Society Transactions, 25 (1): 188–194. 
Brennan, P.J. and Nikaido, H. (1995) The envelope of mycobacteria. Annual review of 
biochemistry, 64 (1): 29–63.  
Cambau, E. and Drancourt, M. (2014) Steps towards the discovery of Mycobacterium 
tuberculosis by Robert Koch, 1882. Clinical Microbiology and Infection, 20 (3): 196–201.  
Cantaloube, S., Veyron-Churlet, R., Haddache, N., Daffé, M. and Zerbib, D. (2011) The 
Mycobacterium tuberculosis FAS-II Dehydratases and Methyltransferases Define the 
Specificity of the Mycolic Acid Elongation Complexes Cardona, P.-J. (ed.). PLoS ONE, 6 (12):  
Carbadox (2014). Antibacterials pp. 216. 
Cavanagh, R., Begon, M., Bennett, M., Ergon, T., Graham, I.M., De Haas, P.E.W., Hart, C.A., 
Koedam, M., Kremer, K., Lambin, X., Roholl, P. and Soolingen Dv, D.V. (2002) 
Mycobacterium microti infection (vole tuberculosis) in wild rodent populations. Journal of 
Clinical Microbiology, 40 (9): 3281–3285.  
Cave, A.J.E. and Demonstrator, A. (1939) The evidence for the incidence of tuberculosis in 
ancient Egypt. British Journal of Tuberculosis, 33 (3): 142–152.  
Chafetz, L., Greenough, R.C. and Frank, J. (1986) Thermal decomposition of thonzonium 
bromide. Pharmaceutical research, 3 (5): 298–301.  
Chahine, E.B., Karaoui, L.R. and Mansour, H. (2013) Bedaquiline. Annals of 
Pharmacotherapy, 48 (1): 107–115.  
Chambers, H.F., Moreau, D., Yajko, D., Miick, C., Wagner, C., Hackbarth, C., Kocagoz, S., 
Rosenberg, E., Hadley, W.K. and Nikaido, H. (1995) Can penicillins and other beta-lactam 
antibiotics be used to treat tuberculosis? Antimicrobial agents and chemotherapy, 39 (12): 
2620–2624.  
Chambers, H.F., Turner, J., Schecter, G.F., Kawamura, M. and Hopewell, P.C. (2005) 
Imipenem for treatment of tuberculosis in mice and humans. Antimicrobial agents and 
chemotherapy, 49 (7): 2816–2821.  
Chan, C.-Y., Prudom, C., Raines, S.M., Charkhzarrin, S., Melman, S.D., De Haro, L.P., Allen, 
C., Lee, S.A., Sklar, L.A. and Parra, K.J. (2012) Inhibitors of V-ATPase proton transport reveal 
References 
 198 
uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a 
(Vph1p). The Journal of biological chemistry, 287 (13): 10236–10250.  
Chang, Y.H., Labgold, M.R. and Richards, J.H. (1990) Altering enzymatic activity: recruitment 
of carboxypeptidase activity into an RTEM beta-lactamase/penicillin-binding protein 5 
chimera. Proceedings of the National Academy of Sciences, 87 (7): 2823–2827. 
Chatterjee, D. (1997) The mycobacterial cell wall: structure, biosynthesis and sites of drug 
action. Current opinion in chemical biology, 1 (4): 579–588. 
Cho, S.H., Warit, S., Wan, B., Hwang, C.H., Pauli, G.F. and Franzblau, S.G. (2007) Low-
oxygen-recovery assay for high-throughput screening of compounds against nonreplicating 
Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 51 (4): 1380–1385.  
Christen, M.O. (1990) Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal 
motility disorders. General pharmacology, 21 (6): 821–825. 
Christophe, T., Jackson, M., Jeon, H.K., Fenistein, D., Contreras-Dominguez, M., Kim, J., 
Genovesio, A., Carralot, J.-P., Ewann, F., Kim, E.H., Lee, S.Y., Kang, S., Seo, M.J., Park, E.J., 
Škovierová, H., Pham, H., Riccardi, G., Nam, J.Y., Marsollier, L., Kempf, M., Joly-Guillou, 
M.-L., Oh, T., Shin, W.K., No, Z., Nehrbass, U., Brosch, R., Cole, S.T. and Brodin, P. (2009) 
High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for 
Intracellular Antimycobacterial Inhibitors Bishai, W. (ed.). PLoS Pathogens, 5 (10): e1000645.  
Clark-Curtiss, J.E. and Haydel, S.E. (2003) Molecular Genetics of Mycobacterium tuberculosis 
Pathogenesis. 57 (1): 517–549.  
Cole, S.T. (1994) Mycobacterium tuberculosis: drug-resistance mechanisms. Trends in 
microbiology, 2 (10): 411–415.  
Cole, S.T. (2016) Inhibiting Mycobacterium tuberculosis within and without. Philosophical 
Transactions of the Royal Society: Biological Sciences, 371 (1707): 20150506–8.  
Cole, S.T. and Riccardi, G. (2011) New tuberculosis drugs on the horizon. Current opinion in 
microbiology, 14 (5): 570–576.  
Collins, L. and Franzblau, S.G. (1997) Microplate alamar blue assay versus BACTEC 460 
system for high-throughput screening of compounds against Mycobacterium tuberculosis and 
Mycobacterium avium. Antimicrobial agents and chemotherapy, 41 (5): 1004–1009. 
Cooksey, R.C., Crawford, J.T., Jacobs, W.R., Jr and Shinnick, T.M. (1993) A rapid method for 
screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis 
expressing firefly luciferase. Antimicrobial agents and chemotherapy, 37 (6): 1348–1352.  
Cooper, C.B. (2013) Development of Mycobacterium tuberculosis Whole Cell Screening Hits 
as Potential Antituberculosis Agents. Journal of Medicinal Chemistry, 56 (20): 7755–7760.  
References 
 199 
Cousins, D.V. (2003) Tuberculosis in seals caused by a novel member of the Mycobacterium 
tuberculosis complex: Mycobacterium pinnipedii sp. nov. International journal of systematic 
and evolutionary microbiology, 53 (5): 1305–1314.  
Cox, J.A.G., Abrahams, K.A., Alemparte, C., Ghidelli-Disse, S., Rullas, J., Angulo-Barturen, 
I., Singh, A., Gurcha, S.S., Nataraj, V., Bethell, S., Remuiñán, M.J., Encinas, L., Jervis, P.J., 
Cammack, N.C., Bhatt, A., Kruse, U., Bantscheff, M., Fütterer, K., Barros, D., Ballell, L., 
Drewes, G. and Besra, G.S. (2016) THPP target assignment reveals EchA6 as an essential fatty 
acid shuttle in mycobacteria. Nature microbiology, 1 (2): 15006–15010.  
Cox, J.A.G., Mugumbate, G., Del Peral, L.V.-G., Jankute, M., Abrahams, K.A., Jervis, P., 
Jackenkroll, S., Perez, A., Alemparte, C., Esquivias, J., Lelièvre, J., Ramon, F., Barros, D., 
Ballell, L. and Besra, G.S. (2016) Novel inhibitors of Mycobacterium tuberculosis GuaB2 
identified by a target based high-throughput phenotypic screen. Scientific Reports, 6 (1): 420.  
Crellin, P.K., Brammananth, R. and Coppel, R.L. (2011) Decaprenylphosphoryl-β-D-Ribose 
2′-Epimerase, the Target of Benzothiazinones and Dinitrobenzamides, Is an Essential Enzyme 
in Mycobacterium smegmatis. PLoS ONE, 6 (2): e16869.  
Crellin, P.K., Kovacevic, S., Martin, K.L., Brammananth, R., Morita, Y.S., Billman-Jacobe, H., 
McConville, M.J. and Coppel, R.L. (2008) Mutations in pimE restore lipoarabinomannan 
synthesis and growth in a Mycobacterium smegmatis lpqW mutant. Journal of Bacteriology, 
190 (10): 3690–3699.  
CROFTON, J. and Mitchison, D.A. (1948) Streptomycin resistance in pulmonary tuberculosis. 
British medical journal, 2 (4588): 1009–1015. 
Daffé, M. and Lanéelle, M.-A. (2001) “Analysis of the Capsule of Mycobacterium 
tuberculosis.” In Mycobacterium tuberculosis Protocols. vol. New Jersey: Humana Press. pp. 
217–227.  
Daffe, M., Brennan, P.J. and McNeil, M. (1990) Predominant structural features of the cell wall 
arabinogalactan of Mycobacterium tuberculosis as revealed through characterisation of 
oligoglycosyl alditol fragments by gas chromatography/mass spectrometry and by 1H and 13C 
NMR analyses. Journal of Biological Chemistry, 265 (12): 6734–6743. 
de Mendonça, J.D., Ely, F., Palma, M.S., Frazzon, J., Basso, L.A. and Santos, D.S. (2007) 
Functional characterisation by genetic complementation of aroB-encoded dehydroquinate 
synthase from Mycobacterium tuberculosis H37Rv and its heterologous expression and 
purification. Journal of Bacteriology, 189 (17): 6246–6252.  
Deoxyribonucleic acid relatedness among selected strains of Mycobacterium tuberculosis, 
Mycobacterium bovis, Mycobacterium bovis BCG, Mycobacterium microti, and 
Mycobacterium africanum (1986). Clinical Microbiology Newsletter, 8 (2): 14.  
Diacon, A.H., van der Merwe, L., Barnard, M., Groote-Bidlingmaier, von, F., Lange, C., 
García-Basteiro, A.L., Sevene, E., Ballell, L. and Barros-Aguirre, D. (2016) β-Lactams against 
References 
 200 
Tuberculosis — New Trick for an Old Dog? New England Journal of Medicine, 375 (4): 393–
394.  
Dogra, M., Palmer, B.D., Bashiri, G., Tingle, M.D., Shinde, S.S., Anderson, R.F., O'Toole, 
R., Baker, E.N., Denny, W.A. and Helsby, N.A. (2010) Comparative bioactivation of the 
novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human 
liver. British Journal of Pharmacology, 162 (1): 226–236.  
Domenech, P., Rog, A., Moolji, J. U. D., Radomski, N., Fallow, A., Leon-Solis, L., Bowes, J., 
Behr, M.A. and Reed, M.B. (2014) Origins of a 350-kilobase genomic duplication in 
Mycobacterium tuberculosis and its impact on virulence. Infection and immunity, 82 (7): 2902–
2912. 
Donini, S., Garavaglia, S., Ferraris, D.M., Miggiano, R., Mori, S., Shibayama, K. and Rizzi, M. 
(2017) Biochemical and structural investigations on phosphoribosylpyrophosphate synthetase 
from Mycobacterium smegmatis. Permyakov, E.A. (ed.). PLoS ONE, 12 (4): e0175815.  
Dorey, L., Hobson, S. and Lees, P. (2016) Activity of florfenicol for Actinobacillus 
pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised 
methodology. Veterinary journal (London, England: 1997), 218: 65–70.  
Dorlo, T.P.C. and Kager, P.A. (2008) Pentamidine dosage: a base/salt confusion. Utzinger, J. 
(ed.). PLoS Neglected Tropical Diseases, 2 (5): e225.  
Draper, P., Khoo, K.-H., Chatterjee, D., Dell, A. and Morris, R.H. (1997) Galactosamine in 
walls of slow-growing mycobacteria. Biochemical Journal, 327 (2): 519–525.  
Dubée, V., Triboulet, S., Mainardi, J.-L., Ethève-Quelquejeu, M., Gutmann, L., Marie, A., 
Dubost, L., Hugonnet, J. E. and Arthur, M. (2012) Inactivation of Mycobacterium tuberculosis 
l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins. Antimicrobial agents and 
chemotherapy, 56 (8): 4189–4195. 
Dubnau, E. (2002) Mycobacterium tuberculosis Genes Induced during Infection of Human 
Macrophages. Infection and immunity, 70 (6): 2787–2795.  
Dubnau, E., Chan, J., Raynaud, C., Mohan, V.P., Lanéelle, M.-A., Yu, K., Quémard, A., Smith, 
I. and Daffé, M. (2002) Oxygenated mycolic acids are necessary for virulence of 
Mycobacterium tuberculosis in mice. Molecular microbiology, 36 (3): 630–637.  
Ekins, S., Casey, A.C., Roberts, D., Parish, T. and Bunin, B.A. (2014) Bayesian models for 
screening and TB Mobile for target inference with Mycobacterium tuberculosis. Tuberculosis, 
94 (2): 162–169.  
Engohang-Ndong, J. (2012) Antimycobacterial drugs currently in Phase II clinical trials and 
preclinical phase for tuberculosis treatment. Expert Opinion on Investigational Drugs, 21 
(12): 1789–1800.  
References 
 201 
Escuyer, V.E., Lety, M.A., Torrelles, J.B., Khoo, K.H., Tang, J.B., Rithner, C.D., Frehel, C., 
McNeil, M.R., Brennan, P.J. and Chatterjee, D. (2001) The role of the embA and embB gene 
products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium 
smegmatis arabinogalactan. Journal of Biological Chemistry, 276 (52): 48854–48862.  
Esposito, M., Szadocka, S., Degiacomi, G., Orena, B.S., Mori, G., Piano, V., Boldrin, F., 
Zemanová, J., Huszár, S., Barros, D., Ekins, S., Lelièvre, J., Manganelli, R., Mattevi, A., Pasca, 
M.R., Riccardi, G., Ballell, L., Mikušová, K. and Chiarelli, L.R. (2017) A Phenotypic Based 
Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. ACS 
Infectious Diseases, 3 (6): 428–437.  
Evangelopoulos, D., da Fonseca, J.D. and Waddell, S.J. (2015) Understanding anti-tuberculosis 
drug efficacy: rethinking bacterial populations and how we model them. International journal 
of infectious diseases : IJID : official publication of the International Society for Infectious 
Diseases, 32: 76–80. 
Farnia, P., Mohammad, R.M., Merza, M.A., Tabarsi, P., Zhavnerko, G.K., Ibrahim, T.A., Kuan, 
H.O., Ghanavei, J., Farnia, P., Ranjbar, R., Poleschuyk, N.N., Titov, L.P., Owlia, P., 
Kazampour, M., Setareh, M., sheikolslami, M., Migliori, G.B. and Velayati, A.A. (2010) 
Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) 
tuberculosis strains: transmission and atomic force observation. International Journal of 
Clinical and Experimental Medicine, 3 (4): 308–314. 
Feng, Z. and Barletta, R.G. (2003) Roles of Mycobacterium smegmatis D-alanine:D-alanine 
ligase and D-alanine racemase in the mechanisms of action of and resistance to the 
peptidoglycan inhibitor D-cycloserine. Antimicrobial agents and chemotherapy, 47 (1): 283–
291.  
Fenner, L., Egger, M., Bodmer, T., Altpeter, E., Zwahlen, M., Jaton, K., Pfyffer, G.E., Borrell, 
S., Dubuis, O., Bruderer, T., Siegrist, H.H., Furrer, H., Calmy, A., Fehr, J., Stalder, J.M., Ninet, 
B., Böttger, E.C., Gagneux, S.Swiss HIV Cohort Study and the Swiss Molecular Epidemiology 
of Tuberculosis Study Group (2012) Effect of mutation and genetic background on drug 
resistance in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 56 (6): 
3047–3053.  
Fleischman, J.K., MD and Greenberg, H.E., MD (1998) Tuberculosis. Medical Update for 
Psychiatrists, 3 (1): 16–21.  
Flores, A.R. (2005) Genetic analysis of the  b-lactamases of Mycobacterium tuberculosis and 
Mycobacterium smegmatis and susceptibility to b-lactam antibiotics. Microbiology, 151 (2): 
521–532.  
Flynn, J.L. and Chan, J. (2001) Tuberculosis: latency and reactivation. Infection and immunity, 
69 (7): 4195–4201.  
Freiberg, C. and Brötz-Oesterhelt, H. (2005) Functional genomics in antibacterial drug 
discovery. Drug Discovery Today, 10 (13): 927–935. 
References 
 202 
Fritzler, J.M. and Zhu, G. (2012) Novel anti-Cryptosporidium activity of known drugs 
identified by high-throughput screening against parasite fatty acyl-CoA binding protein 
(ACBP). The Journal of antimicrobial chemotherapy, 67 (3): 609–617.  
Fujita, Y., Shimakata, T. and Kusaka, T. (1980) Purification of Two Forms of Enoyl-CoA 
Hydratase from Mycobacterium smegmatis. Journal of biochemistry, 88 (4): 1045–1050.  
Gande, R., Gibson, K.J.C., Brown, A.K., Krumbach, K., Dover, L.G., Sahm, H., Shioyama, S., 
Oikawa, T., Besra, G.S. and Eggeling, L. (2004) Acyl-CoA carboxylases (accD2 and accD3), 
together with a unique polyketide synthase (Cg-pks), are key to mycolic acid biosynthesis in 
Corynebacterianeae such as Corynebacterium glutamicum and Mycobacterium tuberculosis. 
Journal of Biological Chemistry, 279 (43): 44847–44857.  
Gangwar, S.P., Meena, S.R. and Saxena, A.K. (2014) Comparison of four different crystal 
forms of the Mycobacterium tuberculosis ESX-1 secreted protein regulator EspR. Acta 
crystallographica. Structural biology communications, 70:433–437.  
Garbe, T., Servos, S., Hawkins, A., Dimitriadis, G., Young, D., Dougan, G. and Charles, I. 
(1991) The Mycobacterium tuberculosis shikimate pathway genes: evolutionary relationship 
between biosynthetic and catabolic 3-dehydroquinases. Molecular & general genetics, 228 (3): 
385–392. 
Ghuysen, J.M. (1991) Serine Beta-Lactamases and Penicillin-Binding Proteins. Annual Review 
of Microbiology, 45 (1): 37–67.  
Gillespie, S.H. (2016) The role of moxifloxacin in tuberculosis therapy. European respiratory 
review: an official journal of the European Respiratory Society, 25 (139): 19–28.  
Glickman, M.S. and Jacobs, W.R. (2001) Microbial pathogenesis of Mycobacterium 
tuberculosis: dawn of a discipline. Cell, 104 (4): 477–485. 
Glickman, M.S., Cahill, S.M. and Jacobs, W.R. (2001) The Mycobacterium tuberculosis 
cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetase. Journal of Biological 
Chemistry, 276 (3): 2228–2233.  
Glickman, M.S., Cox, J.S. and Jacobs, W.R., Jr (2000) A Novel Mycolic Acid Cyclopropane 
Synthetase Is Required for Cording, Persistence, and Virulence of Mycobacterium tuberculosis. 
Molecular Cell, 5 (4): 717–727.  
Gold, B., Smith, R., Nguyen, Q., Roberts, J., Ling, Y., Lopez Quezada, L., Somersan, S., 
Warrier, T., Little, D., Pingle, M., Zhang, D., Ballinger, E., Zimmerman, M., Dartois, V., 
Hanson, P., Mitscher, L.A., Porubsky, P., Rogers, S., Schoenen, F.J., Nathan, C. and Aubé, J. 
(2016) Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium 
tuberculosis. Journal of Medicinal Chemistry, 59 (13): 6027–6044.  
Goldman, R.C. (2013) Why are membrane targets discovered by phenotypic screens and 
genome sequencing in Mycobacterium tuberculosis? Tuberculosis, 93 (6): 569–588.  
References 
 203 
Goyal, K., Qamra, R. and Mande, S.C. (2006) Multiple gene duplication and rapid evolution in 
the groEL gene: functional implications. Journal of molecular evolution, 63 (6): 781–787.  
Grant, S.S., Kawate, T., Nag, P.P., Silvis, M.R., Gordon, K., Stanley, S.A., Kazyanskaya, E., 
Nietupski, R., Golas, A., Fitzgerald, M., Cho, S., Franzblau, S.G. and Hung, D.T. (2013) 
Identification of Novel Inhibitors of Nonreplicating Mycobacterium tuberculosis Using a 
Carbon Starvation Model. ACS Chemical Biology, 8 (10): 2224–2234.  
Griffith, R.S. (1981) Introduction to vancomycin. Reviews of infectious diseases, 3 suppl: 
S200–4. 
Grundy, D., Blackshaw, L.A. and Hillsley, K. (1994) Role of 5-hydroxytryptamine in 
gastrointestinal chemosensitivity. Digestive diseases and sciences, 39 (12 Suppl): 44S–47S. 
Grzegorzewicz, A.E., de Sousa-d'Auria, C., McNeil, M.R., Huc-Claustre, E., Jones, V., Petit, 
C., Angala, S.K., Zemanová, J., Wang, Q., Belardinelli, J.M., Gao, Q., Ishizaki, Y., Mikušová, 
K., Brennan, P.J., Ronning, D.R., Chami, M., Houssin, C. and Jackson, M. (2016) Assembling 
of the Mycobacterium tuberculosis Cell Wall Core. The Journal of biological chemistry, 291 
(36): 18867–18879.  
Gupta, A., Kaul, A., Tsolaki, A.G., Kishore, U. and Bhakta, S. (2012) Mycobacterium 
tuberculosis: immune evasion, latency and reactivation. Immunobiology, 217 (3): 363–374.  
Gupta, R., Kim, J.Y., Espinal, M.A., Caudron, J.M., Pecoul, B., Farmer, P.E. and Raviglione, 
M.C. (2001) Public health. Responding to market failures in tuberculosis control. Science, 293 
(5532): 1049–1051.  
Haites, R.E., Morita, Y.S., McConville, M.J. and Billman-Jacobe, H. (2005) Function of 
phosphatidylinositol in mycobacteria. Journal of Biological Chemistry, 280 (12): 10981–
10987. 
Hamed, R.B., Batchelar, E.T., Clifton, I.J. and Schofield, C.J. (2008) Mechanisms and 
structures of crotonase superfamily enzymes – How nature controls enolate and oxyanion 
reactivity. Cellular and Molecular Life Sciences, 65 (16): 2507–2527.  
Harrison, J., Lloyd, G., Joe, M., Lowary, T.L., Reynolds, E., Walters-Morgan, H., Bhatt, A., 
Lovering, A., Besra, G.S. and Alderwick, L.J. (2016) Lcp1 is a phosphotransferase responsible 
for ligating arabinogalactan to peptidoglycan in Mycobacterium tuberculosis. mBio, 7 (4). 
 Hayman, J. (1984) Mycobacterium ulcerans: an infection from Jurassic time? Lancet, 2 (8410): 
1015–1016. 
Hayward C. M., O’Gaora P., Young D. B., Griffin G. E., Thole J., Hirst T. R., Castello-
Branco L. R., Lewis D. J. (1999) Construction and murine immunogenicity of recombinant 
Bacille Calmette Guerin vaccines expressing the B subunit of Escherichia coli heat labile 
enterotoxin. Vaccine, 17, 1272–1281 
References 
 204 
Hazbón, M.H., Brimacombe, M., Bobadilla del Valle, M., Cavatore, M., Guerrero, M.I., 
Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L., León, C.I., 
Bose, M., Chaves, F., Murray, M., Eisenach, K.D., Sifuentes-Osornio, J., Cave, M.D., Ponce 
de León, A. and Alland, D. (2006) Population genetics study of isoniazid resistance mutations 
and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrobial agents and 
chemotherapy, 50 (8): 2640–2649.  
He, S., Zhou, Z., Liu, Y., Cao, Y., Meng, K., Shi, P., Yao, B. and Ringø, E. (2010) Effects of 
the antibiotic growth promoters flavomycin and florfenicol on the autochthonous intestinal 
microbiota of hybrid tilapia (Oreochromis niloticus ♀ × O. aureus ♂). Archives of 
microbiology, 192 (12): 985–994.  
Hett, E.C., Chao, M.C. and Rubin, E.J. (2010) Interaction and Modulation of Two Antagonistic 
Cell Wall Enzymes of Mycobacteria. PLoS Pathogens, 6 (7): e1001020.  
Hu, Y.-Q., Zhang, S., Zhao, F., Gao, C., Feng, L.-S., Lv, Z.-S., Xu, Z. and Wu, X. (2017) 
Isoniazid derivatives and their anti-tubercular activity. European Journal of Medicinal 
Chemistry, 133: 255–267.  
Huard, R.C., Fabre, M., de Haas, P., Lazzarini, L.C.O., van Soolingen, D., Cousins, D. and Ho, 
J.L. (2006) Novel genetic polymorphisms that further delineate the phylogeny of the 
Mycobacterium tuberculosis complex. Journal of Bacteriology, 188 (12): 4271–4287.  
Humanes, L., García-Fernández, J.M., Roldán, J.M. and Diez, J. (1999) Cloning of an ORF 
with homology to Mycobacterium echA1, encoding the enoyl-CoA hydratase, in Rhodococcus 
fascians. DNA sequence: the journal of DNA sequencing and mapping, 10 (4-5): 309–315. 
Hunter, S.W. and Brennan, P.J. (1990) Evidence for the presence of a phosphatidylinositol 
anchor on the lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. Journal of 
Biological Chemistry, 265 (16): 9272–9279. 
Hwang, H.-H., Moon, P.-G., Lee, J.-E., Kim, J.-G., Lee, W., Ryu, S.-H. and Baek, M.-C. (2011) 
Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic 
analysis of cytosolic and secreted proteins. Molecules and cells, 31 (3): 239–246.  
Jackson, C.J., Lamb, D.C., Kelly, D.E. and Kelly, S.L. (2000) Bactericidal and inhibitory 
effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiology 
Letters, 192 (2): 159–162. 
Jackson, M., Crick, D.C. and Brennan, P.J. (2000) Phosphatidylinositol Is an Essential 
Phospholipid of Mycobacteria. Journal of Biological Chemistry, 275 (39): 30092–30099.  
Jadaun, A., Sudhakar D, R., Subbarao, N. and Dixit, A. (2015) Correction: In Silico Screening 
for Novel Inhibitors of DNA Polymerase III Alpha Subunit of Mycobacterium tuberculosis 
(MtbDnaE2, H37Rv). PLoS ONE, 10 (5): e0128613.  
References 
 205 
James, B.W., Williams, A. and Marsh, P.D. (2000) The physiology and pathogenicity of 
Mycobacterium tuberculosis grown under controlled conditions in a defined medium. Journal 
of Applied Microbiology, 88 (4): 669–677.  
Jankute, M., Cox, J.A.G., Harrison, J. and Besra, G.S. (2015) Assembly of the Mycobacterial 
Cell Wall. Annual Review of Microbiology, 69 (1): 405–423.  
Jankute, M., Grover, S., Birch, H.L. and Besra, G.S. (2014) Genetics of mycobacterial 
arabinogalactan and lipoarabinomannan assembly. Microbiology Spectrum, 2 (4). 
Jarlier, V. and Nikaido, H. (1994) Mycobacterial cell wall: structure and role in natural 
resistance to antibiotics. FEMS Microbiology Letters, 123 (1-2): 11–18. 
Jawed Ahsan, M., Yousuf Ansari, M., Yasmin, S., Singh Jadav, S., Kumar, P., Kumar Garg, S., 
Aseri, A. and Khalilullah, H. (2015) Tuberculosis: Current Treatment, Diagnostics, and Newer 
Antitubercular Agents in Clinical Trials. Infectious Disorders- Drug Targets, 15(1): 32-41. 
Ji, B., Chauffour, A., Andries, K. and Jarlier, V. (2006) Bactericidal activities of R207910 and 
other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrobial agents 
and chemotherapy, 50 (4): 1558–1560.  
Jiang, T., He, L., Zhan, Y., Zang, S., Ma, Y., Zhao, X., Zhang, C. and Xin, Y. (2011) The effect 
of MSMEG_6402 gene disruption on the cell wall structure of Mycobacterium smegmatis. 
Microbial Pathogenesis, 51 (3): 156–160. 
Jin, Y., Xin, Y., Zhang, W. and Ma, Y. (2010) Mycobacterium tuberculosis Rv1302 and 
Mycobacterium smegmatis MSMEG___4947 have WecA function and MSMEG__4947 is 
required for the growth of M. smegmatis. FEMS Microbiology Letters, 310 (1): 54–61.  
Jureen, P., Werngren, J., Toro, J.-C. and Hoffner, S. (2008) Pyrazinamide resistance and pncA 
gene mutations in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 52 
(5): 1852–1854.  
Kafri, R., Levy, M. and Pilpel, Y. (2006) The regulatory utilisation of genetic redundancy 
through responsive backup circuits. Proceedings of the National Academy of Sciences, 103 
(31): 11653–11658. 
Kana, B.D., Karakousis, P.C., Parish, T. and Dick, T. (2014) Future target-based drug discovery 
for tuberculosis? Tuberculosis (Edinburgh, Scotland), 94 (6): 551–556.  
Kaur, D., Guerin, M.E., Škovierová, H., Brennan, P.J. and Jackson, M. (2009) Chapter 2: 
Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Advances 
in applied microbiology, 69: 23–78.  
Keating, L.A., Wheeler, P.R., Mansoor, H., Inwald, J.K., Dale, J., Hewinson, R.G. and Gordon, 
S.V. (2005) The pyruvate requirement of some members of the Mycobacterium tuberculosis 
complex is due to an inactive pyruvate kinase: implications for in vivo growth. Molecular 
microbiology, 56 (1): 163–174.  
References 
 206 
Khovidhunkit, W. and Shoback, D.M. (1999) Clinical effects of raloxifene hydrochloride in 
women. Annals of internal medicine, 130 (5): 431–439. 
Kinsella, R.J., Fitzpatrick, D.A., Creevey, C.J. and McInerney, J.O. (2003) Fatty acid 
biosynthesis in Mycobacterium tuberculosis: lateral gene transfer, adaptive evolution, and gene 
duplication. Proceedings of the National Academy of Sciences, 100 (18): 10320–10325.  
Knechel, N.A. (2009) Tuberculosis: pathophysiology, clinical features, and diagnosis. Critical 
care nurse, 29 (2): 34–43. 
Koch, R. (1982) The Etiology of Tuberculosis. Clinical Infectious Diseases, 4 (6): 1270–1274.  
Koeck, J.L., Fabre, M., Simon, F., Daffe, M., Garnotel, É., Matan, A.B., Gérôme, P., Bernatas, 
J.J., Buisson, Y. and Pourcel, C. (2011) Clinical characteristics of the smooth tubercle bacilli 
‘Mycobacterium canettii’ infection suggest the existence of an environmental reservoir. 
Clinical Microbiology and Infection, 17 (7): 1013–1019.  
Kolattukudy, P.E., Fernandes, N.D., Azad, A.K., Fitzmaurice, A.M. and Sirakova, T.D. (1997) 
Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Molecular 
microbiology, 24 (2): 263–270. 
Kolattukudy, P.E., Fernandes, N.D., Azad, A.K., Fitzmaurice, A.M. and Sirakova, T.D. (1997) 
Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Molecular 
microbiology, 24 (2): 263–270. 
Konno, K., Feldmann, F.M. and McDermott, W. (1967) Pyrazinamide susceptibility and 
amidase activity of tubercle bacilli. The American review of respiratory disease, 95 (3): 461–
469.  
Kordulakova, J., Gilleron, M., Mikus̃ová, K., Puzo, G., Brennan, P.J., Gicquel, B. and Jackson, 
M. (2002) Definition of the First Mannosylation Step in Phosphatidylinositol Mannoside 
Synthesis PimA is essential for growth of mycobacteria. Journal of Biological Chemistry, 277 
(35): 31335–31344.  
Kordulakova, J., Gilleron, M., Puzo, G., Brennan, P.J., Gicquel, B., Mikušová, K. and Jackson, 
M. (2003) Identification of the required acyltransferase step in the biosynthesis of the 
phosphatidylinositol mannosides of mycobacterium species. Journal of Biological Chemistry, 
278 (38): 36285–36295.  
Koul, A., Arnoult, E., Lounis, N., Guillemont, J. and Andries, K. (2011) The challenge of new 
drug discovery for tuberculosis. Nature, 469 (7331): 483–490.  
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., 
Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D. and Andries, K. (2007) 
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology, 3 
(6): 323–324.  
References 
 207 
Kremer, L., Dover, L.G., Morbidoni, H.R., Vilcheze, C., Maughan, W.N., Baulard, A., Tu, S.-
C., Honoré, N., Deretic, V., Sacchettini, J.C., Locht, C., Jacobs, W.R. and Besra, G.S. (2003) 
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing 
complex in mycobacteria. Journal of Biological Chemistry, 278 (23): 20547–20554.  
Kremer, L., Dover, L.G., Morehouse, C., Hitchin, P., Everett, M., Morris, H.R., Dell, A., 
Brennan, P.J., McNeil, M.R., Flaherty, C., Duncan, K. and Besra, G.S. (2001) Galactan 
Biosynthesis in Mycobacterium tuberculosis identification of a bifunctional udp-
galactofuranosyltransferase. Journal of Biological Chemistry, 276 (28): 26430–26440.  
Kumar, A., Casey, A., Odingo, J., Kesicki, E.A., Abrahams, G., Vieth, M., Masquelin, T., 
Mizrahi, V., Hipskind, P.A., Sherman, D.R. and Parish, T. (2013) A high-throughput screen 
against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic 
acids as a new class of inhibitor with activity against Mycobacterium tuberculosis. PLoS ONE, 
8 (11): e72786.  
Kumar, A., Zhang, M., Zhu, L., Liao, R.P., Mutai, C., Hafsat, S., Sherman, D.R. and Wang, 
M.W. (2012) High-throughput Screening and Sensitized Bacteria Identify an M. tuberculosis 
Dihydrofolate Reductase Inhibitor with Whole Cell Activity Roe, A.J. (ed.). PLoS ONE, 7 (6): 
e39961.  
Kurosu, M., Mahapatra, S., Narayanasamy, P. and Crick, D.C. (2007) Chemoenzymatic 
synthesis of Park’s nucleotide: toward the development of high-throughput screening for MraY 
inhibitors. Tetrahedron Letters, 48 (5): 799–803.  
Labesse, G., Daffé, M., Quémard, A., Emorine, L., Charpentier, X., Marrakchi, H., Montrozier, 
H., Margeat, E. and Ducasse, S. (2002) MabA (FabG1), a Mycobacterium tuberculosis protein 
involved in the long-chain fatty acid elongation system FAS-II. Microbiology, 148 (4): 951–
960.  
Lalloo, U.G. and Ambaram, A. (2010) New antituberculous drugs in development. Current 
HIV/AIDS reports, 7 (3): 143–151.  
Lapage, G. (1947) Tuberculosis of Voles and Shrews. Nature, 160 (4072): 687–687.  
Lea-Smith, D.J., Martin, K.L., Pyke, J.S., Tull, D., McConville, M.J., Coppel, R.L. and Crellin, 
P.K. (2008) Analysis of a new mannosyltransferase required for the synthesis of 
phosphatidylinositol mannosides and lipoarbinomannan reveals two lipomannan pools in 
corynebacterineae. Journal of Biological Chemistry, 283 (11): 6773–6782.  
Lechartier, B., Hartkoorn, R.C. and Cole, S.T. (2012) In vitro combination studies of 
benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial 
agents and chemotherapy, 56 (11): 5790–5793. 
Lechartier, B., Rybniker, J., Zumla, A. and Cole, S.T. (2014) Tuberculosis drug discovery in 
the post-post-genomic era. EMBO molecular medicine, 6 (2): 158–168.  
References 
 208 
Lee, M.-Y., Hung, W.-P. and Tsai, S.-H. (2017) Improvement of shikimic acid production in 
Escherichia coli with growth phase-dependent regulation in the biosynthetic pathway from 
glycerol. World journal of microbiology & biotechnology, 33 (2): 25.  
Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., Via, L.E., Goldfeder, L.C., Kang, 
E., Jin, B., Park, H., Kwak, H., Kim, H., Jeon, H.-S., Jeong, I., Joh, J.S., Chen, R.Y., Olivier, 
K.N., Shaw, P.A., Follmann, D., Song, S.D., Lee, J.-K., Lee, D., Kim, C.T., Dartois, V., Park, 
S.-K., Cho, S.-N. and Barry, C.E. (2012) Linezolid for treatment of chronic extensively drug-
resistant tuberculosis. The New England journal of medicine, 367 (16): 1508–1518.  
Lee, O.Y.-C., Wu, H.H.T., Besra, G.S., Rothschild, B.M., Spigelman, M., Hershkovitz, I., Bar-
Gal, G.K., Donoghue, H.D. and Minnikin, D.E. (2015) Lipid biomarkers provide evolutionary 
signposts for the oldest known cases of tuberculosis. Tuberculosis (Edinburgh, Scotland),95 
Suppl 1: S127–32.  
Lewis, K. (2013) Platforms for antibiotic discovery. Nature Publishing Group, 12 (5): 371–
387.  
Li, X.-Z., Zhang, L. and Nikaido, H. (2004) Efflux pump-mediated intrinsic drug resistance in 
Mycobacterium smegmatis. Antimicrobial agents and chemotherapy, 48 (7): 2415–2423.  
Lin, Y., Zhu, N., Han, Y., Jiang, J. and Si, S. (2014) Identification of anti-tuberculosis agents 
that target the cell-division protein FtsZ. The Journal of antibiotics, 67 (9): 671–676.  
Lipinski, C.A. (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug 
Discovery Today: Technologies, 1 (4): 337–341.  
Lounis, N., Veziris, N., Chauffour, A., Truffot-Pernot, C., Andries, K. and Jarlier, V. (2006) 
Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have 
the Potential To Shorten Treatment Duration. Antimicrobial agents and chemotherapy, 50 
(11): 3543–3547. 
Lucarelli, A.P., Buroni, S., Pasca, M.R., Rizzi, M., Cavagnino, A., Valentini, G., Riccardi, G. 
and Chiarelli, L.R. (2010) Mycobacterium tuberculosis phosphoribosylpyrophosphate 
synthetase: biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis. 
PLoS ONE, 5 (11): e15494.  
Luna-Herrera, J., Reddy, V.M., Daneluzzi, D. and Gangadharam, P.R. (1995) Antituberculosis 
activity of clarithromycin. Antimicrobial agents and chemotherapy, 39 (12): 2692–2695. 
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A.J. and Wang, X. (2010) Global tuberculosis 
drug development pipeline: the need and the reality. Lancet, 375 (9731): 2100–2109.  
Magdalena, J., Supply, P. and Locht, C. (1998) Specific differentiation between Mycobacterium 
bovis BCG and virulent strains of the Mycobacterium tuberculosis complex. Journal of Clinical 
Microbiology, 36 (9): 2471–2476. 
References 
 209 
Mah, F.S., O'Brien, T., Kim, T. and Torkildsen, G. (2008) Evaluation of the effects of 
olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic 
conjunctivitis and dry eye. Current medical research and opinion, 24 (2): 441–447.  
Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C. and Stover, C.K. (1996) Molecular 
analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. 
Journal of Bacteriology, 178 (5): 1274–1282. 
Mahapatra, S., Crick, D.C. and Brennan, P.J. (2000) Comparison of the UDP-N-
acetylmuramate:L-alanine ligase enzymes from Mycobacterium tuberculosis and 
Mycobacterium leprae. Journal of Bacteriology, 182 (23): 6827–6830. 
Maiga, M., Agarwal, N., Ammerman, N.C., Gupta, R., Guo, H., Maiga, M.C., Lun, S. and 
Bishai, W.R. (2012) Successful shortening of tuberculosis treatment using adjuvant host-
directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS 
ONE, 7 (2): e30749.  
Maitra, A., Bates, S., Kolvekar, T., Devarajan, P.V., Guzman, J.D. and Bhakta, S. (2015) 
Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis. 
International Journal of Infectious Diseases, 32: 50–55.  
Mak, P.A., Rao, S.P.S., Tan, M.P., Lin, X., Chyba, J., Tay, J., Ng, S.H., Tan, B.H., Cherian, J., 
Duraiswamy, J., Bifani, P., Lim, V., Lee, B.H., Ma, N.L., Beer, D., Thayalan, P., Kuhen, K., 
Chatterjee, A., Supek, F., Glynne, R., Zheng, J., Boshoff, H.I., Clifton E Barry, 3., Dick, T., 
Pethe, K. and Camacho, L.R. (2012) A High-Throughput Screen To Identify Inhibitors of ATP 
Homeostasis in Non-replicating Mycobacterium tuberculosis. ACS Chemical Biology, 7 (7): 
1190–1197.  
Makarov, V., Manina, G., Mikušová, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, 
N., Pasca, M.R., Buroni, S., Lucarelli, A.P., Milano, A., De Rossi, E., Belanova, M., 
Bobovska, A., Dianiskova, P., Kordulakova, J., Sala, C., Fullam, E., Schneider, P., 
McKinney, J.D., Brodin, P., Christophe, T., Waddell, S., Butcher, P., Albrethsen, J., 
Rosenkrands, I., Brosch, R., Nandi, V., Bharath, S., Gaonkar, S., Shandil, R.K., 
Balasubramanian, V., Balganesh, T., Tyagi, S., Grosset, J., Riccardi, G. and Cole, S.T. (2009) 
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science, 
324 (5928): 801–804.  
Makarov, V., Neres, J., Hartkoorn, R.C., Ryabova, O.B., Kazakova, E., Šarkan, M., Huszár, S., 
Piton, J., Kolly, G.S., Vocat, A., Conroy, T.M., Mikušová, K. and Cole, S.T. (2015) The 8-
Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium 
tuberculosis. Antimicrobial agents and chemotherapy, 59 (8): 4446–4452.  
Maloney, E., Madiraju, S.C., Rajagopalan, M. and Madiraju, M. (2011) Localisation of acidic 
phospholipid cardiolipin and DnaA in mycobacteria. Tuberculosis, 91: S150–S155.  
Manjunatha, U., Boshoff, H.I. and Barry, C.E. (2009) The mechanism of action of PA-824: 




Manjunatha, U., Boshoff, H.I. and Barry, C.E. (2009) The mechanism of action of PA-824: 
Novel insights from transcriptional profiling. Communicative & integrative biology, 2 (3): 215–
218. 
Marrakchi, H., Lanéelle, G. and Quemard, A. (2000) InhA, a target of the antituberculous drug 
isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology, 
146 ( Pt 2) (2): 289–296.  
Martínez-Jiménez, F., Papadatos, G., Yang, L., Wallace, I.M., Kumar, V., Pieper, U., Sali, A., 
Brown, J.R., Overington, J.P. and Marti-Renom, M.A. (2013) Target prediction for an open 
access set of compounds active against Mycobacterium tuberculosis. MacKerell, A.D. (ed.). 
PLoS computational biology, 9 (10): e1003253.  
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., 
Shimokawa, Y. and Komatsu, M. (2006) OPC-67683, a nitro-dihydro-imidazooxazole 
derivative with promising action against tuberculosis in vitro and in mice. Hopewell, P. (ed.). 
PLoS Medicine, 3 (11): e466.  
Matthew B Soellner, Katherine A Rawls, Christoph Grundner, Tom Alber, A. Jonathan A 
Ellman (2007) Fragment-Based Substrate Activity Screening Method for the Identification of 
Potent Inhibitors of the Mycobacterium tuberculosis Phosphatase PtpB. American Chemical 
Society, 129(31): 9613-15.  
Mawuenyega, K.G., Forst, C.V., Dobos, K.M., Belisle, J.T., Chen, J., Bradbury, E.M., 
Bradbury, A.R.M. and Chen, X. (2005) Mycobacterium tuberculosis functional network 
analysis by global subcellular protein profiling. Molecular biology of the cell, 16 (1): 396–404.  
McCaleb, M.L., Maloff, B.L., Nowak, S.M. and Lockwood, D.H. (1984) Sulfonylurea effects 
on target tissues for insulin. Diabetes care, 7(1): 42–46. 
McClure, W.R. and Cech, C.L. (1978) On the mechanism of rifampicin inhibition of RNA 
synthesis. Journal of Biological Chemistry, 253 (24): 8949–8956. 
McDonnell, G. and Russell, A.D. (1999) Antiseptics and disinfectants: activity, action, and 
resistance. Clinical Microbiology Reviews, 12 (1): 147–179. 
McNeil, M., Daffe, M. and Brennan, P.J. (1990) Evidence for the nature of the link between 
the arabinogalactan and peptidoglycan of mycobacterial cell walls. Journal of Biological 
Chemistry, 265 (30): 18200–18206. 
McNeil, M., Daffe, M. and Brennan, P.J. (1991) Location of the mycolyl ester substituents in 
the cell walls of mycobacteria. Journal of Biological Chemistry, 266 (20): 13217–13223. 
McNeil, M., Wallner, S.J., Hunter, S.W. and Brennan, P.J. (1987) Demonstration that the 
galactosyl and arabinosyl residues in the cell-wall arabinogalactan of Mycobacterium leprae 
and Mycobacterium tuberculosis are furanoid. Carbohydrate Research, 166 (2): 299–308. 
References 
 211 
Mdluli, K., Kaneko, T. and Upton, A. (2014) Tuberculosis drug discovery and emerging targets. 
Annals of the New York Academy of Sciences, 1323 (1): 56–75.  
Meeske, A.J., Sham, L.-T., Kimsey, H., Koo, B.-M., Gross, C.A., Bernhardt, T.G. and Rudner, 
D.Z. (2015) MurJ and a novel lipid II flippase are required for cell wall biogenesis in Bacillus 
subtilis. Proceedings of the National Academy of Sciences of the United States of America, 112 
(20): 6437–6442. 
Mehta, M., Rajmani, R.S. and Singh, A. (2016) Mycobacterium tuberculosis WhiB3 Responds 
to Vacuolar pH-induced Changes in Mycothiol Redox Potential to Modulate Phagosomal 
Maturation and Virulence. The Journal of biological chemistry, 291 (6): 2888–2903.  
Meniche, X., de Sousa-d'Auria, C., Van-der-Rest, B., Bhamidi, S., Huc, E., Huang, H., De 
Paepe, D., Tropis, M., McNeil, M., Daffé, M. and Houssin, C. (2008) Partial redundancy in the 
synthesis of the d-arabinose incorporated in the cell wall arabinan of Corynebacterineae. 
Microbiology (Reading, England), 154 (8): 2315–2326.  
Middlebrook, G. and cohn, M.L. (1953) Some observations on the pathogenicity of isoniazid-
resistant variants of tubercle bacilli. Science, 118 (3063): 297–299. 
Mikušová, K. and Ekins, S. (2017) Learning from the past for TB drug discovery in the future. 
Drug Discovery Today, 22 (3): 534–545.  
Mikušová, K., Mikus, M., Besra, G.S., Hancock, I. and Brennan, P.J. (1996) Biosynthesis of 
the Linkage Region of the Mycobacterial Cell Wall. Journal of Biological Chemistry, 271 (13): 
7820–7828.  
Mikusova, K., Slayden, R.A., Besra, G.S. and Brennan, P.J. (1995) Biogenesis of the 
mycobacterial cell wall and the site of action of ethambutol. Antimicrobial agents and 
chemotherapy, 39 (11): 2484–2489.  
Mills, J.A., Motichka, K., Jucker, M., Wu, H.P., Uhlik, B.C., Stern, R.J., Scherman, M.S., 
Vissa, V.D., Pan, F., Kundu, M., Ma, Y.F. and McNeil, M. (2004) Inactivation of the 
mycobacterial rhamnosyltransferase, which is needed for the formation of the arabinogalactan-
peptidoglycan linker, leads to irreversible loss of viability. Journal of Biological Chemistry, 
279 (42): 43540–43546.  
Minnikin, D.E. (1982) Complex lipids: their chemistry, biosynthesis and roles. The biology of 
mycobacteria, pp. 94–184. 
Mishra, A.K., Driessen, N.N., Appelmelk, B.J. and Besra, G.S. (2011) Lipoarabinomannan and 
related glycoconjugates: Structure, biogenesis and role in Mycobacterium tuberculosis 
physiology and host-pathogen interaction. FEMS Microbiology Reviews, 35 (6): 1126–1157. 
Mishra, A.K., Klein, C., Gurcha, S.S., Alderwick, L.J., Babu, P., Hitchen, P.G., Morris, H.R., 
Dell, A., Besra, G.S. and Eggeling, L. (2008) Structural characterisation and functional 
properties of a novel lipomannan variant isolated from a Corynebacterium glutamicum pimB′ 
mutant. Antonie van Leeuwenhoek, 94 (2): 277–287.  
References 
 212 
Mitchison, D.A. (1979) Basic Mechanisms of Chemotherapy. Chest, 76 (6): 771–780.  
Mitchison, D.A. (1985) The action of antituberculosis drugs in short-course chemotherapy. 
Tubercle, 66 (3): 219–225.  
Morayya, S., Awasthy, D., Yadav, R., Ambady, A. and Sharma, U. (2015) Revisiting the 
essentiality of glutamate racemase in Mycobacterium tuberculosis. Gene, 555 (2): 269–276.  
Moreland, R.B., Goldstein, I. and Traish, A. (1998) Sildenafil, a novel inhibitor of 
phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life sciences, 62 
(20): PL 309–18. 
Morita, Y.S., Velasquez, R., Taig, E., Waller, R.F., Patterson, J.H., Tull, D., Williams, S.J., 
Billman-Jacobe, H. and McConville, M.J. (2005) Compartmentalisation of lipid biosynthesis 
in mycobacteria. Journal of Biological Chemistry, 280 (22): 21645–21652.  
MORSE, D., BROTHWELL, D.R. and UCKO, P.J. (1964) Tuberculosis in ancient Egypt. The 
American review of respiratory disease, 90: 524–541.  
Motiwala, A.S., Dai, Y., Jones-López, E.C., Hwang, S.-H., Lee, J.S., Cho, S.-N., Via, L.E., 
Barry, C.E. and Alland, D. (2010) Mutations in extensively drug-resistant Mycobacterium 
tuberculosis that do not code for known drug-resistance mechanisms. The Journal of infectious 
diseases, 201 (6): 881–888.  
Mulabagal, V. and Calderón, A.I. (2010) Development of an Ultrafiltration-Liquid 
Chromatography/Mass Spectrometry (UF-LC/MS) Based Ligand-Binding Assay and an 
LC/MS Based Functional Assay for Mycobacterium tuberculosis Shikimate Kinase. Analytical 
Chemistry, 82 (9): 3616–3621.  
Munro, S.A., Lewin, S.A., Smith, H.J., Engel, M.E., Fretheim, A. and Volmink, J. (2007) 
Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research. 
PLoS Medicine, 4 (7): e238.  
Munshi, T., Gupta, A., Evangelopoulos, D., Guzman, J.D., Gibbons, S., Keep, N.H. and Bhakta, 
S. (2013) Characterisation of ATP-Dependent Mur Ligases Involved in the Biogenesis of Cell 
Wall Peptidoglycan in Mycobacterium tuberculosis. PLoS ONE, 8 (3): e60143.  
Munsiff, S.S., Kambili, C. and Ahuja, S.D. (2006) Rifapentine for the treatment of pulmonary 
tuberculosis. Clinical Infectious Diseases, 43 (11): 1468–1475.  
Nataraj, V., Varela, C., Javid, A., Singh, A., Besra, G.S. and Bhatt, A. (2015) Mycolic acids: 
deciphering and targeting the Achilles' heel of the tubercle bacillus. Molecular microbiology, 
98 (1): 7–16.  
Navari, R.M., Kaplan, H.G., Gralla, R.J., Grunberg, S.M., Palmer, R. and Fitts, D. (1994) 
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in 
the prevention of nausea and vomiting induced by high-dose cisplatin. Journal of clinical 
oncology: official journal of the American Society of Clinical Oncology, 12 (10): 2204–2210. 
References 
 213 
O'Gaora P. Expression of genes in mycobacteria. (1998) Mycobacteria Protocols. Totowa: 
Humana Press; pp. 261–273. 
Ojima, I., Awasthi, D., Wei, L. and Haranahalli, K. (2017) Strategic incorporation of fluorine 
in the drug discovery of new-generation antitubercular agents targeting bacterial cell division 
protein FtsZ. Journal of Fluorine Chemistry, 196: 44–56.  
Pang, Y., Lu, J., Wang, Y., Song, Y., Wang, S. and Zhao, Y. (2013) Study of the rifampin 
monoresistance mechanism in Mycobacterium tuberculosis. Antimicrobial agents and 
chemotherapy, 57 (2): 893–900.  
Pease, A.S. (1940) Some Remarks on the Diagnosis and Treatment of Tuberculosis in 
Antiquity. Isis, 31 (2): 380–393.  
Pethe, K., Sequeira, P.C., Agarwalla, S., Rhee, K., Kuhen, K., Phong, W.Y., Patel, V., Beer, 
D., Walker, J.R., Duraiswamy, J., Jiricek, J., Keller, T.H., Chatterjee, A., Tan, M.P., Ujjini, M., 
Rao, S.P.S., Camacho, L., Bifani, P., Mak, P.A., Ma, I., Barnes, S.W., Chen, Z., Plouffe, D., 
Thayalan, P., Ng, S.H., Au, M., Lee, B.H., Tan, B.H., Ravindran, S., Nanjundappa, M., Lin, X., 
Goh, A., Lakshminarayana, S.B., Shoen, C., Cynamon, M., Kreiswirth, B., Dartois, V., Peters, 
E.C., Glynne, R., Brenner, S. and Dick, T. (2010) A chemical genetic screen in Mycobacterium 
tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. 
Nature Communications, 1 (5): 1–8.  
Pipkorn, P., Costantini, C., Reynolds, C., Wall, M., Drake, M., Sanico, A., Proud, D. and 
Togias, A. (2008) The effects of the nasal antihistamines olopatadine and azelastine in nasal 
allergen provocation. Annals of allergy, asthma & immunology: official publication of the 
American College of Allergy, Asthma, & Immunology, 101 (1): 82–89.  
Pontiroli, A.E., Alberetto, M., Bertoletti, A., Baio, G. and Pozza, G. (1984) Sulfonylureas 
enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus. 
Hormone and metabolic research, 16(S 1): 167–170.  
Portevin, D., de Sousa-d'Auria, C., Houssin, C., Grimaldi, C., Chami, M., Daffé, M. and 
Guilhot, C. (2004) A polyketide synthase catalyses the last condensation step of mycolic acid 
biosynthesis in mycobacteria and related organisms. Proceedings of the National Academy of 
Sciences, 101 (1): 314–319.  
Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L. 
and Nacy, C.A. (2005) Identification of a new antitubercular drug candidate, SQ109, from a 
combinatorial library of 1,2-ethylenediamines. Journal of Antimicrobial Chemotherapy, 56 (5): 
968–974.  
Raghavan, S., Manzanillo, P., Chan, K., Dovey, C. and Cox, J.S. (2008) Secreted transcription 
factor controls Mycobacterium tuberculosis virulence. Nature, 454 (7205): 717–721.  
Raimunda, D., Long, J.E., Padilla-Benavides, T., Sassetti, C.M. and Argüello, J.M. (2014) 
Differential roles for the Co(2+) /Ni(2+) transporting ATPases, CtpD and CtpJ, in 
Mycobacterium tuberculosis virulence. Molecular microbiology, 91 (1): 185–197.  
References 
 214 
Ramaswamy, S. and Musser, J.M. (1998) Molecular genetic basis of antimicrobial agent 
resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and lung disease: the official 
journal of the International Union against Tuberculosis and Lung Disease, 79 (1): 3–29.  
Ramaswamy, S.V., Reich, R., Dou, S.-J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T. and 
Graviss, E.A. (2003) Single nucleotide polymorphisms in genes associated with isoniazid 
resistance in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 47 (4): 
1241–1250.  
Ramón-García, S., González del Río, R., Villarejo, A.S., Sweet, G.D., Cunningham, F., Barros, 
D., Ballell, L., Mendoza-Losana, A., Ferrer-Bazaga, S. and Thompson, C.J. (2016) 
Repurposing clinically approved cephalosporins for tuberculosis therapy. Scientific Reports, 6 
(1): 19.  
Rattan, A., Kalia, A. and Ahmad, N. (1998) Multidrug-resistant Mycobacterium tuberculosis: 
molecular perspectives. Emerging infectious diseases, 4 (2): 195–209.  
Rawat, R., Whitty, A. and Tonge, P.J. (2003) The isoniazid-NAD adduct is a slow, tight-binding 
inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug 
resistance. Proceedings of the National Academy of Sciences, 100 (24): 13881–13886.  
Raymond, J.B., Mahapatra, S., Crick, D.C. and Pavelka, M.S. (2005) Identification of the namH 
gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial 
peptidoglycan. Journal of Biological Chemistry, 280 (1): 326–333.  
Reddy, V.M., Dubuisson, T., Einck, L., Wallis, R.S., Jakubiec, W., Ladukto, L., Campbell, S. 
and Nacy, C.A. (2012) SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis 
in vitro. The Journal of antimicrobial chemotherapy, 67 (5): 1163–1166.  
Reddy, V.M., Einck, L., Andries, K. and Nacy, C.A. (2010) In vitro interactions between new 
antitubercular drug candidates SQ109 and TMC207. Antimicrobial agents and chemotherapy, 
54 (7): 2840–2846.  
Rehren, G., Walters, S., Fontan, P., Smith, I. and Zárraga, A.M. (2007) Differential gene 
expression between Mycobacterium bovis and Mycobacterium tuberculosis. Tuberculosis, 87 
(4): 347–359.  
Riddle, M.C. (1999) Oral pharmacologic management of type 2 diabetes. American family 
physician, 60 (9): 2613–2620. 
Rinder, H., Mieskes, K.T. and Löscher, T. (2001) Heteroresistance in Mycobacterium 
tuberculosis. The international journal of tuberculosis and lung disease: the official journal of 
the International Union against Tuberculosis and Lung Disease, 5 (4): 339–345. 
Rodrigues, L., Villellas, C., Bailo, R., Viveiros, M. and Aínsa, J.A. (2013) Role of the Mmr 
efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrobial agents and 
chemotherapy, 57 (2): 751–757.  
References 
 215 
Rook, G.A.W. and Bloom, B.R. (1994) “Mechanisms of Pathogenesis in Tuberculosis.” In 
Tuberculosis. American Society of Microbiology. pp. 485–502.  
Ruan, Q., Liu, Q., Sun, F., Shao, L., Jin, J., Yu, S., Ai, J., Zhang, B. and Zhang, W. (2016) 
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomised 
clinical trials. Emerging microbes & infections, 5 (2): e12.  
Safi, H., Lingaraju, S., Amin, A., Kim, S., Jones, M., Holmes, M., McNeil, M., Peterson, S.N., 
Chatterjee, D., Fleischmann, R. and Alland, D. (2013) Evolution of high-level ethambutol-
resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose 
biosynthetic and utilisation pathway genes. Nature genetics, 45 (10): 1190–1197.  
Sala, C. and Hartkoorn, R.C. (2011) Tuberculosis drugs: new candidates and how to find more. 
Future microbiology, 6 (6): 617–633. 
Sams-Dodd, F. (2005) Target-based drug discovery: is something wrong? Drug Discovery 
Today, 10 (2): 139–147.  
Sarma, P.V.G.K., Usha Sarma, P. and Murthy, P.S. (1998) Isolation, purification and 
characterisation of intracellular calmodulin like protein (CALP) from Mycobacterium phlei. 
FEMS Microbiology Letters, 159 (1): 27–34.  
Sartain, M.J., Dick, D.L., Rithner, C.D., Crick, D.C. and Belisle, J.T. (2011) Lipidomic analyses 
of Mycobacterium tuberculosis based on accurate mass measurements and the novel "Mtb 
LipidDB". Journal of lipid research, 52 (5): 861–872.  
Sassetti, C.M., Boyd, D.H. and Rubin, E.J. (2003) Genes required for mycobacterial growth 
defined by high density mutagenesis. Molecular microbiology, 48 (1): 77–84. 
Sbardella, G., Mai, A., Artico, M., Loddo, R., Setzu, M.G. and La Colla, P. (2004) Synthesis 
and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues 
of PNU-100480. Bioorganic and Medicinal Chemistry Letters, 14 (6): 1537–1541.  
Schifano, J.M., Edifor, R., Sharp, J.D., Ouyang, M., Konkimalla, A., Husson, R.N. and 
Woychik, N.A. (2013) Mycobacterial toxin MazF-mt6 inhibits translation through cleavage of 
23S rRNA at the ribosomal A site. Proceedings of the National Academy of Sciences of the 
United States of America, 110 (21): 8501–8506.  
Schnappinger, D. (2015) Genetic Approaches to Facilitate Antibacterial Drug Development. 
Cold Spring Harbor perspectives in medicine, 5 (7): a021139.  
Scorpio, A. and Zhang, Y. (1996) Mutations in pncA, a gene encoding 
pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in 
tubercle bacillus. Nature Medicine, 2 (6): 662–667. 
Scorpio, A., Lindholm-Levy, P., Heifets, L., Gilman, R., Siddiqi, S., Cynamon, M. and Zhang, 
Y. (1997) Characterisation of pncA mutations in pyrazinamide-resistant Mycobacterium 
tuberculosis. Antimicrobial agents and chemotherapy, 41 (3): 540–543. 
References 
 216 
Segura-Cabrera, A. and Rodríguez-Pérez, M.A. (2008) Structure-based prediction of 
Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening. 
Bioorganic and Medicinal Chemistry Letters, 18 (11): 3152–3157.  
Shah, N.S., Wright, A., Bai, G.-H., Barrera, L., Boulahbal, F., Martín-Casabona, N., 
Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., Lumb, R., Metchock, B., Portaels, F., 
Rodrigues, M.F., Rüsch-Gerdes, S., Van Deun, A., Vincent, V., Laserson, K., Wells, C. and 
Cegielski, J.P. (2007) Worldwide Emergence of Extensively Drug-resistant Tuberculosis. 
Emerging infectious diseases, 13 (3): 380–387.  
Shaw, K.J. and Barbachyn, M.R. (2011) The oxazolidinones: past, present, and future. Annals 
of the New York Academy of Sciences, 1241 (1): 48–70.  
Shi, L., Zhou, R., Liu, Z., Lowary, T.L., Seeberger, P.H., Stocker, B.L., Crick, D.C., Khoo, K.-
H. and Chatterjee, D. (2008) Transfer of the first arabinofuranose residue to galactan is essential 
for Mycobacterium smegmatis viability. Journal of Bacteriology, 190 (15): 5248–5255.  
Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J.S., Barry, C.E., Wang, H., Zhang, W. and Zhang, 
Y. (2011) Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 333 
(6049): 1630–1632.  
Shimakata, T., Fujita, Y. and Kusaka, T. (1980) Involvement of one of two enoyl-CoA 
hydratases and enoyl-CoA reductase in the acetyl-CoA-dependent elongation of medium chain 
fatty acids by Mycobacterium smegmatis. Journal of biochemistry, 88 (4): 1051–1058. 
Shirude, P.S., Shandil, R., Sadler, C., Naik, M., Hosagrahara, V., Hameed, S., Shinde, V., 
Bathula, C., Humnabadkar, V., Kumar, N., Reddy, J., Panduga, V., Sharma, S., Ambady, A., 
Hegde, N., Whiteaker, J., McLaughlin, R.E., Gardner, H., Madhavapeddi, P., Ramachandran, 
V., Kaur, P., Narayan, A., Guptha, S., Awasthy, D., Narayan, C., Mahadevaswamy, J., Vishwas, 
K.G., Ahuja, V., Srivastava, A., Prabhakar, K.R., Bharath, S., Kale, R., Ramaiah, M., 
Choudhury, N.R., Sambandamurthy, V.K., Solapure, S., Iyer, P.S., Narayanan, S. and Chatterji, 
M. (2013) Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill 
Mycobacterium tuberculosis and are efficacious in vivo. Journal of Medicinal Chemistry, 56 
(23): 9701–9708.  
Silva, M.S.N., Senna, S.G., Ribeiro, M.O., Valim, A.R.M., Telles, M.A., Kritski, A., Morlock, 
G.P., Cooksey, R.C., Zaha, A. and Rossetti, M.L.R. (2003) Mutations in katG, inhA, and ahpC 
genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. Journal of 
Clinical Microbiology, 41 (9): 4471–4474.  
Singh, G. and Dey, C.S. (2007) Induction of apoptosis-like cell death by pentamidine and 
doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. 
donovani. Acta tropica, 103 (3): 172–185. 
Singh, P. and Cole, S.T. (2011) Mycobacterium leprae: genes, pseudogenes and genetic 
diversity. Future microbiology, 6 (1): 57–71.  
References 
 217 
Singh, R., Manjunatha, U., Boshoff, H.I.M., Ha, Y.H., Niyomrattanakit, P., Ledwidge, R., 
Dowd, C.S., Lee, I.Y., Kim, P., Zhang, L., Kang, S., Keller, T.H., Jiricek, J. and Barry, C.E. 
(2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. 
Science, 322 (5906): 1392–1395. 
Smith, I. (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of 
virulence. Clinical Microbiology Reviews, 16 (3): 463–496.  
Somoskovi, A., Parsons, L.M. and Salfinger, M. (2001) The molecular basis of resistance to 
isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory research, 2 
(3): 164–168. 
Soro, O., Pesce, A., Raggi, M., Debbia, E.A. and Schito, G.C. (1997) Selection of rifampicin-
resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of 
rifaximin. Clinical microbiology and infection: the official publication of the European Society 
of Clinical Microbiology and Infectious Diseases, 3 (1): 147–151. 
Sorrentino, F., González del Río, R., Zheng, X., Presa Matilla, J., Torres Gomez, P., Martinez 
Hoyos, M., Perez Herran, M.E., Mendoza-Losana, A. and Av-Gay, Y. (2015) Development of 
an Intracellular Screen for New Compounds Able to Inhibit Mycobacterium tuberculosis 
Growth in Human Macrophages. Antimicrobial agents and chemotherapy, 60 (1): 640–645.  
Sreevatsan, S., Stockbauer, K.E., Pan, X., Kreiswirth, B.N., Moghazeh, S.L., Jacobs, W.R., 
Telenti, A. and Musser, J.M. (1997) Ethambutol resistance in Mycobacterium tuberculosis: 
critical role of embB mutations. Antimicrobial agents and chemotherapy, 41 (8): 1677–1681. 
Srivastava, S., Ayyagari, A., Dhole, T.N., Nyati, K.K. and Dwivedi, S.K. (2009) emb nucleotide 
polymorphisms and the role of embB306 mutations in Mycobacterium tuberculosis resistance 
to ethambutol. International journal of medical microbiology, 299 (4): 269–280.  
Srivastava, S., Chaudhary, S., Thukral, L., Shi, C., Gupta, R.D., Gupta, R., Priyadarshan, K., 
Vats, A., Haque, A.S., Sankaranarayanan, R., Natarajan, V.T., Sharma, R., Aldrich, C.C. and 
Gokhale, R.S. (2015) Unsaturated Lipid Assimilation by Mycobacteria Requires Auxiliary cis-
trans Enoyl CoA Isomerase. Chemistry and Biology, 22 (12): 1577–1587.  
Srivastava, S., Musuka, S., Sherman, C., Meek, C., Leff, R. and Gumbo, T. (2010) Efflux-
pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium 
tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. The Journal of 
infectious diseases, 201 (8): 1225–1231.  
Stehr, M., Elamin, A.A. and Singh, M. (2014) Filling the pipeline - new drugs for an old disease. 
Current Topics in Medicinal, 14 (1): 110–129. 
Sterling, T.R., Scott, N.A., Miro, J.M., Calvet, G., La Rosa, A., Infante, R., Chen, M.P., 
Benator, D.A., Gordin, F., Benson, C.A., Chaisson, R.E., Villarino, M.E.Tuberculosis Trials 
Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 
26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials 
Group for the PREVENT TB Trial are listed in the Supplement, item 17 (2016) Three months 
References 
 218 
of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in 
HIV-coinfected persons. AIDS (London, England), 30 (10): 1607–1615.  
Sterling, T.R., Villarino, M.E., Borisov, A.S., Shang, N., Gordin, F., Bliven-Sizemore, E., 
Hackman, J., Hamilton, C.D., Menzies, D., Kerrigan, A., Weis, S.E., Weiner, M., Wing, D., 
Conde, M.B., Bozeman, L., Horsburgh, C.R., Chaisson, R.E.TB Trials Consortium PREVENT 
TB Study Team (2011) Three months of rifapentine and isoniazid for latent tuberculosis 
infection. The New England journal of medicine, 365 (23): 2155–2166.  
Stover, C.K., la Cruz, de, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennett, L.T., Bansal, 
G.P., Young, J.F., Lee, M.H. and Hatfull, G.F. (1991) New use of BCG for recombinant 
vaccines. Nature, 351 (6326): 456–460.  
Stover, C.K., Warrener, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., 
Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., Kreiswirth, B.N., Barry, C.E. and 
Baker, W.R. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of 
tuberculosis. Nature, 405 (6789): 962–966.  
Syriopoulou, V.P., Harding, A.L., Goldmann, D.A. and Smith, A.L. (1981) In vitro antibacterial 
activity of fluorinated analogs of chloramphenicol and thiamphenicol. Antimicrobial agents and 
chemotherapy, 19 (2): 294–297. 
Takayama, K., Armstrong, E.L., Kunugi, K.A. and Kilburn, J.O. (1979) Inhibition by 
ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. 
Antimicrobial agents and chemotherapy, 16 (2): 240–242. 
Takayama, K., Wang, C. and Besra, G.S. (2005) Pathway to Synthesis and Processing of 
Mycolic Acids in Mycobacterium tuberculosis. Clinical Microbiology Reviews, 18 (1): 81–101.  
Tam, P.-H. and Lowary, T.L. (2009) Recent advances in mycobacterial cell wall glycan 
biosynthesis. Current opinion in chemical biology, 13 (5-6): 618–625.  
Tardioli, S., Buijs, J., Gooijer, C. and van der Zwan, G. (2012) pH-dependent complexation of 
histamine H1 receptor antagonists and human serum albumin studied by UV resonance Raman 
spectroscopy. The journal of physical chemistry. B, 116 (12): 3808–3815.  
Tatituri, R.V.V., Alderwick, L.J., Mishra, A.K., Nigou, J., Gilleron, M., Krumbach, K., 
Hitchen, P., Giordano, A., Morris, H.R., Dell, A., Eggeling, L. and Besra, G.S. (2007) Structural 
characterisation of a partially arabinosylated lipoarabinomannan variant isolated from a 
Corynebacterium glutamicum ubiA mutant. Microbiology (Reading, England), 153 (8): 2621–
2629.  
Telenti, A., Philipp, W.J., Sreevatsan, S., Bernasconi, C., Stockbauer, K.E., Wieles, B., Musser, 
J.M. and Jacobs, W.R. (1997) The emb operon, a gene cluster of Mycobacterium tuberculosis 
involved in resistance to ethambutol. Nature Medicine, 3 (5): 567–570.  
Traore, H., Fissette, K., Bastian, I., Devleeschouwer, M. and Portaels, F. (2000) Detection of 
rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a 
References 
 219 
commercial line probe assay as an initial indicator of multidrug resistance. International 
Journal of Tuberculosis and Lung Disease, 4 (5):481-484. 
Trefzer, C., Rengifo-Gonzalez, M., Hinner, M.J., Schneider, P., Makarov, V., Cole, S.T. and 
Johnsson, K. (2010) Benzothiazinones: prodrugs that covalently modify the 
decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. Journal 
of the American Chemical Society, 132 (39): 13663–13665.  
Tufariello, J.M., Chan, J. and Flynn, J.L. (2003) Latent tuberculosis: mechanisms of host and 
bacillus that contribute to persistent infection. The Lancet. Infectious diseases, 3 (9): 578–590. 
Van Soolingen, D., Hoogenboezem, T., De Haas, P.E.W., Hermans, P.W.M., Koedam, M.A., 
Teppema, K.S., Brennan, P.J., Besra, G.S., Portaels, F., Top, J., Schouls, L.M. and Van 
Embden, J.D.A. (1997) A Novel Pathogenic Taxon of the Mycobacterium tuberculosis 
Complex, Canetti: Characterisation of an Exceptional Isolate from Africa. International 
Journal of Systematic Bacteriology, 47 (4): 1236–1245.  
Verschoor, J.A., Baird, M.S. and Grooten, J. (2012) Towards understanding the functional 
diversity of cell wall mycolic acids of Mycobacterium tuberculosis. Progress in Lipid Research, 
51 (4): 325–339.  
Vilchèze, C., Morbidoni, H.R., Weisbrod, T.R., Iwamoto, H., Kuo, M., Sacchettini, J.C. and 
Jacobs, W.R. (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl 
carrier protein reductase induces accumulation of the FASI end products and cell lysis of 
Mycobacterium smegmatis. Journal of Bacteriology, 182 (14): 4059–4067. 
Viljoen, A., Dubois, V., Girard-Misguich, F., Blaise, M., Herrmann, J.L. and Kremer, L. (2017) 
The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial 
developments. Molecular microbiology, 104 (6): 889–904.  
Warrilow, A.G.S., Jackson, C.J., Parker, J.E., Marczylo, T.H., Kelly, D.E., Lamb, D.C. and 
Kelly, S.L. (2009) Identification, characterisation, and azole-binding properties of 
Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene 
of Mycobacterium leprae. Antimicrobial agents and chemotherapy, 53 (3): 1157–1164.  
Watrous, J., Burns, K., Liu, W.-T., Patel, A., Hook, V., Bafna, V., Barry, C.E., Bark, S. and 
Dorrestein, P.C. (2010) Expansion of the mycobacterial "PUPylome". Molecular bioSystems, 
6 (2): 376–385.  
Wayne, L.G. and Hayes, L.G. (1996) An in vitro model for sequential study of shift down of 
Mycobacterium tuberculosis through two stages of non-replicating persistence. Infection and 
immunity, 64 (6): 2062–2069. 
Williams, K.J., Boshoff, H.I., Krishnan, N., Gonzales, J., Schnappinger, D. and Robertson, B.D. 
(2011) The Mycobacterium tuberculosis β-oxidation genes echA5 and fadB3 are dispensable 
for growth in vitro and in vivo. Tuberculosis (Edinburgh, Scotland), 91 (6): 549–555.  
References 
 220 
Williams, K.N., Brickner, S.J., Stover, C.K., Zhu, T., Ogden, A., Tasneen, R., Tyagi, S., 
Grosset, J.H. and Nuermberger, E.L. (2009) Addition of PNU-100480 to first-line drugs 
shortens the time needed to cure murine tuberculosis. American Journal of Respiratory and 
Critical Care Medicine, 180 (4): 371–376.  
Winder, F.G. and Collins, P.B. (1970) Inhibition by isoniazid of synthesis of mycolic acids in 
Mycobacterium tuberculosis. Journal of general microbiology, 63 (1): 41–48.  
Wolfe, L.M., Mahaffey, S.B., Kruh, N.A. and Dobos, K.M. (2010) Proteomic definition of the 
cell wall of Mycobacterium tuberculosis. Journal of proteome research, 9 (11): 5816–5826.  
Wolucka, B.A. (2008) Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway 
with implications for antimycobacterial therapy. The FEBS journal, 275 (11): 2691–2711.  
Wolucka, B.A., McNeil, M.R., de Hoffmann, E., Chojnacki, T. and Brennan, P.J. (1994) 
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its 
relation to the mode of action of ethambutol on mycobacteria. Journal of Biological Chemistry, 
269 (37): 23328–23335. 
Young, D.B., Duncan, K., Gallagher, A., Kempsell, K.E. and De Smet, K.A.L. (1999) 
Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA 
from Mycobacterium tuberculosis. Microbiology, 145 (11): 3177–3184.  
Zabinski, R.F. and Blanchard, J.S. (1997) The Requirement for Manganese and Oxygen in the 
Isoniazid-Dependent Inactivation of Mycobacterium tuberculosis Enoyl Reductase. Journal of 
the American Chemical Society, 119 (9): 2331–2332.  
Zhang, B., Zhou, N., Liu, Y.-M., Liu, C., Lou, C.-B., Jiang, C.-Y. and Liu, S.-J. (2015) 
Ribosome binding site libraries and pathway modules for shikimic acid synthesis with 
Corynebacterium glutamicum. Microbial cell factories, 14 (1): 71.  
Zhang, Y., Wade, M.M., Scorpio, A., Zhang, H. and Sun, Z. (2003) Mode of action of 
pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics 
by pyrazinoic acid. Journal of Antimicrobial Chemotherapy, 52 (5): 790–795. 
Zhu, X., Gao, J.J., Landao-Bassonga, E., Pavlos, N.J., Qin, A., Steer, J.H., Zheng, M.H., Dong, 
Y. and Cheng, T.S. (2016) Thonzonium bromide inhibits RANKL-induced osteoclast formation 
and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochemical 
pharmacology, 104: 118–130.  
Zimhony, O., Vilcheze, C., Arai, M., Welch, J.T. and Jacobs, W.R. (2007) Pyrazinoic acid and 
its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrobial 







Appendix 1: Scatter graphs representing averages of normalised survival percentages 
(from duplicates) of M. smegmatis_pSMT3_eGFP during the preliminary high 
throughput screening of the Prestwick library.  
 


































































































































































































































































































































































Appendix 2: Scatter graphs representing averages of normalised survival 
percentages (from duplicates) of M. bovis BCG_pSMT3_eGFP during the 
preliminary high throughput screening of the Prestwick library.  
 
 














































































































































































































































































Appendix 3: Table listing all the hits with the survival percentages of M. smegmatis 
and M.bovis BCG generated during the preliminary screen  
 




Primary Screen Hits 
 (M. bovis BCG) % Survival 
Sertaconazole nitrate  3.45 Merbromin  6.34 
Thiethylperazine dimalate  3.71 Rifabutin  6.73 
Enilconazole 4.42 Clinafloxacin  7.47 
Thimerosal  4.84 Chlorhexidine  7.61 
Methacycline hydrochloride 5.35 Roxithromycin  7.76 
Ebselen 5.57 Troleandomycin 7.99 
Rifabutin  5.67 Tosufloxacin  8.32 
Minocycline hydrochloride 6.51 Minocycline  8.41 
Doxycycline hydrochloride 6.62 Ciprofloxacin  8.43 
Rifampicin  7.05 Sarafloxacin  8.83 
Apramycin 7.07 Thimerosal  8.83 
Niclosamide 7.33 Erythromycin  8.93 
Oxiconazole Nitrate  7.85 Amikacin  9.11 
Sulconazole nitrate  8.03 Josamycin  9.21 
Methyl benzethonium chloride  8.12 Lomefloxacin  9.27 
Viomycin sulfate  8.14 Dihydrostreptomycin  9.29 
Benzethonium chloride  8.17 Dirithromycin  9.32 
Meclocycline sulfosalicylate 8.3 Disulfiram  9.33 
Chlorhexidine 8.36 Tylosin  9.63 
Pinaverium bromide  8.37 Dequalinium  10.1 
Auranofin  8.44 Linezolid  10.1 
Dequalinium dichloride 8.89 Vancomycin  10.14 
Econazole nitrate 9.05 Chloramphenicol 10.5 
Demecarium bromide  9.3 Rifapentine  10.58 
Sarafloxacin  9.32 Lincomycin  10.67 
Pyrvinium pamoate 9.42 Moxifloxacin  10.68 
Moxifloxacin  10.06 Alexidine  10.82 
Pentamidine isethionate  10.07 Tetracycline  10.93 
Terfenadine 10.08 Clindamycin hydrochloride  11.03 
Astemizole 10.14 Rifaximin  11.16 
Chlorotetracycline 
hydrochloride 10.25 Gatifloxacin  11.27 
Clotrimazole 10.48 Clarithromycin  11.56 
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Tylosin 10.5 Fusidic acid  11.61 
Isoconazole 10.74 Isoniazid  11.74 
Clarithromycin  10.85 Chlortetracycline  11.96 
Tobramycin  11.02 Sparfloxacin  12.56 
Tioconazole 11.05 Pentamidine  13 
Rifapentine 11.32 Doxycycline  13.45 
Clomiphene citrate 11.48 Azithromycin  13.67 
Tamoxifen citrate 11.77 Pinaverium  13.87 
Azithromycin  12.39 Thonzonium  14.39 
Fluspirilen  12.4 Streptomycin  14.5 
Bifonazole  12.89 Methacycline  14.63 
Butoconazole nitrate 13.01 Viomycin  14.75 
Rifaximin  13.02 Thiamphenicol 15.8 
Clofilium tosylate 13.18 Florfenicol  16.01 
Vancomycin hydrochloride  13.37 Demecarium 16.02 
Roxithromycin  13.47 Clavulanate  16.04 
Miconazole 13.76 Demeclocycline  16.09 
Thioridazine hydrochloride 13.77 Granisetron  16.31 
Toremifene  14.12 Rosiglitazone  16.75 
Zuclopenthixol dihydrochloride 15.17 Phentermine  17.19 
Suloctidil 15.5 Gemcitabine  17.2 
Sparfloxacin  15.99 Methyl benzethonium chloride  17.4 
Perhexiline maleate 15.99 N6-methyladenosine  17.7 
Thiostrepton 16.27 Ethambutol 18.75 
Clemizole hydrochloride 16.3 Cladribine  19.48 
Gatifloxacin  16.7 Lamotrigine  19.62 
Propidium iodide  17.24 Cefotaxime  19.65 
Amikacin hydrate 17.38 Olopatadine 19.82 
Mitoxantrone dihydrochloride 17.38 Cefepime  19.94 
Mefloquine hydrochloride 17.46 Pravastatin  19.95 
Erythromycin 17.51 5-fluorouracil  20.25 
Tosufloxacin hydrochloride 17.66 Olmesartan  20.29 
Josamycin 17.87 Methenamine  20.39 
Raloxifene hydrochloride  17.92 Nadifloxacin  20.64 
Ciprofloxacin hydrochloride 




dihydrochloride 18.29 Losartan  21.08 
Alexidine dihydrochloride  18.32 Ceforanide  21.31 
Spiramycin 18.71 Cefotiam  21.63 
Demeclocycline hydrochloride  18.91 4-aminosalicylic acid  21.72 
Streptomycin sulfate 19.49 Cefuroxime  22.01 
Prenylamine lactate  19.61 Moxalactam  22.07 
GBR 12909 dihydrochloride 20.1 Valproic  22.09 
Clinafloxacin  20.22 Fluconazole  22.63 
Lomefloxacin hydrochloride 21.15 Glipizide  22.63 
Paromomycin sulfate  21.2 Pimozide  23.44 
Novobiocin sodium salt  22.17 Benzethonium  23.5 
Amiodarone hydrochloride 22.32 Fludarabine  23.55 
Sertraline 23.18 Cephalothin  23.9 
Dihydrostreptomycin sulfate 23.29 Triclosan  24.66 
Clofazimine 23.34 Bosentan  25.22 
Gestrinone 23.59 Cefoxitin  25.28 
Tridihexethyl chloride 23.98 Tulobuterol  25.41 
Oxytetracycline dihydrate 24.7 Formoterol  25.84 
Tetracycline hydrochloride 25.57 Verapamil  26.44 
Linezolid 26.3 Carprofen  26.75 
Prochlorperazine dimaleate 26.79 Nialamide  27.9 
Lidoflazine 27.58 Cefmetazole  28.03 
Norfloxacin 28.13 Carbadox 28.13 
Gentamicin sulfate 28.27 Spectinomycin  29.1 
R(-) Apomorphine 
hydrochloride hemihydrate 29.05 Astemizole  29.47 
Methiothepin maleate 29.18 Clofazimine  29.89 
Nisoldipine  30.41 Tripelennamine  30.8 
Moxalactam disodium salt  30.53 Imatinib  30.86 
Indatraline hydrochloride 30.79 Ticarcillin  31.25 
Florfenicol  30.93 Cyclophosphamide  31.36 
Carbadox  31.68 Terfenadine  32.46 
Carvedilol 32.41 Mepivacaine  32.49 
Fendiline hydrochloride 32.45 Anthralin  32.67 
Hexachlorophene  32.85 Diclazuril  32.87 
Thonzonium bromide  33.25 Meropenem  33.15 
Zotepine 33.67 Benzylpenicillin  33.7 
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Cefmetazole sodium salt  33.8 Thiethylperazine  34.02 
Bepridil hydrochloride 35.07 Mefloquine hydrochloride  34.24 
Meclozine dihydrochloride 36.07 Nafcillin  34.6 
Ethionamide  36.5 Halofantrine  35.56 
Naftopidil dihydrochloride 36.76 Cycloserine  35.67 
Primaquine diphosphate 37.02 Trifluoperazine  36.32 
Clindamycin hydrochloride 38 Cefoperazone  36.52 
Triclosan  38.39 Dopamine  38.11 
Ribostamycin sulfate 38.94 Piribedil  39.15 
Decamethonium bromide 39.76 Oxiconazole  39.2 
Zardaverine 40.04 Clotrimazole  39.34 
Perphenazine 40.52 Isopropamide  40.01 
Lymecycline 41.08 Chloroxine  41.26 
Darifenacin hydrobromide 41.35 Econazole  41.29 
Benzbromarone 41.95 Anethole-trithione  42.07 
Metergoline 42.18 Ampicillin  42.3 
Fluphenazine dihydrochloride 42.29 Rufloxacin  43.12 
ethambutol 43.33 Cloxacillin  43.58 
Imipenem  43.65 Sertraline  45.7 
Fluoxetine hydrochloride  43.81 Amoxicillin  45.73 
Rufloxacin 43.97 Didanosine  45.96 
Lincomycin hydrochloride 44.03 Talampicillin  46.59 
Halofantrine hydrochloride 44.77 Benzathine benzylpenicillin  46.9 
Chlorpromazine hydrochloride 46.21 Bacampicillin  47.43 
Anethole-trithione 46.58 Cycloheximide  47.6 
Troleandomycin 47.05 Dicloxacillin  48.29 
Deptropine citrate 47.23 Primaquine  48.7 
Omeprazole 48.44 Cefotetan  49.32 
Trimethoprim   48.95 Cefazolin  49.9 
Azaguanine-8 49.43 Tioconazole  50.4 
   Apramycin  50.4 
    Thioridazine hydrochloride  50.42 
   Tamoxifen  50.63 
    Methiothepin  50.69 




Appendix 4: Scatter graph representing correlation analysis between plate A and 











































































































































































































































































































































































Appendix 5: Scatter graph representing correlation analysis between plate A and 

































































































































































































































































































































































Appendix 6: A dose response curve to determine the minimum inhibitory 




































































































































































































































































































Appendix 7: A dose response curve to determine the minimum inhibitory 









































































































































































































































Appendix 8: Solid MIC testing of preliminary hits from the FDA library against 
M. smegmatis  mc2155. The solid MIC testing was performed against a. Sulocitidil, b. 
Auranofin, c. Raloxifen, d. Clomiphene citrate, e. Chlorhexidine, f. Fendiline hydrochloride, g. 
Tamoxifen citrate, h. Meclocyline sulfosalicylate, i. GBR12909, j. Nisoldipine, k. Sertraline, l. 




Appendix 9: Solid MIC testing of preliminary hits from the FDA library against 
M. bovis BCG. The solid MIC testing was done against a. Rosiglitazone, b. Pinaverium, c. 
Astemizole, d. Olopatadine, e. Glipizide, f. Tripelennamine, g. Pentamidine, h. Thonzonium, i. 










Figure: Solid MIC testing of preliminary hits from the FDA library against M. smegmatis. The solid MIC testing was done against a. Sulocitidil, b. Auranofin, 
c. Raloxifen, d. Clomiphene citrate, e. Chlorhexidine, f. Fendiline hydrochloride, g. Tamoxifen citrate, h. Meclocyline sulfosalicylate, i. GBR12909, j. 





















































































a b c d e f g h i j
Figure: Solid MIC testing of preliminary hits from the FDA library against M. bovis BCG. The solid MIC testing was done against a.Rosiglitazone, b. 
Pinaverium, c. Astemizole, d. Olopatadine, e. Glipizide, f. Tripelennamine, g. Pentamidine, h. Thonzonium, i. Florfenicol, j. Josamycin in the 
presence of a negative and positive control.
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Appendix 10: The Prestwick drug library plate map. The table details the drug name 
in each assay plate number with the well identification.  
 
Drug name  Plate number  
Well 
ID  
Azaguanine-8  RN000205  A02  
Allantoin  RN000205  A03  
Acetazolamide  RN000205  A04  
Metformin hydrochloride  RN000205  A05  
Atracurium besylate  RN000205  A06  
Isoflupredone acetate  RN000205  A07  
Amiloride hydrochloride dihydrate  RN000205  A08  
Sulfaguanidine  RN000205  A11  
Meticrane  RN000205  B02  
Benzonatate  RN000205  B03  
Hydroflumethiazide  RN000205  B04  
Sulfacetamide sodic hydrate  RN000205  B05  
Heptaminol hydrochloride  RN000205  B06  
Sulfathiazole  RN000205  B07  
Levodopa  RN000205  B08  
Idoxuridine  RN000205  B09  
Captopril  RN000205  B10  
Minoxidil  RN000205  B11  
Sulfaphenazole  RN000205  C02  
Panthenol (D)  RN000205  C03  
Sulfadiazine  RN000205  C04  
Norethynodrel  RN000205  C05  
Thiamphenicol  RN000205  C06  
Cimetidine  RN000205  C07  
Doxylamine succinate  RN000205  C08  
Ethambutol dihydrochloride  RN000205  C09  
Antipyrine  RN000205  C10  
Antipyrine, 4-hydroxy  RN000205  C11  
Chloramphenicol  RN000205  D02  
Epirizole  RN000205  D03  
Diprophylline  RN000205  D04  
Triamterene  RN000205  D05  
Dapsone  RN000205  D06  
Troleandomycin  RN000205  D07  
Pyrimethamine  RN000205  D08  
Hexamethonium dibromide dihydrate  RN000205  D09  
Diflunisal  RN000205  D10  
Niclosamide  RN000205  D11  
Procaine hydrochloride  RN000205  E02  
Moxisylyte hydrochoride  RN000205  E03  
Betazole hydrochloride  RN000205  E04  
Isoxicam  RN000205  E05  
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Naproxen  RN000205  E06  
Naphazoline hydrochloride  RN000205  E07  
Ticlopidine hydrochloride  RN000205  E08  
Dicyclomine hydrochloride  RN000205  E09  
Amyleine hydrochloride  RN000205  E10  
Lidocaine hydrochloride  RN000205  E11  
Trichlorfon  RN000205  F02  
Carbamazepine  RN000205  F03  
Triflupromazine hydrochloride  RN000205  F04  
Mefenamic acid  RN000205  F05  
Acetohexamide  RN000205  F06  
Sulpiride  RN000205  F07  
Benoxinate hydrochloride  RN000205  F08  
Oxethazaine  RN000205  F09  
Pheniramine maleate  RN000205  F10  
Tolazoline hydrochloride  RN000205  F11  
Morantel tartrate  RN000205  G02  
Homatropine hydrobromide (R,S)  RN000205  G03  
Nifedipine  RN000205  G04  
Chlorpromazine hydrochloride  RN000205  G05  
Diphenhydramine hydrochloride  RN000205  G06  
Minaprine dihydrochloride  RN000205  G07  
Miconazole  RN000205  G08  
Isoxsuprine hydrochloride  RN000205  G09  
Acebutolol hydrochloride  RN000205  G10  
Tolnaftate  RN000205  G11  
Todralazine hydrochloride  RN000205  H02  
Imipramine hydrochloride  RN000205  H03  
Sulindac  RN000205  H04  
Amitryptiline hydrochloride  RN000205  H05  
Fulvestrant  RN000206  A03  
Busulfan  RN000206  A10  
Nocodazole  RN000206  B11  
R(-) Apomorphine hydrochloride hemihydrate  RN000206  C02  
Amoxapine  RN000206  C03  
Cyproheptadine hydrochloride  RN000206  C04  
Famotidine  RN000206  C05  
Danazol  RN000206  C06  
Nicorandil  RN000206  C07  
Pioglitazone  RN000206  C08  
Nomifensine maleate  RN000206  C09  
Dizocilpine maleate  RN000206  C10  
Oxandrolone  RN000206  C11  
Naloxone hydrochloride  RN000206  D02  
Metolazone  RN000206  D03  
Ciprofloxacin hydrochloride monohydrate  RN000206  D04  
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Ampicillin trihydrate  RN000206  D05  
Haloperidol  RN000206  D06  
Naltrexone hydrochloride dihydrate  RN000206  D07  
Chlorpheniramine maleate  RN000206  D08  
Nalbuphine hydrochloride  RN000206  D09  
Picotamide monohydrate  RN000206  D10  
Triamcinolone  RN000206  D11  
Bromocryptine mesylate  RN000206  E02  
Amfepramone hydrochloride  RN000206  E03  
Dehydrocholic acid  RN000206  E04  
Tioconazole  RN000206  E05  
Perphenazine  RN000206  E06  
Mefloquine hydrochloride  RN000206  E07  
Isoconazole  RN000206  E08  
Spironolactone  RN000206  E09  
Pirenzepine dihydrochloride  RN000206  E10  
Dexamethasone acetate  RN000206  E11  
Glipizide  RN000206  F02  
Loxapine succinate  RN000206  F03  
Hydroxyzine dihydrochloride  RN000206  F04  
Diltiazem hydrochloride  RN000206  F05  
Methotrexate  RN000206  F06  
Astemizole  RN000206  F07  
Clindamycin hydrochloride  RN000206  F08  
Terfenadine  RN000206  F09  
Cefotaxime sodium salt  RN000206  F10  
Tetracycline hydrochloride  RN000206  F11  
Verapamil hydrochloride  RN000206  G02  
Dipyridamole  RN000206  G03  
Chlorhexidine  RN000206  G04  
Loperamide hydrochloride  RN000206  G05  
Chlortetracycline hydrochloride  RN000206  G06  
Tamoxifen citrate  RN000206  G07  
Nicergoline  RN000206  G08  
Canrenoic acid potassium salt  RN000206  G09  
Thioproperazine dimesylate  RN000206  G10  
Dihydroergotamine tartrate  RN000206  G11  
Erythromycin  RN000206  H02  
Chloroxine  RN000206  H03  
Didanosine  RN000206  H04  
Josamycin  RN000206  H05  
Paclitaxel  RN000206  H06  
Ivermectin  RN000206  H07  
Gallamine triethiodide  RN000206  H08  
Neomycin sulfate  RN000206  H09  
Dihydrostreptomycin sulfate  RN000206  H10  
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Gentamicine sulfate  RN000206  H11  
      
Isoniazid  RN000207  A02  
Pentylenetetrazole  RN000207  A03  
Chlorzoxazone  RN000207  A04  
Ornidazole  RN000207  A05  
Ethosuximide  RN000207  A06  
Mafenide hydrochloride  RN000207  A07  
Riluzole hydrochloride  RN000207  A08  
Nitrofurantoin  RN000207  A09  
Hydralazine hydrochloride  RN000207  A10  
Phenelzine sulfate  RN000207  A11  
Tranexamic acid  RN000207  B02  
Etofylline  RN000207  B03  
Tranylcypromine hydrochloride  RN000207  B04  
Alverine citrate salt  RN000207  B05  
Aceclofenac  RN000207  B06  
Iproniazide phosphate  RN000207  B07  
Sulfamethoxazole  RN000207  B08  
Mephenesin  RN000207  B09  
Phenformin hydrochloride  RN000207  B10  
Flutamide  RN000207  B11  
Ampyrone  RN000207  C02  
Levamisole hydrochloride  RN000207  C03  
Pargyline hydrochloride  RN000207  C04  
Methocarbamol  RN000207  C05  
Aztreonam  RN000207  C06  
Cloxacillin sodium salt  RN000207  C07  
Catharanthine  RN000207  C08  
Pentolinium bitartrate  RN000207  C09  
Aminopurine, 6-benzyl  RN000207  C10  
Tolbutamide  RN000207  C11  
Midodrine hydrochloride  RN000207  D02  
Thalidomide  RN000207  D03  
Oxolinic acid  RN000207  D04  
Nimesulide  RN000207  D05  
Asenapine maleate  RN000207  D06  
Pentoxifylline  RN000207  D07  
Metaraminol bitartrate  RN000207  D08  
Salbutamol  RN000207  D09  
Prilocaine hydrochloride  RN000207  D10  
Camptothecine (S,+)  RN000207  D11  
Ranitidine hydrochloride  RN000207  E02  
Tiratricol, 3,3',5-triiodothyroacetic acid  RN000207  E03  
Flufenamic acid  RN000207  E04  
Flumequine  RN000207  E05  
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Tolfenamic acid  RN000207  E06  
Meclofenamic acid sodium salt monohydrate  RN000207  E07  
Tibolone  RN000207  E08  
Trimethoprim  RN000207  E09  
Metoclopramide monohydrochloride  RN000207  E10  
Fenbendazole  RN000207  E11  
Piroxicam  RN000207  F02  
Pyrantel tartrate  RN000207  F03  
Fenspiride hydrochloride  RN000207  F04  
Gemfibrozil  RN000207  F05  
Mefexamide hydrochloride  RN000207  F06  
Tiapride hydrochloride  RN000207  F07  
Mebendazole  RN000207  F08  
Fenbufen  RN000207  F09  
Ketoprofen  RN000207  F10  
Indapamide  RN000207  F11  
Norfloxacin  RN000207  G02  
Antimycin A  RN000207  G03  
Xylometazoline hydrochloride  RN000207  G04  
Oxymetazoline hydrochloride  RN000207  G05  
Nifenazone  RN000207  G06  
Griseofulvin  RN000207  G07  
Clemizole hydrochloride  RN000207  G08  
Tropicamide  RN000207  G09  
Nefopam hydrochloride  RN000207  G10  
Phentolamine hydrochloride  RN000207  G11  
Etodolac  RN000207  H02  
Scopolamin-N-oxide hydrobromide  RN000207  H03  
Hyoscyamine (L)  RN000207  H04  
Chlorphensin carbamate  RN000207  H05  
Fadrozole hydrochloride  RN000207  H06  
Dilazep dihydrochloride  RN000207  H07  
Ofloxacin  RN000207  H08  
Lomefloxacin hydrochloride  RN000207  H09  
Orphenadrine hydrochloride  RN000207  H10  
Proglumide  RN000207  H11  
Mexiletine hydrochloride  RN000208  A02  
Flavoxate hydrochloride  RN000208  A03  
Bufexamac  RN000208  A04  
Glutethimide, para-amino  RN000208  A05  
Dropropizine (R,S)  RN000208  A06  
Pinacidil  RN000208  A07  
Albendazole  RN000208  A08  
Clonidine hydrochloride  RN000208  A09  
Bupropion hydrochloride  RN000208  A10  
Alprenolol hydrochloride  RN000208  A11  
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Chlorothiazide  RN000208  B02  
Diphenidol hydrochloride  RN000208  B03  
Norethindrone  RN000208  B04  
Nortriptyline hydrochloride  RN000208  B05  
Niflumic acid  RN000208  B06  
Isotretinoin  RN000208  B07  
Retinoic acid  RN000208  B08  
Antazoline hydrochloride  RN000208  B09  
Ethacrynic acid  RN000208  B10  
Praziquantel  RN000208  B11  
Ethisterone  RN000208  C02  
Triprolidine hydrochloride  RN000208  C03  
Doxepin hydrochloride  RN000208  C04  
Dyclonine hydrochloride  RN000208  C05  
Dimenhydrinate  RN000208  C06  
Disopyramide  RN000208  C07  
Clotrimazole  RN000208  C08  
Vinpocetine  RN000208  C09  
Clomipramine hydrochloride  RN000208  C10  
Fendiline hydrochloride  RN000208  C11  
Vincamine  RN000208  D02  
Indomethacin  RN000208  D03  
Cortisone  RN000208  D04  
Prednisolone  RN000208  D05  
Fenofibrate  RN000208  D06  
Bumetanide  RN000208  D07  
Labetalol hydrochloride  RN000208  D08  
Cinnarizine  RN000208  D09  
Methylprednisolone, 6-alpha  RN000208  D10  
Quinidine hydrochloride monohydrate  RN000208  D11  
Fludrocortisone acetate  RN000208  E02  
Fenoterol hydrobromide  RN000208  E03  
Homochlorcyclizine dihydrochloride  RN000208  E04  
Diethylcarbamazine citrate  RN000208  E05  
Chenodiol  RN000208  E06  
Perhexiline maleate  RN000208  E07  
Oxybutynin chloride  RN000208  E08  
Spiperone  RN000208  E09  
Pyrilamine maleate  RN000208  E10  
Sulfinpyrazone  RN000208  E11  
Dantrolene sodium salt  RN000208  F02  
Trazodone hydrochloride  RN000208  F03  
Glafenine hydrochloride  RN000208  F04  
Pimethixene maleate  RN000208  F05  
Pergolide mesylate  RN000208  F06  
Acemetacin  RN000208  F07  
Appendix 
 245 
Benzydamine hydrochloride  RN000208  F08  
Fipexide hydrochloride  RN000208  F09  
Mifepristone  RN000208  F10  
Diperodon hydrochloride  RN000208  F11  
Lisinopril  RN000208  G02  
Lincomycin hydrochloride  RN000208  G03  
Telenzepine dihydrochloride  RN000208  G04  
Econazole nitrate  RN000208  G05  
Bupivacaine hydrochloride  RN000208  G06  
Clemastine fumarate  RN000208  G07  
Oxytetracycline dihydrate  RN000208  G08  
Pimozide  RN000208  G09  
Amodiaquin dihydrochloride dihydrate  RN000208  G10  
Mebeverine hydrochloride  RN000208  G11  
Ifenprodil tartrate  RN000208  H02  
Flunarizine dihydrochloride  RN000208  H03  
Trifluoperazine dihydrochloride  RN000208  H04  
Enalapril maleate  RN000208  H05  
Minocycline hydrochloride  RN000208  H06  
Glibenclamide  RN000208  H07  
Guanethidine sulfate  RN000208  H08  
Quinacrine dihydrochloride dihydrate  RN000208  H09  
Clofilium tosylate  RN000208  H10  
Fluphenazine dihydrochloride  RN000208  H11  
Streptomycin sulfate  RN000209  A02  
Alfuzosin hydrochloride  RN000209  A03  
Chlorpropamide  RN000209  A04  
Phenylpropanolamine hydrochloride  RN000209  A05  
Ascorbic acid  RN000209  A06  
Methyldopa (L,-)  RN000209  A07  
Cefoperazone dihydrate  RN000209  A08  
Zoxazolamine  RN000209  A09  
Tacrine hydrochloride  RN000209  A10  
Bisoprolol fumarate  RN000209  A11  
Tremorine dihydrochloride  RN000209  B02  
Practolol  RN000209  B03  
Zidovudine, AZT  RN000209  B04  
Sulfisoxazole  RN000209  B05  
Zaprinast  RN000209  B06  
Chlormezanone  RN000209  B07  
Procainamide hydrochloride  RN000209  B08  
N6-methyladenosine  RN000209  B09  
Guanfacine hydrochloride  RN000209  B10  
Domperidone  RN000209  B11  
Furosemide  RN000209  C02  
Methapyrilene hydrochloride  RN000209  C03  
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Desipramine hydrochloride  RN000209  C04  
Clorgyline hydrochloride  RN000209  C05  
Clenbuterol hydrochloride  RN000209  C06  
Maprotiline hydrochloride  RN000209  C07  
Thioguanosine  RN000209  C08  
Chlorprothixene hydrochloride  RN000209  C09  
Ritodrine hydrochloride  RN000209  C10  
Clozapine  RN000209  C11  
Chlorthalidone  RN000209  D02  
Dobutamine hydrochloride  RN000209  D03  
Moclobemide  RN000209  D04  
Clopamide  RN000209  D05  
Hycanthone  RN000209  D06  
Adenosine 5'-monophosphate monohydrate  RN000209  D07  
Amoxicillin  RN000209  D08  
Pemirolast potassium  RN000209  D09  
Dextromethorphan hydrobromide monohydrate  RN000209  D10  
Droperidol  RN000209  D11  
Bambuterol hydrochloride  RN000209  E02  
Betamethasone  RN000209  E03  
Colchicine  RN000209  E04  
Metergoline  RN000209  E05  
Brinzolamide  RN000209  E06  
Ambroxol hydrochloride  RN000209  E07  
Benfluorex hydrochloride  RN000209  E08  
Bepridil hydrochloride  RN000209  E09  
Meloxicam  RN000209  E10  
Benzbromarone  RN000209  E11  
Ketotifen fumarate  RN000209  F02  
Debrisoquin sulfate  RN000209  F03  
Amethopterin (R,S)  RN000209  F04  
Methylergometrine maleate  RN000209  F05  
Methiothepin maleate  RN000209  F06  
Clofazimine  RN000209  F07  
Nafronyl oxalate  RN000209  F08  
Bezafibrate  RN000209  F09  
Nefazodone hcl  RN000209  F10  
Clebopride maleate  RN000209  F11  
Lidoflazine  RN000209  G02  
Betaxolol hydrochloride  RN000209  G03  
Nicardipine hydrochloride  RN000209  G04  
Probucol  RN000209  G05  
Mitoxantrone dihydrochloride  RN000209  G06  
GBR 12909 dihydrochloride  RN000209  G07  
Carbetapentane citrate  RN000209  G08  
Dequalinium dichloride  RN000209  G09  
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Ketoconazole  RN000209  G10  
Fusidic acid sodium salt  RN000209  G11  
Terbutaline hemisulfate  RN000209  H02  
Ketanserin tartrate hydrate  RN000209  H03  
Hemicholinium bromide  RN000209  H04  
Kanamycin A sulfate  RN000209  H05  
Amikacin hydrate  RN000209  H06  
Etoposide  RN000209  H07  
Clomiphene citrate (Z,E)  RN000209  H08  
Oxantel pamoate  RN000209  H09  
Prochlorperazine dimaleate  RN000209  H10  
Hesperidin  RN000209  H11  
Testosterone propionate  RN000210  A02  
Haloprogin  RN000210  A03  
Thyroxine (L)  RN000210  A04  
Idebenone  RN000210  A05  
Pepstatin A  RN000210  A06  
Morpholinoethylamino-3- benzocyclohepta-(5,6-c)- pyridazine 
dihydrochloride  RN000210  A07  
Adamantamine fumarate  RN000210  A08  
Butoconazole nitrate  RN000210  A09  
Amiodarone hydrochloride  RN000210  A10  
Amphotericin B  RN000210  A11  
Androsterone  RN000210  B02  
Amifostine  RN000210  B03  
Carbarsone  RN000210  B04  
Amlodipine  RN000210  B05  
Modafinil  RN000210  B06  
Bacampicillin hydrochloride  RN000210  B07  
Lamivudine  RN000210  B08  
Biotin  RN000210  B09  
Bisacodyl  RN000210  B10  
Erlotinib  RN000210  B11  
Suloctidil  RN000210  C02  
Zotepine  RN000210  C03  
Carisoprodol  RN000210  C04  
Cephalosporanic acid, 7-amino  RN000210  C05  
Chicago sky blue 6B  RN000210  C06  
Buflomedil hydrochloride  RN000210  C07  
Dibenzepine hydrochloride  RN000210  C08  
Roxatidine Acetate hcl  RN000210  C09  
Valacyclovir hydrochloride  RN000210  C10  
Cisapride  RN000210  C11  
Pefloxacine  RN000210  D02  
Corticosterone  RN000210  D03  
Cyanocobalamin  RN000210  D04  
Cefadroxil  RN000210  D05  
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Cyclosporin A  RN000210  D06  
Digitoxigenin  RN000210  D07  
Digoxin  RN000210  D08  
Doxorubicin hydrochloride  RN000210  D09  
Carbimazole  RN000210  D10  
Epiandrosterone  RN000210  D11  
Estradiol-17 beta  RN000210  E02  
Clobutinol hydrochloride  RN000210  E03  
Gabazine bromide  RN000210  E04  
Oxcarbazepine  RN000210  E05  
Cyclobenzaprine hydrochloride  RN000210  E06  
Carteolol hydrochloride  RN000210  E07  
Hydrocortisone base  RN000210  E08  
Hydroxytacrine maleate (R,S)  RN000210  E09  
Pilocarpine nitrate  RN000210  E10  
Dicloxacillin sodium salt hydrate  RN000210  E11  
Alizapride hcl  RN000210  F02  
Stanozolol  RN000210  F03  
Calcipotriene  RN000210  F04  
Linezolid  RN000210  F05  
Mebhydroline 1,5- naphtalenedisulfonate  RN000210  F06  
Meclocycline sulfosalicylate  RN000210  F07  
Meclozine dihydrochloride  RN000210  F08  
Melatonin  RN000210  F09  
Butalbital  RN000210  F10  
Dinoprost trometamol  RN000210  F11  
Tropisetron hcl  RN000210  G02  
Cefixime  RN000210  G03  
Metrizamide  RN000210  G04  
Quetiapine hemifumarate  RN000210  G05  
Tosufloxacin hydrochloride  RN000210  G06  
Efavirenz  RN000210  G07  
Rifapentine  RN000210  G08  
Neostigmine bromide  RN000210  G09  
Niridazole  RN000210  G10  
Ceforanide  RN000210  G11  
Vatalanib  RN000210  H02  
Itopride  RN000210  H03  
Cefotetan  RN000210  H04  
Fentiazac  RN000210  H05  
Brompheniramine maleate  RN000210  H06  
Primaquine diphosphate  RN000210  H07  
Progesterone  RN000210  H08  
Felodipine  RN000210  H09  
Raclopride  RN000210  H10  
Closantel  RN000210  H11  
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Serotonin hydrochloride  RN000211  A02  
Cefotiam hydrochloride  RN000211  A03  
Rofecoxib  RN000211  A04  
Benperidol  RN000211  A05  
Cefaclor hydrate  RN000211  A06  
Colistin sulfate  RN000211  A07  
Daunorubicin hydrochloride  RN000211  A08  
Dosulepin hydrochloride  RN000211  A09  
Ceftazidime pentahydrate  RN000211  A10  
Iobenguane sulfate  RN000211  A11  
Metixene hydrochloride  RN000211  B02  
Nitrofural  RN000211  B03  
Omeprazole  RN000211  B04  
Propylthiouracil  RN000211  B05  
Terconazole  RN000211  B06  
Tiaprofenic acid  RN000211  B07  
Vancomycin hydrochloride  RN000211  B08  
Artemisinin  RN000211  B09  
Propafenone hydrochloride  RN000211  B10  
Ethamivan  RN000211  B11  
Vigabatrin  RN000211  C02  
Biperiden hydrochloride  RN000211  C03  
Cetirizine dihydrochloride  RN000211  C04  
Etifenin  RN000211  C05  
Metaproterenol sulfate, orciprenaline sulfate  RN000211  C06  
Sisomicin sulfate  RN000211  C07  
Sibutramine hcl  RN000211  C08  
Acenocoumarol  RN000211  C09  
Bromperidol  RN000211  C10  
Cyclizine hydrochloride  RN000211  C11  
Fluoxetine hydrochloride  RN000211  D02  
Iohexol  RN000211  D03  
Norcyclobenzaprine  RN000211  D04  
Pyrazinamide  RN000211  D05  
Trimethadione  RN000211  D06  
Lovastatin  RN000211  D07  
Nystatine  RN000211  D08  
Budesonide  RN000211  D09  
Imipenem  RN000211  D10  
Sulfasalazine  RN000211  D11  
Lofexidine  RN000211  E02  
Thiostrepton  RN000211  E03  
Miglitol  RN000211  E04  
Tiabendazole  RN000211  E05  
Rifampicin  RN000211  E06  
Ethionamide  RN000211  E07  
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Tenoxicam  RN000211  E08  
Triflusal  RN000211  E09  
Mesoridazine besylate  RN000211  E10  
Trolox  RN000211  E11  
Pirenperone  RN000211  F02  
Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, 
hydrochloride  RN000211  F03  
Phenacetin  RN000211  F04  
Atovaquone  RN000211  F05  
Methoxamine hydrochloride  RN000211  F06  
(S)-(-)-Atenolol  RN000211  F07  
Piracetam  RN000211  F08  
Phenindione  RN000211  F09  
Thiocolchicoside  RN000211  F10  
Clorsulon  RN000211  F11  
Ciclopirox ethanolamine  RN000211  G02  
Probenecid  RN000211  G03  
Betahistine mesylate  RN000211  G04  
Tobramycin  RN000211  G05  
Tetramisole hydrochloride  RN000211  G06  
Pregnenolone  RN000211  G07  
Molsidomine  RN000211  G08  
Chloroquine diphosphate  RN000211  G09  
Trimetazidine dihydrochloride  RN000211  G10  
Parthenolide  RN000211  G11  
Hexetidine  RN000211  H02  
Selegiline hydrochloride  RN000211  H03  
Pentamidine isethionate  RN000211  H04  
Tolazamide  RN000211  H05  
Nifuroxazide  RN000211  H06  
Mirtazapine  RN000211  H07  
Dirithromycin  RN000211  H08  
Gliclazide  RN000211  H09  
DO 897/99  RN000211  H10  
Prenylamine lactate  RN000211  H11  
Ziprasidone Hydrochloride  RN000212  A02  
Mevastatin  RN000212  A03  
Pyridostigmine iodide  RN000212  A04  
Pentobarbital  RN000212  A05  
Atropine sulfate monohydrate  RN000212  A06  
Eserine hemisulfate salt  RN000212  A07  
Itraconazole  RN000212  A08  
Acarbose  RN000212  A09  
Entacapone  RN000212  A10  
Nicotinamide  RN000212  A11  
Tetracaïne hydrochloride  RN000212  B02  
Mometasone furoate  RN000212  B03  
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Troglitazone  RN000212  B04  
Dacarbazine  RN000212  B05  
Tenatoprazole  RN000212  B06  
Acetopromazine maleate salt  RN000212  B07  
Escitalopram  RN000212  B08  
Ropinirole hcl  RN000212  B09  
Lacidipine  RN000212  B10  
Argatroban  RN000212  B11  
Reboxetine mesylate  RN000212  C02  
Camylofine chlorhydrate  RN000212  C03  
Papaverine hydrochloride  RN000212  C04  
Yohimbine hydrochloride  RN000212  C05  
Voriconazole  RN000212  C06  
Alfacalcidol  RN000212  C07  
Cilostazol  RN000212  C08  
Galanthamine hydrobromide  RN000212  C09  
Azelastine hcl  RN000212  C10  
Etretinate  RN000212  C11  
Emedastine  RN000212  D02  
Etofenamate  RN000212  D03  
Zaleplon  RN000212  D04  
Diclofenac sodium  RN000212  D05  
Exemestane  RN000212  D06  
Fomepizole  RN000212  D07  
Temozolomide  RN000212  D08  
Xylazine  RN000212  D09  
Celiprolol hcl  RN000212  D10  
Zopiclone  RN000212  D11  
Tranilast  RN000212  E02  
Tizanidine hcl  RN000212  E03  
Zafirlukast  RN000212  E04  
Butenafine Hydrochloride  RN000212  E05  
Carbadox  RN000212  E06  
Rimantadine Hydrochloride  RN000212  E07  
Eburnamonine (-)  RN000212  E08  
Oxibendazol  RN000212  E09  
Ipsapirone  RN000212  E10  
Hydroxychloroquine sulfate  RN000212  E11  
Loracarbef  RN000212  F02  
Fenipentol  RN000212  F03  
Diosmin  RN000212  F04  
Carbidopa  RN000212  F05  
(-)-Emtricitabine  RN000212  F06  
Demecarium bromide  RN000212  F07  
Quipazine dimaleate salt  RN000212  F08  
Acipimox  RN000212  F09  
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Diflorasone Diacetate  RN000212  F10  
Acamprosate calcium  RN000212  F11  
Mizolastine  RN000212  G02  
Amisulpride  RN000212  G03  
Pyridoxine hydrochloride  RN000212  G04  
Mercaptopurine  RN000212  G05  
Cytarabine  RN000212  G06  
Racecadotril  RN000212  G07  
Folic acid  RN000212  G08  
Benazepril hcl  RN000212  G09  
Aniracetam  RN000212  G10  
Dimethisoquin hydrochloride  RN000212  G11  
Alendronate sodium  RN000212  H02  
Dipivefrin hydrochloride  RN000212  H03  
Thiorphan  RN000212  H04  
Tomoxetine hydrochloride  RN000212  H05  
Aceclidine Hydrochloride  RN000212  H06  
Penciclovir  RN000212  H07  
Levetiracetam  RN000212  H08  
Dexfenfluramine hydrochloride  RN000212  H09  
Etoricoxib  RN000212  H10  
Sertindole  RN000212  H11  
Sulmazole  RN000213  A02  
Gefitinib  RN000213  A03  
Flunisolide  RN000213  A04  
N-Acetyl-DL-homocysteine Thiolactone  RN000213  A05  
Flurandrenolide  RN000213  A06  
Oxiconazole Nitrate  RN000213  A07  
Rebamipide  RN000213  A08  
Nilvadipine  RN000213  A09  
Etanidazole  RN000213  A10  
Pinaverium bromide  RN000213  A11  
Glimepiride  RN000213  B02  
Picrotoxinin  RN000213  B03  
Mepenzolate bromide  RN000213  B04  
Benfotiamine  RN000213  B05  
Halcinonide  RN000213  B06  
Lanatoside C  RN000213  B07  
Benzamil hydrochloride  RN000213  B08  
Suxibuzone  RN000213  B09  
6-Furfurylaminopurine  RN000213  B10  
Avermectin B1a  RN000213  B11  
Pranlukast  RN000213  C02  
Penicillamine  RN000213  C03  
Zileuton  RN000213  C04  
Loratadine  RN000213  C05  
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Tetraethylenepentamine pentahydrochloride  RN000213  C06  
Nisoldipine  RN000213  C07  
Acefylline  RN000213  C08  
Acitretin  RN000213  C09  
Zonisamide  RN000213  C10  
Irsogladine maleate  RN000213  C11  
Dydrogesterone  RN000213  D02  
Sumatriptan succinate  RN000213  D03  
Opipramol dihydrochloride  RN000213  D04  
Nalidixic acid sodium salt  RN000213  D05  
Oxacillin sodium  RN000213  D06  
Beta-Escin  RN000213  D07  
Thiamine hydrochloride  RN000213  D08  
Tazobactam  RN000213  D09  
Ibandronate sodium  RN000213  D10  
Warfarin  RN000213  D11  
Pranoprofen  RN000213  E02  
Secnidazole  RN000213  E03  
Pempidine tartrate  RN000213  E04  
Clodronate  RN000213  E05  
Ibutilide fumarate  RN000213  E06  
Thimerosal  RN000213  E07  
Tramadol hydrochloride  RN000213  E08  
Estropipate  RN000213  E09  
Butylscopolammonium (n-) bromide  RN000213  E10  
Irinotecan hydrochloride trihydrate  RN000213  E11  
Tylosin  RN000213  F02  
Citalopram Hydrobromide  RN000213  F03  
Promazine hydrochloride  RN000213  F04  
Sulfamerazine  RN000213  F05  
Venlafaxine  RN000213  F06  
Ethotoin  RN000213  F07  
3-alpha-Hydroxy-5-beta-androstan-17-one  RN000213  F08  
Tetrahydrozoline hydrochloride  RN000213  F09  
Hexestrol  RN000213  F10  
Cefmetazole sodium salt  RN000213  F11  
Trihexyphenidyl-D,L Hydrochloride  RN000213  G02  
Succinylsulfathiazole  RN000213  G03  
Famprofazone  RN000213  G04  
Bromopride  RN000213  G05  
Methyl benzethonium chloride  RN000213  G06  
Chlorcyclizine hydrochloride  RN000213  G07  
Diphenylpyraline hydrochloride  RN000213  G08  
Benzethonium chloride  RN000213  G09  
Trioxsalen  RN000213  G10  
Doxofylline  RN000213  G11  
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Sulfabenzamide  RN000213  H02  
Benzocaine  RN000213  H03  
Dipyrone  RN000213  H04  
Isosorbide dinitrate  RN000213  H05  
Sulfachloropyridazine  RN000213  H06  
Pramoxine hydrochloride  RN000213  H07  
Finasteride  RN000213  H08  
Fluorometholone  RN000213  H09  
Cephalothin sodium salt  RN000213  H10  
Cefuroxime sodium salt  RN000213  H11  
Althiazide  RN000214  A02  
Isopyrin hydrochloride  RN000214  A03  
Phenethicillin potassium salt  RN000214  A04  
Sulfamethoxypyridazine  RN000214  A05  
Deferoxamine mesylate  RN000214  A06  
Mephentermine hemisulfate  RN000214  A07  
Liranaftate  RN000214  A08  
Sulfadimethoxine  RN000214  A09  
Sulfanilamide  RN000214  A10  
Balsalazide Sodium  RN000214  A11  
Sulfaquinoxaline sodium salt  RN000214  B02  
Streptozotocin  RN000214  B03  
Metoprolol-(+,-) (+)-tartrate salt  RN000214  B04  
Flumethasone  RN000214  B05  
Flecainide acetate  RN000214  B06  
Cefazolin sodium salt  RN000214  B07  
Atractyloside potassium salt  RN000214  B08  
Folinic acid calcium salt  RN000214  B09  
Levonordefrin  RN000214  B10  
Ebselen  RN000214  B11  
Nadide  RN000214  C02  
Sulfamethizole  RN000214  C03  
Medrysone  RN000214  C04  
Flunixin meglumine  RN000214  C05  
Glycopyrrolate  RN000214  C07  
Aprepitant  RN000214  C08  
Monensin sodium salt  RN000214  C09  
Isoetharine mesylate salt  RN000214  C10  
Mevalonic-D, L acid lactone  RN000214  C11  
Terazosin hydrochloride  RN000214  D02  
Phenazopyridine hydrochloride  RN000214  D03  
Demeclocycline hydrochloride  RN000214  D04  
Fenoprofen calcium salt dihydrate  RN000214  D05  
Piperacillin sodium salt  RN000214  D06  
Diethylstilbestrol  RN000214  D07  
Chlorotrianisene  RN000214  D08  
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Ribostamycin sulfate salt  RN000214  D09  
Methacholine chloride  RN000214  D10  
Pipenzolate bromide  RN000214  D11  
Butamben  RN000214  E02  
Sulfapyridine  RN000214  E03  
Meclofenoxate hydrochloride  RN000214  E04  
Furaltadone hydrochloride  RN000214  E05  
Ethoxyquin  RN000214  E06  
Tinidazole  RN000214  E07  
Guanadrel sulfate  RN000214  E08  
Vidarabine  RN000214  E09  
Sulfameter  RN000214  E10  
Isopropamide iodide  RN000214  E11  
Alclometasone dipropionate  RN000214  F02  
Leflunomide  RN000214  F03  
Norgestrel-(-)-D  RN000214  F04  
Fluocinonide  RN000214  F05  
Sulfamethazine sodium salt  RN000214  F06  
Guaifenesin  RN000214  F07  
Alexidine dihydrochloride  RN000214  F08  
Proadifen hydrochloride  RN000214  F09  
Zomepirac sodium salt  RN000214  F10  
Cinoxacin  RN000214  F11  
Clobetasol propionate  RN000214  G02  
Podophyllotoxin  RN000214  G03  
Clofibric acid  RN000214  G04  
Bendroflumethiazide  RN000214  G05  
Dicumarol  RN000214  G06  
Methimazole  RN000214  G07  
Merbromin  RN000214  G08  
Hexylcaine hydrochloride  RN000214  G09  
Drofenine hydrochloride  RN000214  G10  
Cycloheximide  RN000214  G11  
(R) -Naproxen sodium salt  RN000214  H02  
Propidium iodide  RN000214  H03  
Cloperastine hydrochloride  RN000214  H04  
Eucatropine hydrochloride  RN000214  H05  
Isocarboxazid  RN000214  H06  
Lithocholic acid  RN000214  H07  
Methotrimeprazine maleat salt  RN000214  H08  
Dienestrol  RN000214  H09  
Pridinol methanesulfonate salt  RN000214  H10  
Amrinone  RN000214  H11  
Carbinoxamine maleate salt  RN000215  A02  
Methazolamide  RN000215  A03  
Pyrithyldione  RN000215  A04  
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Spectinomycin dihydrochloride  RN000215  A05  
Piromidic acid  RN000215  A06  
Trimipramine maleate salt  RN000215  A07  
Chloropyramine hydrochloride  RN000215  A08  
Furazolidone  RN000215  A09  
Dichlorphenamide  RN000215  A10  
Sulconazole nitrate  RN000215  A11  
Auranofin  RN000215  B02  
Cromolyn disodium salt  RN000215  B03  
Bucladesine sodium salt  RN000215  B04  
Cefsulodin sodium salt  RN000215  B05  
Fosfosal  RN000215  B06  
Suprofen  RN000215  B07  
Deflazacort  RN000215  B08  
Nadolol  RN000215  B09  
Moxalactam disodium salt  RN000215  B10  
Aminophylline  RN000215  B11  
Azlocillin sodium salt  RN000215  C02  
Clidinium bromide  RN000215  C03  
Sulfamonomethoxine  RN000215  C04  
Benzthiazide  RN000215  C05  
Trichlormethiazide  RN000215  C06  
Oxalamine citrate salt  RN000215  C07  
Propantheline bromide  RN000215  C08  
Viloxazine hydrochloride  RN000215  C09  
Dimethadione  RN000215  C10  
Ethaverine hydrochloride  RN000215  C11  
Butacaine  RN000215  D02  
Cefoxitin sodium salt  RN000215  D03  
Ifosfamide  RN000215  D04  
Novobiocin sodium salt  RN000215  D05  
Tetrahydroxy-1,4-quinone monohydrate  RN000215  D06  
Indoprofen  RN000215  D07  
Carbenoxolone disodium salt  RN000215  D08  
Iocetamic acid  RN000215  D09  
Ganciclovir  RN000215  D10  
Ethopropazine hydrochloride  RN000215  D11  
Olanzapine  RN000215  E02  
Trimeprazine tartrate  RN000215  E03  
Nafcillin sodium salt monohydrate  RN000215  E04  
Procyclidine hydrochloride  RN000215  E05  
Amiprilose hydrochloride  RN000215  E06  
Ethynylestradiol 3-methyl ether  RN000215  E07  
(-) -Levobunolol hydrochloride  RN000215  E08  
Iodixanol  RN000215  E09  
Clinafloxacin  RN000215  E10  
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Equilin  RN000215  E11  
Paroxetine Hydrochloride  RN000215  F02  
Nylidrin  RN000215  F03  
Liothyronine  RN000215  F04  
Roxithromycin  RN000215  F05  
Beclomethasone dipropionate  RN000215  F06  
Tolmetin sodium salt dihydrate  RN000215  F07  
(+) -Levobunolol hydrochloride  RN000215  F08  
Doxazosin mesylate  RN000215  F09  
Fluvastatin sodium salt  RN000215  F10  
Methylhydantoin-5-(L)  RN000215  F11  
Gabapentin  RN000215  G02  
Raloxifene hydrochloride  RN000215  G03  
Etidronic acid, disodium salt  RN000215  G04  
Methylhydantoin-5-(D)  RN000215  G05  
Simvastatin  RN000215  G06  
Azacytidine-5  RN000215  G07  
Paromomycin sulfate  RN000215  G08  
Acetaminophen  RN000215  G09  
Phthalylsulfathiazole  RN000215  G10  
Luteolin  RN000215  G11  
Iopamidol  RN000215  H02  
Iopromide  RN000215  H03  
Theophylline monohydrate  RN000215  H04  
Theobromine  RN000215  H05  
Reserpine  RN000215  H06  
Bicalutamide  RN000215  H07  
Scopolamine hydrochloride  RN000215  H08  
Ioversol  RN000215  H09  
Rabeprazole Sodium salt  RN000215  H10  
Carbachol  RN000215  H11  
Niacin  RN000216  A02  
Bemegride  RN000216  A03  
Digoxigenin  RN000216  A04  
Meglumine  RN000216  A05  
Dolasetron mesilate  RN000216  A06  
Clioquinol  RN000216  A07  
Oxybenzone  RN000216  A08  
Promethazine hydrochloride  RN000216  A09  
Diacerein  RN000216  A10  
Esmolol hydrochloride  RN000216  A11  
Cortisol acetate  RN000216  B02  
Flubendazol  RN000216  B03  
Felbinac  RN000216  B04  
Butylparaben  RN000216  B05  
Aminohippuric acid  RN000216  B06  
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N-Acetyl-L-leucine  RN000216  B07  
Pipemidic acid  RN000216  B08  
Dioxybenzone  RN000216  B09  
Adrenosterone  RN000216  B10  
Methylatropine nitrate  RN000216  B11  
Hymecromone  RN000216  C02  
Abacavir Sulfate  RN000216  C03  
Diloxanide furoate  RN000216  C04  
Metyrapone  RN000216  C05  
Urapidil hydrochloride  RN000216  C06  
Fluspirilen  RN000216  C07  
S-(+)-ibuprofen  RN000216  C08  
Ethynodiol diacetate  RN000216  C09  
Nabumetone  RN000216  C10  
Nisoxetine hydrochloride  RN000216  C11  
(+)-Isoproterenol (+)-bitartrate salt  RN000216  D02  
Monobenzone  RN000216  D03  
2-Aminobenzenesulfonamide  RN000216  D04  
Estrone  RN000216  D05  
Lorglumide sodium salt  RN000216  D06  
Nitrendipine  RN000216  D07  
Flurbiprofen  RN000216  D08  
Nimodipine  RN000216  D09  
Bacitracin  RN000216  D10  
L(-)-vesamicol hydrochloride  RN000216  D11  
Nizatidine  RN000216  E02  
Thioperamide maleate  RN000216  E03  
Xamoterol hemifumarate  RN000216  E04  
Rolipram  RN000216  E05  
Thonzonium bromide  RN000216  E06  
Idazoxan hydrochloride  RN000216  E07  
Quinapril HCl  RN000216  E08  
Nilutamide  RN000216  E09  
Ketorolac tromethamine  RN000216  E10  
Protriptyline hydrochloride  RN000216  E11  
Propofol  RN000216  F02  
S(-)Eticlopride hydrochloride  RN000216  F03  
Primidone  RN000216  F04  
Flucytosine  RN000216  F05  
(-)-MK 801 hydrogen maleate  RN000216  F06  
Bephenium hydroxynaphthoate  RN000216  F07  
Dehydroisoandosterone 3-acetate  RN000216  F08  
Benserazide hydrochloride  RN000216  F09  
Iodipamide  RN000216  F10  
Allopurinol  RN000216  F11  
Pentetic acid  RN000216  G02  
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Bretylium tosylate  RN000216  G03  
Pralidoxime chloride  RN000216  G04  
Phenoxybenzamine hydrochloride  RN000216  G05  
Salmeterol  RN000216  G06  
Altretamine  RN000216  G07  
Prazosin hydrochloride  RN000216  G08  
Timolol maleate salt  RN000216  G09  
(+,-)-Octopamine hydrochloride  RN000216  G10  
Stavudine  RN000216  G11  
Crotamiton  RN000216  H02  
Toremifene  RN000216  H03  
(R)-(+)-Atenolol  RN000216  H04  
Tyloxapol  RN000216  H05  
Florfenicol  RN000216  H06  
Megestrol acetate  RN000216  H07  
Deoxycorticosterone  RN000216  H08  
Urosiol  RN000216  H09  
Proparacaine hydrochloride  RN000216  H10  
Aminocaproic acid  RN000216  H11  
Denatonium benzoate  RN000217  A02  
Canrenone  RN000217  A03  
Enilconazole  RN000217  A04  
Methacycline hydrochloride  RN000217  A05  
Floxuridine  RN000217  A06  
Sotalol hydrochloride  RN000217  A07  
Gestrinone  RN000217  A08  
Decamethonium bromide  RN000217  A09  
Darifenacin hydrobromide  RN000217  A10  
Indatraline hydrochloride  RN000217  A11  
Remoxipride Hydrochloride  RN000217  B02  
THIP Hydrochloride  RN000217  B03  
Pirlindole mesylate  RN000217  B04  
Pronethalol hydrochloride  RN000217  B05  
Naftopidil dihydrochloride  RN000217  B06  
Tracazolate hydrochloride  RN000217  B07  
Zardaverine  RN000217  B08  
Memantine Hydrochloride  RN000217  B09  
Ozagrel hydrochloride  RN000217  B10  
Piribedil hydrochloride  RN000217  B11  
Nitrocaramiphen hydrochloride  RN000217  C02  
Nandrolone  RN000217  C03  
Dimaprit dihydrochloride  RN000217  C04  
Oxfendazol  RN000217  C05  
Guaiacol  RN000217  C06  
Proscillaridin A  RN000217  C07  
Pramipexole  RN000217  C08  
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Norgestimate  RN000217  C09  
Chlormadinone acetate  RN000217  C10  
Phenylbutazone  RN000217  C11  
Gliquidone  RN000217  D02  
Pizotifen malate  RN000217  D03  
Ribavirin  RN000217  D04  
Cyclopenthiazide  RN000217  D05  
Fluvoxamine maleate  RN000217  D06  
Prothionamide  RN000217  D07  
Fluticasone propionate  RN000217  D08  
Zuclopenthixol dihydrochloride  RN000217  D09  
Proguanil hydrochloride  RN000217  D10  
Lymecycline  RN000217  D11  
Alfadolone acetate  RN000217  E02  
Alfaxalone  RN000217  E03  
Azapropazone  RN000217  E04  
Meptazinol hydrochloride  RN000217  E05  
Apramycin  RN000217  E06  
Epitiostanol  RN000217  E07  
Fursultiamine Hydrochloride  RN000217  E08  
Gabexate mesilate  RN000217  E09  
Pivampicillin  RN000217  E10  
Talampicillin hydrochloride  RN000217  E11  
Flucloxacillin sodium  RN000217  F02  
Trapidil  RN000217  F03  
Deptropine citrate  RN000217  F04  
Sertraline  RN000217  F05  
Ethamsylate  RN000217  F06  
Moxonidine  RN000217  F07  
Etilefrine hydrochloride  RN000217  F08  
Alprostadil  RN000217  F09  
Tribenoside  RN000217  F10  
Rimexolone  RN000217  F11  
Isradipine  RN000217  G02  
Tiletamine hydrochloride  RN000217  G03  
Isometheptene mucate  RN000217  G04  
Nifurtimox  RN000217  G05  
Letrozole  RN000217  G06  
Arbutin  RN000217  G07  
Tocainide hydrochloride  RN000217  G08  
Benzathine benzylpenicillin  RN000217  G09  
Risperidone  RN000217  G10  
Torsemide  RN000217  G11  
Halofantrine hydrochloride  RN000217  H02  
Articaine hydrochloride  RN000217  H03  
Nomegestrol acetate  RN000217  H04  
Appendix 
 261 
Pancuronium bromide  RN000217  H05  
Molindone hydrochloride  RN000217  H06  
Alcuronium chloride  RN000217  H07  
Zalcitabine  RN000217  H08  
Methyldopate hydrochloride  RN000217  H09  
Levocabastine hydrochloride  RN000217  H10  
Pyrvinium pamoate  RN000217  H11  
Etomidate  RN000218  A02  
Tridihexethyl chloride  RN000218  A03  
Penbutolol sulfate  RN000218  A04  
Prednicarbate  RN000218  A05  
Sertaconazole nitrate  RN000218  A06  
Repaglinide  RN000218  A07  
Piretanide  RN000218  A08  
Piperacetazine  RN000218  A09  
Oxyphenbutazone  RN000218  A10  
Quinethazone  RN000218  A11  
Moricizine hydrochloride  RN000218  B02  
Iopanoic acid  RN000218  B03  
Pivmecillinam hydrochloride  RN000218  B04  
Levopropoxyphene napsylate  RN000218  B05  
Piperidolate hydrochloride  RN000218  B06  
Trifluridine  RN000218  B07  
Oxprenolol hydrochloride  RN000218  B08  
Ondansetron Hydrochloride  RN000218  B09  
Propoxycaine hydrochloride  RN000218  B10  
Oxaprozin  RN000218  B11  
Phensuximide  RN000218  C02  
Ioxaglic acid  RN000218  C03  
Naftifine hydrochloride  RN000218  C04  
Meprylcaine hydrochloride  RN000218  C05  
Milrinone  RN000218  C06  
Methantheline bromide  RN000218  C07  
Ticarcillin sodium  RN000218  C08  
Thiethylperazine dimalate  RN000218  C09  
Mesalamine  RN000218  C10  
Vorinostat  RN000218  C11  
Imidurea  RN000218  D02  
Lansoprazole  RN000218  D03  
Bethanechol chloride  RN000218  D04  
Cyproterone acetate  RN000218  D05  
(R)-Propranolol hydrochloride  RN000218  D06  
Ciprofibrate  RN000218  D07  
Formestane  RN000218  D08  
Benzylpenicillin sodium  RN000218  D09  
Chlorambucil  RN000218  D10  
Appendix 
 262 
Methiazole  RN000218  D11  
(S)-propranolol hydrochloride  RN000218  E02  
(-)-Eseroline fumarate salt  RN000218  E03  
Isosorbide mononitrate  RN000218  E04  
Levalbuterol hydrochloride  RN000218  E05  
Topiramate  RN000218  E06  
D-cycloserine  RN000218  E07  
2-Chloropyrazine  RN000218  E08  
(+,-)-Synephrine  RN000218  E09  
(S)-(-)-Cycloserine  RN000218  E10  
Homosalate  RN000218  E11  
Spaglumic acid  RN000218  F02  
Ranolazine  RN000218  F03  
Misoprostol  RN000218  F04  
Sulfadoxine  RN000218  F05  
Cyclopentolate hydrochloride  RN000218  F06  
Estriol  RN000218  F07  
(-)-Isoproterenol hydrochloride  RN000218  F08  
Sarafloxacin  RN000218  F09  
Nialamide  RN000218  F10  
Toltrazuril  RN000218  F11  
Perindopril  RN000218  G02  
Fexofenadine HCl  RN000218  G03  
4-aminosalicylic acid  RN000218  G04  
Clonixin Lysinate  RN000218  G05  
Verteporfin  RN000218  G06  
Meropenem  RN000218  G07  
Ramipril  RN000218  G08  
Mephenytoin  RN000218  G09  
Rifabutin  RN000218  G10  
Parbendazole  RN000218  G11  
Mecamylamine hydrochloride  RN000218  H02  
Procarbazine hydrochloride  RN000218  H03  
Viomycin sulfate  RN000218  H04  
Saquinavir mesylate  RN000218  H05  
Ronidazole  RN000218  H06  
Dorzolamide hydrochloride  RN000218  H07  
Azaperone  RN000218  H08  
Cefepime hydrochloride  RN000218  H09  
Clocortolone pivalate  RN000218  H10  







Appendix 11: Apolar lipids separated by 2-D TLC on a silica gel plate using 
Chloroform: Methanol (96:4) in direction one (D1) and Toluene: Acetone (80:20) 
in direction two (D2). The TLC separation of apolar lipids from four different strains of M. 
smegmatis mc2155 was carried out using two different solvent systems in two directions. The 
M. smegmatis mc2155 strains used are depicted based on the overexpression plasmids they 
contain: A. mc2155_pVV16, B. mc2155_pVV16_echA12_Rv, C. 
mc2155_pVV16_echA12_BCG, D. mc2155_pVV16_G239R_echA12. The strains were treated 



















Appendix 12: Apolar lipids separated by 2-D TLC on a silica gel plate using 
Chloroform: Methanol: Water (100:14:0.8:) in direction one (D1) and Chloroform: 
Acetone: Methanol: Water (50:60:2.5:3) in direction two (D2). The TLC separation of 
apolar lipids from four different strains of M. smegmatis mc2155 was carried out using two 
different solvent systems in two directions. The M. smegmatis mc2155 strains used are depicted 
based on the overexpression plasmids they contain: A. mc2155_pVV16, B. 
mc2155_pVV16_echA12_Rv, C. mc2155_pVV16_echA12_BCG, D. 
mc2155_pVV16_G239R_echA12. The strains were treated with 0x, 1x, 2x, 5x and 10x MIC of 


















Appendix 13: Apolar lipids separated by 2-D TLC on a silica gel plate using 
Chloroform: Methanol (96:4) in direction one (D1) and Toluene: Acetone (80:20) 
in direction two (D2). The TLC separation of apolar lipids from four different strains of M. 
bovis BCG was carried out using two different solvent systems in two directions. The M. bovis  
BCG strains used are depicted based on the overexpression plasmids they contain; A. M. bovis 
BCG_pVV16, B. M. bovis BCG_pVV16_echA12_Rv, C. M. bovis 
BCG_pVV16_echA12_BCG, D. M. bovis BCG_pVV16_G239_echA12. The strains were 
























Appendix 14: Apolar lipids separated by 2-D TLC on a silica gel plate using 
Chloroform: Methanol: Water (100:14:0.8:) in direction one (D1) and Chloroform: 
Acetone: Methanol: Water (50:60:2.5:3) in direction two (D2). The TLC separation of 
apolar lipids from four different strains of M. bovis BCG was carried out using two different 
solvent systems in two directions. The M. bovis  BCG strains used are depicted based on the 
overexpression plasmids they contain; A. M. bovis BCG_pVV16, B. M. bovis 
BCG_pVV16_echA12_Rv, C. M. bovis BCG_pVV16_echA12_BCG, D. M. bovis 
BCG_pVV16_G239_echA12. The strains were treated with 0x, 1x, 2x, 5x and 10x MIC of 
florfenicol.GMM, Glucose monomycolate; TDM, Trehalose dimycolate; DAT, Diacylated 
























Appendix 15: Fold change values for the overexpression screen against the 
extended GSK177 library.  
 
Plate 1 
Sample number Fold change Plate bar code Compound Identification Well ID 
X1 0.737827534 G214G8D GSK1859936A A2 
X2 0.728844663 G214G8D GSK991960A A3 
X3 0.975761609 G214G8D GW339685X A4 
X4 0.927707416 G214G8D GI103688B A5 
X5 0.674843954 G214G8D SB-204804-A A6 
X6 0.686566918 G214G8D GSK1788487A A7 
X7 1.210016841 G214G8D GSK1832831A A8 
X8 0.973956806 G214G8D GSK1589673A A9 
X9 0.774270411 G214G8D GSK347301A A10 
X10 1.561607378 G214G8D GSK353071A A11 
X11 1.687240787 G214G8D GSK1857145A B2 
X12 1.182563541 G214G8D GSK1955236A B3 
X13 0.689766052 G214G8D GSK2260003B B4 
X14 1.113060903 G214G8D GW369335X B5 
X15 0.902096101 G214G8D GSK829969A B6 
X16 0.853294757 G214G8D GSK1742694A B7 
X17 0.528381779 G214G8D GSK1990858A B8 
X18 0.911632334 G214G8D GSK749336A B9 
X19 1.758904866 G214G8D GSK921295A B10 
X20 1.171862757 G214G8D GSK920703A B11 
X21 0.793860766 G214G8D GSK1863309A C2 
X22 1.973013763 G214G8D GSK2059310A C3 
X23 1.58547645 G214G8D GSK1329151A C4 
X24 1.131015477 G214G8D BRL-51093AM C5 
X25 1.006854046 G214G8D GSK847913A C6 
X26 1.746275598 G214G8D GSK1783710A C7 
X27 1.164603028 G214G8D GSK468214A C8 
X28 1.935942344 Empty  C9 
X29 2.201886684 G214G8D GSK1051703A C10 
X30 0.522310065 G214G8D GSK426032A C11 
X31 1.336947359 G214G8D GSK1733953A D2 
X32 1.463835533 G214G8D GSK1996236A D3 
X33 1.079096075 G214G8D GSK353069A D4 
X34 1.770412504 G214G8D GSK1985270A D5 
X35 0.787866504 G214G8D GSK754716A D6 
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X36 0.700768591 G214G8D GSK1759150A D7 
X37 0.720431195 G214G8D GSK1829816A D8 
X38 1.762582588 G214G8D GSK2379464A D9 
X39 0.94785988 G214G8D GSK146660A D10 
X40 1.120800284 G214G8D GSK731389A D11 
X41 1.553098075 G214G8D GSK1925843A E2 
X42 1.861113789 G214G8D GSK2215855A E3 
X43 0.967715341 G214G8D GSK2200150A E4 
X44 1.106090893 G214G8D GSK2437987A E5 
X45 1.142144075 G214G8D GSK437009A E6 
X46 1.170384852 G214G8D GSK1941290A E7 
X47 1.165443323 G214G8D GSK1982256A E8 
X48 1.572040771 G214G8D GR153167X E9 
X49 2.1521069 G214G8D GR135487X E10 
X50 0.535425083 G214G8D GW857165X E11 
X51 1.292782118 G214G8D GSK1829676A F2 
X52 1.532106617 G214G8D GSK735816A F3 
X53 0.904429114 G214G8D GSK1589671A F4 
X54 1.228417282 G214G8D GV187303X F5 
X55 1.073408697 G214G8D SB-829405 F6 
X56 0.948336708 G214G8D GSK1829819A F7 
X57 1.856661181 G214G8D GSK2247256A F8 
X58 1.062911648 G214G8D CCI7967 F9 
X59 0.942499114 G214G8D GSK124576A F10 
X60 0.388100255 G214G8D SB-811137-V F11 
X61 1.583842997 G214G8D GSK1829729A G2 
X62 1.102690927 G214G8D AH24761A G3 
X63 1.258342587 G214G8D GSK270670A G4 
X64 0.755355436 G214G8D GSK888636A G5 
X65 0.971884702 Empty  G6 
X66 0.715454842 G214G8D GSK1829736A G7 
X67 0.893209171 G214G8D GSK1873486A G8 
X68 0.660854727 G214G8D GSK345724A G9 
X69 0.885001787 G214G8D GSK798463A G10 
X70 0.749617641 G214G8D GW369808A G11 
X71 0.973376203 G214G8D GSK2043267A H2 
X72 1.026310168 G214G8D GR135490X H3 
X73 1.166808055 G214G8D BRL-8903SA H4 
X74 0.90714021 G214G8D GSK276001A H5 
X75 1.242465651 G214G8D SB-811796-V H6 
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X76 0.556586056 G214G8D GSK1829674A H7 
X77 1.087724533 G214G8D CCI14012 H8 
X78 1.058415814 G214G8D GSK479031A H9 
X79 0.730840216 G214G8D GSK892651A H10 
X80 0.800935537 G214G8D SB-746177 H11 
 
Plate 2 
Sample number Fold change Plate bar code Compound Identification Well ID 
X1 0.848123619 Empty  A2 
X2 0.5376698 G214G8E GSK1812410A A3 
X3 0.480460907 G214G8E GSK1829732A A4 
X4 0.623746545 G214G8E SKF-98621-A A5 
X5 0.532093892 G214G8E GW859039X A6 
X6 1.036425265 G214G8E GSK498315A A7 
X7 0.53178537 G214G8E SB-650816 A8 
X8 1.167167867 G214G8E GSK1310678A A9 
X9 0.345019537 G214G8E GW288013X A10 
X10 1.031923669 G214G8E GSK237561A A11 
X11 1.141507972 G214G8E GSK937733A B2 
X12 0.565513925 G214G8E GSK1691553A B3 
X13 2.004920259 G214G8E GSK1829728A B4 
X14 0.450953358 G214G8E GW508363A B5 
X15 1.982787313 G214G8E GSK810016A B6 
X16 1.144895769 G214G8E GSK937213A B7 
X17 0.641206488 G214G8E GSK275628A B8 
X18 0.487951391 G214G8E GSK1372568A B9 
X19 0.830407331 G214G8E GSK445886A B10 
X20 0.650308827 G214G8E GR135486X B11 
X21 1.035464732 G214G8E GSK622400A C2 
X22 1.164921621 G214G8E GSK1750922A C3 
X23 0.65594806 G214G8E GSK1829820A C4 
X24 0.752029391 G214G8E GSK2423307A C5 
X25 1.368678028 G214G8E GSK352635A C6 
X26 0.478002986 G214G8E GSK275984A C7 
X27 0.43952968 G214G8E GSK262906A C8 
X28 0.996946661 G214G8E GSK1570606A C9 
X29 1.409252758 G214G8E GSK735826A C10 
X30 0.601981902 G214G8E GW664700A C11 
X31 0.984865239 G214G8E GSK1434490A D2 
X32 0.768965226 G214G8E GSK1731114A D3 
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X33 0.774186685 G214G8E GSK1829733A D4 
X34 1.594065384 G214G8E GSK2200160A D5 
X35 0.977097565 G214G8E GSK153890A D6 
X36 0.743145125 G214G8E GSK385518A D7 
X37 0.716694688 G214G8E GSK358607A D8 
X38 0.85837146 G214G8E GSK1402290A D9 
X39 0.73895632 G214G8E BRL-51091AM D10 
X40 0.572440257 G214G8E GSK2457140A D11 
X41 1.291889288 G214G8E GSK1668869A E2 
X42 0.743925011 G214G8E GSK1758774A E3 
X43 0.862108435 G214G8E GSK2266306A E4 
X44 0.814701363 G214G8E GSK2623870A E5 
X45 0.459987911 G214G8E GSK1107112A E6 
X46 0.286467339 G214G8E GW623128X E7 
X47 0.730942067 G214G8E GSK547481A E8 
X48 0.665443747 G214G8E GSK1611550A E9 
X49 0.531499718 G214G8E BRL-8088SA E10 
X50 0.46891923 G214G8E GSK1905227A E11 
X51 0.944150369 G214G8E GSK3011724A F2 
X52 0.853172007 G214G8E GSK1829671A F3 
X53 0.547677079 G214G8E GSK1793659A F4 
X54 0.879536026 G214G8E GSK1744926A F5 
X55 0.758542214 G214G8E GSK463114A F6 
X56 0.361607421 G214G8E GSK921190A F7 
X57 0.617218802 G214G8E GSK695914A F8 
X58 0.530175256 G214G8E GSK1385423A F9 
X59 0.695748336 G214G8E GSK1072678A F10 
X60 0.715107256 G214G8E GSK762874A F11 
X61 0.998873757 G214G8E GSK1826247A G2 
X62 0.768345846 G214G8E GSK1829727A G3 
X63 1.19958166 G214G8E GSK2225703A G4 
X64 0.791600793 G214G8E GSK316438A G5 
X65 0.659855135 G214G8E GSK636544A G6 
X66 0.375661494 G214G8E GSK2352192A G7 
X67 0.811234766 G214G8E GSK1180781A G8 
X68 0.961572149 G214G8E GSK1055950A G9 
X69 0.402298956 G214G8E SB-435634 G10 
X70 0.551086703 G214G8E GSK1174628A G11 
X71 0.908952114 G214G8E GSK1826089A H2 
X72 0.846006443 G214G8E GSK1829660A H3 
Appendix 
 271 
X73 0.836245128 G214G8E GSK2119567A H4 
X74 0.496008641 G214G8E GSK847920A H5 
X75 0.552142575 G214G8E GSK810037A H6 
X76 0.687767244 G214G8E BRL-10143SA H7 
X77 0.535235908 G214G8E GSK1302651A H8 
X78 0.839294143 G214G8E GSK2032710A H9 
X79 0.384108407 G214G8E GSK889423A H10 
X80 0.447366159 G214G8E GI207342A H11 
 
Plate 3 
Sample number Fold change Plate bar code Compound Identification Well ID 
X1 0.508800209 G214FNZ GSK920684A A2 
X2 0.466476112 G214FNZ GR232543X A3 
X3 0.86007699 G214FNZ GSK1650514A A4 
X4 0.78645034 G214FNZ GSK353496A A5 
X5 0.902319687 G214FNZ GW356807A A6 
X6 0.627513394 G214FNZ SB-516933 A7 
X7 1.159225301 Empty  A8 
X8 0.923235025 Empty  A9 
X9 0.81582318 Empty  A10 
X10 0.492296339 Empty  A11 
X11 1.097739074 G214FNZ BRL-7940SA B2 
X12 0.827571596 G214FNZ GI247341A B3 
X13 0.489584148 G214FNZ GW713556X B4 
X14 0.786629139 G214FNZ GSK2584213A B5 
X15 1.071513683 G214FNZ GSK547543A B6 
X16 0.707021793 G214FNZ GSK1148219A B7 
X17 1.039419778 Empty  B8 
X18 0.89810849 Empty  B9 
X19 1.184698107 Empty  B10 
X20 1.097591833 Empty  B11 
X21 0.623283561 G214FNZ GSK2595326A C2 
X22 0.611213861 G214FNZ GSK2523007A C3 
X23 1.623751314 G214FNZ GSK2595882A C4 
X24 0.851936041 G214FNZ GSK2428832A C5 
X25 0.900129304 G214FNZ GSK2425105A C6 
X26 0.46730337 G214FNZ GSK1518999A C7 
X27 1.10149435 Empty  C8 
X28 0.922671964 Empty  C9 
X29 1.168033723 Empty  C10 
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X30 1.125935455 Empty  C11 
X31 0.984992896 G214FNZ BRL-10988SA D2 
X32 0.872510082 G214FNZ GSK2479712A D3 
X33 0.817370575 G214FNZ GSK848336A D4 
X34 0.982308523 G214FNZ GW861072X D5 
X35 0.894285139 G214FNZ GSK957094A D6 
X36 1.296573563 G214FNZ GSK2157753A D7 
X37 1.172754629 Empty  D8 
X38 0.958679834 Empty  D9 
X39 0.960562085 Empty  D10 
X40 1.20715095 Empty  D11 
X41 0.612980823 G214FNZ GW360240X E2 
X42 0.644288512 G214FNZ GSK1826825A E3 
X43 0.804675041 G214FNZ GSK2582297A E4 
X44 1.033219599 G214FNZ GSK2240645A E5 
X45 0.810316851 G214FNZ GSK994258A E6 
X46 1.149546938 Empty  E7 
X47 0.59539256 Empty  E8 
X48 0.952383668 Empty  E9 
X49 0.947813341 Empty  E10 
X50 0.902709803 Empty  E11 
X51 1.016774601 G214FNZ SB-626246 F2 
X52 0.835323203 G214FNZ GSK381407A F3 
X53 1.38908045 G214FNZ GSK2429242A F4 
X54 0.797350014 G214FNZ GSK861337A F5 
X55 0.811708914 G214FNZ SB-354364 F6 
X56 1.01985396 Empty  F7 
X57 0.621879808 Empty  F8 
X58 0.802226909 Empty  F9 
X59 0.938894162 Empty  F10 
X60 0.873138069 Empty  F11 
X61 0.61912727 G214FNZ GSK1066288A G2 
X62 0.923348088 G214FNZ SB-712970 G3 
X63 0.626430762 G214FNZ GSK2527753A G4 
X64 0.740728268 G214FNZ GSK2548665A G5 
X65 0.618136736 G214FNZ GSK831784A G6 
X66 0.970841479 Empty  G7 
X67 0.95959454 Empty  G8 
X68 0.887397185 Empty  G9 
X69 0.907243823 Empty  G10 
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X70 0.638752465 Empty  G11 
X71 1.329512644 G214FNZ GSK2423650A H2 
X72 0.637212599 G214FNZ GSK163574A H3 
X73 0.56542354 G214FNZ GSK2440337A H4 
X74 0.789970624 G214FNZ GSK560927A H5 
X75 0.99354367 G214FNZ GSK1121877A H6 
X76 0.967352396 Empty  H7 
X77 0.893127627 Empty  H8 
X78 1.039508433 Empty  H9 
X79 0.806904112 Empty  H10 
X80 0.61637511 Empty  H11 
 
Appendix 16: GSK177 extended library plate map 
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G214G8D GSK1859936A ST/1348528 410.489 A1 A2 
G214G8D GSK1857145A ST/1346270 377.459 B1 B2 
G214G8D GSK1863309A ST/1342494 352.45 C1 C2 
G214G8D GSK1733953A ST/1264695 385.816 D1 D2 
G214G8D GSK1925843A ST/1388681 392.926 E1 E2 
G214G8D GSK1829676A ST/1325472 411.387 F1 F2 
G214G8D GSK1829729A ST/1325525 339.341 G1 G2 
G214G8D GSK2043267A ST/1473690 433.432 H1 H2 
G214G8D GSK991960A ST/796668 412.871 A2 A3 
G214G8D GSK1955236A ST/1414819 349.826 B2 B3 
G214G8D GSK2059310A ST/1488738 450.557 C2 C3 
G214G8D GSK1996236A ST/1439630 368.38 D2 D3 
G214G8D GSK2215855A N6398-41-1 489.563 E2 E3 
G214G8D GSK735816A ST/642098 328.387 F2 F3 
G214G8D AH24761A 420/150 345.272 G2 G3 
G214G8D GR135490X C1789/8/1 215.257 H2 H3 
G214G8D GW339685X 0037U 73*** 324.356 A3 A4 
G214G8D GSK2260003B N8444-19-4 513.419 B3 B4 
G214G8D GSK1329151A VMPA/7572/91/A2 396.49 C3 C4 
G214G8D GSK353069A SC/104322 205.279 D3 D4 
G214G8D GSK2200150A JM108692-131D2 357.467 E3 E4 
G214G8D GSK1589671A ST/1140264 434.478 F3 F4 
G214G8D GSK270670A U20764/121/2 373.426 G3 G4 
G214G8D BRL-8903SA IM100406-132E8 386.287 H3 H4 
G214G8D GI103688B 0013X 55U*B 466.925 A4 A5 
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G214G8D GW369335X 1747U 88U*A 318.396 B4 B5 
G214G8D BRL-51093AM IM100406-198N6 400.314 C4 C5 
G214G8D GSK1985270A N5160-40-3 383.835 D4 D5 
G214G8D GSK2437987A N21274-25-1 356.803 E4 E5 
G214G8D GV187303X VMEG/1774/72/2 290.359 F4 F5 
G214G8D GSK888636A N15309-56-2 345.398 G4 G5 
G214G8D GSK276001A SC/90411 349.405 H4 H5 
G214G8D SB-204804-A 
EXSB/LNB14457-
77 388.934 A5 A6 
G214G8D GSK829969A ST/704868 319.402 B5 B6 
G214G8D GSK847913A SC/121801 347.357 C5 C6 
G214G8D GSK754716A SC/118156 318.126 D5 D6 
G214G8D GSK437009A ST/510821 320.392 E5 E6 
G214G8D SB-829405 
DF202930-
012A4B7C7 385.884 F5 F6 
     G6 
G214G8D SB-811796-V 
YW200769-
143A22B12C5 655.649 H5 H6 
G214G8D GSK1788487A ST/1288745 423.316 A6 A7 
G214G8D GSK1742694A ST/1251778 332.444 B6 B7 
G214G8D GSK1783710A ST/1284842 383.467 C6 C7 
G214G8D GSK1759150A ST/1239788 446.492 D6 D7 
G214G8D GSK1941290A ST/1393958 475.606 E6 E7 
G214G8D GSK1829819A ST/1325613 269.306 F6 F7 
G214G8D GSK1829736A ST/1325532 402.206 G6 G7 
G214G8D GSK1829674A ST/1325470 388.179 H6 H7 
G214G8D GSK1832831A ST/1327779 359.467 A7 A8 
G214G8D GSK1990858A 
JM108964-
082A2F8 475.518 B7 B8 
G214G8D GSK468214A ST/541154 389.455 C7 C8 
G214G8D GSK1829816A ST/1325610 245.327 D7 D8 
G214G8D GSK1982256A N3440-21-A2 310.443 E7 E8 
G214G8D GSK2247256A N8628-22-A3 399.946 F7 F8 
G214G8D GSK1873486A JA209270-002A2 479.624 G7 G8 
G214G8D CCI14012 PWS/700/1 246.249 H7 H8 
G214G8D GSK1589673A ST/1140266 458.476 A8 A9 
G214G8D GSK749336A ST/651380 350.411 B8 B9 
     C9 
G214G8D GSK2379464A N26258-34-A1 330.83 D8 D9 
G214G8D GR153167X GDD/40216 357.427 E8 E9 
G214G8D CCI7967 GDD/636 380.874 F8 F9 
G214G8D GSK345724A SC/96881 256.224 G8 G9 
G214G8D GSK479031A ST/551212 302.822 H8 H9 
G214G8D GSK347301A N22583-50-5 325.276 A9 A10 
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G214G8D GSK921295A ST/759089 327.424 B9 B10 
G214G8D GSK1051703A ST/816262 335.357 C9 C10 
G214G8D GSK146660A ST/415658 368.38 D9 D10 
G214G8D GR135487X C1789/11/1 253.223 E9 E10 
G214G8D GSK124576A ST/397469 385.254 F9 F10 
G214G8D GSK798463A ST/688668 335.357 G9 G10 
G214G8D GSK892651A ST/754412 271.343 H9 H10 
G214G8D GSK353071A SC/104324 231.317 A10 A11 
G214G8D GSK920703A ST/758791 375.896 B10 B11 
G214G8D GSK426032A ST/501405 425.392 C10 C11 
G214G8D GSK731389A ST/644172 335.444 D10 D11 
G214G8D GW857165X ST/366979 371.228 E10 E11 
G214G8D SB-811137-V 
YW200769-
143A17B11C3 671.691 F10 F11 
G214G8D GW369808A 9145W 95C*A 322.323 G10 G11 
G214G8D SB-746177 
GA200759-
052A5B6 305.374 H10 H11 
 
Plate 2 






     A2 
G214G8E GSK937733A ST/784417 458.444 B1 B2 
G214G8E GSK622400A U21612/131/1 301.383 C1 C2 
G214G8E GSK1434490A ST/1057085 382.388 D1 D2 
G214G8E GSK1668869A ST/1198663 344.772 E1 E2 
G214G8E GSK3011724A 
MV103783-
173A4B1 267.347 F1 F2 
G214G8E GSK1826247A 
DJ107586-
048A5B4 465.543 G1 G2 
G214G8E GSK1826089A 
DJ107586-
046A6B9 494.629 H1 H2 
G214G8E GSK1812410A ST/1317324 301.339 A2 A3 
G214G8E GSK1691553A ST/1224178 347.394 B2 B3 
G214G8E GSK1750922A ST/1256539 364.365 C2 C3 
G214G8E GSK1731114A ST/1262042 370.465 D2 D3 
G214G8E GSK1758774A ST/1239379 412.32 E2 E3 
G214G8E GSK1829671A ST/1325467 363.299 F2 F3 
G214G8E GSK1829727A ST/1325523 323.277 G2 G3 
G214G8E GSK1829660A ST/1325456 307.389 H2 H3 
G214G8E GSK1829732A ST/1325528 377.326 A3 A4 
G214G8E GSK1829728A ST/1325524 337.304 B3 B4 
G214G8E GSK1829820A ST/1325614 285.364 C3 C4 
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G214G8E GSK1829733A ST/1325529 391.396 D3 D4 
G214G8E GSK2266306A ST/1702103 351.389 E3 E4 
G214G8E GSK1793659A JA207862-149A3 502.417 F3 F4 
G214G8E GSK2225703A N7713-10-1 699.557 G3 G4 
G214G8E GSK2119567A N4136-29-D1 382.507 H3 H4 
G214G8E SKF-98621-A EXSB/154/4665/C 397.93 A4 A5 
G214G8E GW508363A R4670/61/3 395.925 B4 B5 
G214G8E GSK2423307A ST/2078881 280.173 C4 C5 
G214G8E GSK2200160A N17110-20-2 333.511 D4 D5 
G214G8E GSK2623870A N21285-13-1 329.397 E4 E5 
G214G8E GSK1744926A N22583-50-6 397.353 F4 F5 
G214G8E GSK316438A ST/459399 346.212 G4 G5 
G214G8E GSK847920A SC/121808 302.382 H4 H5 
G214G8E GW859039X ST/365235 374.497 A5 A6 
G214G8E GSK810016A ST/691898 379.482 B5 B6 
G214G8E GSK352635A N21275-55-3 222.555 C5 C6 
G214G8E GSK153890A FNDO/U1016/10/1 320.372 D5 D6 
G214G8E GSK1107112A ST/838662 314.786 E5 E6 
G214G8E GSK463114A ST/536298 336.384 F5 F6 
G214G8E GSK636544A ST/619924 345.866 G5 G6 
G214G8E GSK810037A ST/691920 328.415 H5 H6 
G214G8E GSK498315A ST/564849 309.327 A6 A7 
G214G8E GSK937213A ST/783889 365.426 B6 B7 
G214G8E GSK275984A SC/90390 331.414 C6 C7 
G214G8E GSK385518A ST/471267 240.3 D6 D7 
G214G8E GW623128X N15054-12-1 328.836 E6 E7 
G214G8E GSK921190A ST/2357076 327.424 F6 F7 
G214G8E GSK2352192A ST/2279683 321.395 G6 G7 
G214G8E BRL-10143SA IM100406-152B1 400.314 H6 H7 
G214G8E SB-650816 
MV49014-
067A33B21 348.398 A7 A8 
G214G8E GSK275628A SC/89993 435.32 B7 B8 
G214G8E GSK262906A ST/436268 345.433 C7 C8 
G214G8E GSK358607A ST/464156 352.384 D7 D8 
G214G8E GSK547481A 
GA203953-
122A11B1C11 549.714 E7 E8 
G214G8E GSK695914A 
AS104968-
001A1B12 397.466 F7 F8 
G214G8E GSK1180781A ST/894921 410.471 G7 G8 
G214G8E GSK1302651A ST/982060 283.755 H7 H8 
G214G8E GSK1310678A ST/986476 300.241 A8 A9 
G214G8E GSK1372568A ST/1013805 301.387 B8 B9 
G214G8E GSK1570606A ST/1129554 313.349 C8 C9 
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G214G8E GSK1402290A ST/1032424 315.372 D8 D9 
G214G8E GSK1611550A ST/1170223 325.385 E8 E9 
G214G8E GSK1385423A ST/1023242 430.456 F8 F9 
G214G8E GSK1055950A ST/1259151 435.539 G8 G9 
G214G8E GSK2032710A ST/1469817 435.585 H8 H9 
G214G8E GW288013X 6010W 95C*A 301.199 A9 A10 
G214G8E GSK445886A N21275-66-1 288.755 B9 B10 
G214G8E GSK735826A ST/642108 354.406 C9 C10 
G214G8E BRL-51091AM IM100406-198N7 441.151 D9 D10 
G214G8E BRL-8088SA IM100406-130H1 392.294 E9 E10 
G214G8E GSK1072678A ST/817840 327.424 F9 F10 
G214G8E SB-435634 JH99186-039A1 228.247 G9 G10 
G214G8E GSK889423A ST/751070 344.835 H9 H10 
G214G8E GSK237561A FCBS/U1038/66/1 336.368 A10 A11 
G214G8E GR135486X C1789/10/1 219.67 B10 B11 
G214G8E GW664700A R4564/113/1 485.519 C10 C11 
G214G8E GSK2457140A ST/2400260 343.427 D10 D11 
G214G8E GSK1905227A N31856-90-A2 291.39 E10 E11 
G214G8E GSK762874A ST/2357078 309.362 F10 F11 
G214G8E GSK1174628A ST/2357077 259.305 G10 G11 
G214G8E GI207342A 0277C 76*** 255.143 H10 H11 
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G214FNZ GSK920684A ST/762581 329.349 A1 A2 
G214FNZ BRL-7940SA IM100406-081J4 428.367 B1 B2 
G214FNZ GSK2595326A ST/2298269 328.412 C1 C2 
G214FNZ BRL-10988SA IM100406-082R2 456.377 D1 D2 
G214FNZ GW360240X 0358U 83UA 324.38 E1 E2 
G214FNZ SB-626246 N26788-35-A2 219.193 F1 F2 
G214FNZ GSK1066288A M476/72/1 424.934 G1 G2 
G214FNZ GSK2423650A ST/2400259 354.267 H1 H2 
G214FNZ GR232543X M179/15/4 314.362 A2 A3 
G214FNZ GI247341A U4907/144/1 732.566 B2 B3 
G214FNZ GSK2523007A ST/2400218 339.84 C2 C3 
G214FNZ GSK2479712A ST/2400217 341.404 D2 D3 
G214FNZ GSK1826825A ST/1332234 427.641 E2 E3 
G214FNZ GSK381407A ST/476208 358.824 F2 F3 
G214FNZ SB-712970 ST/958820 368.43 G2 G3 
G214FNZ GSK163574A FFJG/252/176/1 370.859 H2 H3 
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G214FNZ GSK1650514A ST/1195396 351.831 A3 A4 
G214FNZ GW713556X ST/276160 340.373 B3 B4 
G214FNZ GSK2595882A ST/2400266 343.377 C3 C4 
G214FNZ GSK848336A SC/122269 294.394 D3 D4 
G214FNZ GSK2582297A ST/2400270 312.363 E3 E4 
G214FNZ GSK2429242A ST/2400268 233.697 F3 F4 
G214FNZ GSK2527753A ST/2400271 305.395 G3 G4 
G214FNZ GSK2440337A N32690-7-1 348.392 H3 H4 
G214FNZ GSK353496A SC/104897 211.307 A4 A5 
G214FNZ GSK2584213A ST/1925584 357.478 B4 B5 
G214FNZ GSK2428832A ST/1768863 306.363 C4 C5 
G214FNZ GW861072X ST/371072 356.439 D4 D5 
G214FNZ GSK2240645A N5936-27-A9B6 379.528 E4 E5 
G214FNZ GSK861337A ST/717997 364.395 F4 F5 
G214FNZ GSK2548665A ST/1880136 350.399 G4 G5 
G214FNZ GSK560927A U21540/77/1 425.343 H4 H5 
G214FNZ GW356807A 0039Y64 555.459 A5 A6 
G214FNZ GSK547543A 
GA203953-
122A11B7C11 544.674 B5 B6 
G214FNZ GSK2425105A ST/1763945 229.281 C5 C6 
G214FNZ GSK957094A ST/767164 265.317 D5 D6 
G214FNZ GSK994258A ST/798779 336.427 E5 E6 
G214FNZ SB-354364 ST97588-129J2 349.423 F5 F6 
G214FNZ GSK831784A 
DY103972-
187A22B13 406.478 G5 G6 
G214FNZ GSK1121877A SC/131398 467.562 H5 H6 
G214FNZ SB-516933 ST97588-166E0 350.411 A6 A7 
G214FNZ GSK1148219A VBEJ/7059/132/1 425.863 B6 B7 
G214FNZ GSK1518999A 
RW105197-
087A63B12 540.536 C6 C7 
G214FNZ GSK2157753A ST/1546914 320.43 D6 D7 
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G2140M1 GW859039X ST/365235 374.497 A1 A2 
G2140M1 GSK276001A SC/90411 349.414 B1 B2 
G2140M1 GSK124945A ST/398039 307.33 C1 C2 
G2140M1 GW713556X ST/276160 340.373 D1 D2 
G2140M1 GSK889423A ST/751070 344.835 E1 E2 
G2140M1 GSK957094A ST/767164 265.317 F1 F2 
G2140M1 GSK1072678A ST/817840 327.424 G1 G2 
G2140M1 GSK1826089A DJ107586-046A6B9 494.639 H1 H2 
G2140M1 GSK1783710A ST/1284842 383.467 A2 A3 
G2140M1 GSK1731114A ST/1262042 370.474 B2 B3 
G2140M1 GSK1758774A ST/1239379 412.327 C2 C3 
G2140M1 GSK1829728A ST/1325524 337.304 D2 D3 
G2140M1 GSK1829819A ST/1325613 269.306 E2 E3 
G2140M1 GSK1829733A ST/1325529 391.396 F2 F3 
G2140M1 GSK2200157A JM108692-133D4 317.453 G2 G3 
G2140M1 SB-650816 
MV49014-
067A33B21 348.408 H2 H3 
G2140M1 SB-204804-A EXSB/LNB14457-77 388.934 A3 A4 
G2140M1 GSK754716A SC/118156 318.126 B3 B4 
G2140M1 GSK810016A ST/691898 379.482 C3 C4 
G2140M1 GSK829969A ST/704868 319.402 D3 D4 
G2140M1 GSK1650514A ST/1195396 351.831 E3 E4 
G2140M1 GSK1859936A ST/1348528 410.498 F3 F4 
G2140M1 GSK1733953A ST/1264695 385.826 G3 G4 
G2140M1 GSK1925843A ST/1388681 392.932 H3 H4 
G2140M1 GSK1829660A ST/1325456 307.399 A4 A5 
G2140M1 GSK1832831A ST/1327779 359.478 B4 B5 
G2140M1 GSK1829816A ST/1325610 245.327 C4 C5 
G2140M1 GW857165X ST/397470 371.236 D4 D5 
G2140M1 GSK547543A 
GA203953-
122A11B7C11 544.686 E4 E5 
G2140M1 GSK498315A ST/564849 309.327 F4 F5 
G2140M1 GSK463114A ST/536298 336.394 G4 G5 
G2140M1 GSK762874A ST/658375 309.371 H4 H5 
G2140M1 GSK798463A ST/688668 335.357 A5 A6 
G2140M1 GSK810037A ST/691920 328.415 B5 B6 
G2140M1 GSK847913A SC/121801 347.357 C5 C6 
G2140M1 GSK1829732A ST/1325528 377.326 D5 D6 
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G2140M1 GSK1829736A ST/1325532 402.206 E5 E6 
G2140M1 GSK731389A ST/644172 335.45 F5 F6 
G2140M1 BRL-7940SA IM100406-081J4 428.367 G5 G6 
G2140M1 SB-516933 ST97588-166E0 350.411 H5 H6 
G2140M1 SB-811137-V 
YW200769-
143A17B11C3 671.705 A6 A7 
G2140M1 GSK124576A ST/397469 385.263 B6 B7 
G2140M1 GSK353071A SC/104324 231.322 C6 C7 
G2140M1 GSK636544A ST/619924 345.876 D6 D7 
G2140M1 GSK892651A ST/754412 271.343 E6 E7 
G2140M1 GSK937213A ST/783889 365.426 F6 F7 
G2140M1 GSK921295A ST/759089 327.429 G6 G7 
G2140M1 GSK1180781A ST/894921 410.471 H6 H7 
G2140M1 GSK1107112A ST/838662 314.786 A7 A8 
G2140M1 GSK1402290A ST/1032424 315.372 B7 B8 
G2140M1 GSK1826247A DJ107586-048A5B4 465.553 C7 C8 
G2140M1 GSK1691553A ST/1224178 347.401 D7 D8 
G2140M1 GSK1750922A ST/1256539 364.365 E7 E8 
G2140M1 GSK1863309A ST/1342494 352.458 F7 F8 
G2140M1 GSK1829727A ST/1325523 323.277 G7 G8 
G2140M1 GR135487X C1789/11/1 253.223 H7 H8 
G2140M1 SB-435634 JH99186-039A1 228.253 A8 A9 
G2140M1 GSK275984A SC/90390 331.424 B8 B9 
G2140M1 GSK437009A ST/510821 320.4 C8 C9 
G2140M1 GSK695914A 
AS104968-
001A1B12 397.478 D8 D9 
G2140M1 GSK831784A 
DY103972-
187A22B13 406.489 E8 E9 
G2140M1 GSK994258A ST/798779 336.427 F8 F9 
G2140M1 GSK1051703A ST/816262 335.357 G8 G9 
G2140M1 GSK1310678A ST/986476 300.241 H8 H9 
G2140M1 GSK1519001A 
RW105197-
087A65B12 526.523 A9 A10 
G2140M1 GSK1434490A ST/1057085 382.388 B9 B10 
G2140M1 GSK1611550A ST/1170223 325.385 C9 C10 
G2140M1 GSK920684A ST/762581 329.349 D9 D10 
G2140M1 GSK1788487A ST/1288745 423.316 E9 E10 
G2140M1 GSK1759150A ST/1239788 446.501 F9 F10 
G2140M1 GSK2059310A ST/1488738 450.566 G9 G10 
G2140M1 GSK2157753A ST/1546914 320.43 H9 H10 
G2140M1 GSK1742694A ST/1251778 332.444 A10 A11 
G2140M1 GSK1826825A ST/1332234 427.649 B10 B11 
G2140M1 GSK1744926A ST/1252505 397.353 C10 C11 
G2140M1 GSK847920A SC/121808 302.382 D10 D11 
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G2140M1 GSK921190A ST/759036 327.429 E10 E11 
G2140M1 GSK888636A ST/750242 345.398 F10 F11 
G2140M1 GSK1385423A ST/1023242 430.456 G10 G11 
G2140M1 SB-712970 ST/958820 368.43 H10 H11 
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G2140M1 GSK861337A ST/717997 364.395 A11 A2 
G2140M1 GSK1729177A N5160-41-1 435.539 B11 B2 
G2140M1 GSK445886A N21275-66-1 288.755 C11 C2 
G2140M1 GSK254610A 
AP103231-
016A1B176 441.522 D11 D2 
G2140M1 GSK385518A ST/471267 240.308 E11 E2 
G2140M1 GSK547511A 
GA203953-
122A10B4C11 543.699 F11 F2 
G2140M1 GSK547481A 
GA203953-
122A11B1C11 549.724 G11 G2 
G2140M1 GSK479031A ST/551212 302.822 H11 H2 
G2140LL GV187303X VMEG/1774/72/2 290.359 A1 A3 
G2140LL GSK1174628A ST/876385 259.305 B1 B3 
G2140LL GSK1372568A ST/1013805 301.387 C1 C3 
G2140LL GSK1518999A 
RW105197-
087A63B12 540.55 D1 D3 
G2140LL GSK1570606A ST/1129554 313.349 E1 E3 
G2140LL GSK1829676A ST/1325472 411.387 F1 F3 
G2140LL GSK1829674A ST/1325470 388.179 G1 G3 
G2140LL GSK1955236A ST/1414819 349.826 H1 H3 
G2140LL GSK1985270A N5160-40-3 383.835 A2 A4 
G2140LL GSK2200150A JM108692-131D2 357.475 B2 B4 
G2140LL GSK735816A ST/642098 328.392 C2 C4 
G2140LL GI247341A U4907/144/1 732.566 D2 D4 
G2140LL GSK1905227A ST/1367355 291.399 E2 E4 
G2140LL GSK749336A ST/651380 350.411 F2 F4 
G2140LL GSK1598164A R14229/126/205 416.549 G2 G4 
G2140LL CCI7967 GDD/636 380.874 H2 H4 
G2140LL GW664700A R4564/113/1 485.519 A3 A5 
G2140LL GSK735826A ST/642108 354.406 B3 B5 
G2140LL GI103688B 0013X 55U*B 466.925 C3 C5 
G2140LL GSK275628A SC/89993 435.33 D3 D5 
G2140LL 
BRL-
51093AM IM100406-198N6 400.314 E3 E5 
G2140LL GSK316438A ST/459399 346.215 F3 F5 
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G2140LL GSK130506A SC/84383 367.717 G3 G5 
G2140LL GSK1829820A ST/1325614 285.37 H3 H5 
G2140LL SB-354364 ST97588-129J2 349.423 A4 A6 
G2140LL GSK690382A ST/638013 340.428 B4 B6 
G2140LL GSK1857145A ST/1346270 377.468 C4 C6 
G2140LL GSK163574A FFJG/252/176/1 370.859 D4 D6 
G2140LL SB-811796-V 
YW200769-
143A22B12C5 655.662 E4 E6 
G2140LL GSK347301A SC/98355 325.276 F4 F6 
G2140LL GSK426032A ST/501405 425.401 G4 G6 
G2140LL GW360240X 0358U 83U*A 324.38 H4 H6 
G2140LL BRL-10143SA IM100406-152B1 400.314 A5 A7 
G2140LL GSK270670A U20764/121/2 373.434 B5 B7 
G2140LL BRL-8903SA IM100406-132E8 386.287 C5 C7 
G2140LL 
BRL-
51091AM IM100406-198N7 441.151 D5 D7 
G2140LL GSK381407A ST/476208 358.833 E5 E7 
G2140LL GSK146660A ST/415658 368.39 F5 F7 
G2140LL GR135486X C1789/10/1 219.67 G5 G7 
G2140LL GSK848336A SC/122269 294.394 H5 H7 
G2140LL GW369335X 1747U 88U*A 318.396 A6 A8 
G2140LL GSK262906A ST/436268 345.442 B6 B8 
G2140LL GSK352635A SC/103704 222.555 C6 C8 
G2140LL GSK2043267A ST/1473690 433.432 D6 D8 
G2140LL GW356807A 0039Y 64*** 555.471 E6 E8 
G2140LL GSK1365028A ST/1009933 339.408 F6 F8 
G2140LL GSK1941290A ST/1393958 475.606 G6 G8 
G2140LL GSK2032710A ST/1469817 435.585 H6 H8 
G2140LL SB-829405 
DF202930-
012A4B7C7 385.894 A7 A9 
G2140LL GW623128X N15054-12-1 328.836 B7 B9 
G2140LL GSK345724A SC/96881 256.229 C7 C9 
G2140LL GSK1829671A ST/1325467 363.299 D7 D9 
G2140LL GSK1829729A ST/1325525 339.341 E7 E9 
G2140LL GSK358607A ST/464156 352.393 F7 F9 
G2140LL GSK1589671A ST/1140264 434.478 G7 G9 
G2140LL GSK133167A 
JT101283-
005A8B13C12 491.506 H7 H9 
G2140LL GSK1812410A ST/1317324 301.339 A8 A10 
G2140LL GSK2111534A ST/1535805 299.762 B8 B10 
G2140LL GSK1996236A ST/1439630 368.38 C8 C10 
G2140LL GSK237561A FCBS/U1038/66/1 336.375 D8 D10 
G2140LL GR223839X GDD/58841 324.423 E8 E10 
G2140LL GR153167X GDD/40216 357.427 F8 F10 
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G2140LL GSK353496A SC/104897 211.309 G8 G10 
G2140LL GSK1635139A 
NS107584-
055A93B10 380.513 H8 H10 
G2140LL GW861072X ST/371072 356.447 A9 A11 
G2140LL GSK468214A ST/541154 389.46 B9 B11 
G2140LL GSK991960A ST/796668 412.876 C9 C11 
G2140LL SB-746177 GA200759-052A5B6 305.383 D9 D11 
G2140LL GSK353069A SC/104322 205.283 E9 E11 
G2140LL BRL-10988SA IM100406-082R2 456.377 F9 F11 
G2140LL BRL-8088SA IM100406-130H1 392.294 G9 G11 
G2140LL GSK2200160A JM108692-134C3 333.518 H9 H11 
 
 
 
